[CLS]
The
psychiatric
symptoms
in
the
vast
majority
of
patients
in
both
controlled
and
open
-
label
trials
resolved
within
7
days
of
disco
##ntin
##uation
of
P
##OT
##IG
##A
.
[SEP]
[CLS]
Chicken
##pox
and
me
##as
##les
,
for
example
,
can
have
a
more
serious
or
even
fatal
course
in
susceptible
children
or
adults
using
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
The
risk
of
th
##rom
##boe
##mbo
##lic
disease
due
to
oral
con
##tra
##ceptive
##s
gradually
disappears
after
CO
##C
use
is
discontinued
.
[SEP]
[CLS]
b
includes
ne
##uro
##pathy
peripheral
,
ne
##uro
##pathy
,
peripheral
motor
ne
##uro
##pathy
,
p
##oly
##ne
##uro
##pathy
,
peripheral
sensory
##ne
##uro
##pathy
,
and
para
##est
##hesia
.
[SEP]
[CLS]
Grade
3
-
4
cardiac
failure
occurred
in
1
.
6
%
of
patients
taking
Z
##Y
##TI
##GA
and
led
to
5
treatment
disco
##ntin
##uations
and
2
deaths
.
[SEP]
[CLS]
Monitor
liver
laboratory
tests
at
least
monthly
.
[SEP]
[CLS]
Counsel
patients
regarding
the
potential
risk
for
M
##TC
with
the
use
of
T
##R
##U
##L
##IC
##IT
##Y
and
inform
them
of
symptoms
of
thy
##roid
tumors
(
e
.
g
.
[SEP]
[CLS]
The
effect
that
s
##ym
##pt
##oma
##tic
suppression
has
upon
the
long
-
term
course
of
the
syndrome
is
unknown
.
[SEP]
[CLS]
In
addition
,
beta
-
ago
##nist
##s
have
been
reported
to
produce
electro
##card
##io
##graphic
changes
,
such
as
flat
##ten
##ing
of
the
T
wave
,
pro
##long
##ation
of
the
Q
##T
##c
interval
,
and
ST
segment
depression
,
although
the
clinical
significance
of
these
findings
is
unknown
.
[SEP]
[CLS]
Sam
##ples
from
6
patients
with
confirmed
binding
activity
to
the
modified
c
##yt
##oto
##xi
##c
T
-
l
##ymph
##oc
##yte
-
associated
anti
##gen
4
(
CT
##LA
-
4
)
region
of
the
be
##lat
##ace
##pt
molecule
were
assessed
by
an
in
v
##it
##ro
bio
##ass
##ay
for
the
presence
of
neutral
##izing
antibodies
.
[SEP]
[CLS]
Consider
other
anti
##dia
##bet
##ic
the
##rap
##ies
in
patients
with
history
of
pan
##cre
##ati
##tis
(
5
.
2
)
.
[SEP]
[CLS]
Because
FA
##NA
##P
##T
was
not
marketed
at
the
time
these
studies
were
performed
,
it
is
not
known
if
FA
##NA
##P
##T
is
associated
with
this
increased
risk
.
[SEP]
[CLS]
T
##R
##U
##L
##IC
##IT
##Y
has
not
been
studied
in
patients
with
severe
gas
##tro
##int
##est
##inal
disease
,
including
severe
gas
##tro
##par
##esis
,
and
is
therefore
not
recommended
in
these
patients
.
[SEP]
[CLS]
He
##mor
##r
##hage
:
Se
##vere
,
sometimes
fatal
,
hem
##or
##r
##hage
including
hem
##op
##ty
##sis
and
gas
##tro
##int
##est
##inal
hem
##or
##r
##hage
occurred
in
3
%
of
CO
##ME
##TR
##I
##Q
-
treated
patients
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ten
##don
r
##up
##ture
or
serious
injury
to
the
injected
finger
:
A
##vo
##id
in
##ject
##ing
XI
##AF
##LE
##X
into
tend
##ons
,
nerves
,
blood
vessels
,
or
other
co
##lla
##gen
-
containing
structure
of
the
hand
.
[SEP]
[CLS]
The
most
frequent
reactions
were
h
##y
##pot
##ens
##ion
and
h
##yper
##tens
##ion
.
[SEP]
[CLS]
Sin
##us
ta
##chy
##card
##ia
was
reported
in
3
.
0
%
,
2
.
8
%
,
and
5
.
6
%
of
patient
treated
with
place
##bo
,
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
and
T
##R
##U
##L
##IC
##IT
##Y
1
.
5
mg
,
respectively
.
[SEP]
[CLS]
The
proportion
of
patients
with
elevations
in
t
##rig
##ly
##cer
##ides
>
=
200
mg
/
d
##L
(
at
End
##point
)
was
13
.
2
%
for
SA
##P
##H
##RI
##S
-
treated
patients
versus
10
.
5
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Rest
##art
treatment
based
on
AN
##C
and
plate
##let
count
recovery
.
[SEP]
[CLS]
5
.
4
H
##y
##po
##gly
##ce
##mia
with
Con
##com
##ita
##nt
Use
with
In
##sul
##in
and
In
##sul
##in
Secret
##ago
##gues
In
##sul
##in
and
insulin
secret
##ago
##gues
are
known
to
cause
h
##y
##po
##gly
##ce
##mia
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
V
##im
##iz
##im
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
Monitor
patients
with
skin
reactions
closely
.
[SEP]
[CLS]
Gen
##ital
My
##cot
##ic
In
##fect
##ions
In
the
pool
of
four
place
##bo
-
controlled
clinical
trials
,
female
g
##eni
##tal
my
##cot
##ic
infections
(
e
.
g
.
,
v
##ul
##vo
##va
##gin
##al
my
##cot
##ic
infection
,
v
##ul
##vo
##va
##gin
##al
can
##di
##dia
##sis
,
and
v
##ul
##vo
##va
##gin
##itis
)
occurred
in
3
.
2
%
,
10
.
4
%
,
and
11
.
4
%
of
females
treated
with
place
##bo
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
*
140
patients
with
advanced
phase
C
##ML
including
76
patients
with
AP
C
##ML
and
64
patients
with
BP
C
##ML
.
[SEP]
[CLS]
Adult
Pat
##ients
:
Poole
##d
data
from
the
short
-
term
place
##bo
-
controlled
s
##chi
##zophrenia
and
bi
##pol
##ar
man
##ia
trials
are
presented
in
Table
1
.
[SEP]
[CLS]
*
For
patients
at
highest
risk
for
N
##SF
,
do
not
exceed
the
recommended
D
##OT
##AR
##EM
dose
and
allow
a
sufficient
period
of
time
for
elimination
of
the
drug
from
the
body
prior
to
any
re
-
administration
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
The
safety
of
con
##ju
##gated
est
##rogen
##s
/
b
##azed
##ox
##ife
##ne
was
evaluated
in
four
Phase
3
clinical
trials
ranging
from
12
weeks
to
24
months
in
duration
and
en
##roll
##ing
6
,
210
post
##men
##op
##aus
##al
women
age
40
to
75
years
(
mean
age
55
years
)
.
[SEP]
[CLS]
Of
the
patients
in
those
trials
,
95
%
were
between
18
and
65
years
old
;
48
%
were
male
,
and
84
%
were
Caucasian
.
[SEP]
[CLS]
Other
adverse
reactions
reported
included
r
##ash
,
nausea
,
and
headache
in
patients
exposed
to
F
##IR
##A
##Z
##Y
##R
.
[SEP]
[CLS]
The
most
commonly
observed
adverse
reactions
(
>
=
5
%
and
at
least
2
times
the
rate
of
place
##bo
)
in
these
trials
for
the
600
mg
dose
of
H
##OR
##I
##Z
##AN
##T
were
so
##m
##no
##len
##ce
/
se
##dation
and
di
##zzi
##ness
(
see
Table
4
)
.
[SEP]
[CLS]
Laboratory
abnormal
##ities
are
described
separately
in
Table
9
.
[SEP]
[CLS]
(
5
.
1
)
*
Ad
##mini
##ster
a
thy
##roid
-
blocking
agent
before
Da
##T
##sca
##n
administration
.
[SEP]
[CLS]
5
.
5
Beta
-
Block
##er
With
##dra
##wal
C
##lev
##ip
##re
##x
is
not
a
beta
-
block
##er
,
does
not
reduce
heart
rate
,
and
gives
no
protection
against
the
effects
of
abrupt
beta
-
block
##er
withdrawal
.
[SEP]
[CLS]
In
some
instances
,
H
##B
##V
react
##ivation
occurring
in
conjunction
with
T
##NF
-
block
##er
therapy
has
been
fatal
.
[SEP]
[CLS]
No
serious
adverse
reactions
related
to
N
##eur
##ace
##q
administration
have
been
reported
.
[SEP]
[CLS]
C
##aut
##ion
is
recommended
in
patients
with
hem
##og
##lo
##bin
<
10
g
/
d
##l
.
[SEP]
[CLS]
The
et
##iology
of
he
##pa
##to
##cellular
injury
was
possibly
related
to
T
##AN
##Z
##E
##UM
but
direct
at
##tribution
to
T
##AN
##Z
##E
##UM
was
con
##founded
by
the
presence
of
gal
##lston
##e
disease
diagnosed
on
ultra
##sound
3
weeks
after
the
event
.
[SEP]
[CLS]
Therefore
,
a
lower
dose
of
the
insulin
secret
##ago
##gue
or
insulin
may
be
required
to
reduce
the
risk
of
h
##y
##po
##gly
##ce
##mia
when
used
in
combination
with
J
##AR
##DI
##AN
##CE
.
[SEP]
[CLS]
A
total
of
9
serious
adverse
reactions
were
reported
for
CA
##PS
patients
.
[SEP]
[CLS]
The
most
common
related
adverse
reactions
that
were
not
hem
##ato
##log
##ic
,
he
##pa
##tic
or
re
##nal
events
were
par
##est
##hesia
,
flush
##ing
,
and
nausea
and
/
or
vomit
##ing
,
which
each
occurred
in
2
%
of
patients
(
Table
1
)
.
[SEP]
[CLS]
AD
##CE
##TR
##IS
-
induced
peripheral
ne
##uro
##pathy
is
cumulative
.
[SEP]
[CLS]
*
viral
,
and
other
infections
.
[SEP]
[CLS]
No
patients
treated
with
SA
##P
##H
##RI
##S
experienced
Q
##T
##c
increases
>
=
60
m
##se
##c
from
base
##line
measurements
,
nor
did
any
patient
experience
a
Q
##T
##c
of
>
=
500
m
##se
##c
.
[SEP]
[CLS]
In
most
cases
,
these
effects
appear
to
be
re
##versible
upon
drug
disco
##ntin
##uation
and
with
appropriate
medical
treatment
.
[SEP]
[CLS]
Auto
##im
##mu
##ne
disorders
(
such
as
Graves
'
disease
,
p
##oly
##my
##os
##itis
,
and
G
##uil
##lain
-
Barr
##e
syndrome
)
have
also
been
reported
to
occur
in
the
setting
of
immune
re
##con
##st
##itution
,
however
,
the
time
to
onset
is
more
variable
,
and
can
occur
many
months
after
initiation
of
treatment
.
[SEP]
[CLS]
Many
of
the
drugs
meta
##bol
##ized
by
C
##YP
##2
##D
##6
can
pro
##long
the
Q
##T
interval
and
should
not
be
administered
with
Co
##arte
##m
Table
##ts
due
to
the
potential
add
##itive
effect
on
the
Q
##T
interval
(
e
.
g
.
,
fl
##eca
##ini
##de
,
im
##ip
##ram
##ine
,
am
##it
##rip
##ty
##line
,
c
##lo
##mi
##pra
##mine
)
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
,
Drug
Inter
##actions
(
7
.
6
)
,
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
6
.
1
Clinical
Trial
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
The
risks
and
benefits
of
treatment
with
C
##IM
##Z
##IA
should
be
carefully
considered
prior
to
in
##iti
##ating
therapy
in
patients
with
chronic
or
re
##current
infection
.
[SEP]
[CLS]
(
5
.
3
)
*
W
##orse
##ning
of
u
##rina
##ry
retention
may
occur
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
the
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
The
most
common
adverse
reactions
,
di
##zzi
##ness
,
r
##ash
,
p
##ru
##rit
##is
,
flush
##ing
,
headache
,
and
injection
site
hem
##or
##r
##hage
occurred
in
<
1
.
3
%
of
patients
.
[SEP]
[CLS]
Death
related
to
di
##ar
##r
##hea
and
electro
##ly
##te
im
##bal
##ance
occurred
in
the
random
##ized
clinical
trial
.
[SEP]
[CLS]
*
viral
and
other
infections
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Jan
##ssen
B
##iot
##ech
,
Inc
.
at
1
-
800
-
52
##6
-
77
##36
(
1
-
800
-
J
##AN
##SS
##EN
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Table
1
presents
the
adverse
reactions
reported
when
ST
##EN
##DR
##A
was
taken
as
recommended
(
on
an
as
-
needed
basis
)
from
these
3
clinical
trials
.
[SEP]
[CLS]
While
this
normally
would
be
expected
to
be
of
little
consequence
in
most
patients
,
prior
to
pre
##s
##cribing
ST
##EN
##DR
##A
,
physicians
should
carefully
consider
whether
patients
with
underlying
card
##iovascular
disease
could
be
affected
adverse
##ly
by
such
v
##as
##od
##ila
##tory
effects
,
especially
in
combination
with
sexual
activity
.
[SEP]
[CLS]
5
.
3
Spin
##al
/
E
##pid
##ural
An
##est
##hesia
or
P
##un
##cture
When
ne
##ura
##xial
an
##est
##hesia
(
spinal
/
e
##pid
##ural
an
##est
##hesia
)
or
spinal
/
e
##pid
##ural
pu
##nc
##ture
is
employed
,
patients
treated
with
anti
##th
##rom
##bot
##ic
agents
for
prevention
of
th
##rom
##boe
##mbo
##lic
complications
are
at
risk
of
developing
an
spinal
hem
##ato
##ma
which
can
result
in
permanent
para
##lysis
.
[SEP]
[CLS]
On
##set
of
d
##ys
##p
##nea
or
non
-
productive
cough
may
be
related
to
pulmonary
toxicity
and
patients
should
be
carefully
evaluated
clinical
##ly
.
[SEP]
[CLS]
T
##hr
##omb
##oe
##mbo
##lic
events
have
been
associated
with
E
##SA
use
in
other
disease
states
;
and
have
also
been
reported
with
p
##eg
##int
##er
##fer
##on
al
##fa
use
in
he
##pa
##titis
C
patients
.
[SEP]
[CLS]
c
Includes
skin
p
##ap
##illo
##ma
and
p
##ap
##illo
##ma
.
[SEP]
[CLS]
The
incidence
in
the
D
##ME
studies
from
base
##line
to
week
52
was
3
.
3
%
(
19
out
of
57
##8
)
in
the
combined
group
of
patients
treated
with
E
##Y
##LE
##A
compared
with
2
.
8
%
(
8
out
of
287
)
in
the
control
group
;
from
base
##line
to
week
100
,
the
incidence
was
6
.
4
%
(
37
out
of
57
##8
)
in
the
combined
group
of
patients
treated
with
E
##Y
##LE
##A
compared
with
4
.
2
%
(
12
out
of
287
)
in
the
control
group
.
[SEP]
[CLS]
Inc
##rease
in
He
##mat
##oc
##rit
In
a
pool
of
four
place
##bo
-
controlled
studies
,
median
hem
##ato
##c
##rit
decreased
by
2
.
8
%
in
J
##AR
##DI
##AN
##CE
10
mg
and
2
.
8
%
in
J
##AR
##DI
##AN
##CE
25
mg
treated
patients
.
[SEP]
[CLS]
Six
##ty
-
two
patients
were
exposed
to
IL
##AR
##IS
for
at
least
6
months
,
56
for
at
least
1
year
and
4
for
at
least
3
years
.
[SEP]
[CLS]
*
Ser
##ious
der
##mat
##olo
##gic
reactions
:
Disco
##ntin
##ue
if
Stevens
-
Johnson
syndrome
or
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
occurs
(
5
.
10
)
.
[SEP]
[CLS]
(
5
.
5
)
*
Se
##iz
##ures
:
Use
cautiously
in
patients
with
a
history
of
seizure
##s
or
with
conditions
that
lower
seizure
threshold
.
[SEP]
[CLS]
*
No
dos
##ing
adjustments
are
recommended
in
the
presence
of
moderate
C
##YP
##3
##A
##4
inhibitor
##s
(
e
.
g
.
,
er
##yt
##hr
##omy
##cin
,
flu
##cona
##zo
##le
,
di
##lt
##ia
##ze
##m
,
ve
##rap
##ami
##l
and
grape
##f
##ruit
juice
)
.
[SEP]
[CLS]
Inc
##reased
Mortal
##ity
In
the
c
##IA
##I
trials
(
Phase
2
and
3
)
,
death
occurred
in
2
.
5
%
(
14
/
56
##4
)
of
patients
receiving
Z
##ER
##BA
##X
##A
and
in
1
.
5
%
(
8
/
53
##6
)
of
patients
receiving
me
##rop
##ene
##m
.
[SEP]
[CLS]
In
addition
to
the
reactions
shown
in
Table
1
,
adverse
reactions
occurring
in
greater
than
or
equal
to
3
%
of
the
subjects
treated
with
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
(
n
=
80
##6
)
for
12
months
included
back
pain
,
pneumonia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
,
br
##on
##chi
##tis
,
sin
##us
##itis
,
cough
,
or
##op
##har
##yn
##ge
##al
pain
,
art
##hra
##l
##gia
,
in
##fluenza
,
p
##har
##yn
##git
##is
,
and
p
##yre
##xia
.
[SEP]
[CLS]
The
safety
of
self
-
administration
was
evaluated
in
a
separate
,
open
-
label
trial
in
56
patients
with
H
##A
##E
.
[SEP]
[CLS]
at
1
-
800
-
67
##8
-
160
##5
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
5
.
2
Lac
##k
of
Inter
##chang
##ea
##bility
between
Bo
##tu
##lin
##um
To
##xin
Products
The
pot
##ency
Units
of
X
##E
##OM
##IN
are
specific
to
the
preparation
and
ass
##ay
method
utilized
.
[SEP]
[CLS]
Table
8
:
Ad
##verse
Re
##actions
Report
##ed
in
2
%
or
More
of
Adult
Pat
##ients
in
Any
SA
##P
##H
##RI
##S
Do
##se
Group
and
Which
O
##cc
##ur
##red
at
Greater
Inc
##iden
##ce
Than
in
the
Place
##bo
Group
in
6
-
Week
Sc
##hi
##zophrenia
Trials
*
A
##kat
##his
##ia
includes
:
aka
##thi
##sia
and
h
##yper
##kin
##esi
##a
.
[SEP]
[CLS]
Table
2
presents
the
most
common
laboratory
abnormal
##ities
reported
in
>
=
10
%
patients
who
received
IN
##L
##Y
##TA
or
so
##ra
##fen
##ib
.
[SEP]
[CLS]
D
##U
##AV
##EE
is
used
after
men
##op
##aus
##e
for
women
with
a
u
##ter
##us
to
:
*
reduce
moderate
to
severe
hot
flush
##es
##Es
##tro
##gens
are
hormones
made
by
a
woman
'
s
o
##var
##ies
.
[SEP]
[CLS]
G
##la
##bella
##r
Lines
Testing
for
antibodies
to
D
##Y
##SP
##OR
##T
(
r
)
was
performed
for
155
##4
subjects
who
had
up
to
nine
cycles
of
treatment
.
[SEP]
[CLS]
This
information
does
not
take
the
place
of
talking
to
your
healthcare
provider
about
your
medical
condition
or
your
treatment
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
:
Adults
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Der
##mat
##olo
##gic
Re
##actions
A
significantly
higher
number
of
patients
treated
with
Pro
##lia
developed
der
##mal
adverse
events
(
such
as
der
##mat
##itis
,
e
##cz
##ema
,
and
r
##ash
##es
)
,
with
these
events
reported
in
8
.
2
%
of
the
place
##bo
and
10
.
8
%
of
the
Pro
##lia
groups
(
p
<
0
.
000
##1
)
.
[SEP]
[CLS]
(
5
.
1
)
*
This
finding
of
an
increased
risk
of
as
##th
##ma
-
related
death
with
sa
##lm
##eter
##ol
is
considered
a
class
effect
of
LA
##BA
,
including
in
##da
##cate
##rol
,
the
active
ingredient
in
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
.
[SEP]
[CLS]
If
signs
and
symptoms
of
TD
appear
in
a
patient
on
SA
##P
##H
##RI
##S
,
drug
disco
##ntin
##uation
should
be
considered
.
[SEP]
[CLS]
Where
skin
reactions
occur
,
they
may
be
progressive
and
increase
in
severity
with
further
treatment
.
[SEP]
[CLS]
However
,
there
may
be
an
increased
risk
of
severe
skin
toxicity
when
T
##RE
##AN
##DA
and
all
##op
##uri
##no
##l
are
administered
con
##com
##ita
##ntly
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
H
##y
##pot
##ens
##ion
:
Before
in
##iti
##ating
IN
##VO
##KA
##NA
,
assess
volume
status
and
correct
h
##y
##po
##vo
##lem
##ia
in
patients
with
re
##nal
imp
##air
##ment
,
the
elderly
,
in
patients
with
low
s
##ys
##to
##lic
blood
pressure
,
or
if
on
di
##ure
##tics
,
AC
##E
##i
,
or
AR
##B
.
[SEP]
[CLS]
Amy
##lase
and
Li
##pas
##e
Inc
##rease
Pat
##ients
exposed
to
T
##R
##U
##L
##IC
##IT
##Y
had
mean
increases
from
base
##line
in
lip
##ase
of
14
%
to
20
%
,
while
place
##bo
-
treated
patients
had
mean
increases
of
up
to
3
%
.
[SEP]
[CLS]
Pat
##ients
with
an
established
diagnosis
of
diabetes
me
##lli
##tus
who
are
started
on
at
##y
##pical
anti
##psy
##cho
##tics
should
be
monitored
regularly
for
worse
##ning
of
glucose
control
.
[SEP]
[CLS]
*
My
##elo
##su
##pp
##ression
[
see
Do
##sa
##ge
and
Administration
(
2
.
4
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Fat
##ali
##ties
have
been
reported
in
association
with
excessive
use
of
inhaled
s
##ym
##path
##omi
##met
##ic
drugs
.
[SEP]
[CLS]
Do
not
restart
if
pan
##cre
##ati
##tis
is
confirmed
.
[SEP]
[CLS]
There
were
7
(
0
.
5
%
)
deaths
due
to
card
##ior
##es
##pi
##rator
##y
arrest
in
the
Z
##Y
##TI
##GA
arms
and
3
(
0
.
3
%
)
deaths
in
the
place
##bo
arms
.
[SEP]
[CLS]
*
Con
##com
##ita
##nt
co
##l
##chi
##cine
or
and
##rogen
-
de
##p
##ri
##vation
therapeutic
drugs
(
such
as
l
##ute
##ini
##zing
hormone
-
releasing
analog
##s
and
anti
-
and
##rogen
drugs
)
may
interfere
with
11
C
-
ch
##olin
##e
P
##ET
imaging
.
[SEP]
[CLS]
(
6
.
1
)
*
In
patients
with
chronic
he
##pa
##titis
C
-
associated
th
##rom
##bo
##cy
##top
##enia
,
the
most
common
adverse
reactions
(
greater
than
or
equal
to
10
%
and
greater
than
place
##bo
)
were
:
an
##emia
,
p
##yre
##xia
,
fatigue
,
headache
,
nausea
,
di
##ar
##r
##hea
,
decreased
appetite
,
in
##fluenza
-
like
illness
,
as
##the
##nia
,
ins
##om
##nia
,
cough
,
p
##ru
##rit
##us
,
chill
##s
,
my
##al
##gia
,
al
##ope
##cia
,
and
peripheral
ed
##ema
.
[SEP]
[CLS]
5
.
5
I
##maging
E
##rro
##rs
due
to
Con
##ditions
that
A
##ffe
##ct
the
S
##ym
##path
##etic
N
##er
##vous
System
Individuals
with
conditions
that
affect
the
sympathetic
nervous
system
,
e
.
g
.
,
Parkinson
##ian
syndrome
##s
such
as
Parkinson
'
s
disease
or
multiple
system
at
##rop
##hy
,
may
show
decreased
cardiac
up
##take
of
Ad
##re
##V
##ie
##w
independent
of
heart
disease
.
[SEP]
[CLS]
*
Fat
##al
and
/
or
serious
and
severe
di
##ar
##r
##hea
or
co
##lit
##is
occurred
in
14
%
of
Z
##yd
##eli
##g
-
treated
patients
.
[SEP]
[CLS]
The
majority
of
P
##ey
##ron
##ie
'
s
patients
experienced
at
least
one
adverse
reaction
(
92
%
XI
##AF
##LE
##X
-
treated
patients
,
61
%
place
##bo
-
treated
)
.
[SEP]
[CLS]
3
-
Month
and
6
-
Month
Trials
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
was
studied
in
two
3
-
month
(
Trials
B
and
C
)
and
one
6
-
month
(
Trial
D
)
place
##bo
-
controlled
trials
in
patients
with
CO
##PD
.
[SEP]
[CLS]
5
.
6
I
##mm
##uno
##su
##pp
##ression
Persons
who
are
using
drugs
that
suppress
the
immune
system
are
more
susceptible
to
infections
than
healthy
individuals
.
[SEP]
[CLS]
Approximately
two
-
thirds
of
patients
with
ps
##ych
##osis
in
controlled
trials
had
no
prior
psychiatric
history
.
[SEP]
[CLS]
(
2
.
2
,
5
.
4
)
*
H
##yper
##gly
##ce
##mia
:
Z
##Y
##KA
##DI
##A
can
cause
h
##yper
##gly
##ce
##mia
.
[SEP]
[CLS]
Ser
##ious
Ad
##verse
Re
##actions
and
Ad
##verse
Re
##actions
Leading
to
Disco
##ntin
##uation
In
the
four
pool
##ed
Phase
3
clinical
trials
,
serious
adverse
reactions
(
SA
##R
##s
)
occurred
in
98
/
1300
(
7
.
5
%
)
of
patients
receiving
Te
##f
##lar
##o
and
100
/
129
##7
(
7
.
7
%
)
of
patients
receiving
com
##par
##ator
drugs
.
[SEP]
[CLS]
In
##iti
##ate
or
op
##ti
##mize
anti
-
h
##yper
##gly
##ce
##mic
medications
as
indicated
.
[SEP]
[CLS]
V
##as
##cular
disorders
:
h
##y
##pot
##ens
##ion
,
h
##yper
##tens
##ion
.
[SEP]
[CLS]
These
effects
were
dose
-
related
and
generally
appeared
within
the
first
8
weeks
of
treatment
.
[SEP]
[CLS]
The
population
had
a
mean
age
of
64
years
(
ranging
from
40
to
89
years
)
,
with
58
%
males
,
94
%
Caucasian
,
and
had
CO
##PD
with
a
mean
pre
-
br
##on
##cho
##di
##lator
forced
ex
##pi
##rator
##y
volume
in
one
second
(
F
##E
##V
##1
)
percent
predicted
of
48
%
.
[SEP]
[CLS]
Clinical
status
including
liver
trans
##ami
##nas
##es
should
be
monitored
and
appropriate
therapy
initiated
.
[SEP]
[CLS]
Because
of
the
possibility
of
significant
systemic
absorption
of
inhaled
co
##rt
##ico
##ster
##oids
in
sensitive
patients
,
patients
treated
with
BR
##E
##O
E
##LL
##IP
##TA
should
be
observed
carefully
for
any
evidence
of
systemic
co
##rt
##ico
##ster
##oid
effects
.
[SEP]
[CLS]
*
Blood
PS
##A
levels
<
2
ng
/
m
##L
have
been
associated
with
poor
performance
of
11
C
-
ch
##olin
##e
P
##ET
imaging
(
higher
numbers
of
false
positive
and
false
negative
results
)
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
In
Study
1
and
2
,
the
majority
of
a
##rr
##hy
##th
##mia
##s
were
grade
1
or
2
.
[SEP]
[CLS]
Inter
##rup
##t
and
then
reduce
or
disco
##ntin
##ue
Z
##yd
##eli
##g
as
recommended
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Table
2
:
Ad
##verse
Re
##actions
Report
##ed
in
Clinical
Trials
(
N
=
55
##5
patients
)
a
Includes
the
terms
blood
pressure
increased
and
h
##yper
##tens
##ion
.
[SEP]
[CLS]
5
.
17
Effect
on
Growth
Oral
##ly
inhaled
co
##rt
##ico
##ster
##oids
may
cause
a
reduction
in
growth
velocity
when
administered
to
children
and
adolescent
##s
.
[SEP]
[CLS]
Any
patient
treated
with
at
##y
##pical
anti
##psy
##cho
##tics
should
be
monitored
for
symptoms
of
h
##yper
##gly
##ce
##mia
including
p
##oly
##di
##ps
##ia
,
p
##oly
##uria
,
p
##oly
##pha
##gia
,
and
weakness
.
[SEP]
[CLS]
(
5
.
1
)
[SEP]
[CLS]
I
##mm
##une
system
disorders
:
Al
##ope
##cia
total
##is
.
[SEP]
[CLS]
(
5
.
2
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
T
##hr
##omb
##otic
Events
:
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
for
my
##oc
##ard
##ial
in
##far
##ction
,
cerebral
in
##far
##ction
,
or
other
serious
art
##erial
th
##rom
##boe
##mbo
##lic
events
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
P
##ER
##F
##OR
##AT
##ION
##S
AND
F
##IS
##TU
##LA
##S
,
and
##H
##EM
##OR
##R
##HA
##GE
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
It
is
unknown
whether
T
##R
##U
##L
##IC
##IT
##Y
causes
thy
##roid
C
-
cell
tumors
,
including
me
##du
##llar
##y
thy
##roid
car
##cin
##oma
(
M
##TC
)
,
in
humans
as
human
relevance
of
du
##lag
##lut
##ide
-
induced
rode
##nt
thy
##roid
C
-
cell
tumors
has
not
been
determined
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
,
and
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
1
)
]
.
[SEP]
[CLS]
*
In
##fect
##ions
:
Monitor
patients
for
fever
and
infections
and
evaluate
promptly
(
5
.
2
)
.
[SEP]
[CLS]
Do
##se
modifications
or
temporary
delay
of
treatment
due
to
an
adverse
reaction
occurred
in
199
/
35
##9
patients
(
55
%
)
receiving
IN
##L
##Y
##TA
and
220
/
35
##5
patients
(
62
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
(
5
.
2
)
*
Ana
##phy
##lax
##is
and
In
##fusion
Re
##actions
:
Se
##vere
and
an
##aph
##yla
##ctic
reactions
have
occurred
;
monitor
clinical
##ly
and
disco
##ntin
##ue
T
##RE
##AN
##DA
.
[SEP]
[CLS]
Table
1
:
Ad
##verse
Re
##actions
in
Study
1
and
2
reported
for
T
##EC
##FI
##DE
##RA
240
mg
B
##ID
at
>
=
2
%
higher
incidence
than
place
##bo
T
##EC
##FI
##DE
##RA
N
=
76
##9
%
Place
##bo
N
=
77
##1
%
F
##lus
##hing
40
6
Abd
##omi
##nal
pain
18
10
Di
##ar
##r
##hea
14
11
Na
##use
##a
12
9
V
##omi
##ting
9
5
P
##ru
##rit
##us
8
4
Ra
##sh
8
3
Album
##in
urine
present
6
4
E
##ry
##them
##a
5
1
D
##ys
##pe
##ps
##ia
5
3
As
##par
##tate
amino
##tra
##ns
##fer
##ase
increased
4
2
L
##ymph
##ope
##nia
2
<
1
Gas
##tro
##int
##est
##inal
T
##EC
##FI
##DE
##RA
caused
G
##I
events
(
e
.
g
.
,
nausea
,
vomit
##ing
,
di
##ar
##r
##hea
,
abdominal
pain
,
and
d
##ys
##pe
##ps
##ia
)
.
[SEP]
[CLS]
Ad
##verse
reactions
from
the
MC
##L
trial
(
N
=
111
)
using
single
agent
I
##MB
##R
##U
##VI
##CA
560
mg
daily
occurring
at
a
rate
of
>
=
10
%
are
presented
in
Table
1
.
[SEP]
[CLS]
J
##E
##V
##TA
##NA
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
The
association
with
T
##RE
##AN
##DA
therapy
has
not
been
determined
.
[SEP]
[CLS]
(
5
.
2
)
*
He
##pa
##to
##to
##xi
##city
may
occur
with
use
of
S
##IR
##TU
##RO
.
[SEP]
[CLS]
Table
3
identifies
adverse
reactions
greater
than
or
equal
to
10
%
for
all
grades
and
grades
3
or
4
for
the
Phase
1
/
2
C
##ML
safety
population
.
[SEP]
[CLS]
A
total
of
62
%
of
patients
were
female
and
46
%
were
Asian
.
[SEP]
[CLS]
O
##ste
##one
##c
##rosis
of
the
J
##aw
ON
##J
has
been
reported
in
the
o
##ste
##op
##oro
##sis
clinical
trial
program
in
patients
treated
with
Pro
##lia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
D
##U
##AV
##EE
is
a
prescription
medicine
that
contains
a
mixture
of
est
##rogen
##s
and
b
##azed
##ox
##ife
##ne
.
[SEP]
[CLS]
The
commonly
reported
adverse
events
were
falls
(
24
%
)
,
u
##rina
##ry
tract
infections
(
15
%
)
,
headache
(
13
%
)
,
s
##ync
##ope
(
13
%
)
,
and
di
##zzi
##ness
(
10
%
)
.
[SEP]
[CLS]
Table
6
:
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
in
>
=
1
%
of
Pat
##ients
T
##reate
##d
for
D
##V
##T
and
P
##E
in
the
AM
##PL
##IF
##Y
Study
E
##L
##I
##Q
##UI
##SN
=
26
##7
##6
##n
(
%
)
En
##ox
##apa
##rin
/
War
##fari
##n
##N
=
26
##8
##9
##n
(
%
)
E
##pis
##ta
##xi
##s
77
(
2
.
9
)
146
(
5
.
4
)
Con
##tus
##ion
49
(
1
.
8
)
97
(
3
.
6
)
He
##mat
##uria
46
(
1
.
7
)
102
(
3
.
8
)
Men
##or
##r
##ha
##gia
38
(
1
.
4
)
30
(
1
.
1
)
He
##mat
##oma
35
(
1
.
3
)
76
(
2
.
8
)
He
##mo
##pt
##ys
##is
32
(
1
.
2
)
31
(
1
.
2
)
Re
##ct
##al
hem
##or
##r
##hage
26
(
1
.
0
)
39
(
1
.
5
)
G
##ing
##ival
bleeding
26
(
1
.
0
)
50
(
1
.
9
)
AM
##PL
##IF
##Y
-
E
##XT
Study
The
mean
duration
of
exposure
to
E
##L
##I
##Q
##UI
##S
was
approximately
330
days
and
to
place
##bo
was
312
days
in
the
AM
##PL
##IF
##Y
-
E
##XT
study
.
[SEP]
[CLS]
In
Trial
2
,
card
##io
##my
##op
##athy
occurred
in
9
%
(
5
/
55
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
and
in
none
of
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
In
##jection
site
pain
has
also
been
reported
.
[SEP]
[CLS]
Eva
##lu
##ate
patients
for
tuberculosis
risk
factors
and
test
for
late
##nt
infection
prior
to
in
##iti
##ating
S
##IM
##PO
##NI
ARIA
and
periodically
during
therapy
.
[SEP]
[CLS]
In
Trial
2
,
treatment
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
resulted
in
an
increased
incidence
of
deep
ve
##nous
th
##rom
##bos
##is
(
D
##V
##T
)
and
pulmonary
em
##bol
##ism
(
P
##E
)
:
7
%
(
4
/
55
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
compared
with
none
of
the
53
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
Man
##age
by
dose
reduction
or
disco
##ntin
##uation
until
symptoms
resolve
,
and
consider
use
of
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
H
##y
##pot
##ens
##ion
:
Before
in
##iti
##ating
J
##AR
##DI
##AN
##CE
assess
and
correct
volume
status
in
patients
with
re
##nal
imp
##air
##ment
,
the
elderly
,
in
patients
with
low
s
##ys
##to
##lic
blood
pressure
,
and
in
patients
on
di
##ure
##tics
.
[SEP]
[CLS]
Case
##s
of
peripheral
motor
ne
##uro
##pathy
have
also
been
reported
.
[SEP]
[CLS]
In
Trial
1
,
the
incidence
of
fever
(
serious
and
non
-
serious
)
was
28
%
in
patients
treated
with
T
##AF
##IN
##LA
##R
and
10
%
in
patients
treated
with
da
##car
##ba
##zine
.
[SEP]
[CLS]
In
##d
##well
##ing
e
##pid
##ural
or
in
##tra
##the
##cal
cat
##he
##ters
should
not
be
removed
earlier
than
24
hours
after
the
last
administration
of
E
##L
##I
##Q
##UI
##S
.
[SEP]
[CLS]
Consider
em
##pi
##ric
anti
-
fun
##gal
therapy
in
patients
at
risk
for
invasive
fun
##gal
infections
who
develop
severe
systemic
illness
.
[SEP]
[CLS]
Pat
##ients
should
be
instructed
to
report
any
symptoms
suggest
##ive
of
end
##op
##ht
##hal
##mit
##is
or
re
##tina
##l
detachment
without
delay
and
should
be
managed
appropriately
.
[SEP]
[CLS]
The
most
common
adverse
reaction
resulting
in
permanent
disco
##ntin
##uation
was
p
##yre
##xia
(
4
%
)
.
[SEP]
[CLS]
For
patients
at
risk
for
chronic
##ally
reduced
re
##nal
function
(
for
example
,
age
>
60
years
,
h
##yper
##tens
##ion
or
diabetes
)
,
estimate
the
g
##lo
##mer
##ular
fi
##ltration
rate
(
G
##F
##R
)
through
laboratory
testing
.
[SEP]
[CLS]
Ad
##verse
reactions
that
led
to
treatment
disco
##ntin
##uation
in
2
or
more
patients
with
classical
H
##L
or
s
##AL
##CL
were
peripheral
sensory
ne
##uro
##pathy
(
8
%
)
and
peripheral
motor
ne
##uro
##pathy
(
3
%
)
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
commonly
reported
adverse
reactions
(
greater
than
35
%
of
subjects
)
in
clinical
trials
in
adult
subjects
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
and
R
##E
##BE
##TO
##L
were
fatigue
,
an
##emia
,
nausea
,
headache
and
d
##ys
##ge
##us
##ia
.
[SEP]
[CLS]
Eva
##lu
##ate
abnormal
serum
liver
tests
with
repeat
testing
within
3
to
5
days
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Me
##rc
##k
Sharp
&
Do
##hm
##e
Corp
.
,
a
subsidiary
of
Me
##rc
##k
&
Co
.
,
Inc
.
,
at
1
-
87
##7
-
88
##8
-
42
##31
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Among
the
71
##2
patients
who
participated
in
this
open
-
label
extension
study
,
the
mean
age
of
the
population
was
56
.
4
years
(
range
from
23
to
88
years
)
.
[SEP]
[CLS]
The
most
common
laboratory
abnormal
##ities
(
>
20
%
)
are
an
##emia
,
elevated
al
##kal
##ine
p
##hos
##pha
##tase
,
h
##yper
##tri
##gly
##cer
##ide
##mia
,
l
##ymph
##ope
##nia
,
h
##yper
##cho
##les
##tero
##lem
##ia
,
h
##yper
##gly
##ce
##mia
,
elevated
AS
##T
,
h
##y
##pop
##hos
##phate
##mia
,
elevated
AL
##T
and
h
##y
##po
##kal
##emia
.
[SEP]
[CLS]
(
5
.
1
)
*
Para
##dox
##ical
br
##on
##cho
##sp
##as
##m
:
Disco
##ntin
##ue
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
and
consider
other
treatments
if
para
##dox
##ical
br
##on
##cho
##sp
##as
##m
occurs
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
em
##pi
##ric
anti
##fu
##nga
##l
therapy
should
be
considered
while
a
diagnostic
work
##up
is
being
performed
.
[SEP]
[CLS]
(
2
.
2
)
(
4
)
(
5
.
1
)
*
H
##yper
##sen
##si
##ti
##vity
:
Se
##vere
h
##yper
##sen
##si
##ti
##vity
reactions
can
occur
.
[SEP]
[CLS]
Table
5
:
Inc
##iden
##ce
(
%
)
of
Pat
##ients
with
Pro
##tein
##uria
in
the
Fi
##xed
-
dose
Clinical
Studies
PR
##IS
##TI
##Q
Place
##bo
50
mg
100
mg
200
mg
400
mg
Pro
##tein
##uria
4
6
8
5
7
Vita
##l
sign
changes
Table
6
sum
##mar
##izes
the
changes
that
were
observed
in
place
##bo
-
controlled
,
short
-
term
,
pre
-
marketing
studies
with
PR
##IS
##TI
##Q
in
patients
with
MD
##D
(
doses
50
to
400
mg
)
.
[SEP]
[CLS]
Treatment
of
late
##nt
tuberculosis
infection
prior
to
therapy
with
T
##NF
-
block
##ers
has
been
shown
to
reduce
the
risk
of
tuberculosis
react
##ivation
during
therapy
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
H
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
following
Da
##T
##sca
##n
administration
.
[SEP]
[CLS]
In
255
H
##A
##E
patients
treated
with
in
##tra
##ven
##ous
or
sub
##cut
##aneous
K
##AL
##BI
##TO
##R
in
clinical
studies
,
10
patients
(
4
%
)
experienced
an
##aph
##yla
##xi
##s
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
CA
##PS
:
The
most
common
adverse
reactions
greater
than
10
%
reported
by
patients
with
CA
##PS
treated
with
IL
##AR
##IS
are
na
##so
##pha
##ryn
##git
##is
,
di
##ar
##r
##hea
,
in
##fluenza
,
headache
and
nausea
.
[SEP]
[CLS]
There
were
no
deaths
in
the
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
600
m
##c
##g
dose
group
or
in
the
sa
##lm
##eter
##ol
active
control
group
.
[SEP]
[CLS]
S
##ym
##pt
##oms
include
fever
,
chill
##s
,
art
##hra
##l
##gia
,
my
##al
##gia
,
facial
flush
##ing
,
facial
ed
##ema
,
vomit
##ing
,
weakness
,
short
##ness
of
breath
,
h
##y
##pot
##ens
##ion
,
s
##ync
##ope
,
chest
tight
##ness
,
or
an
##gin
##a
.
[SEP]
[CLS]
The
most
common
adverse
reaction
leading
to
A
##FI
##NI
##TO
##R
dose
adjustment
was
s
##tom
##ati
##tis
.
[SEP]
[CLS]
(
2
.
2
,
5
.
4
)
*
Depression
:
Depression
and
su
##icidal
##ity
have
been
reported
in
trials
with
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
Sub
##jects
received
1
in
##hala
##tion
once
daily
of
the
following
:
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
,
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
,
flu
##tica
##son
##e
fur
##oat
##e
/
v
##ila
##nter
##ol
50
m
##c
##g
/
25
m
##c
##g
,
or
v
##ila
##nter
##ol
25
m
##c
##g
.
[SEP]
[CLS]
Treatment
-
experienced
,
In
##te
##gra
##se
Strand
Transfer
In
##hibit
##or
-
experienced
Sub
##jects
:
The
most
common
treatment
-
emerge
##nt
laboratory
abnormal
##ities
(
greater
than
5
%
for
Grades
2
to
4
combined
)
observed
in
VI
##K
##ING
-
3
at
Week
48
were
elevated
AL
##T
(
10
%
)
.
[SEP]
[CLS]
5
.
6
Human
Album
##in
This
product
contains
album
##in
,
a
derivative
of
human
blood
.
[SEP]
[CLS]
5
.
9
My
##ast
##hen
##ia
G
##ra
##vis
To
##via
##z
should
be
used
with
caution
in
patients
with
my
##ast
##hen
##ia
g
##ra
##vis
,
a
disease
characterized
by
decreased
ch
##olin
##ergic
activity
at
the
ne
##uro
##mus
##cular
junction
.
[SEP]
[CLS]
In
the
place
##bo
controlled
ad
##junct
##ive
therapy
trials
in
patients
with
partial
-
onset
seizure
##s
(
Study
3
,
Study
4
and
Study
5
)
,
102
##1
patients
received
AP
##TI
##OM
.
[SEP]
[CLS]
The
other
cases
represented
a
variety
of
ma
##li
##gna
##ncies
,
including
rare
ma
##li
##gna
##ncies
that
are
usually
associated
with
im
##mu
##nos
##up
##press
##ion
,
and
ma
##li
##gna
##ncies
that
are
not
usually
observed
in
children
and
adolescent
##s
.
[SEP]
[CLS]
There
have
been
post
-
marketing
reports
of
serious
breathing
difficulties
,
including
respiratory
failure
,
in
patients
with
c
##er
##vic
##al
d
##ys
##ton
##ia
treated
with
b
##ot
##ulin
##um
to
##xin
products
.
[SEP]
[CLS]
Eva
##lu
##ate
patients
with
symptoms
compatible
with
pan
##cre
##ati
##tis
to
establish
a
diagnosis
.
[SEP]
[CLS]
Most
adverse
events
were
mild
in
severity
and
trans
##ient
in
nature
,
and
all
patients
recovered
without
treatment
.
[SEP]
[CLS]
There
may
be
new
information
.
[SEP]
[CLS]
Pat
##ients
with
New
York
Heart
Association
Class
III
and
IV
heart
failure
,
recent
my
##oc
##ard
##ial
in
##far
##ction
,
and
conduct
##ion
abnormal
##ities
un
##con
##tro
##lled
by
medications
were
not
eligible
for
the
clinical
trials
.
[SEP]
[CLS]
None
of
the
subjects
tested
positive
for
neutral
##izing
antibodies
.
[SEP]
[CLS]
Most
of
these
events
were
not
specific
to
the
injection
site
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
7
)
]
.
[SEP]
[CLS]
In
clinical
studies
,
subjects
with
impaired
re
##nal
function
were
more
likely
to
have
greater
reduction
##s
in
serum
calcium
levels
compared
to
subjects
with
normal
re
##nal
function
.
[SEP]
[CLS]
Data
are
not
available
to
determine
whether
the
rate
of
death
in
patients
with
CO
##PD
is
increased
by
long
-
acting
beta
2
-
ad
##rene
##rg
##ic
ago
##nist
##s
.
[SEP]
[CLS]
6
.
1
Ad
##verse
Re
##actions
in
Clinical
Trials
Ad
##verse
reactions
were
evaluated
for
1778
patients
treated
with
D
##AL
##VA
##NC
##E
and
122
##4
patients
treated
with
com
##par
##ator
anti
##ba
##cter
##ial
drugs
in
seven
Phase
2
and
Phase
3
clinical
trials
.
[SEP]
[CLS]
5
.
7
Extra
##vas
##ation
In
##ju
##ry
T
##RE
##AN
##DA
extra
##vas
##ations
have
been
reported
in
post
marketing
resulting
in
hospital
##izations
from
er
##yt
##hem
##a
,
marked
swelling
,
and
pain
.
[SEP]
[CLS]
On
average
,
pain
scores
returned
to
base
##line
by
the
end
of
the
treatment
day
and
then
remained
at
or
below
base
##line
levels
.
[SEP]
[CLS]
5
.
3
L
##ymph
##ope
##nia
T
##EC
##FI
##DE
##RA
may
decrease
l
##ymph
##oc
##yte
counts
.
[SEP]
[CLS]
(
5
.
1
)
*
In
##fect
##ions
:
Monitor
for
fever
and
other
signs
of
infection
and
treat
promptly
.
[SEP]
[CLS]
Therefore
,
a
lower
dose
of
insulin
or
insulin
secret
##ago
##gue
may
be
required
to
minimize
the
risk
of
h
##y
##po
##gly
##ce
##mia
when
used
in
combination
with
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
[
See
Clinical
Studies
(
14
)
.
]
[SEP]
[CLS]
Do
not
administer
CO
##ME
##TR
##I
##Q
to
patients
with
severe
hem
##or
##r
##hage
[
See
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Pat
##ients
were
treated
with
p
##em
##et
##re
##xed
500
mg
/
m
##2
followed
after
30
minutes
by
c
##is
##p
##lat
##in
75
mg
/
m
##2
every
three
weeks
for
a
maximum
of
six
treatment
courses
.
[SEP]
[CLS]
These
adverse
reactions
occurred
more
frequently
among
patients
with
a
base
##line
history
of
h
##yper
##tens
##ion
and
among
patients
receiving
con
##com
##ita
##nt
co
##rt
##ico
##ster
##oids
and
non
-
s
##tero
##idal
anti
-
inflammatory
drugs
.
[SEP]
[CLS]
Place
##bo
-
Control
##led
Experience
The
most
commonly
observed
adverse
reactions
(
those
occurring
at
an
incidence
of
greater
than
5
%
in
the
NO
##RT
##H
##ER
##A
group
and
with
at
least
a
3
%
greater
incidence
in
the
NO
##RT
##H
##ER
##A
group
than
in
the
place
##bo
group
)
in
NO
##RT
##H
##ER
##A
-
treated
patients
during
the
three
place
##bo
-
controlled
trials
were
headache
,
di
##zzi
##ness
,
nausea
,
h
##yper
##tens
##ion
.
[SEP]
[CLS]
Pat
##ients
with
risk
factors
for
diabetes
me
##lli
##tus
(
e
.
g
.
,
o
##besity
,
family
history
of
diabetes
)
who
are
starting
treatment
with
at
##y
##pical
anti
##psy
##cho
##tics
should
undergo
fast
##ing
blood
glucose
testing
at
the
beginning
of
treatment
and
periodically
during
treatment
.
[SEP]
[CLS]
(
5
.
6
)
*
Monitor
for
su
##icidal
thoughts
or
behaviors
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
are
discussed
in
greater
detail
in
other
sections
of
the
label
##ing
:
*
Gas
##tro
##int
##est
##inal
toxicity
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
He
##pa
##to
##bil
##iary
disorders
:
j
##au
##ndi
##ce
,
he
##pa
##tom
##eg
##aly
.
[SEP]
[CLS]
Grade
3
-
4
low
serum
p
##hos
##phorus
(
7
%
)
and
low
potassium
(
5
%
)
occurred
at
a
greater
than
or
equal
to
5
%
rate
in
the
Z
##Y
##TI
##GA
arm
.
[SEP]
[CLS]
Event
PR
##AD
##A
##X
##A
150
mg
##N
=
60
##5
##9
##n
(
%
/
year
b
)
War
##fari
##n
##N
=
59
##9
##8
##n
(
%
/
year
b
)
PR
##AD
##A
##X
##A
150
mg
##v
##s
.
[SEP]
[CLS]
Information
on
the
consequences
,
re
##vers
##ibility
,
time
to
onset
,
and
path
##op
##hy
##sio
##logy
of
the
skin
abnormal
##ities
remains
incomplete
.
[SEP]
[CLS]
(
2
.
2
,
5
.
6
)
*
Pan
##cre
##ati
##tis
:
El
##eva
##tions
of
lip
##ase
and
pan
##cre
##ati
##tis
can
occur
.
[SEP]
[CLS]
Treatment
disco
##ntin
##uation
due
to
adverse
reactions
occurred
in
35
/
1300
(
2
.
7
%
)
of
patients
receiving
Te
##f
##lar
##o
and
48
/
129
##7
(
3
.
7
%
)
of
patients
receiving
com
##par
##ator
drugs
with
the
most
common
adverse
reactions
leading
to
disco
##ntin
##uation
being
h
##yper
##sen
##si
##ti
##vity
for
both
treatment
groups
at
a
rate
of
0
.
3
%
in
the
Te
##f
##lar
##o
group
and
0
.
5
%
in
com
##par
##ator
group
.
[SEP]
[CLS]
N
##er
##vous
system
disorders
:
c
##ere
##bella
##r
syndrome
,
cerebral
hem
##or
##r
##hage
,
con
##vu
##ls
##ion
,
g
##ait
disturbance
,
in
##tra
##c
##rani
##al
pressure
increased
,
ps
##ych
##omo
##tor
skills
impaired
,
pyramid
##al
tract
syndrome
,
so
##m
##no
##len
##ce
.
[SEP]
[CLS]
Pat
##ients
were
ineligible
if
AS
##T
and
/
or
AL
##T
>
=
2
.
5
*
U
##L
##N
and
patients
were
excluded
if
they
had
liver
meta
##sta
##ses
.
[SEP]
[CLS]
The
adverse
reactions
described
in
Table
2
were
identified
in
750
patients
treated
in
Study
1
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
(
4
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
V
##as
##cular
risks
:
Stop
Nat
##azi
##a
if
a
th
##rom
##bot
##ic
event
occurs
.
[SEP]
[CLS]
I
n
##fect
##ions
and
in
##fest
##ations
:
cry
##pt
##oc
##oc
##cal
cut
##aneous
infection
,
enter
##ov
##ira
##l
en
##ce
##pha
##lit
##is
,
p
##har
##yn
##git
##is
,
pneumonia
,
se
##psis
,
fur
##un
##cle
,
infectious
he
##pa
##titis
,
r
##ash
pu
##st
##ular
,
sub
##cut
##aneous
a
##bs
##cess
.
[SEP]
[CLS]
It
is
predominantly
on
or
around
the
lips
or
in
the
nail
beds
of
the
fingers
or
toes
,
but
more
widespread
involvement
of
the
face
and
legs
has
also
been
reported
.
[SEP]
[CLS]
In
##hale
##d
co
##rt
##ico
##ster
##oids
should
be
used
with
caution
,
if
at
all
,
in
patients
with
active
or
q
##ui
##es
##cent
tuberculosis
infections
of
the
respiratory
tract
;
systemic
fun
##gal
,
bacterial
,
viral
,
or
para
##sitic
infections
;
or
o
##cular
her
##pes
simple
##x
.
[SEP]
[CLS]
Upper
respiratory
tract
infection
was
the
most
common
adverse
reaction
reported
in
the
trial
through
Week
24
occurring
in
6
.
5
%
of
S
##IM
##PO
##NI
ARIA
-
treated
patients
as
compared
with
7
.
6
%
of
control
-
treated
patients
,
respectively
.
[SEP]
[CLS]
The
most
common
adverse
event
leading
to
disco
##ntin
##uation
,
h
##y
##pot
##ens
##ion
/
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
,
was
reported
by
0
.
4
%
(
8
/
214
##6
)
patients
random
##ized
to
Ed
##ar
##bi
40
mg
or
80
mg
compared
to
0
%
(
0
/
80
##1
)
patients
random
##ized
to
place
##bo
.
[SEP]
[CLS]
If
a
patient
develops
skin
disco
##lora
##tion
,
serious
consideration
should
be
given
to
an
alternative
treatment
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
with
NO
##RT
##H
##ER
##A
are
included
in
more
detail
in
the
Warning
##s
and
Pre
##ca
##ution
##s
section
of
the
label
:
*
Su
##pine
H
##yper
##tens
##ion
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
H
##yper
##py
##re
##xia
and
Con
##fusion
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
May
ex
##ace
##rb
##ate
existing
is
##che
##mic
heart
disease
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
E
##X
##CE
##RP
##T
:
Head
##ache
,
di
##zzi
##ness
,
nausea
,
h
##yper
##tens
##ion
,
and
fatigue
(
greater
than
5
%
)
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Lund
##beck
at
1
-
800
-
45
##5
-
114
##1
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Pat
##ients
with
major
risk
factors
for
decreased
bone
mineral
content
,
such
as
prolonged
im
##mo
##bil
##ization
,
family
history
of
o
##ste
##op
##oro
##sis
,
post
##men
##op
##aus
##al
status
,
tobacco
use
,
advanced
age
,
poor
nutrition
,
or
chronic
use
of
drugs
that
can
reduce
bone
mass
(
e
.
g
.
,
anti
##con
##vu
##ls
##ants
,
oral
co
##rt
##ico
##ster
##oids
)
should
be
monitored
and
treated
with
established
standards
of
care
.
[SEP]
[CLS]
Forty
percent
of
patients
had
elevated
u
##ric
acid
levels
on
study
including
13
%
with
values
above
10
mg
/
d
##L
.
[SEP]
[CLS]
Ad
##verse
events
leading
to
dose
reduction
occurred
in
11
%
of
patients
.
[SEP]
[CLS]
The
safety
and
efficacy
of
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
in
patients
with
as
##th
##ma
have
not
been
established
.
[SEP]
[CLS]
Ch
##em
##otherapy
was
given
by
in
##tra
##ven
##ous
in
##fusion
every
3
weeks
for
up
to
6
cycles
,
in
the
absence
of
dose
-
limiting
ch
##em
##otherapy
-
related
toxic
##ities
.
[SEP]
[CLS]
There
is
no
known
treatment
for
established
cases
of
TD
,
although
the
syndrome
may
re
##mit
,
partially
or
completely
,
if
anti
##psy
##cho
##tic
treatment
is
withdrawn
.
[SEP]
[CLS]
(
5
.
4
)
*
Life
-
threatening
para
##dox
##ical
br
##on
##cho
##sp
##as
##m
can
occur
.
[SEP]
[CLS]
The
safety
of
re
##suming
T
##NF
-
block
##ers
after
H
##B
##V
react
##ivation
has
been
controlled
is
not
known
.
[SEP]
[CLS]
Women
enrolled
in
Studies
1
and
2
received
calcium
(
600
-
1200
mg
)
and
vitamin
D
(
200
-
400
I
##U
)
daily
,
while
women
in
Studies
3
and
4
received
no
calcium
and
vitamin
D
supplement
##ation
as
part
of
the
protocol
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
Because
adverse
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
The
changes
in
mean
serum
c
##rea
##tin
##ine
were
similar
to
those
observed
in
adults
.
[SEP]
[CLS]
b
Of
the
reported
adverse
drug
reactions
none
were
serious
.
[SEP]
[CLS]
The
safety
of
re
##ini
##tia
##ting
K
##y
##p
##rol
##is
therapy
in
patients
previously
experiencing
PR
##ES
is
not
known
.
[SEP]
[CLS]
*
Fat
##al
an
##aph
##yla
##xi
##s
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
Pro
##tein
##uria
(
all
grades
)
occurred
in
52
%
of
subjects
receiving
ST
##RI
##BI
##LD
,
41
%
of
subjects
receiving
AT
##RI
##PL
##A
,
and
42
%
of
subjects
receiving
AT
##V
+
R
##TV
+
T
##R
##U
##VA
##DA
.
[SEP]
[CLS]
A
total
of
225
patients
were
treated
with
1
,
07
##6
doses
of
30
mg
F
##IR
##A
##Z
##Y
##R
for
98
##7
attacks
of
acute
H
##A
##E
.
[SEP]
[CLS]
If
PM
##L
is
confirmed
,
consider
disco
##ntin
##uation
of
im
##mu
##nos
##up
##press
##ant
therapy
,
including
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
(
5
.
2
)
*
Ang
##io
##ede
##ma
:
Pat
##ients
taking
con
##com
##ita
##nt
AC
##E
inhibitor
therapy
may
be
at
increased
risk
for
an
##gio
##ede
##ma
.
[SEP]
[CLS]
(
5
.
4
)
5
.
1
Inc
##reased
Risk
of
T
##hr
##omb
##otic
Events
after
Pre
##mat
##ure
Disco
##ntin
##uation
Pre
##mat
##ure
disco
##ntin
##uation
of
any
oral
anti
##coa
##gu
##lant
,
including
E
##L
##I
##Q
##UI
##S
,
in
the
absence
of
adequate
alternative
anti
##coa
##gu
##lation
increases
the
risk
of
th
##rom
##bot
##ic
events
.
[SEP]
[CLS]
Ren
##al
and
u
##rina
##ry
disorders
-
U
##rina
##ry
retention
.
[SEP]
[CLS]
Study
2
enrolled
patients
with
a
median
age
of
17
years
(
6
months
to
85
years
)
;
64
%
were
male
,
and
the
underlying
ma
##li
##gna
##ncies
were
o
##ste
##ogenic
sa
##rc
##oma
in
32
%
,
and
le
##uke
##mia
or
l
##ymph
##oma
in
62
%
of
patients
.
[SEP]
[CLS]
Some
of
these
infections
have
been
severe
(
e
.
g
.
,
leading
to
se
##psis
,
he
##pa
##tic
failure
)
or
fatal
.
[SEP]
[CLS]
Use
with
caution
in
patients
with
pro
##static
h
##yper
##p
##lasia
or
bladder
-
neck
o
##bs
##truction
and
ins
##truct
patients
to
consult
a
physician
immediately
if
this
occurs
.
[SEP]
[CLS]
Pro
##cedural
Co
##mp
##lication
##s
:
con
##tus
##ion
.
[SEP]
[CLS]
SP
##RI
##NT
-
1
(
subjects
who
were
previously
un
##tre
##ated
)
evaluated
the
use
of
VI
##CT
##RE
##L
##IS
in
combination
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
with
or
without
a
four
-
week
lead
-
in
period
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
compared
to
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
.
[SEP]
[CLS]
In
post
##market
##ing
experience
with
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
,
immediate
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
,
an
##gio
##ede
##ma
(
including
swelling
of
the
lips
)
,
u
##rt
##ica
##ria
,
r
##ash
,
br
##on
##cho
##sp
##as
##m
,
or
it
##ching
have
been
reported
.
[SEP]
[CLS]
There
is
neither
scientific
rational
##e
for
reversal
nor
experience
with
systemic
hem
##ost
##atic
##s
(
des
##mo
##press
##in
and
a
##p
##rot
##ini
##n
)
in
individuals
receiving
a
##pi
##xa
##ban
.
[SEP]
[CLS]
H
##y
##pop
##hos
##phate
##mia
and
o
##ste
##oma
##la
##cia
secondary
to
pro
##ximal
re
##nal
tub
##ulo
##pathy
should
be
considered
in
patients
at
risk
of
re
##nal
d
##ys
##function
who
present
with
persistent
or
worse
##ning
bone
or
muscle
symptoms
while
receiving
products
containing
ten
##of
##ov
##ir
D
##F
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
If
CD
##AD
is
suspected
or
confirmed
,
ongoing
anti
##ba
##cter
##ial
use
not
directed
against
C
.
di
##ff
##ici
##le
should
be
discontinued
,
if
possible
.
[SEP]
[CLS]
Do
not
restart
M
##U
##LT
##A
##Q
in
patients
without
another
explanation
for
the
observed
liver
injury
.
[SEP]
[CLS]
Approximately
half
of
the
patients
(
54
%
)
were
male
.
[SEP]
[CLS]
J
##E
##V
##TA
##NA
treatment
delay
or
disco
##ntin
##uation
may
be
necessary
.
[SEP]
[CLS]
Similar
SV
##R
rates
were
reported
in
subjects
who
were
random
##ized
to
receive
rib
##avi
##rin
dose
reduction
compared
to
subjects
who
were
random
##ized
to
receive
an
E
##SA
.
[SEP]
[CLS]
The
safety
of
the
combination
of
VI
##CT
##RE
##L
##IS
800
mg
three
times
daily
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
was
assessed
in
209
##5
subjects
with
chronic
he
##pa
##titis
C
in
one
Phase
2
,
open
-
label
trial
and
two
Phase
3
,
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
clinical
trials
.
[SEP]
[CLS]
Pre
##s
##cribe
##rs
and
patients
should
be
alert
for
signs
and
symptoms
of
acute
narrow
-
angle
g
##lau
##com
##a
(
e
.
g
.
,
eye
pain
or
discomfort
,
blurred
vision
,
visual
ha
##los
or
colored
images
in
association
with
red
eyes
from
con
##junct
##ival
congestion
and
corn
##eal
ed
##ema
)
.
[SEP]
[CLS]
Disco
##ntin
##ue
S
##IM
##PO
##NI
ARIA
if
a
patient
develops
a
serious
infection
,
an
op
##port
##uni
##stic
infection
,
or
se
##psis
.
[SEP]
[CLS]
In
three
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
trials
lasting
up
to
3
months
in
duration
,
the
mean
age
of
patients
was
56
.
4
years
(
range
from
23
to
88
years
)
.
[SEP]
[CLS]
(
5
.
2
)
*
T
##hr
##omb
##oe
##mbo
##lic
Co
##mp
##lication
##s
:
Portal
vein
th
##rom
##bos
##is
has
been
reported
in
patients
with
chronic
liver
disease
receiving
PR
##OM
##AC
##TA
.
[SEP]
[CLS]
5
.
5
H
##yper
##sen
##si
##ti
##vity
Ser
##ious
acute
h
##yper
##sen
##si
##ti
##vity
reactions
(
e
.
g
.
,
u
##rt
##ica
##ria
,
an
##gio
##ede
##ma
)
have
been
observed
during
combination
therapy
with
VI
##CT
##RE
##L
##IS
,
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
.
[SEP]
[CLS]
Most
Common
Ad
##verse
Re
##actions
The
most
common
adverse
reactions
in
patients
treated
with
D
##AL
##VA
##NC
##E
were
nausea
(
5
.
5
%
)
,
headache
(
4
.
7
%
)
,
and
di
##ar
##r
##hea
(
4
.
4
%
)
.
[SEP]
[CLS]
Most
adverse
reactions
were
mild
to
moderate
in
intensity
and
resolved
spontaneous
##ly
.
[SEP]
[CLS]
In
one
of
the
3
cases
an
alternate
et
##iology
was
identified
to
explain
the
rise
in
liver
enzyme
(
acute
viral
he
##pa
##titis
)
.
[SEP]
[CLS]
Pro
##st
##hetic
heart
valves
:
E
##L
##I
##Q
##UI
##S
use
not
recommended
.
[SEP]
[CLS]
If
resolution
of
the
R
##P
##ED
is
documented
on
repeat
op
##ht
##hal
##mo
##logical
evaluation
within
3
weeks
,
resume
tram
##eti
##ni
##b
at
a
lower
dose
level
.
[SEP]
[CLS]
(
5
.
3
)
*
Oral
ul
##cer
##ation
:
Mouth
ul
##cer
##s
,
s
##tom
##ati
##tis
,
and
oral
m
##uc
##os
##itis
are
common
.
[SEP]
[CLS]
(
2
.
1
)
(
5
.
2
)
*
Con
##tra
##ind
##ica
##ted
if
history
of
severe
h
##yper
##sen
##si
##ti
##vity
reactions
to
J
##E
##V
##TA
##NA
or
to
drugs
formulated
with
p
##oly
##sor
##bate
80
.
[SEP]
[CLS]
The
adverse
reaction
profile
was
similar
to
that
for
adults
.
[SEP]
[CLS]
Consider
whether
to
restart
K
##y
##p
##rol
##is
based
on
a
benefit
/
risk
assessment
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
,
Warning
##s
and
Pre
##ca
##ution
##s
-
Card
##iac
To
##xi
##ci
##ties
(
5
.
1
)
,
P
##ul
##mona
##ry
To
##xi
##city
(
5
.
4
)
,
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
Di
##zzi
##ness
,
so
##m
##no
##len
##ce
,
fatigue
,
and
ins
##om
##nia
appeared
to
show
a
dose
relationship
.
[SEP]
[CLS]
c
n
(
%
)
indicates
number
of
patients
and
percent
.
[SEP]
[CLS]
The
most
common
laboratory
abnormal
##ities
(
incidence
>
=
50
%
)
were
h
##yper
##cho
##les
##tero
##lem
##ia
,
h
##yper
##tri
##gly
##cer
##ide
##mia
,
and
an
##emia
.
[SEP]
[CLS]
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
D
##Y
##SP
##OR
##T
(
r
)
:
ve
##rt
##igo
,
photo
##ph
##obia
,
in
##fluenza
-
like
illness
,
am
##yo
##tro
##phy
,
burning
sensation
,
facial
par
##esis
,
h
##y
##po
##est
##hesia
,
er
##yt
##hem
##a
,
and
excessive
g
##ran
##ulation
tissue
.
[SEP]
[CLS]
In
all
clinical
studies
,
including
un
##con
##tro
##lled
extension
studies
,
the
exposure
to
G
##IL
##EN
##Y
##A
0
.
5
mg
was
approximately
41
##19
person
-
years
.
[SEP]
[CLS]
breathing
difficulties
can
be
life
threatening
and
there
have
been
reports
of
death
related
to
the
spread
of
to
##xin
effects
.
[SEP]
[CLS]
In
arriving
at
a
diagnosis
,
it
is
important
to
identify
cases
in
which
the
clinical
presentation
includes
both
serious
medical
illness
(
e
.
g
.
,
pneumonia
,
systemic
infection
,
etc
.
)
[SEP]
[CLS]
After
6
cycles
,
patients
remained
on
study
with
no
additional
anti
##can
##cer
treatment
,
and
tumor
assessments
continued
until
documented
disease
progression
.
[SEP]
[CLS]
Single
in
##tra
##per
##ito
##nea
##l
doses
of
bend
##am
##ust
##ine
in
mice
and
rats
administered
during
organ
##ogen
##esis
caused
an
increase
in
re
##sor
##ption
##s
,
v
##is
##cer
##al
ma
##lf
##orm
##ations
,
and
decreased
f
##etal
body
weights
.
[SEP]
[CLS]
Monitor
serum
potassium
levels
periodically
after
in
##iti
##ating
IN
##VO
##KA
##NA
in
patients
with
impaired
re
##nal
function
and
in
patients
pre
##dis
##posed
to
h
##yper
##kal
##emia
due
to
medications
or
other
medical
conditions
.
[SEP]
[CLS]
Pat
##ients
should
be
instructed
to
disco
##ntin
##ue
T
##EC
##FI
##DE
##RA
and
seek
immediate
medical
care
should
they
experience
signs
and
symptoms
of
an
##aph
##yla
##xi
##s
or
an
##gio
##ede
##ma
.
[SEP]
[CLS]
Three
patients
(
2
%
)
died
from
my
##elo
##su
##pp
##ression
-
related
adverse
reactions
;
one
each
from
ne
##ut
##rop
##eni
##c
se
##psis
,
di
##ff
##use
al
##ve
##olar
hem
##or
##r
##hage
with
Grade
3
th
##rom
##bo
##cy
##top
##enia
,
and
pneumonia
from
an
infection
(
C
##M
##V
)
.
[SEP]
[CLS]
The
results
of
these
evaluation
##s
were
consistent
with
a
re
##tina
##l
d
##ys
##tro
##phy
,
including
abnormal
##ities
in
the
electro
##ret
##ino
##gram
of
both
patients
,
with
abnormal
flu
##ores
##ce
##in
an
##gio
##graphy
and
diminished
sensitivity
on
visual
field
testing
in
one
patient
.
[SEP]
[CLS]
5
.
5
Met
##ab
##olic
Changes
At
##y
##pical
anti
##psy
##cho
##tic
drugs
have
been
associated
with
metabolic
changes
that
may
increase
card
##iovascular
/
c
##ere
##bro
##vas
##cular
risk
.
[SEP]
[CLS]
The
majority
of
events
resolved
following
interrupt
##ion
of
B
##L
##IN
##C
##Y
##TO
,
but
some
resulted
in
treatment
disco
##ntin
##uation
.
[SEP]
[CLS]
In
acute
pu
##ru
##lent
conditions
,
s
##tero
##ids
may
mask
infection
or
enhance
existing
infection
.
[SEP]
[CLS]
*
F
##lu
##id
retention
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
Generally
,
adverse
reactions
were
mild
,
not
dose
related
,
and
similar
regardless
of
age
,
gender
,
and
race
.
[SEP]
[CLS]
In
such
children
or
adults
who
have
not
had
these
diseases
or
been
properly
im
##mu
##ni
##zed
,
particular
care
should
be
taken
to
avoid
exposure
.
[SEP]
[CLS]
Pat
##ients
experiencing
new
,
worse
##ning
,
or
re
##current
he
##pa
##to
##to
##xi
##city
may
require
a
delay
,
change
in
dose
,
or
disco
##ntin
##uation
of
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
the
patient
becomes
pregnant
while
receiving
the
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
the
f
##etus
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
5
.
12
Card
##iovascular
Effects
V
##ila
##nter
##ol
,
like
other
beta
##2
-
ago
##nist
##s
,
can
produce
a
clinical
##ly
significant
card
##iovascular
effect
in
some
patients
as
measured
by
increases
in
pulse
rate
,
and
also
cardiac
a
##rr
##hy
##th
##mia
##s
,
such
as
su
##pra
##vent
##ric
##ular
ta
##chy
##card
##ia
and
extra
##sy
##sto
##les
.
[SEP]
[CLS]
These
risks
importantly
may
limit
the
role
of
Ad
##re
##V
##ie
##w
in
the
diagnostic
evaluation
of
patients
with
severe
re
##nal
imp
##air
##ment
.
[SEP]
[CLS]
Fifty
percent
(
50
%
)
of
the
population
were
male
;
81
%
were
White
,
14
%
were
Asian
,
and
3
%
were
Black
or
African
American
.
[SEP]
[CLS]
After
initiation
of
T
##R
##U
##L
##IC
##IT
##Y
,
observe
patients
carefully
for
signs
and
symptoms
of
pan
##cre
##ati
##tis
,
including
persistent
severe
abdominal
pain
.
[SEP]
[CLS]
(
4
)
*
C
##iga
##ret
##te
smoking
increases
the
risk
of
serious
card
##iovascular
events
from
combination
oral
con
##tra
##ceptive
(
CO
##C
)
use
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
in
>
=
1
%
of
XI
##AF
##LE
##X
-
T
##reate
##d
Pat
##ients
with
P
##ey
##ron
##ie
'
s
disease
and
at
a
Greater
Inc
##iden
##ce
than
Place
##bo
After
Up
to
Four
Treatment
Cycle
##s
in
Studies
1
and
2
Combined
a
Includes
:
injection
site
hem
##ato
##ma
and
pen
##ile
hem
##ato
##ma
were
reported
with
the
verb
##ati
##m
term
of
pen
##ile
br
##ui
##sing
or
injection
site
br
##ui
##sing
in
87
%
of
subjects
.
[SEP]
[CLS]
There
were
no
clinical
##ly
meaningful
differences
in
the
incidence
of
adverse
events
following
treatment
with
XI
##AF
##LE
##X
based
on
the
severity
of
base
##line
erect
##ile
d
##ys
##function
or
con
##com
##ita
##nt
p
##hos
##ph
##odies
##tera
##se
type
5
(
PD
##E
##5
)
inhibitor
use
.
[SEP]
[CLS]
The
impact
of
disco
##ntin
##uation
of
and
##rogen
-
de
##p
##ri
##vation
therapy
upon
11
C
-
ch
##olin
##e
P
##ET
imaging
has
not
been
established
[
see
Drug
Inter
##actions
(
7
)
]
.
[SEP]
[CLS]
The
average
age
was
57
years
(
age
range
from
19
to
84
years
)
.
[SEP]
[CLS]
Table
5
shows
the
incidence
of
adverse
reactions
that
were
reported
in
greater
than
or
equal
to
1
%
of
XI
##AF
##LE
##X
-
treated
patients
and
at
a
frequency
greater
than
place
##bo
-
treated
patients
after
up
to
8
injection
##s
in
the
pool
##ed
place
##bo
-
controlled
trials
through
Day
365
.
[SEP]
[CLS]
Treatment
and
Red
##uction
in
the
Risk
of
Re
##cu
##rrence
of
Deep
V
##eno
##us
T
##hr
##omb
##osis
and
P
##ul
##mona
##ry
Em
##bol
##ism
PR
##AD
##A
##X
##A
was
studied
in
43
##8
##7
patients
in
4
pivotal
,
parallel
,
random
##ized
,
double
-
blind
trials
.
[SEP]
[CLS]
The
risk
of
V
##TE
in
women
using
CO
##Cs
has
been
estimated
to
be
3
to
9
per
10
,
000
woman
-
years
.
[SEP]
[CLS]
Because
these
reactions
may
worse
##n
re
##nal
function
,
use
caution
when
in
##iti
##ating
or
es
##cal
##ating
doses
of
T
##R
##U
##L
##IC
##IT
##Y
in
patients
with
re
##nal
imp
##air
##ment
.
[SEP]
[CLS]
5
.
8
Le
##uk
##ope
##nia
,
N
##eu
##tro
##pen
##ia
and
A
##gra
##nu
##loc
##yt
##osis
In
clinical
trial
and
post
##market
##ing
experience
,
events
of
le
##uk
##ope
##nia
/
ne
##ut
##rop
##enia
have
been
reported
temporal
##ly
related
to
anti
##psy
##cho
##tic
agents
.
[SEP]
[CLS]
When
in
##ject
##ing
a
cord
affecting
a
P
##IP
joint
of
the
fifth
finger
,
the
needle
insertion
should
not
be
more
than
2
to
3
mm
in
depth
and
avoid
in
##ject
##ing
more
than
4
mm
di
##stal
to
the
palm
##ar
digital
c
##rease
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
For
these
events
,
the
median
time
to
onset
was
15
days
.
[SEP]
[CLS]
If
signs
and
symptoms
of
ta
##rdi
##ve
d
##ys
##kin
##esi
##a
appear
in
a
patient
on
FA
##NA
##P
##T
,
drug
disco
##ntin
##uation
should
be
considered
.
[SEP]
[CLS]
Although
some
of
the
patients
with
re
##tina
##l
abnormal
##ities
have
been
found
to
have
abnormal
visual
a
##cu
##ity
,
it
is
not
possible
to
assess
whether
P
##OT
##IG
##A
caused
their
decreased
visual
a
##cu
##ity
,
as
base
##line
assessments
are
not
available
for
these
patients
.
[SEP]
[CLS]
(
5
.
2
)
*
P
##OT
##IG
##A
can
cause
skin
disco
##lora
##tion
.
[SEP]
[CLS]
Assessment
of
the
relationship
between
at
##y
##pical
anti
##psy
##cho
##tic
use
and
glucose
abnormal
##ities
is
complicated
by
the
possibility
of
an
increased
background
risk
of
diabetes
me
##lli
##tus
in
patients
with
s
##chi
##zophrenia
and
the
increasing
incidence
of
diabetes
me
##lli
##tus
in
the
general
population
.
[SEP]
[CLS]
The
initial
prescription
and
renewal
of
the
medication
order
beyond
28
days
should
be
made
by
a
physician
only
after
examination
of
the
patient
with
the
aid
of
ma
##gni
##fication
such
as
slit
lamp
bio
##mic
##ros
##copy
and
,
where
appropriate
,
flu
##ores
##ce
##in
stain
##ing
.
[SEP]
[CLS]
per
##i
-
in
##fusion
##al
reactions
consistent
with
h
##yper
##sen
##si
##ti
##vity
or
an
##aph
##yla
##xi
##s
were
not
reported
in
these
11
patients
nor
were
neutral
##izing
antibodies
against
i
##pi
##lim
##uma
##b
detected
.
[SEP]
[CLS]
Bin
##ding
to
this
receptor
is
required
for
V
##im
##iz
##im
to
be
taken
into
cells
where
it
is
active
.
[SEP]
[CLS]
Ad
##verse
reaction
of
h
##yper
##uri
##ce
##mia
was
reported
for
15
%
of
patients
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
:
an
##aph
##yla
##xi
##s
;
and
in
##fusion
site
reactions
;
p
##ne
##um
##oc
##ys
##tis
ji
##rove
##ci
pneumonia
and
p
##ne
##um
##oni
##tis
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
discussed
in
more
detail
in
other
sections
of
the
label
##ing
:
*
Op
##ht
##hal
##mic
Ad
##verse
Re
##action
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
=
2
%
)
are
local
skin
reactions
,
application
site
pain
,
application
site
p
##ru
##rit
##us
,
application
site
irritation
,
application
site
infection
,
per
##ior
##bit
##al
ed
##ema
,
na
##so
##pha
##ryn
##git
##is
and
headache
.
[SEP]
[CLS]
Table
2
lists
adverse
reactions
that
occurred
in
>
=
0
.
1
%
subjects
who
received
G
##ada
##vist
.
[SEP]
[CLS]
Pro
##vide
supportive
medical
care
if
short
##ness
of
breath
develops
.
[SEP]
[CLS]
In
a
study
of
T
##RE
##AN
##DA
(
90
mg
/
m
2
)
in
combination
with
r
##it
##ux
##ima
##b
,
one
case
of
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
(
T
##EN
)
occurred
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Du
##rata
The
##rap
##eu
##tics
,
Inc
.
at
1
-
85
##5
-
38
##7
-
28
##25
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
H
##y
##po
##gly
##ce
##mia
In
all
clinical
trials
,
h
##y
##po
##gly
##ce
##mia
was
defined
as
any
event
regardless
of
symptoms
,
where
bio
##chemical
h
##y
##po
##gly
##ce
##mia
was
documented
(
any
glucose
value
below
or
equal
to
70
mg
/
d
##L
)
.
[SEP]
[CLS]
Given
these
considerations
,
SA
##P
##H
##RI
##S
should
be
prescribed
in
a
manner
that
is
most
likely
to
minimize
the
occurrence
of
TD
.
[SEP]
[CLS]
Con
##com
##ita
##nt
short
-
acting
beta
##2
-
ago
##nist
##s
can
be
used
as
needed
for
acute
relief
(
5
.
2
)
*
Do
not
exceed
the
recommended
dose
.
[SEP]
[CLS]
A
majority
of
Q
##ute
##nza
-
treated
patients
in
clinical
studies
had
adverse
reactions
with
a
maximum
intensity
of
`
`
mild
'
'
or
`
`
moderate
'
'
.
[SEP]
[CLS]
(
5
.
11
)
*
The
starting
dose
of
IN
##L
##Y
##TA
should
be
decreased
if
used
in
patients
with
moderate
he
##pa
##tic
imp
##air
##ment
.
[SEP]
[CLS]
5
.
3
Progressive
Multi
##fo
##cal
Le
##uk
##oe
##nce
##pha
##lop
##athy
A
case
of
progressive
multi
##fo
##cal
le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
and
a
case
of
probable
PM
##L
occurred
in
patients
with
MS
who
received
G
##IL
##EN
##Y
##A
in
the
post
marketing
setting
.
[SEP]
[CLS]
Ad
##e
##qua
##te
data
are
not
available
on
whether
anti
-
viral
therapy
can
reduce
the
risk
of
H
##B
##V
react
##ivation
in
H
##B
##V
carriers
who
are
treated
with
T
##NF
-
block
##ers
.
[SEP]
[CLS]
Additional
signs
may
include
elevated
c
##rea
##tine
p
##hos
##ph
##oki
##nas
##e
,
my
##og
##lo
##bin
##uria
(
r
##hab
##dom
##yo
##lysis
)
,
and
acute
re
##nal
failure
.
[SEP]
[CLS]
Overall
,
3
.
9
%
of
patients
reported
at
least
one
adverse
reaction
,
primarily
occurring
immediately
or
several
days
following
D
##OT
##AR
##EM
administration
.
[SEP]
[CLS]
Ser
##ious
infections
occurred
at
a
rate
of
2
.
3
%
in
the
G
##IL
##EN
##Y
##A
group
versus
1
.
6
%
in
the
place
##bo
group
.
[SEP]
[CLS]
The
route
of
administration
was
in
##tra
##mus
##cular
n
=
85
##2
,
in
##tra
##ven
##ous
n
=
29
,
other
or
unknown
n
=
59
.
[SEP]
[CLS]
*
Report
any
unusual
v
##agi
##nal
bleeding
right
away
while
you
are
taking
D
##U
##AV
##EE
.
[SEP]
[CLS]
The
median
age
of
patients
was
31
years
(
range
18
to
61
years
)
,
89
%
were
Caucasian
,
and
34
%
were
male
.
[SEP]
[CLS]
Del
##ay
in
stopping
treatment
with
T
##I
##VI
##CA
##Y
or
other
suspect
agents
after
the
onset
of
h
##yper
##sen
##si
##ti
##vity
may
result
in
a
life
-
threatening
reaction
.
[SEP]
[CLS]
(
5
.
2
)
*
Progressive
Multi
##fo
##cal
Le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
:
Pat
##ients
presenting
with
new
-
onset
or
de
##ter
##ior
##ating
ne
##uro
##logical
signs
and
symptoms
should
be
evaluated
for
PM
##L
by
an
appropriate
specialist
.
[SEP]
[CLS]
Trials
3
and
4
included
3
,
255
subjects
,
of
which
57
%
were
male
and
85
%
were
white
.
[SEP]
[CLS]
Based
on
effective
donor
screening
and
product
manufacturing
processes
,
it
carries
an
extremely
remote
risk
for
transmission
of
viral
diseases
.
[SEP]
[CLS]
The
risk
of
impaired
re
##nal
function
with
J
##AR
##DI
##AN
##CE
is
increased
in
elderly
patients
and
patients
with
moderate
re
##nal
imp
##air
##ment
.
[SEP]
[CLS]
Human
relevance
of
G
##LP
-
1
receptor
ago
##nist
induced
C
-
cell
tumors
in
rode
##nts
has
not
been
determined
.
[SEP]
[CLS]
5
.
4
Progressive
Multi
##fo
##cal
Le
##uk
##oe
##nce
##pha
##lop
##athy
Progressive
multi
##fo
##cal
le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
is
an
often
rapidly
progressive
and
fatal
op
##port
##uni
##stic
infection
of
the
C
##NS
that
is
caused
by
the
J
##C
virus
,
a
human
p
##oly
##oma
virus
.
[SEP]
[CLS]
Twenty
-
one
of
290
patients
(
7
%
)
experienced
adverse
reactions
that
were
assessed
as
related
to
V
##OR
##A
##X
##A
##Z
##E
.
[SEP]
[CLS]
Pat
##ients
experiencing
new
or
worse
##ning
peripheral
ne
##uro
##pathy
may
require
a
delay
,
change
in
dose
,
or
disco
##ntin
##uation
of
AD
##CE
##TR
##IS
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
To
avoid
transfer
of
the
drug
into
the
eyes
and
to
the
per
##io
##cular
area
during
and
after
application
,
patients
should
wash
hands
well
after
applying
Pi
##cat
##o
(
r
)
gel
.
[SEP]
[CLS]
The
reactions
generally
related
to
r
##ash
and
p
##ru
##rit
##is
within
minutes
of
Da
##T
##sca
##n
administration
.
[SEP]
[CLS]
(
5
.
7
)
(
8
.
1
)
5
.
1
Bone
Mar
##row
Su
##pp
##ression
Bone
ma
##rrow
suppression
manifest
##ed
as
ne
##ut
##rop
##enia
,
an
##emia
,
th
##rom
##bo
##cy
##top
##enia
and
/
or
pan
##cy
##top
##enia
may
occur
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Three
hundred
ninety
-
five
patients
,
including
approximately
250
children
(
aged
2
to
17
years
)
have
been
treated
with
IL
##AR
##IS
in
intervention
##al
trials
in
CA
##PS
or
S
##J
##IA
.
[SEP]
[CLS]
Overall
,
177
patients
were
enrolled
into
the
study
and
received
IL
##AR
##IS
4
mg
/
kg
(
up
to
300
mg
maximum
)
in
Part
I
,
and
100
patients
received
IL
##AR
##IS
4
mg
/
kg
(
up
to
300
mg
maximum
)
every
4
weeks
or
place
##bo
in
Part
II
.
[SEP]
[CLS]
The
disco
##ntin
##uation
rate
due
to
adverse
reactions
for
patients
treated
with
ST
##EN
##DR
##A
(
50
mg
,
100
mg
,
or
200
mg
)
was
2
.
8
%
.
[SEP]
[CLS]
Case
##s
of
pulmonary
toxicity
have
also
been
reported
in
patients
receiving
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
G
##ado
##lini
##um
-
based
contrast
agents
(
GB
##CA
##s
)
increase
the
risk
for
N
##SF
among
patients
with
impaired
elimination
of
the
drugs
.
[SEP]
[CLS]
(
5
.
5
)
5
.
1
Not
for
A
##cute
Use
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
is
intended
as
a
twice
-
daily
maintenance
treatment
for
CO
##PD
and
is
not
indicated
for
the
initial
treatment
of
acute
episodes
of
br
##on
##cho
##sp
##as
##m
(
i
.
e
.
,
rescue
therapy
)
.
[SEP]
[CLS]
In
##tra
##oc
##ular
pressure
and
the
per
##fusion
of
the
op
##tic
nerve
head
should
be
monitored
and
managed
appropriately
[
see
##D
##osa
##ge
and
Administration
(
2
.
7
)
]
.
[SEP]
[CLS]
It
is
not
possible
to
determine
whether
these
events
are
related
directly
to
the
use
of
PD
##E
##5
inhibitor
##s
,
to
the
patient
'
s
underlying
vascular
risk
factors
or
an
##ato
##mic
##al
defects
,
to
a
combination
of
these
factors
,
or
to
other
factors
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
and
##P
##ati
##ent
Counsel
##ing
Information
(
17
.
6
)
]
.
[SEP]
[CLS]
If
bone
abnormal
##ities
are
suspected
,
then
appropriate
consultation
should
be
obtained
.
[SEP]
[CLS]
Re
##fer
to
the
pre
##s
##cribing
information
for
rib
##avi
##rin
for
additional
information
regarding
dose
reduction
and
/
or
disco
##ntin
##uation
.
[SEP]
[CLS]
Per
##form
a
base
##line
o
##cular
examination
prior
to
administration
of
PR
##OM
##AC
##TA
and
,
during
therapy
with
PR
##OM
##AC
##TA
,
regularly
monitor
patients
for
signs
and
symptoms
of
cat
##ara
##cts
.
[SEP]
[CLS]
Among
these
202
patients
,
66
(
33
%
)
were
exposed
to
T
##AF
##IN
##LA
##R
and
68
(
34
%
)
were
exposed
to
tram
##eti
##ni
##b
for
greater
than
6
to
12
months
while
40
(
20
%
)
were
exposed
to
T
##AF
##IN
##LA
##R
and
36
(
18
%
)
were
exposed
to
tram
##eti
##ni
##b
for
greater
than
one
year
.
[SEP]
[CLS]
Among
the
factors
that
may
increase
the
risk
for
N
##SF
are
repeated
or
higher
than
recommended
doses
of
a
GB
##CA
and
degree
of
re
##nal
imp
##air
##ment
at
the
time
of
exposure
.
[SEP]
[CLS]
Clinical
Trials
in
In
##fant
##ile
-
On
##set
and
Ju
##ven
##ile
-
On
##set
Po
##mp
##e
Disease
Two
multi
##cent
##er
,
open
-
label
clinical
trials
were
conducted
in
39
infant
##ile
-
onset
Po
##mp
##e
disease
patients
,
ages
1
month
to
3
.
5
years
old
.
[SEP]
[CLS]
Sub
##group
analyses
of
women
50
to
59
years
of
age
suggest
no
increased
risk
of
stroke
for
those
women
receiving
con
##ju
##gated
est
##rogen
##s
(
0
.
625
mg
)
-
alone
versus
those
receiving
place
##bo
(
18
versus
21
per
10
,
000
women
-
years
)
.
[SEP]
[CLS]
Although
the
effect
of
supplement
##ation
with
calcium
and
vitamin
D
was
not
studied
,
such
supplement
##ation
may
be
beneficial
in
all
patients
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
NE
##P
##H
##RO
##GE
##NI
##C
S
##Y
##ST
##EM
##IC
F
##IB
##RO
##SI
##S
(
N
##SF
)
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
Death
##s
due
to
adverse
events
within
30
days
of
the
last
dose
of
any
therapy
in
the
K
##R
##d
arm
occurred
in
27
/
39
##2
(
7
%
)
patients
compared
with
27
/
38
##9
(
7
%
)
patients
who
died
due
to
adverse
events
within
30
days
of
the
last
dose
of
any
Rd
therapy
.
[SEP]
[CLS]
*
Store
D
##U
##AV
##EE
at
room
temperature
between
68
degrees
F
to
77
degrees
F
(
20
degrees
C
to
25
degrees
C
)
.
[SEP]
[CLS]
b
Grade
4
adverse
reactions
limited
to
h
##yper
##ker
##ato
##sis
(
n
=
1
)
and
con
##st
##ip
##ation
(
n
=
1
)
.
[SEP]
[CLS]
Management
includes
mouth
##wash
##es
and
topic
##al
treatments
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
:
Skin
and
sub
##cut
##aneous
tissue
disorders
-
Stevens
-
Johnson
syndrome
.
[SEP]
[CLS]
More
frequent
monitoring
of
re
##nal
function
is
recommended
in
these
patients
[
see
Use
in
S
##pecific
Population
##s
(
8
.
5
,
8
.
6
)
]
.
[SEP]
[CLS]
(
5
.
4
)
5
.
[SEP]
[CLS]
Disco
##ntin
##ue
in
##fusion
immediately
if
h
##yper
##sen
##si
##ti
##vity
is
observed
and
treat
as
indicated
.
[SEP]
[CLS]
Depression
was
reported
as
serious
in
0
.
1
%
(
1
/
130
##8
)
of
subjects
exposed
to
O
##TE
##Z
##LA
,
compared
to
none
in
place
##bo
-
treated
subjects
(
0
/
50
##6
)
.
[SEP]
[CLS]
5
.
4
He
##pa
##tic
To
##xi
##city
In
38
##65
patients
who
received
G
##IL
##OT
##RI
##F
across
clinical
trials
,
10
.
1
%
had
liver
test
abnormal
##ities
,
of
which
7
(
0
.
18
%
)
were
fatal
.
[SEP]
[CLS]
In
all
three
controlled
trials
,
patients
were
eligible
for
treatment
of
subsequent
attacks
in
an
open
-
label
extension
.
[SEP]
[CLS]
Ad
##verse
reactions
leading
to
permanent
disco
##ntin
##uation
in
the
A
##FI
##NI
##TO
##R
arm
were
h
##yper
##sen
##si
##ti
##vity
/
an
##gio
##ede
##ma
/
br
##on
##cho
##sp
##as
##m
,
con
##vu
##ls
##ion
,
and
h
##y
##pop
##hos
##phate
##mia
.
[SEP]
[CLS]
A
##vo
##id
use
of
FA
##NA
##P
##T
in
combination
with
other
drugs
that
are
known
to
pro
##long
Q
##T
##c
;
use
caution
and
consider
dose
modification
when
pre
##s
##cribing
FA
##NA
##P
##T
with
other
drugs
that
in
##hibit
FA
##NA
##P
##T
metabolism
.
[SEP]
[CLS]
What
is
D
##U
##AV
##EE
?
[SEP]
[CLS]
Pat
##ients
received
ER
##WI
##NA
##Z
##E
according
to
several
schedules
,
and
treatment
center
specifications
with
doses
that
ranged
from
20
,
000
to
25
,
000
International
Units
/
m
2
.
[SEP]
[CLS]
The
incidence
of
serious
adverse
reactions
was
3
.
5
%
in
the
D
##U
##AV
##EE
group
and
4
.
8
%
in
the
place
##bo
group
.
[SEP]
[CLS]
The
majority
of
adult
patients
were
enrolled
in
studies
in
Thailand
,
while
the
majority
of
p
##ediatric
patients
were
enrolled
in
Africa
.
[SEP]
[CLS]
The
risk
of
developing
TD
and
the
likelihood
that
it
will
become
i
##rre
##versible
are
believed
to
increase
as
the
duration
of
treatment
and
the
total
cumulative
dose
of
anti
##psy
##cho
##tic
drugs
administered
to
the
patient
increase
.
[SEP]
[CLS]
The
median
duration
of
study
treatment
was
10
.
9
months
for
patients
in
the
X
##AL
##KO
##RI
arm
and
4
.
1
months
for
patients
in
the
ch
##em
##otherapy
arm
.
[SEP]
[CLS]
In
these
trials
,
which
had
a
median
treatment
duration
of
12
weeks
,
the
estimated
incidence
of
su
##icidal
behavior
among
27
,
86
##3
A
##ED
-
treated
patients
was
0
.
43
%
,
compared
to
0
.
24
%
among
16
,
02
##9
place
##bo
-
treated
patients
,
representing
an
increase
of
approximately
one
case
of
su
##icidal
thinking
for
every
530
patients
treated
.
[SEP]
[CLS]
Use
caution
when
driving
or
operating
machinery
.
[SEP]
[CLS]
Although
the
majority
of
these
events
were
observed
in
the
setting
of
CR
##S
,
some
were
observed
outside
of
this
setting
.
[SEP]
[CLS]
The
safety
of
H
##OR
##I
##Z
##AN
##T
in
doses
ranging
from
600
to
2
,
400
mg
has
been
evaluated
in
51
##5
patients
with
R
##LS
in
3
double
blind
,
place
##bo
-
controlled
,
12
week
clinical
trials
.
[SEP]
[CLS]
Other
XI
##AF
##LE
##X
-
associated
serious
local
adverse
reactions
included
pull
##ey
r
##up
##ture
,
l
##iga
##ment
injury
,
complex
regional
pain
syndrome
(
CR
##PS
)
,
sensory
abnormal
##ity
of
the
hand
,
and
skin
lace
##ration
)
.
[SEP]
[CLS]
Elder
##ly
patients
may
be
at
greater
risk
of
developing
h
##y
##po
##nat
##rem
##ia
with
SSR
##I
##s
and
S
##NR
##I
##s
.
[SEP]
[CLS]
Monitor
##ing
of
or
##th
##ost
##atic
vital
signs
should
be
considered
in
patients
who
are
vulnerable
to
h
##y
##pot
##ens
##ion
.
[SEP]
[CLS]
A
majority
of
reported
events
occurred
in
patients
who
had
experienced
nausea
,
vomit
##ing
,
di
##ar
##r
##hea
,
or
de
##hy
##dra
##tion
.
[SEP]
[CLS]
After
withdrawal
from
systemic
co
##rt
##ico
##ster
##oids
,
a
number
of
months
are
required
for
recovery
of
h
##y
##pot
##hala
##mic
-
pit
##uit
##ary
-
ad
##rena
##l
(
HP
##A
)
function
.
[SEP]
[CLS]
Case
##s
have
occurred
after
the
first
dose
of
AD
##CE
##TR
##IS
or
after
AD
##CE
##TR
##IS
re
##chal
##len
##ge
.
[SEP]
[CLS]
(
2
.
2
,
5
.
2
)
*
Inter
##st
##iti
##al
Lu
##ng
Disease
(
IL
##D
)
/
P
##ne
##um
##oni
##tis
:
O
##cc
##ur
##red
in
4
%
of
patients
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
associated
with
PR
##OM
##AC
##TA
are
described
in
other
sections
.
[SEP]
[CLS]
d
##I
##nt
##rac
##rani
##al
bleed
included
sub
##du
##ral
bleed
##s
.
[SEP]
[CLS]
If
Grade
3
or
4
ne
##ut
##rop
##enia
develops
,
consider
dose
delays
,
reduction
##s
,
disco
##ntin
##uation
,
or
G
-
CS
##F
prop
##hyl
##ax
##is
with
subsequent
AD
##CE
##TR
##IS
doses
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
5
.
4
Inc
##reased
Ra
##diation
Expo
##sure
in
Pat
##ients
with
Se
##vere
Ren
##al
I
##mp
##air
##ment
Ad
##re
##V
##ie
##w
is
cleared
by
g
##lo
##mer
##ular
fi
##ltration
and
is
not
dial
##y
##zable
.
[SEP]
[CLS]
Inter
##rup
##t
Fe
##rri
##p
##ro
##x
if
infection
develops
,
and
monitor
the
AN
##C
more
frequently
.
[SEP]
[CLS]
Blood
Di
##sor
##ders
:
An
##emia
,
e
##os
##ino
##phi
##lia
,
le
##uk
##ope
##nia
,
th
##rom
##bo
##cy
##top
##enia
Eye
Di
##sor
##ders
:
Di
##p
##lop
##ia
,
vision
blurred
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
:
Abd
##omi
##nal
di
##sten
##tion
General
Di
##sor
##ders
and
Administration
Site
Con
##ditions
:
H
##y
##pot
##her
##mia
Investigation
##s
:
He
##pa
##tic
enzyme
increased
Mu
##s
##cu
##los
##kel
##etal
:
Mu
##s
##cle
spa
##sm
##s
P
##sy
##chia
##tric
Di
##sor
##ders
:
A
##git
##ation
,
anxiety
,
a
##pathy
,
confusion
##al
state
,
depression
,
del
##iri
##um
,
del
##usion
,
hall
##uc
##ination
Ren
##al
and
U
##rina
##ry
Di
##sor
##ders
:
U
##rina
##ry
retention
Re
##sp
##ira
##tory
Di
##sor
##ders
:
As
##piration
,
respiratory
depression
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
:
Ra
##sh
,
u
##rt
##ica
##ria
,
an
##gio
##ede
##ma
,
and
lip
ed
##ema
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
So
##m
##no
##len
##ce
or
Se
##dation
:
Monitor
for
central
nervous
system
(
C
##NS
)
depression
.
[SEP]
[CLS]
For
CO
##PD
,
increasing
the
daily
dose
of
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
is
not
appropriate
in
this
situation
.
[SEP]
[CLS]
A
total
of
27
##11
patients
treated
with
E
##Y
##LE
##A
constituted
the
safety
population
in
seven
phase
3
studies
.
[SEP]
[CLS]
B
##lad
##der
cancer
risk
factors
and
hem
##at
##uria
(
a
potential
indicator
of
pre
-
existing
tumors
)
were
balanced
between
treatment
arms
at
base
##line
.
[SEP]
[CLS]
In
these
trials
,
patients
were
given
up
to
4
treatment
cycles
of
XI
##AF
##LE
##X
or
place
##bo
.
[SEP]
[CLS]
Pre
##scription
##s
for
FA
##NA
##P
##T
should
be
written
for
the
smallest
quantity
of
tablets
consistent
with
good
patient
management
in
order
to
reduce
the
risk
of
over
##dos
##e
.
[SEP]
[CLS]
The
median
time
to
onset
of
T
##B
for
all
patients
exposed
to
C
##IM
##Z
##IA
across
all
indication
##s
was
345
days
.
[SEP]
[CLS]
The
race
distribution
was
89
%
White
,
7
%
Black
,
3
%
Hispanic
,
1
%
other
,
and
<
1
%
Asian
.
[SEP]
[CLS]
Monitor
complete
blood
counts
monthly
.
[SEP]
[CLS]
He
##mat
##olo
##gic
toxic
##ities
,
based
on
laboratory
values
and
CT
##C
grade
,
in
NHL
patients
treated
in
both
single
arm
studies
combined
are
described
in
Table
4
.
[SEP]
[CLS]
It
is
important
to
note
that
early
manifest
##ations
of
h
##yper
##sen
##si
##ti
##vity
,
such
as
fever
or
l
##ymph
##ade
##no
##pathy
,
may
be
present
even
though
r
##ash
is
not
evident
.
[SEP]
[CLS]
Therefore
,
consider
dos
##age
modifications
of
both
AP
##TI
##OM
and
car
##ba
##ma
##ze
##pine
if
these
drugs
are
used
con
##com
##ita
##ntly
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
Te
##mpo
##rar
##ily
su
##sp
##end
,
dose
reduce
,
or
permanently
disco
##ntin
##ue
X
##AL
##KO
##RI
.
[SEP]
[CLS]
Table
2
:
Pro
##port
##ion
of
Pat
##ients
With
at
Lea
##st
One
Volume
De
##ple
##tion
-
Re
##lated
Ad
##verse
Re
##action
(
Poole
##d
Results
from
8
Clinical
Trials
)
Basel
##ine
Character
##istic
Co
##mp
##ara
##tor
Group
%
IN
##VO
##KA
##NA
100
mg
%
IN
##VO
##KA
##NA
300
mg
%
Overall
population
1
.
5
%
2
.
3
%
3
.
4
%
75
years
of
age
and
older
2
.
6
%
4
.
9
%
8
.
7
%
e
##G
##F
##R
less
than
60
m
##L
/
min
/
1
.
73
m
2
2
.
5
%
4
.
7
%
8
.
1
%
Use
of
loop
di
##ure
##tic
4
.
7
%
3
.
2
%
8
.
8
%
Falls
In
a
pool
of
nine
clinical
trials
with
mean
duration
of
exposure
to
IN
##VO
##KA
##NA
of
85
weeks
,
the
proportion
of
patients
who
experienced
falls
was
1
.
3
%
,
1
.
5
%
,
and
2
.
1
%
with
com
##par
##ator
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
Risk
of
Su
##icidal
Thought
##s
by
In
##dication
for
Anti
##ep
##ile
##ptic
Drugs
in
the
Poole
##d
Analysis
In
##dication
Place
##bo
Pat
##ients
with
Events
per
1
,
000
Pat
##ients
Drug
Pat
##ients
with
Events
per
1
,
000
Pat
##ients
Re
##lative
Risk
:
Inc
##iden
##ce
of
Events
in
Drug
Pat
##ients
/
Inc
##iden
##ce
in
Place
##bo
Pat
##ients
Risk
Di
##fference
:
Additional
Drug
Pat
##ients
with
Events
per
1
,
000
Pat
##ients
E
##pile
##psy
1
.
0
3
.
4
3
.
5
2
.
4
P
##sy
##chia
##tric
5
.
7
8
.
5
1
.
5
2
.
9
Other
1
.
0
1
.
8
1
.
9
0
.
9
Total
2
.
4
4
.
3
1
.
8
1
.
9
The
relative
risk
for
su
##icidal
thoughts
was
higher
in
clinical
trials
in
patients
with
e
##pile
##psy
than
in
clinical
trials
in
patients
with
psychiatric
or
other
conditions
,
but
the
absolute
risk
differences
were
similar
for
e
##pile
##psy
and
psychiatric
indication
##s
.
[SEP]
[CLS]
Therefore
,
use
of
B
##EN
##L
##Y
##ST
##A
is
not
recommended
in
combination
with
bio
##log
##ic
the
##rap
##ies
or
in
##tra
##ven
##ous
c
##y
##c
##lop
##hos
##pha
##mi
##de
.
[SEP]
[CLS]
El
##ec
##tro
##card
##io
##graphic
Finding
##s
EC
##G
measurements
were
only
recorded
in
a
limited
number
of
patients
in
an
open
-
label
study
without
a
place
##bo
or
active
control
.
[SEP]
[CLS]
Ad
##verse
events
leading
to
disco
##ntin
##uation
of
K
##y
##p
##rol
##is
occurred
in
12
%
of
patients
and
the
most
common
events
included
pneumonia
(
1
%
)
,
my
##oc
##ard
##ial
in
##far
##ction
(
0
.
8
%
)
,
and
upper
respiratory
tract
infection
(
0
.
8
%
)
.
[SEP]
[CLS]
*
currently
have
or
have
had
certain
cancer
##s
.
[SEP]
[CLS]
More
serious
or
even
fatal
course
of
chicken
##pox
or
me
##as
##les
can
occur
in
susceptible
patients
.
[SEP]
[CLS]
B
##EN
##L
##Y
##ST
##A
should
be
administered
by
healthcare
providers
prepared
to
manage
in
##fusion
reactions
.
[SEP]
[CLS]
B
##reath
##ing
Di
##ff
##ic
##ult
##y
B
##reath
##ing
difficulties
were
reported
by
approximately
3
%
of
patients
following
D
##Y
##SP
##OR
##T
(
r
)
administration
and
in
1
%
of
place
##bo
patients
in
clinical
trials
during
the
double
-
blind
phase
.
[SEP]
[CLS]
Your
healthcare
provider
may
need
to
check
you
more
carefully
if
you
have
certain
conditions
,
such
as
as
##th
##ma
(
w
##hee
##zing
)
,
e
##pile
##psy
(
seizure
##s
)
,
diabetes
,
mi
##gra
##ine
,
end
##ome
##tri
##osis
,
l
##up
##us
,
or
problems
with
your
heart
,
liver
,
thy
##roid
,
kidney
##s
,
or
have
high
calcium
levels
in
your
blood
.
[SEP]
[CLS]
In
addition
to
the
reactions
shown
in
Table
##s
2
and
3
,
adverse
reactions
occurring
in
greater
than
or
equal
to
2
%
of
subjects
treated
with
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
included
viral
respiratory
tract
infection
,
p
##har
##yn
##git
##is
,
p
##yre
##xia
,
and
art
##hra
##l
##gia
.
[SEP]
[CLS]
Six
of
the
9
patients
were
hospital
##ized
for
severe
end
##oc
##rino
##path
##ies
.
[SEP]
[CLS]
Less
Common
Ad
##verse
Re
##actions
O
##bs
##erve
##d
in
Treatment
-
naive
and
Treatment
-
experienced
Trials
The
following
AD
##R
##s
occurred
in
less
than
2
%
of
treatment
-
naive
or
treatment
-
experienced
subjects
receiving
T
##I
##VI
##CA
##Y
in
a
combination
regime
##n
in
any
one
trial
.
[SEP]
[CLS]
Do
not
administer
in
combination
with
H
##EP
##SE
##RA
.
[SEP]
[CLS]
Sub
##jects
participating
in
this
trial
had
a
history
of
one
or
more
as
##th
##ma
ex
##ace
##rb
##ations
that
required
treatment
with
oral
/
systemic
co
##rt
##ico
##ster
##oids
or
emergency
department
visit
or
in
-
patient
hospital
##ization
for
the
treatment
of
as
##th
##ma
in
the
year
prior
to
trial
entry
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
incidence
>
=
30
%
)
were
s
##tom
##ati
##tis
,
r
##ash
,
di
##ar
##r
##hea
,
fatigue
,
ed
##ema
,
abdominal
pain
,
nausea
,
fever
,
and
headache
.
[SEP]
[CLS]
Unless
an
alternate
et
##iology
has
been
identified
,
signs
or
symptoms
of
end
##oc
##rino
##path
##ies
should
be
considered
immune
-
mediated
.
[SEP]
[CLS]
Of
the
35
##3
patients
included
in
the
pool
##ed
analyses
of
patients
with
CF
who
had
either
a
G
##55
##1
##D
mutation
or
were
ho
##mo
##zy
##go
##us
for
the
F
##50
##8
##del
mutation
in
the
CF
##TR
gene
,
50
%
of
patients
were
female
and
97
%
were
Caucasian
;
221
received
K
##AL
##Y
##DE
##CO
,
and
132
received
place
##bo
from
16
to
48
weeks
.
[SEP]
[CLS]
In
these
studies
,
a
total
of
62
##8
##5
patients
were
random
##ized
and
treated
,
32
##8
##2
patients
with
M
##U
##LT
##A
##Q
400
mg
twice
daily
,
and
287
##5
with
place
##bo
.
[SEP]
[CLS]
There
were
two
additional
reports
of
R
##PL
##S
in
other
clinical
trials
with
IN
##L
##Y
##TA
.
[SEP]
[CLS]
Good
oral
h
##ygiene
practices
should
be
maintained
during
treatment
with
Pro
##lia
.
[SEP]
[CLS]
Although
a
ca
##usal
link
between
the
emergence
of
such
symptoms
and
either
the
worse
##ning
of
depression
and
/
or
the
emergence
of
su
##icidal
impulse
##s
has
not
been
established
,
there
is
concern
that
such
symptoms
may
represent
precursor
##s
to
emerging
su
##icidal
##ity
.
[SEP]
[CLS]
ON
##J
has
been
reported
in
patients
receiving
den
##os
##uma
##b
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
In
the
post
-
marketing
period
seizure
##s
have
been
reported
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
In
clinical
trials
,
the
most
common
related
adverse
events
(
occurring
in
>
1
%
of
patients
)
were
para
##est
##hesia
,
flush
##ing
,
nausea
and
/
or
vomit
##ing
,
h
##y
##pot
##ens
##ion
and
headache
.
[SEP]
[CLS]
It
is
possible
that
use
of
IL
-
1
inhibitor
##s
such
as
IL
##AR
##IS
increases
the
risk
of
react
##ivation
of
tuberculosis
or
of
op
##port
##uni
##stic
infections
.
[SEP]
[CLS]
*
b
See
below
for
other
events
of
injection
site
reactions
reported
.
[SEP]
[CLS]
Due
to
the
long
half
-
life
of
D
##AM
##PA
(
t
##1
/
2
##of
approximately
9
hours
)
,
measurement
of
met
##hot
##re
##xa
##te
using
im
##mu
##no
##ass
##ays
is
unreliable
for
samples
collected
within
48
hours
following
V
##OR
##A
##X
##A
##Z
##E
administration
[
see
Clinical
Ph
##arma
##cology
(
12
.
1
)
]
.
[SEP]
[CLS]
Other
Ad
##verse
Re
##actions
Table
1
sum
##mar
##izes
the
adverse
drug
reactions
that
occurred
at
a
rate
of
at
least
1
%
in
the
S
##IM
##PO
##NI
ARIA
+
M
##T
##X
group
with
a
higher
incidence
than
in
the
place
##bo
+
M
##T
##X
group
during
the
controlled
period
of
Trial
1
through
Week
24
.
[SEP]
[CLS]
Table
8
.
[SEP]
[CLS]
The
median
time
from
onset
to
resolution
or
improvement
of
any
grade
was
23
weeks
(
range
,
0
.
1
-
138
)
,
of
Grade
2
was
24
weeks
(
range
,
1
-
108
)
and
of
Grade
3
was
25
weeks
(
range
,
2
-
98
)
.
[SEP]
[CLS]
Because
this
adverse
reaction
was
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
possible
to
estimate
its
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
Therefore
,
caution
should
be
used
when
administer
##ing
general
an
##est
##hesia
.
[SEP]
[CLS]
Ex
##er
##cise
caution
in
patients
with
heart
failure
and
monitor
them
carefully
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Pat
##ients
should
be
monitored
for
the
emergence
of
se
##rot
##oni
##n
syndrome
.
[SEP]
[CLS]
5
.
2
H
##yper
##sen
##si
##ti
##vity
Re
##actions
h
##yper
##sen
##si
##ti
##vity
reactions
with
cut
##aneous
manifest
##ations
,
ranging
from
mild
to
severe
,
including
shock
have
uncommon
##ly
occurred
following
E
##O
##VI
##ST
administration
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
If
me
##f
##lo
##quin
##e
is
administered
immediately
prior
to
Co
##arte
##m
Table
##ts
there
may
be
a
decreased
exposure
to
l
##ume
##fant
##rine
,
possibly
due
to
a
me
##f
##lo
##quin
##e
-
induced
decrease
in
bi
##le
production
.
[SEP]
[CLS]
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
:
generalized
r
##ash
,
Stevens
Johnson
S
##yn
##drome
,
h
##yper
##sen
##si
##ti
##vity
skin
reactions
.
[SEP]
[CLS]
Events
resulting
in
disco
##ntin
##uation
were
similar
to
those
seen
in
previous
studies
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
.
[SEP]
[CLS]
*
In
those
patients
who
are
stable
on
alpha
-
block
##er
therapy
,
PD
##E
##5
inhibitor
##s
should
be
initiated
at
the
lowest
dose
(
ST
##EN
##DR
##A
50
mg
)
.
[SEP]
[CLS]
Therefore
,
physicians
should
inform
patients
that
substantial
consumption
of
alcohol
(
e
.
g
.
,
greater
than
3
units
)
in
combination
with
ST
##EN
##DR
##A
may
increase
the
potential
for
or
##th
##ost
##atic
signs
and
symptoms
,
including
increase
in
heart
rate
,
decrease
in
standing
blood
pressure
,
di
##zzi
##ness
,
and
headache
[
see
##D
##rug
Inter
##actions
(
7
.
1
)
and
##C
##lini
##cal
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
5
.
4
Extra
##vas
##ation
and
In
##jection
Site
Re
##actions
En
##sure
cat
##he
##ter
and
ve
##nous
pat
##ency
before
the
injection
of
G
##ada
##vist
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
Review
the
Full
Pre
##s
##cribing
Information
for
tram
##eti
##ni
##b
prior
to
initiation
of
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Monitor
##ing
of
re
##nal
function
,
including
measurement
of
blood
u
##rea
nitrogen
(
B
##UN
)
,
u
##rina
##ry
protein
,
or
serum
c
##rea
##tin
##ine
,
is
recommended
prior
to
the
start
of
A
##FI
##NI
##TO
##R
therapy
and
periodically
thereafter
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
in
Place
##bo
-
controlled
Trials
Report
##ed
in
>
=
5
%
of
Pat
##ients
T
##reate
##d
with
T
##AN
##Z
##E
##UM
a
Ad
##verse
Re
##action
Place
##bo
(
N
=
46
##8
)
%
T
##AN
##Z
##E
##UM
(
N
=
92
##3
)
%
Upper
respiratory
tract
infection
13
.
0
14
.
2
Di
##ar
##r
##hea
10
.
5
13
.
1
Na
##use
##a
9
.
6
11
.
1
In
##jection
site
reaction
##b
2
.
1
10
.
5
Co
##ugh
6
.
2
6
.
9
Back
pain
5
.
8
6
.
7
Art
##hra
##l
##gia
6
.
4
6
.
6
Sin
##us
##itis
5
.
8
6
.
2
In
##fluenza
3
.
2
5
.
2
*
a
Ad
##verse
reactions
reported
includes
adverse
reactions
occurring
with
the
use
of
g
##ly
##ce
##mic
rescue
medications
which
included
met
##form
##in
(
17
%
for
place
##bo
and
10
%
for
T
##AN
##Z
##E
##UM
)
and
insulin
(
24
%
for
place
##bo
and
14
%
for
T
##AN
##Z
##E
##UM
)
.
[SEP]
[CLS]
Eight
of
these
11
patients
had
received
a
single
dose
of
V
##OR
##A
##X
##A
##Z
##E
.
[SEP]
[CLS]
For
patients
with
SE
##GA
and
mild
or
moderate
he
##pa
##tic
imp
##air
##ment
,
adjust
the
dose
of
A
##FI
##NI
##TO
##R
Table
##ts
or
A
##FI
##NI
##TO
##R
D
##IS
##P
##ER
##Z
based
on
therapeutic
drug
monitoring
.
[SEP]
[CLS]
Disco
##ntin
##ue
G
##RA
##NI
##X
in
patients
with
AR
##DS
.
[SEP]
[CLS]
Table
3
:
B
##lee
##ding
During
the
Treatment
Period
in
Pat
##ients
Under
##going
El
##ec
##tive
Hip
or
K
##nee
Rep
##lace
##ment
Surgery
B
##lee
##ding
End
##point
*
AD
##VA
##NC
##E
-
3
##H
##ip
Rep
##lace
##ment
Surgery
AD
##VA
##NC
##E
-
2
##K
##nee
Rep
##lace
##ment
Surgery
AD
##VA
##NC
##E
-
1
##K
##nee
Rep
##lace
##ment
Surgery
*
All
bleeding
criteria
included
surgical
site
bleeding
.
[SEP]
[CLS]
Ad
##vise
female
patients
of
reproductive
potential
to
use
a
highly
effective
non
-
ho
##rmon
##al
method
of
con
##tra
##ception
since
T
##AF
##IN
##LA
##R
can
render
ho
##rmon
##al
con
##tra
##ceptive
##s
ineffective
,
during
treatment
and
for
at
least
2
weeks
after
treatment
with
T
##AF
##IN
##LA
##R
or
for
4
months
after
treatment
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
The
majority
of
seizure
##s
occurred
at
the
recommended
dose
and
in
patients
without
a
history
of
seizure
##s
,
and
generally
within
days
to
weeks
of
starting
therapy
.
[SEP]
[CLS]
If
either
occurs
,
decrease
the
dose
of
C
##lev
##ip
##re
##x
.
[SEP]
[CLS]
The
proportion
of
patients
who
premature
##ly
discontinued
study
drug
due
to
adverse
reactions
was
2
%
for
K
##AL
##Y
##DE
##CO
-
treated
patients
and
5
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
All
patients
started
the
study
at
a
dose
of
100
mg
/
m
2
in
##tra
##ven
##ously
over
30
minutes
on
Days
1
and
2
every
28
days
.
[SEP]
[CLS]
5
.
9
Rev
##ers
##ible
Post
##eri
##or
Le
##uk
##oe
##nce
##pha
##lop
##athy
S
##yn
##drome
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
re
##versible
posterior
le
##uk
##oe
##nce
##pha
##lop
##athy
syndrome
(
R
##PL
##S
)
was
reported
in
1
/
35
##9
patients
(
<
1
%
)
receiving
IN
##L
##Y
##TA
and
none
of
the
patients
receiving
so
##ra
##fen
##ib
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
The
mean
exposure
across
studies
was
12
months
.
[SEP]
[CLS]
In
some
patients
infected
with
H
##B
##V
and
treated
with
E
##MT
##RI
##VA
,
the
ex
##ace
##rb
##ations
of
he
##pa
##titis
B
were
associated
with
liver
de
##com
##pen
##sation
and
liver
failure
.
[SEP]
[CLS]
I
##mm
##une
-
mediated
reactions
presenting
as
protein
##uria
,
ne
##ph
##rot
##ic
syndrome
,
and
ne
##c
##rot
##izing
skin
lesions
have
occurred
in
some
patients
following
al
##g
##lu
##cos
##idas
##e
al
##fa
treatment
.
[SEP]
[CLS]
Overall
,
67
%
were
female
and
73
%
were
white
;
the
mean
age
was
42
years
(
adolescent
##s
aged
12
to
17
years
made
up
14
%
of
the
population
)
.
[SEP]
[CLS]
The
most
common
Grade
3
-
4
adverse
reactions
(
incidence
>
=
5
%
)
were
s
##tom
##ati
##tis
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
(
5
.
3
)
*
To
##via
##z
should
be
used
with
caution
in
patients
being
treated
for
narrow
-
angle
g
##lau
##com
##a
,
and
only
where
the
potential
benefits
out
##wei
##gh
the
risks
(
5
.
4
)
*
Central
N
##er
##vous
System
Effects
:
So
##m
##no
##len
##ce
has
been
reported
with
To
##via
##z
.
[SEP]
[CLS]
5
.
2
B
##lad
##der
Out
##let
O
##bs
##truction
To
##via
##z
should
be
administered
with
caution
to
patients
with
clinical
##ly
significant
bladder
outlet
o
##bs
##truction
because
of
the
risk
of
u
##rina
##ry
retention
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
The
proportion
of
patients
with
C
##K
elevations
>
=
3
times
U
##L
##N
during
a
3
-
week
trial
in
p
##ediatric
bi
##pol
##ar
I
disorder
at
any
time
were
1
%
,
0
%
,
and
1
%
for
patients
treated
with
SA
##P
##H
##RI
##S
2
.
5
mg
,
5
mg
,
and
10
mg
twice
daily
,
respectively
,
versus
3
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
*
Take
1
D
##U
##AV
##EE
tablet
at
the
same
time
each
day
.
[SEP]
[CLS]
*
are
going
to
have
surgery
or
will
be
on
bed
rest
.
[SEP]
[CLS]
Other
errors
may
be
due
to
extensive
brain
at
##rop
##hy
that
limits
the
ability
to
distinguish
gray
and
white
matter
on
the
Amy
##vid
scan
as
well
as
motion
artifacts
that
di
##sto
##rt
the
image
.
[SEP]
[CLS]
No
serious
adverse
events
occurred
in
patients
who
received
X
##E
##OM
##IN
;
one
place
##bo
-
treated
patient
experienced
a
serious
adverse
event
(
d
##ys
##p
##nea
)
.
[SEP]
[CLS]
V
##as
##cular
Events
V
##as
##cular
events
,
including
hem
##or
##r
##ha
##gic
strokes
,
and
peripheral
art
##erial
o
##cc
##lus
##ive
disease
were
reported
in
pre
##market
##ing
clinical
trials
in
patients
who
received
G
##IL
##EN
##Y
##A
doses
(
1
.
25
-
5
mg
)
higher
than
recommended
for
use
in
MS
.
[SEP]
[CLS]
In
clinical
trials
with
IN
##L
##Y
##TA
,
gas
##tro
##int
##est
##inal
per
##fo
##ration
was
reported
in
5
/
71
##5
patients
(
1
%
)
,
including
one
death
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
at
an
Inc
##iden
##ce
of
2
%
or
More
Among
SA
##P
##H
##RI
##S
-
T
##reate
##d
(
Ad
##junct
##ive
)
B
##ip
##olar
Pat
##ients
:
Ad
##verse
reactions
associated
with
the
use
of
SA
##P
##H
##RI
##S
(
incidence
of
2
%
or
greater
,
rounded
to
the
nearest
percent
,
and
SA
##P
##H
##RI
##S
incidence
greater
than
place
##bo
)
that
occurred
during
acute
ad
##junct
##ive
therapy
at
3
weeks
,
a
time
when
most
of
the
patients
were
still
participating
in
the
trial
,
are
shown
in
Table
11
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Most
Common
##ly
Leading
to
Disco
##ntin
##uation
of
Treatment
in
Pre
##market
##ing
Control
##led
Trials
The
proportion
of
patients
with
C
##ro
##hn
'
s
disease
who
discontinued
treatment
due
to
adverse
reactions
in
the
controlled
clinical
studies
was
8
%
for
C
##IM
##Z
##IA
and
7
%
for
place
##bo
.
[SEP]
[CLS]
5
.
7
Co
##ex
##ist
##ing
Con
##ditions
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
,
like
other
s
##ym
##path
##omi
##met
##ic
am
##ines
,
should
be
used
with
caution
in
patients
with
con
##vu
##lsive
disorders
or
thy
##rot
##ox
##ico
##sis
,
and
in
patients
who
are
unusually
re
##sp
##ons
##ive
to
s
##ym
##path
##omi
##met
##ic
am
##ines
.
[SEP]
[CLS]
The
safety
and
efficacy
of
C
##IM
##Z
##IA
in
patients
with
im
##mu
##nos
##up
##press
##ion
has
not
been
formally
evaluated
.
[SEP]
[CLS]
Co
-
administration
of
S
##IR
##TU
##RO
with
strong
C
##YP
##3
##A
##4
inhibitor
##s
may
increase
the
systemic
exposure
to
bed
##aq
##uil
##ine
,
which
could
potentially
increase
the
risk
of
adverse
reactions
.
[SEP]
[CLS]
The
incidence
of
di
##zzi
##ness
was
greater
with
the
con
##com
##ita
##nt
use
of
AP
##TI
##OM
and
car
##ba
##ma
##ze
##pine
compared
to
the
use
of
AP
##TI
##OM
without
car
##ba
##ma
##ze
##pine
(
up
to
37
%
vs
.
19
%
,
respectively
)
.
[SEP]
[CLS]
Ad
##vise
women
to
avoid
becoming
pregnant
while
taking
I
##MB
##R
##U
##VI
##CA
.
[SEP]
[CLS]
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
The
majority
of
these
immune
-
mediated
reactions
initially
manifest
##ed
during
treatment
;
however
,
a
minority
occurred
weeks
to
months
after
disco
##ntin
##uation
of
Y
##ER
##VO
##Y
.
[SEP]
[CLS]
Some
women
may
encounter
am
##eno
##rr
##hea
or
o
##li
##go
##men
##or
##r
##hea
after
stopping
CO
##Cs
,
especially
when
such
a
condition
was
pre
-
exist
##ent
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
,
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Consider
administration
of
plate
##let
concentrate
##s
in
cases
where
th
##rom
##bo
##cy
##top
##enia
is
present
or
long
-
acting
anti
##plate
##let
drugs
have
been
used
.
[SEP]
[CLS]
(
5
.
2
)
*
He
##pa
##to
##to
##xi
##city
:
Bel
##eo
##da
##q
may
cause
he
##pa
##tic
toxicity
and
liver
function
test
abnormal
##ities
.
[SEP]
[CLS]
(
5
.
5
)
*
Ana
##phy
##lax
##is
:
Monitor
patients
for
an
##aph
##yla
##xi
##s
and
disco
##ntin
##ue
Z
##yd
##eli
##g
.
[SEP]
[CLS]
5
.
2
I
##maging
E
##rro
##rs
due
to
Con
##com
##ita
##nt
Me
##dication
##s
and
Risk
##s
Associated
with
With
##dra
##wal
of
Me
##dication
##s
Many
medications
have
the
potential
to
interfere
with
Ad
##re
##V
##ie
##w
imaging
and
review
of
the
patient
'
s
medications
is
required
prior
to
Ad
##re
##V
##ie
##w
dos
##ing
due
to
the
risk
for
unreliable
imaging
results
.
[SEP]
[CLS]
5
.
5
P
##ne
##um
##onia
An
increase
in
the
incidence
of
pneumonia
has
been
observed
in
subjects
with
CO
##PD
receiving
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
in
clinical
trials
.
[SEP]
[CLS]
Women
should
be
advised
of
the
potential
hazard
to
the
f
##etus
and
to
avoid
pregnancy
while
on
this
drug
.
[SEP]
[CLS]
CO
##Cs
have
been
shown
to
increase
both
the
relative
and
at
##tri
##but
##able
risks
of
c
##ere
##bro
##vas
##cular
events
(
hem
##or
##r
##ha
##gic
strokes
)
,
although
,
in
general
,
the
risk
is
greatest
among
older
(
>
35
years
of
age
)
,
h
##yper
##tensive
women
who
also
smoke
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Y
##ER
##VO
##Y
in
patients
with
Grade
3
-
5
he
##pa
##to
##to
##xi
##city
and
administer
systemic
co
##rt
##ico
##ster
##oids
at
a
dose
of
1
to
2
mg
/
kg
/
day
of
pre
##dn
##ison
##e
or
equivalent
.
[SEP]
[CLS]
Inc
##rea
##sing
use
of
inhaled
,
short
-
acting
beta
##2
-
ago
##nist
##s
is
a
marker
of
de
##ter
##ior
##ating
as
##th
##ma
.
[SEP]
[CLS]
Ad
##verse
reactions
are
categorized
by
system
organ
class
.
[SEP]
[CLS]
Fe
##rri
##p
##ro
##x
can
also
cause
ne
##ut
##rop
##enia
,
which
may
fore
##sha
##do
##w
a
##gra
##nu
##loc
##yt
##osis
.
[SEP]
[CLS]
Table
3
B
##lee
##ding
Events
in
R
##E
-
CO
##VE
##R
and
R
##E
-
CO
##VE
##R
II
T
##reate
##d
Pat
##ients
Note
:
MBE
can
belong
to
more
than
one
criterion
.
[SEP]
[CLS]
Risk
may
be
increased
with
con
##com
##ita
##nt
use
of
other
C
##NS
de
##press
##ants
.
[SEP]
[CLS]
Pat
##ients
should
not
use
more
than
1
in
##hala
##tion
once
daily
of
BR
##E
##O
E
##LL
##IP
##TA
.
[SEP]
[CLS]
Oral
con
##tra
##ceptive
##s
must
be
used
with
caution
in
women
with
card
##iovascular
disease
risk
factors
.
[SEP]
[CLS]
*
Se
##vere
pen
##ile
hem
##ato
##ma
was
also
reported
as
an
adverse
reaction
in
39
of
104
##4
patients
(
3
.
7
%
)
in
the
controlled
and
un
##con
##tro
##lled
clinical
trials
in
P
##ey
##ron
##ie
'
s
disease
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
If
the
patient
is
known
or
strongly
suspected
to
have
h
##yper
##sen
##si
##ti
##vity
to
i
##od
##ine
,
an
i
##od
##ine
-
containing
contrast
agent
or
other
products
containing
i
##od
##ine
,
the
decision
to
administer
Ad
##re
##V
##ie
##w
should
be
based
upon
an
assessment
of
the
expected
benefits
compared
to
the
potential
h
##yper
##sen
##si
##ti
##vity
risks
.
[SEP]
[CLS]
Disco
##ntin
##ue
Z
##yd
##eli
##g
if
in
##test
##inal
per
##fo
##ration
is
suspected
.
[SEP]
[CLS]
5
.
14
Other
Con
##ditions
In
women
with
hereditary
an
##gio
##ede
##ma
,
ex
##ogen
##ous
est
##rogen
##s
may
induce
or
ex
##ace
##rb
##ate
symptoms
of
an
##gio
##ede
##ma
.
[SEP]
[CLS]
The
rate
of
progression
of
re
##tina
##l
abnormal
##ities
and
their
re
##vers
##ibility
are
unknown
.
[SEP]
[CLS]
Tu
##ber
##cu
##los
##is
and
Op
##port
##uni
##stic
In
##fect
##ions
In
completed
and
ongoing
global
clinical
studies
in
all
indication
##s
including
5
,
118
C
##IM
##Z
##IA
-
treated
patients
,
the
overall
rate
of
tuberculosis
is
approximately
0
.
61
per
100
patient
-
years
across
all
indication
##s
.
[SEP]
[CLS]
Doc
##ume
##nted
s
##ym
##pt
##oma
##tic
h
##y
##po
##gly
##ce
##mia
occurred
in
85
%
and
80
%
of
patients
when
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
and
1
.
5
mg
,
respectively
,
was
co
-
administered
with
p
##rand
##ial
insulin
.
[SEP]
[CLS]
E
##pile
##psy
and
many
other
illness
##es
for
which
A
##ED
##s
are
prescribed
are
themselves
associated
with
m
##or
##bid
##ity
and
mortality
and
an
increased
risk
of
su
##icidal
thoughts
.
[SEP]
[CLS]
Fr
##e
##quent
symptoms
of
h
##yper
##sen
##si
##ti
##vity
reactions
(
occurring
in
more
than
2
patients
)
included
an
##aph
##yla
##ctic
reactions
,
u
##rt
##ica
##ria
,
peripheral
ed
##ema
,
cough
,
d
##ys
##p
##nea
,
and
flush
##ing
.
[SEP]
[CLS]
These
findings
confirm
the
my
##elo
##su
##pp
##ress
##ive
effects
seen
in
patients
treated
with
T
##RE
##AN
##DA
.
[SEP]
[CLS]
A
##vo
##id
use
of
X
##AL
##KO
##RI
in
patients
with
con
##gen
##ital
long
Q
##T
syndrome
.
[SEP]
[CLS]
Other
binding
proteins
may
be
elevated
in
serum
,
for
example
,
co
##rt
##ico
##ster
##oid
binding
g
##lo
##bul
##in
)
,
leading
to
increased
total
circulating
co
##rt
##ico
##ster
##oids
,
respectively
.
[SEP]
[CLS]
IN
##L
##Y
##TA
has
not
been
studied
in
patients
with
severe
he
##pa
##tic
imp
##air
##ment
(
Child
-
P
##ugh
class
C
)
[
see
##D
##osa
##ge
and
Administration
(
2
.
2
)
,
Use
in
S
##pecific
Population
##s
(
8
.
6
)
,
and
##C
##lini
##cal
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
5
.
11
I
##mm
##uno
##su
##pp
##ression
Since
T
##NF
media
##tes
inflammation
and
m
##od
##ulates
cellular
immune
responses
,
the
possibility
exists
for
T
##NF
block
##ers
,
including
C
##IM
##Z
##IA
,
to
affect
host
defenses
against
infections
and
ma
##li
##gna
##ncies
.
[SEP]
[CLS]
Following
the
second
dose
,
a
further
decrease
in
heart
rate
may
occur
when
compared
to
the
heart
rate
prior
to
the
second
dose
,
but
this
change
is
of
a
smaller
magnitude
than
that
observed
following
the
first
dose
.
[SEP]
[CLS]
The
proportion
of
patients
with
r
##he
##uma
##to
##id
art
##hr
##itis
who
discontinued
treatment
due
to
adverse
reactions
in
the
controlled
clinical
studies
was
5
%
for
C
##IM
##Z
##IA
and
2
.
5
%
for
place
##bo
.
[SEP]
[CLS]
Without
knowledge
of
the
background
incidence
and
re
##cu
##rrence
in
a
similar
population
not
treated
with
g
##aba
##pent
##in
,
it
is
impossible
to
know
whether
the
incidence
reported
in
this
co
##hor
##t
is
or
is
not
affected
by
treatment
.
[SEP]
[CLS]
I
##mm
##une
-
mediated
der
##mat
##itis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Laboratory
A
##b
##nor
##mal
##ities
Table
8
describes
Grade
3
-
4
laboratory
abnormal
##ities
reported
at
a
rate
of
>
10
%
for
patients
who
received
K
##y
##p
##rol
##is
mon
##otherapy
.
[SEP]
[CLS]
The
risk
of
acute
kidney
injury
may
increase
with
increasing
dose
of
the
contrast
agent
;
administer
the
lowest
dose
necessary
for
adequate
imaging
.
[SEP]
[CLS]
During
the
trial
,
48
%
of
patients
on
the
X
##TA
##ND
##I
arm
and
46
%
of
patients
on
the
place
##bo
arm
received
g
##lu
##co
##cor
##tic
##oids
.
[SEP]
[CLS]
Out
of
2
,
133
patients
in
3
clinical
trials
,
a
total
of
14
deaths
occurred
during
the
place
##bo
-
controlled
,
double
-
blind
treatment
periods
:
3
/
67
##5
(
0
.
4
%
)
,
5
/
67
##3
(
0
.
7
%
)
,
0
/
111
(
0
%
)
,
and
6
/
67
##4
(
0
.
9
%
)
deaths
in
the
groups
receiving
place
##bo
,
B
##EN
##L
##Y
##ST
##A
1
mg
/
kg
,
B
##EN
##L
##Y
##ST
##A
4
mg
/
kg
,
and
B
##EN
##L
##Y
##ST
##A
10
mg
/
kg
,
respectively
.
[SEP]
[CLS]
The
mean
age
was
39
years
;
adolescent
##s
(
aged
12
to
17
years
)
made
up
16
%
of
the
population
.
[SEP]
[CLS]
The
adverse
events
observed
during
long
-
term
,
open
-
label
studies
were
similar
to
those
observed
in
the
12
-
week
,
place
##bo
-
controlled
studies
,
and
included
dry
mouth
,
con
##st
##ip
##ation
,
dry
eyes
,
d
##ys
##pe
##ps
##ia
,
and
abdominal
pain
.
[SEP]
[CLS]
In
short
-
term
trials
with
E
##NT
##ER
##EG
(
r
)
,
no
increased
risk
of
my
##oc
##ard
##ial
in
##far
##ction
was
observed
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
treatment
disco
##ntin
##uation
in
the
J
##E
##V
##TA
##NA
group
were
ne
##ut
##rop
##enia
and
re
##nal
failure
.
[SEP]
[CLS]
5
.
9
Auto
##im
##mu
##nity
Treatment
with
C
##IM
##Z
##IA
may
result
in
the
formation
of
auto
##anti
##bo
##dies
and
rarely
,
in
the
development
of
a
l
##up
##us
-
like
syndrome
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
AN
##AP
##H
##Y
##LA
##X
##IS
WA
##R
##NI
##NG
:
AN
##AP
##H
##Y
##LA
##X
##IS
Ana
##phy
##lax
##is
has
been
reported
after
administration
of
K
##AL
##BI
##TO
##R
.
[SEP]
[CLS]
Close
##ly
observe
patients
with
G
##6
##PD
deficiency
for
signs
of
hem
##oly
##tic
an
##emia
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Division
of
Nuclear
Medicine
,
Department
of
Radio
##logy
,
Mayo
Clinic
at
50
##7
-
28
##4
-
251
##1
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
I
##maging
errors
have
been
reported
;
blood
PS
##A
levels
<
2
ng
/
m
##L
have
been
associated
with
poor
imaging
performance
(
5
.
1
)
.
[SEP]
[CLS]
5
.
2
Monitor
##ing
Met
##hot
##re
##xa
##te
Con
##cent
##ration
/
Inter
##ference
with
As
##say
Met
##hot
##re
##xa
##te
concentrations
within
48
hours
following
administration
of
V
##OR
##A
##X
##A
##Z
##E
can
only
be
re
##lia
##bly
measured
by
a
ch
##roma
##to
##graphic
method
.
[SEP]
[CLS]
Pat
##ients
should
be
informed
of
the
signs
and
symptoms
of
an
##aph
##yla
##xi
##s
and
instructed
to
disco
##ntin
##ue
AM
##P
##Y
##RA
and
seek
immediate
medical
care
should
these
signs
and
symptoms
occur
(
17
.
3
)
.
[SEP]
[CLS]
Elder
##ly
Population
:
The
following
grade
1
-
4
adverse
reactions
were
reported
at
rates
>
=
5
%
higher
in
patients
65
years
of
age
or
greater
compared
to
younger
patients
:
fatigue
(
40
%
vs
.
30
%
)
,
ne
##ut
##rop
##enia
(
97
%
vs
.
89
%
)
,
as
##the
##nia
(
24
%
vs
.
15
%
)
,
p
##yre
##xia
(
15
%
vs
.
8
%
)
,
di
##zzi
##ness
(
10
%
vs
.
5
%
)
,
u
##rina
##ry
tract
infection
(
10
%
vs
.
3
%
)
and
de
##hy
##dra
##tion
(
7
%
vs
.
2
%
)
,
respectively
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
LA
##BA
,
such
as
v
##ila
##nter
##ol
,
one
of
the
active
ingredients
in
BR
##E
##O
E
##LL
##IP
##TA
,
increase
the
risk
of
as
##th
##ma
-
related
death
.
[SEP]
[CLS]
Q
##T
Pro
##long
##ation
:
In
Trial
2
,
Q
##T
##c
##F
pro
##long
##ation
to
>
500
m
##se
##c
occurred
in
4
%
(
2
/
55
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
and
in
2
%
(
1
/
53
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
The
reported
end
##ome
##tri
##al
cancer
risk
among
unopposed
est
##rogen
users
is
about
2
to
12
times
greater
than
in
non
-
users
,
and
appears
dependent
on
duration
of
treatment
and
on
est
##rogen
dose
.
[SEP]
[CLS]
5
.
3
Inc
##reased
Risk
of
St
##roke
in
Permanent
A
##F
In
a
place
##bo
-
controlled
study
in
patients
with
permanent
at
##rial
fi
##bri
##lla
##tion
,
drone
##dar
##one
was
associated
with
an
increased
risk
of
stroke
,
particularly
in
the
first
two
weeks
of
therapy
[
see
Clinical
Studies
(
14
.
4
)
]
.
[SEP]
[CLS]
Consider
##ation
should
be
given
to
the
following
:
*
Pat
##ients
should
be
stable
on
alpha
-
block
##er
therapy
prior
to
in
##iti
##ating
treatment
with
a
PD
##E
##5
inhibitor
.
[SEP]
[CLS]
Seven
of
the
patients
treated
with
PR
##OM
##AC
##TA
in
the
controlled
trials
with
he
##pa
##to
##bil
##iary
laboratory
abnormal
##ities
were
re
-
exposed
to
PR
##OM
##AC
##TA
in
the
extension
trial
.
[SEP]
[CLS]
Period
##ic
skin
examinations
are
recommended
for
all
patients
,
particularly
those
with
risk
factors
for
skin
cancer
.
[SEP]
[CLS]
5
.
3
A
##cute
Kid
##ney
In
##ju
##ry
In
patients
with
chronic
re
##nal
imp
##air
##ment
,
acute
kidney
injury
sometimes
requiring
dial
##ys
##is
has
been
observed
with
the
use
of
some
GB
##CA
##s
.
[SEP]
[CLS]
(
2
.
4
,
5
.
1
)
*
Card
##iovascular
Events
:
A
higher
rate
of
card
##iovascular
th
##rom
##boe
##mbo
##lic
events
was
observed
in
patients
treated
with
U
##L
##OR
##IC
than
all
##op
##uri
##no
##l
in
clinical
trials
.
[SEP]
[CLS]
Screen
##ing
patients
for
bi
##pol
##ar
disorder
A
major
de
##pressive
episode
may
be
the
initial
presentation
of
bi
##pol
##ar
disorder
.
[SEP]
[CLS]
(
14
.
4
)
.
[SEP]
[CLS]
5
.
7
Al
##co
##hol
Pat
##ients
should
be
made
aware
that
both
alcohol
and
PD
##E
##5
inhibitor
##s
including
ST
##EN
##DR
##A
act
as
v
##as
##od
##ila
##tors
.
[SEP]
[CLS]
Blood
and
l
##ymph
##atic
system
disorders
-
An
##emia
,
E
##os
##ino
##phi
##lia
,
N
##eu
##tro
##pen
##ia
,
T
##hr
##omb
##oc
##yt
##ope
##nia
Card
##iac
disorders
-
Brady
##card
##ia
,
Pa
##l
##pit
##ations
Gas
##tro
##int
##est
##inal
disorders
-
Abd
##omi
##nal
pain
General
disorders
and
administration
site
conditions
-
P
##yre
##xia
He
##pa
##to
##bil
##iary
disorders
-
He
##pa
##titis
I
##mm
##une
system
disorders
-
H
##yper
##sen
##si
##ti
##vity
,
Ana
##phy
##lax
##is
In
##fect
##ions
and
in
##fest
##ations
-
C
##los
##tri
##dium
di
##ff
##ici
##le
co
##lit
##is
Met
##ab
##olis
##m
and
nutrition
disorders
-
H
##yper
##gly
##ce
##mia
,
H
##yper
##kal
##emia
N
##er
##vous
system
disorders
-
Di
##zzi
##ness
,
Con
##vu
##ls
##ion
Ren
##al
and
u
##rina
##ry
disorders
-
Ren
##al
failure
Skin
and
sub
##cut
##aneous
tissue
disorders
-
U
##rt
##ica
##ria
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reaction
has
been
identified
during
post
##ap
##p
##rov
##al
use
of
Te
##f
##lar
##o
.
[SEP]
[CLS]
The
risk
of
acute
kidney
injury
might
be
lower
with
E
##O
##VI
##ST
due
to
its
dual
ex
##cre
##tory
pathways
.
[SEP]
[CLS]
*
?
[SEP]
[CLS]
(
5
.
1
,
5
.
2
,
12
.
3
)
*
Anti
##mal
##aria
##ls
should
not
be
given
con
##com
##ita
##ntly
,
unless
there
is
no
other
treatment
option
,
due
to
limited
safety
data
.
[SEP]
[CLS]
The
effect
of
treatment
with
D
##U
##AV
##EE
on
the
risk
of
breast
cancer
is
unknown
.
[SEP]
[CLS]
5
.
7
El
##eva
##ted
Blood
Press
##ure
In
a
small
number
of
case
reports
in
women
receiving
est
##rogen
##s
,
substantial
increases
in
blood
pressure
have
been
attributed
to
id
##ios
##ync
##ratic
reactions
to
est
##rogen
##s
.
[SEP]
[CLS]
Even
in
the
absence
of
T
##NF
-
block
##er
therapy
,
patients
with
RA
may
be
at
a
higher
risk
(
approximately
2
-
fold
)
than
the
general
population
for
the
development
of
le
##uke
##mia
.
[SEP]
[CLS]
Most
h
##yper
##sen
##si
##ti
##vity
reactions
to
G
##ada
##vist
have
occurred
within
half
an
hour
after
administration
.
[SEP]
[CLS]
In
patients
with
permanent
A
##F
,
M
##U
##LT
##A
##Q
doubles
the
risk
of
death
,
stroke
,
and
hospital
##ization
for
heart
failure
.
[SEP]
[CLS]
O
##bs
##erve
for
h
##yper
##sen
##si
##ti
##vity
signs
and
symptoms
following
V
##iza
##my
##l
administration
.
[SEP]
[CLS]
Experience
in
System
##ic
Ana
##p
##lastic
Large
Cell
L
##ymph
##oma
Su
##mma
##ry
of
Clinical
Trial
Experience
in
Re
##lap
##sed
s
##AL
##CL
(
Study
2
)
AD
##CE
##TR
##IS
was
studied
in
58
patients
with
s
##AL
##CL
in
a
single
arm
clinical
trial
in
which
the
recommended
starting
dose
and
schedule
was
1
.
8
mg
/
kg
in
##tra
##ven
##ously
every
3
weeks
.
[SEP]
[CLS]
5
.
2
EC
##G
Changes
and
Po
##ten
##tial
for
Card
##iac
A
##rr
##hy
##th
##mia
##s
Use
of
CE
##RD
##EL
##GA
in
patients
with
pre
-
existing
cardiac
conditions
has
not
been
studied
during
clinical
trials
.
[SEP]
[CLS]
He
##pa
##tic
Laboratory
A
##b
##nor
##mal
##ities
:
The
incidence
##s
of
grade
3
-
4
increased
AS
##T
,
increased
AL
##T
,
and
increased
bi
##li
##ru
##bin
were
each
<
=
1
%
.
[SEP]
[CLS]
U
##rina
##ry
tract
infections
occurred
more
frequently
in
female
patients
.
[SEP]
[CLS]
J
##AR
##DI
##AN
##CE
may
increase
the
risk
of
h
##y
##pot
##ens
##ion
in
patients
at
risk
for
volume
contraction
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
and
Use
in
S
##pecific
Population
##s
(
8
.
5
,
8
.
6
)
]
.
[SEP]
[CLS]
C
##aut
##ion
patients
about
risk
of
bleeding
associated
with
con
##com
##ita
##nt
use
of
PR
##IS
##TI
##Q
and
NSA
##ID
##s
,
as
##pi
##rin
,
or
other
drugs
that
affect
co
##agu
##lation
(
5
.
4
)
.
[SEP]
[CLS]
Pat
##ients
who
develop
symptoms
of
cap
##illa
##ry
leak
syndrome
should
be
closely
monitored
and
receive
standard
s
##ym
##pt
##oma
##tic
treatment
,
which
may
include
a
need
for
intensive
care
.
[SEP]
[CLS]
5
.
11
Em
##b
##ryo
##fe
##tal
To
##xi
##city
Based
on
its
mechanism
of
action
,
T
##AF
##IN
##LA
##R
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
In
addition
,
Grade
1
ins
##om
##nia
was
reported
by
1
%
and
less
than
1
%
of
subjects
receiving
T
##I
##VI
##CA
##Y
and
r
##al
##te
##gra
##vir
,
respectively
,
in
SP
##RI
##NG
-
2
;
whereas
in
S
##ING
##LE
the
rates
were
7
%
and
4
%
for
T
##I
##VI
##CA
##Y
and
AT
##RI
##PL
##A
,
respectively
.
[SEP]
[CLS]
Due
to
overlap
in
signs
and
symptoms
,
it
was
not
possible
to
distinguish
between
h
##yper
##sen
##si
##ti
##vity
reactions
and
in
##fusion
reactions
in
all
cases
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
Place
##bo
patients
whose
tender
and
swollen
joint
counts
had
not
improved
by
at
least
20
%
were
re
-
random
##ized
1
:
1
in
a
blinded
fashion
to
either
O
##TE
##Z
##LA
20
mg
twice
daily
or
30
mg
twice
daily
at
week
16
while
O
##TE
##Z
##LA
patients
remained
on
their
initial
treatment
.
[SEP]
[CLS]
Overall
,
63
%
were
female
and
67
%
were
white
.
[SEP]
[CLS]
In
some
cases
an
##gio
##ede
##ma
occurred
after
the
first
dose
.
[SEP]
[CLS]
Ser
##um
c
##rea
##tin
##ine
Small
re
##versible
increases
in
serum
c
##rea
##tin
##ine
are
seen
in
patients
receiving
80
mg
of
Ed
##ar
##bi
.
[SEP]
[CLS]
H
##yper
##tens
##ion
led
to
study
disco
##ntin
##uation
in
<
1
%
of
patients
in
each
arm
.
[SEP]
[CLS]
Additionally
,
elevations
in
AL
##T
greater
than
five
times
the
U
##L
##N
occurred
in
184
(
11
%
)
and
93
(
5
.
7
%
)
patients
,
respectively
.
[SEP]
[CLS]
In
the
controlled
ad
##junct
##ive
e
##pile
##psy
trials
,
these
events
were
reported
in
13
%
of
place
##bo
patients
,
16
%
of
patients
random
##ized
to
receive
800
mg
/
day
AP
##TI
##OM
,
and
28
%
of
patients
random
##ized
to
receive
1200
mg
/
day
AP
##TI
##OM
.
[SEP]
[CLS]
(
5
.
12
)
*
Suicide
:
The
possibility
of
a
suicide
attempt
is
inherent
in
s
##chi
##zophrenia
and
bi
##pol
##ar
disorder
.
[SEP]
[CLS]
B
##EP
##RE
##VE
should
not
be
ins
##til
##led
while
wearing
contact
lenses
.
[SEP]
[CLS]
Se
##vere
h
##y
##po
##gly
##ce
##mia
occurred
in
0
%
and
0
.
7
%
of
patients
when
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
and
1
.
5
mg
,
respectively
,
was
co
-
administered
with
a
su
##lf
##ony
##lu
##rea
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
R
##ET
##IN
##AL
AB
##N
##OR
##MA
##L
##IT
##IE
##S
AND
P
##OT
##EN
##TI
##AL
VI
##SI
##ON
L
##OS
##S
WA
##R
##NI
##NG
:
R
##ET
##IN
##AL
AB
##N
##OR
##MA
##L
##IT
##IE
##S
AND
P
##OT
##EN
##TI
##AL
VI
##SI
##ON
L
##OS
##S
P
##OT
##IG
##A
can
cause
re
##tina
##l
abnormal
##ities
,
which
are
known
to
result
in
damage
to
the
photo
##re
##ceptor
##s
and
vision
loss
.
[SEP]
[CLS]
An
##ky
##los
##ing
S
##po
##ndy
##lit
##is
Clinical
Study
C
##IM
##Z
##IA
has
been
studied
in
325
patients
with
a
##xial
s
##po
##ndy
##lo
##art
##hr
##itis
of
whom
the
majority
had
an
##ky
##los
##ing
s
##po
##ndy
##lit
##is
(
AS
)
in
a
place
##bo
-
controlled
study
(
AS
-
1
)
.
[SEP]
[CLS]
The
adverse
reactions
reported
most
frequently
as
the
reason
for
disco
##ntin
##uation
of
treatment
included
en
##ce
##pha
##lop
##athy
and
se
##psis
.
[SEP]
[CLS]
In
Study
3
,
finger
extension
procedures
were
performed
approximately
24
to
72
hours
after
injection
.
[SEP]
[CLS]
In
animal
studies
,
administration
of
c
##eri
##tin
##ib
to
rats
and
rabbits
during
organ
##ogen
##esis
at
maternal
plasma
exposure
##s
below
the
recommended
human
dose
of
750
mg
daily
caused
increases
in
skeletal
an
##oma
##lies
in
rats
and
rabbits
.
[SEP]
[CLS]
In
the
breast
cancer
study
,
99
%
of
patients
were
female
,
the
median
age
was
50
years
,
and
86
%
of
patients
were
Caucasian
.
[SEP]
[CLS]
El
##eva
##tions
in
AL
##T
greater
than
5
times
the
upper
limit
of
normal
have
occurred
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Monitor
patients
with
advanced
stage
disease
and
/
or
high
tumor
burden
and
take
appropriate
pre
##ca
##ution
##s
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Based
on
the
severity
of
the
adverse
drug
reaction
,
with
##hold
Z
##Y
##KA
##DI
##A
with
re
##sumption
at
a
reduced
dose
,
or
permanently
disco
##ntin
##ue
Z
##Y
##KA
##DI
##A
as
described
in
Table
1
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
Ex
##c
##lude
other
potential
causes
of
IL
##D
/
p
##ne
##um
##oni
##tis
,
and
permanently
disco
##ntin
##ue
Z
##Y
##KA
##DI
##A
in
patients
diagnosed
with
treatment
-
related
IL
##D
/
p
##ne
##um
##oni
##tis
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
Corporal
R
##up
##ture
and
Other
Ser
##ious
Pen
##ile
In
##ju
##ry
*
Corporal
r
##up
##ture
was
reported
as
an
adverse
reaction
after
XI
##AF
##LE
##X
injection
##s
in
5
of
104
##4
(
0
.
5
%
)
XI
##AF
##LE
##X
treated
patients
.
[SEP]
[CLS]
Benz
##yl
alcohol
has
been
associated
with
a
fatal
`
`
Gas
##ping
S
##yn
##drome
'
'
in
premature
infants
and
infants
of
low
birth
weight
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
estimate
re
##lia
##bly
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
The
R
##E
-
ME
##D
##Y
and
R
##E
-
S
##ON
##AT
##E
studies
provided
safety
information
on
the
use
of
PR
##AD
##A
##X
##A
for
the
reduction
in
the
risk
of
re
##cu
##rrence
of
deep
vein
th
##rom
##bos
##is
and
pulmonary
em
##bol
##ism
.
[SEP]
[CLS]
(
5
.
1
)
*
Ad
##vise
patients
taking
Fe
##rri
##p
##ro
##x
to
report
immediately
any
symptoms
in
##dicative
of
infection
.
[SEP]
[CLS]
A
##cute
symptoms
should
be
treated
with
an
inhaled
,
short
-
acting
beta
##2
-
ago
##nist
.
[SEP]
[CLS]
In
this
pool
,
a
total
of
33
##42
patients
with
type
2
diabetes
were
treated
with
T
##R
##U
##L
##IC
##IT
##Y
for
a
mean
duration
of
52
weeks
.
[SEP]
[CLS]
At
base
##line
,
the
population
had
diabetes
for
an
average
of
8
.
0
years
and
had
a
mean
H
##b
##A
##1
##c
of
8
.
0
%
.
[SEP]
[CLS]
Table
1
Ad
##verse
reactions
observed
in
>
1
%
of
patients
with
acute
attacks
of
H
##A
##E
and
at
a
higher
rate
with
F
##IR
##A
##Z
##Y
##R
versus
place
##bo
in
the
place
##bo
-
controlled
trials
##E
##vent
##s
occurring
within
14
days
of
study
drug
administration
F
##IR
##A
##Z
##Y
##R
(
N
=
77
)
Place
##bo
(
N
=
75
)
System
Organ
Class
##P
##re
##ferred
Te
##rm
Sub
##jects
(
%
)
Sub
##jects
(
%
)
General
disorders
and
administration
site
conditions
In
##jection
site
reaction
75
(
97
)
25
(
33
)
P
##yre
##xia
3
(
4
)
0
Investigation
##s
Trans
##ami
##nas
##e
increased
3
(
4
)
0
N
##er
##vous
system
disorders
Di
##zzi
##ness
2
(
3
)
1
(
1
)
The
third
trial
was
active
-
controlled
and
was
comprised
of
35
patients
who
received
F
##IR
##A
##Z
##Y
##R
30
mg
and
38
patients
who
received
the
com
##par
##ator
.
[SEP]
[CLS]
5
.
2
Risk
of
B
##lee
##ding
PR
##AD
##A
##X
##A
increases
the
risk
of
bleeding
and
can
cause
significant
and
,
sometimes
,
fatal
bleeding
.
[SEP]
[CLS]
It
is
not
possible
to
determine
whether
P
##OT
##IG
##A
caused
this
decreased
visual
a
##cu
##ity
,
as
base
##line
assessments
are
not
available
for
these
patients
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
I
##mm
##une
-
mediated
adverse
reactions
:
Permanent
##ly
disco
##ntin
##ue
for
severe
reactions
.
[SEP]
[CLS]
Monitor
for
consequences
of
bone
overs
##up
##press
##ion
(
5
.
9
)
5
.
1
Drug
Products
with
Same
Active
In
##g
##red
##ient
Pro
##lia
contains
the
same
active
ingredient
(
den
##os
##uma
##b
)
found
in
X
##ge
##va
.
[SEP]
[CLS]
Na
##use
##a
and
vomit
##ing
also
occurred
with
these
events
.
[SEP]
[CLS]
Pat
##ients
with
a
prior
der
##mat
##olo
##gic
reaction
with
either
o
##x
##car
##ba
##ze
##pine
or
AP
##TI
##OM
should
not
be
treated
with
AP
##TI
##OM
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
The
median
duration
of
therapy
with
B
##OS
##U
##L
##IF
was
approximately
17
months
(
range
,
0
.
03
to
95
)
for
patients
in
these
studies
.
[SEP]
[CLS]
In
developmental
toxicity
studies
in
mice
,
a
##xi
##tin
##ib
was
te
##rato
##genic
,
em
##b
##ryo
##to
##xi
##c
and
f
##eto
##to
##xi
##c
at
maternal
exposure
##s
that
were
lower
than
human
exposure
##s
at
the
recommended
clinical
dose
.
[SEP]
[CLS]
There
was
an
increased
risk
of
these
adverse
reactions
during
the
t
##it
##ration
period
(
compared
to
the
maintenance
period
)
and
also
in
patients
60
years
of
age
and
older
(
compared
to
younger
adults
)
.
[SEP]
[CLS]
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
should
not
be
used
for
the
relief
of
acute
symptoms
,
i
.
e
.
[SEP]
[CLS]
Ad
##verse
reactions
occurring
in
2
-
5
%
of
subjects
included
anterior
chamber
flare
,
corn
##eal
ed
##ema
,
dry
eye
,
i
##rid
##oc
##y
##c
##lit
##is
,
photo
##ph
##obia
,
and
reduced
visual
a
##cu
##ity
.
[SEP]
[CLS]
Because
these
reactions
were
reported
retrospective
##ly
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
Ta
##per
patients
slowly
from
systemic
co
##rt
##ico
##ster
##oids
if
transferring
to
BR
##E
##O
E
##LL
##IP
##TA
.
[SEP]
[CLS]
6
24
P
##sy
##chia
##tric
disorders
An
##xi
##ety
2
4
Depression
1
2
In
##so
##m
##nia
5
6
Mon
##otherapy
in
P
##ediatric
Pat
##ients
with
B
##ip
##olar
Man
##ia
:
The
following
findings
are
based
on
a
3
-
week
,
place
##bo
-
controlled
trial
for
bi
##pol
##ar
man
##ia
in
which
SA
##P
##H
##RI
##S
was
administered
at
doses
of
2
.
5
mg
,
5
mg
,
or
10
mg
twice
daily
.
[SEP]
[CLS]
Laboratory
Finding
##s
Pat
##ients
treated
with
D
##Y
##SP
##OR
##T
(
r
)
exhibited
a
small
increase
from
base
##line
(
0
.
23
m
##ol
/
L
)
in
mean
blood
glucose
relative
to
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Table
5
:
Common
Ad
##verse
Events
(
>
=
10
%
in
the
K
##R
##d
Arm
)
O
##cc
##ur
##ring
in
Cycle
##s
1
-
12
(
Co
##mb
##ination
Therapy
)
K
##R
##d
=
K
##y
##p
##rol
##is
,
le
##nal
##ido
##mi
##de
,
and
low
-
dose
de
##xa
##met
##has
##one
;
Rd
=
le
##nal
##ido
##mi
##de
and
low
-
dose
de
##xa
##met
##has
##one
a
P
##ne
##um
##onia
includes
preferred
terms
of
pneumonia
,
br
##on
##cho
##p
##ne
##um
##onia
b
Per
##ip
##her
##al
ne
##uro
##path
##ies
NE
##C
includes
preferred
terms
under
H
##LT
peripheral
ne
##uro
##path
##ies
NE
##C
c
D
##ys
##p
##nea
includes
preferred
terms
of
d
##ys
##p
##nea
,
d
##ys
##p
##nea
ex
##ert
##ional
d
Em
##bolic
and
th
##rom
##bot
##ic
events
,
ve
##nous
include
preferred
terms
in
Me
##d
##DR
##A
SM
##Q
narrow
scope
search
of
em
##bolic
and
th
##rom
##bot
##ic
events
,
ve
##nous
.
[SEP]
[CLS]
Similar
to
the
controlled
studies
,
most
adverse
events
of
dry
mouth
and
con
##st
##ip
##ation
were
mild
to
moderate
in
intensity
.
[SEP]
[CLS]
In
##fect
##ions
leading
to
disco
##ntin
##uation
of
treatment
occurred
in
0
.
7
%
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
and
1
.
0
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
*
Ren
##al
F
##ail
##ure
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
*
You
should
not
remove
D
##U
##AV
##EE
from
the
b
##list
##er
until
right
before
you
are
ready
to
take
it
.
[SEP]
[CLS]
Monitor
##ing
of
complete
blood
count
is
recommended
prior
to
the
start
of
A
##FI
##NI
##TO
##R
therapy
and
periodically
thereafter
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
10
%
)
that
occurred
more
commonly
(
>
=
2
%
over
place
##bo
)
in
the
X
##TA
##ND
##I
-
treated
patients
from
the
two
random
##ized
clinical
trials
were
as
##the
##nia
/
fatigue
,
back
pain
,
decreased
appetite
,
con
##st
##ip
##ation
,
art
##hra
##l
##gia
,
di
##ar
##r
##hea
,
hot
flush
,
upper
respiratory
tract
infection
,
peripheral
ed
##ema
,
d
##ys
##p
##nea
,
m
##us
##cu
##los
##kel
##etal
pain
,
weight
decreased
,
headache
,
h
##yper
##tens
##ion
,
and
di
##zzi
##ness
/
ve
##rt
##igo
.
[SEP]
[CLS]
Consider
the
potential
risks
and
benefits
prior
to
the
administration
of
human
g
##ran
##ulo
##cy
##te
colony
-
s
##ti
##mulating
factors
in
patients
with
sick
##le
cell
disease
.
[SEP]
[CLS]
Pat
##ients
with
moderate
re
##nal
imp
##air
##ment
at
base
##line
had
larger
mean
changes
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
and
Use
in
S
##pecific
Population
##s
(
8
.
5
,
8
.
6
)
]
.
[SEP]
[CLS]
For
patients
with
mild
(
Child
-
P
##ugh
class
A
)
or
moderate
(
Child
-
P
##ugh
class
B
)
he
##pa
##tic
imp
##air
##ment
,
a
dose
reduction
is
recommended
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
In
a
clinical
trial
of
liver
transplant
patients
,
use
of
N
##U
##L
##O
##J
##IX
regime
##ns
with
more
frequent
administration
of
be
##lat
##ace
##pt
than
any
of
those
studied
in
kidney
transplant
,
along
with
my
##co
##phe
##no
##late
m
##of
##eti
##l
(
M
##MF
)
and
co
##rt
##ico
##ster
##oids
,
was
associated
with
a
higher
rate
of
g
##raft
loss
and
death
compared
to
the
ta
##c
##rol
##imus
control
arms
.
[SEP]
[CLS]
Del
##ay
in
diagnosis
and
treatment
may
lead
to
permanent
ne
##uro
##logical
sequel
##ae
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
controlled
but
widely
varying
conditions
,
adverse
reaction
rates
observed
in
clinical
trials
of
V
##OR
##A
##X
##A
##Z
##E
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
other
drugs
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
The
experience
in
open
-
label
clinical
trials
is
consistent
with
the
safety
profile
observed
in
the
place
##bo
-
controlled
clinical
trials
.
[SEP]
[CLS]
Pat
##ients
who
se
##ro
##con
##vert
may
be
at
a
higher
risk
of
a
h
##yper
##sen
##si
##ti
##vity
reaction
.
[SEP]
[CLS]
He
##pa
##tic
Trans
##ami
##nas
##es
El
##eva
##tions
of
trans
##ami
##nas
##es
have
been
observed
in
patients
treated
with
IL
##AR
##IS
.
[SEP]
[CLS]
En
##sure
safe
handling
to
protect
the
patient
and
health
care
worker
(
5
.
3
)
.
[SEP]
[CLS]
New
primary
me
##lan
##oma
occurred
in
2
%
(
1
/
53
)
of
patients
receiving
T
##AF
##IN
##LA
##R
as
a
single
agent
and
in
none
of
the
55
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Monitor
serum
glucose
levels
as
clinical
##ly
appropriate
when
T
##AF
##IN
##LA
##R
is
administered
as
a
single
agent
or
when
used
in
combination
with
tram
##eti
##ni
##b
in
patients
with
pre
-
existing
diabetes
or
h
##yper
##gly
##ce
##mia
.
[SEP]
[CLS]
The
most
common
reason
for
dose
reduction
was
an
##emia
,
which
occurred
more
frequently
in
subjects
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
than
in
subjects
receiving
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
.
[SEP]
[CLS]
However
,
the
duration
of
exposure
associated
with
increased
risk
is
not
consistent
across
all
e
##pid
##em
##iol
##og
##ic
studies
,
and
some
report
no
association
.
[SEP]
[CLS]
Most
Common
Ad
##verse
Re
##actions
No
adverse
reactions
occurred
in
greater
than
5
%
of
patients
receiving
Te
##f
##lar
##o
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Bristol
-
Myers
S
##qui
##bb
at
1
-
800
-
72
##1
-
50
##7
##2
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Consider
##ation
should
be
given
to
changing
the
therapeutic
regime
##n
,
including
possibly
disco
##ntin
##uing
the
medication
,
in
patients
whose
depression
is
persistent
##ly
worse
,
or
who
are
experiencing
emerge
##nt
su
##icidal
##ity
or
symptoms
that
might
be
precursor
##s
to
worse
##ning
depression
or
su
##icidal
##ity
,
especially
if
these
symptoms
are
severe
,
abrupt
in
onset
,
or
were
not
part
of
the
patient
'
s
presenting
symptoms
.
[SEP]
[CLS]
The
most
common
reported
adverse
reaction
occurring
in
approximately
25
%
of
subjects
was
a
mild
taste
following
ins
##til
##lation
.
[SEP]
[CLS]
Four
patients
(
1
%
)
treated
with
PR
##OM
##AC
##TA
and
three
patients
in
the
place
##bo
group
(
2
%
)
discontinued
treatment
due
to
he
##pa
##to
##bil
##iary
laboratory
abnormal
##ities
.
[SEP]
[CLS]
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
:
Palma
##r
-
plant
##ar
er
##yt
##hr
##ody
##ses
##the
##sia
syndrome
,
h
##yper
##ker
##ato
##sis
,
h
##yper
##hi
##dr
##osis
.
[SEP]
[CLS]
Additionally
,
the
observed
incidence
of
anti
##body
p
##os
##iti
##vity
in
an
ass
##ay
may
be
influenced
by
several
factors
including
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
In
the
short
-
term
place
##bo
-
controlled
trials
for
both
s
##chi
##zophrenia
and
acute
bi
##pol
##ar
disorder
,
the
incidence
of
adverse
reactions
suggest
##ive
of
body
temperature
increases
was
low
(
<
=
1
%
)
and
comparable
to
place
##bo
(
0
%
)
.
[SEP]
[CLS]
B
##rea
##st
Cancer
The
most
important
random
##ized
clinical
study
providing
information
about
breast
cancer
in
est
##rogen
-
alone
users
is
the
W
##H
##I
sub
##st
##ud
##y
of
daily
con
##ju
##gated
est
##rogen
##s
(
0
.
625
mg
)
-
alone
.
[SEP]
[CLS]
Other
clinical
##ly
important
adverse
reactions
(
N
=
202
)
observed
in
<
10
%
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
were
:
Eye
Di
##sor
##ders
:
Vision
blurred
,
trans
##ient
blind
##ness
.
[SEP]
[CLS]
*
Before
G
##ada
##vist
administration
,
assess
all
patients
for
any
history
of
a
reaction
to
contrast
media
,
br
##on
##chia
##l
as
##th
##ma
and
/
or
all
##ergic
disorders
.
[SEP]
[CLS]
(
4
,
5
.
2
)
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
IN
##CR
##EA
##SE
##D
R
##IS
##K
OF
DE
##AT
##H
,
ST
##RO
##KE
AND
H
##EA
##RT
FA
##IL
##UR
##E
IN
PA
##TI
##EN
##TS
W
##IT
##H
DE
##CO
##MP
##EN
##SA
##TE
##D
H
##EA
##RT
FA
##IL
##UR
##E
OR
P
##ER
##MA
##NE
##NT
AT
##RI
##AL
F
##IB
##RI
##LL
##AT
##ION
M
##U
##LT
##A
##Q
is
con
##tra
##ind
##ica
##ted
in
patients
with
s
##ym
##pt
##oma
##tic
heart
failure
with
recent
de
##com
##pen
##sation
requiring
hospital
##ization
or
NY
##HA
Class
IV
heart
failure
.
[SEP]
[CLS]
Other
adverse
reactions
occurring
in
2
-
5
%
of
subjects
were
eye
irritation
,
headache
,
and
na
##so
##pha
##ryn
##git
##is
.
[SEP]
[CLS]
The
most
common
adverse
reactions
occurring
in
>
2
%
of
patients
receiving
Te
##f
##lar
##o
in
the
pool
##ed
phase
3
clinical
trials
were
di
##ar
##r
##hea
,
nausea
,
and
r
##ash
.
[SEP]
[CLS]
Some
patients
have
been
able
to
be
re
##chal
##len
##ged
and
have
continued
to
receive
al
##g
##lu
##cos
##idas
##e
al
##fa
under
close
clinical
supervision
.
[SEP]
[CLS]
The
majority
of
reports
have
occurred
in
patients
con
##com
##ita
##ntly
receiving
other
medications
that
suppress
the
immune
system
,
which
may
also
contribute
to
H
##B
##V
react
##ivation
.
[SEP]
[CLS]
Drugs
that
pro
##long
the
Q
##T
interval
,
including
anti
##mal
##aria
##ls
such
as
q
##uin
##ine
and
q
##uin
##id
##ine
,
should
be
used
cautiously
following
Co
##arte
##m
Table
##ts
,
due
to
the
long
elimination
half
-
life
of
l
##ume
##fant
##rine
(
3
to
6
days
)
and
the
potential
for
add
##itive
effects
on
the
Q
##T
interval
;
EC
##G
monitoring
is
advised
if
use
of
drugs
that
pro
##long
the
Q
##T
interval
is
medical
##ly
required
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
,
Drug
Inter
##actions
(
7
.
7
)
,
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
5
.
7
He
##mat
##ological
Re
##actions
Rare
reports
of
pan
##cy
##top
##enia
,
including
a
##p
##lastic
an
##emia
,
have
been
reported
with
T
##NF
block
##ers
.
[SEP]
[CLS]
In
the
pool
of
five
place
##bo
-
controlled
clinical
trials
,
adverse
reactions
related
to
volume
de
##ple
##tion
(
e
.
g
.
,
blood
pressure
(
am
##bula
##tory
)
decreased
,
blood
pressure
s
##ys
##to
##lic
decreased
,
de
##hy
##dra
##tion
,
h
##y
##pot
##ens
##ion
,
h
##y
##po
##vo
##lem
##ia
,
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
,
and
s
##ync
##ope
)
were
reported
by
0
.
3
%
,
0
.
5
%
,
and
0
.
3
%
of
patients
treated
with
place
##bo
,
J
##AR
##DI
##AN
##CE
10
mg
,
and
J
##AR
##DI
##AN
##CE
25
mg
respectively
.
[SEP]
[CLS]
Disc
##ard
unused
portion
12
hours
after
stop
##per
pu
##nc
##ture
.
[SEP]
[CLS]
Drugs
that
in
##hibit
C
##YP
##2
##D
##6
and
C
##YP
##3
##A
metabolism
pathways
may
significantly
increase
the
exposure
to
el
##ig
##lus
##tat
and
result
in
pro
##long
##ation
of
the
PR
,
Q
##T
##c
,
and
/
or
Q
##RS
cardiac
intervals
that
could
result
in
cardiac
a
##rr
##hy
##th
##mia
##s
[
see
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
:
Gas
##tri
##tis
,
in
##test
##inal
o
##bs
##truction
.
[SEP]
[CLS]
Re
##actions
can
occur
on
initial
exposure
.
[SEP]
[CLS]
Do
##se
delays
were
reported
in
28
%
of
J
##E
##V
##TA
##NA
-
treated
patients
and
15
%
of
mit
##ox
##ant
##rone
-
treated
patients
.
[SEP]
[CLS]
Study
1
:
Met
##ast
##atic
Cast
##ration
-
Re
##sist
##ant
Pro
##state
Cancer
Following
Ch
##em
##otherapy
Study
1
enrolled
119
##9
patients
with
meta
##static
CR
##PC
who
had
previously
received
do
##ce
##ta
##xe
##l
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
Common
adverse
reactions
(
reported
in
>
=
4
%
of
patients
treated
with
NE
##SI
##NA
25
mg
and
more
frequently
than
in
patients
who
received
place
##bo
)
are
:
na
##so
##pha
##ryn
##git
##is
,
headache
and
upper
respiratory
tract
infection
.
[SEP]
[CLS]
With
##hold
or
disco
##ntin
##ue
G
##IL
##OT
##RI
##F
for
severe
or
worse
##ning
liver
tests
.
[SEP]
[CLS]
Ser
##ious
adverse
events
,
judged
to
be
at
least
possibly
related
to
study
medication
by
the
investigator
and
reported
more
than
once
during
the
open
-
label
treatment
period
of
up
to
3
years
,
included
u
##rina
##ry
retention
(
3
cases
)
,
diver
##tic
##uli
##tis
(
3
cases
)
,
con
##st
##ip
##ation
(
2
cases
)
,
i
##rri
##table
bow
##el
syndrome
(
2
cases
)
,
and
electro
##card
##io
##gram
Q
##T
corrected
interval
pro
##long
##ation
(
2
cases
)
.
[SEP]
[CLS]
Of
the
21
patients
with
moderate
to
life
-
threatening
end
##oc
##rino
##pathy
,
17
patients
required
long
-
term
hormone
replacement
therapy
including
,
most
commonly
,
ad
##rena
##l
hormones
(
n
=
10
)
and
thy
##roid
hormones
(
n
=
13
)
.
[SEP]
[CLS]
Through
96
weeks
,
the
rates
of
adverse
events
leading
to
disco
##ntin
##uation
were
3
%
in
subjects
receiving
T
##I
##VI
##CA
##Y
50
mg
once
daily
+
EP
##Z
##IC
##OM
and
12
%
in
subjects
receiving
AT
##RI
##PL
##A
once
daily
.
[SEP]
[CLS]
Laboratory
A
##b
##nor
##mal
##ities
Trans
##ami
##nas
##e
El
##eva
##tions
:
In
Trials
1
,
2
,
and
3
the
incidence
of
maximum
AS
##T
)
>
8
,
>
5
,
or
>
3
*
U
##L
##N
was
2
%
,
2
%
,
and
6
%
in
K
##AL
##Y
##DE
##CO
-
treated
patients
and
2
%
,
2
%
,
and
8
%
in
place
##bo
-
treated
patients
,
respectively
.
[SEP]
[CLS]
The
median
age
of
patients
was
61
years
(
range
28
-
93
years
)
,
and
75
%
were
Caucasian
.
[SEP]
[CLS]
*
During
and
following
D
##OT
##AR
##EM
administration
,
observe
patients
for
signs
and
symptoms
of
h
##yper
##sen
##si
##ti
##vity
reactions
.
[SEP]
[CLS]
IN
##L
##Y
##TA
has
not
been
studied
in
patients
who
had
a
ve
##nous
th
##rom
##boe
##mbo
##lic
event
within
the
previous
6
months
.
[SEP]
[CLS]
It
is
not
known
if
D
##U
##AV
##EE
is
safe
and
effective
in
people
with
kidney
problems
.
[SEP]
[CLS]
Upper
Lim
##b
Spa
##stic
##ity
Table
6
lists
the
most
frequently
reported
adverse
reactions
(
>
=
2
%
)
in
any
D
##Y
##SP
##OR
##T
(
r
)
dose
group
and
more
frequent
than
place
##bo
in
double
blind
studies
evaluating
the
treatment
of
upper
limb
spa
##stic
##ity
in
adults
with
D
##Y
##SP
##OR
##T
(
r
)
.
[SEP]
[CLS]
(
5
.
6
)
*
Risk
of
impaired
ad
##rena
##l
function
when
transferring
from
systemic
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
The
majority
of
patients
who
reported
serious
depression
or
su
##icidal
behavior
had
a
history
of
depression
or
other
serious
psychiatric
disorders
and
most
were
receiving
ps
##ych
##oa
##ctive
medications
.
[SEP]
[CLS]
Extra
##vas
##ation
into
tissues
during
D
##OT
##AR
##EM
administration
may
result
in
tissue
irritation
[
see
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
2
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reactions
occurring
in
at
least
10
%
of
patients
in
either
Study
1
or
2
,
regardless
of
ca
##usal
##ity
,
using
the
NC
##I
Common
To
##xi
##city
C
##rite
##ria
(
CT
##C
)
Version
3
.
0
,
are
shown
in
Table
2
.
[SEP]
[CLS]
When
pre
##s
##cribing
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
,
the
healthcare
provider
should
also
pre
##s
##cribe
an
inhaled
,
short
-
acting
beta
##2
-
ago
##nist
and
ins
##truct
the
patient
on
how
it
should
be
used
.
[SEP]
[CLS]
Co
##gni
##tive
D
##ys
##function
AP
##TI
##OM
causes
dose
-
dependent
increases
in
cognitive
d
##ys
##function
-
related
events
(
memory
imp
##air
##ment
,
disturbance
in
attention
,
am
##nesia
,
confusion
##al
state
,
a
##pha
##sia
,
speech
disorder
,
slow
##ness
of
thought
,
di
##sor
##ient
##ation
,
and
ps
##ych
##omo
##tor
re
##tar
##dation
)
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
I
##OP
)
increase
-
Pro
##long
##ed
use
of
co
##rt
##ico
##ster
##oids
may
result
in
g
##lau
##com
##a
with
damage
to
the
op
##tic
nerve
,
defects
in
visual
a
##cu
##ity
.
[SEP]
[CLS]
B
##lee
##ding
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
Table
2
shows
the
number
of
ad
##ju
##dicated
major
bleeding
events
during
the
treatment
period
in
the
R
##E
-
L
##Y
study
,
with
the
bleeding
rate
per
100
subject
-
years
(
%
)
.
[SEP]
[CLS]
The
incidence
of
all
-
cause
mortality
was
0
.
8
%
(
n
=
1
)
in
the
place
##bo
group
and
0
.
8
%
(
n
=
1
)
in
the
Pro
##lia
group
.
[SEP]
[CLS]
Women
of
child
##be
##aring
potential
should
be
advised
to
avoid
becoming
pregnant
while
receiving
IN
##L
##Y
##TA
.
[SEP]
[CLS]
Clinical
##ly
important
chemistry
laboratory
values
that
were
new
or
worse
##ned
from
base
##line
and
occurred
in
>
1
%
of
patients
at
Grade
3
or
4
,
in
NHL
patients
treated
in
both
single
arm
studies
combined
were
h
##yper
##gly
##ce
##mia
(
3
%
)
,
elevated
c
##rea
##tin
##ine
(
2
%
)
,
h
##y
##po
##nat
##rem
##ia
(
2
%
)
,
and
h
##y
##po
##cal
##ce
##mia
(
2
%
)
.
[SEP]
[CLS]
Re
##mo
##ve
contact
lenses
prior
to
ins
##til
##lation
of
B
##EP
##RE
##VE
.
[SEP]
[CLS]
5
.
5
Second
Primary
Mali
##gna
##ncies
Other
ma
##li
##gna
##ncies
(
range
,
5
to
14
%
)
including
non
-
skin
car
##cin
##oma
##s
(
range
,
1
to
3
%
)
have
occurred
in
patients
treated
with
I
##MB
##R
##U
##VI
##CA
.
[SEP]
[CLS]
Ser
##ious
Ad
##verse
Re
##actions
:
my
##oc
##ard
##ial
in
##far
##ction
(
2
cases
)
,
r
##up
##tured
o
##var
##ian
c
##ys
##t
(
2
cases
)
,
deep
vein
th
##rom
##bos
##is
,
focal
nod
##ular
h
##yper
##p
##lasia
of
the
liver
,
u
##ter
##ine
le
##io
##my
##oma
,
acute
ch
##ole
##cy
##st
##itis
,
and
chronic
a
##cal
##cu
##lous
ch
##ole
##cy
##st
##itis
.
[SEP]
[CLS]
Pat
##ients
treated
with
con
##com
##ita
##nt
im
##mu
##nos
##up
##press
##ants
(
M
##T
##X
)
had
a
lower
rate
of
anti
##body
development
than
patients
not
taking
im
##mu
##nos
##up
##press
##ants
at
base
##line
.
[SEP]
[CLS]
The
infections
consisted
primarily
of
upper
respiratory
infections
(
20
%
for
C
##IM
##Z
##IA
,
13
%
for
place
##bo
)
.
[SEP]
[CLS]
The
mean
age
of
patients
was
56
years
,
2
%
were
75
years
or
older
and
51
%
were
male
.
[SEP]
[CLS]
5
.
2
He
##pa
##to
##to
##xi
##city
Drug
-
induced
he
##pa
##to
##to
##xi
##city
occurred
in
patients
treated
with
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
in
>
=
5
%
of
XI
##AF
##LE
##X
-
T
##reate
##d
Pat
##ients
with
Du
##pu
##yt
##ren
'
s
Con
##tract
##ure
and
at
a
Greater
Inc
##iden
##ce
than
Place
##bo
in
the
Place
##bo
-
Control
##led
Trials
Through
Day
90
After
Up
to
3
In
##jection
##s
a
Most
of
these
events
were
swelling
of
the
injected
hand
.
[SEP]
[CLS]
5
.
2
I
##mm
##une
-
mediated
He
##pa
##titis
In
Study
1
,
severe
,
life
-
threatening
,
or
fatal
he
##pa
##to
##to
##xi
##city
(
AL
##T
elevations
of
more
than
5
times
the
upper
limit
of
normal
or
total
bi
##li
##ru
##bin
elevations
more
than
3
times
the
upper
limit
of
normal
;
Grade
3
-
5
)
occurred
in
8
(
2
%
)
Y
##ER
##VO
##Y
-
treated
patients
,
with
fatal
he
##pa
##tic
failure
in
0
.
2
%
and
hospital
##ization
in
0
.
4
%
of
Y
##ER
##VO
##Y
-
treated
patients
.
[SEP]
[CLS]
The
data
reflect
the
percentage
of
patients
whose
test
results
were
considered
positive
for
antibodies
to
c
##ert
##oli
##zu
##ma
##b
p
##ego
##l
in
an
E
##L
##IS
##A
,
and
are
highly
dependent
on
the
sensitivity
and
specific
##ity
of
the
ass
##ay
.
[SEP]
[CLS]
En
##sure
safe
handling
to
protect
patients
and
health
care
workers
from
un
##int
##ent
##ional
radiation
exposure
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
In
the
controlled
and
un
##con
##tro
##lled
clinical
studies
of
XI
##AF
##LE
##X
in
P
##ey
##ron
##ie
'
s
disease
,
104
##4
patients
received
a
total
of
74
##6
##6
XI
##AF
##LE
##X
injection
##s
.
[SEP]
[CLS]
Ad
##ren
##oc
##ort
##ical
ins
##uff
##iciency
was
reported
in
patients
receiving
Z
##Y
##TI
##GA
in
combination
with
pre
##dn
##ison
##e
,
following
interrupt
##ion
of
daily
s
##tero
##ids
and
/
or
with
concurrent
infection
or
stress
.
[SEP]
[CLS]
Monitor
AL
##T
and
AS
##T
in
all
patients
every
2
weeks
for
the
first
3
months
of
treatment
,
every
4
weeks
for
the
next
3
months
,
then
every
1
to
3
months
thereafter
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
*
Most
common
adverse
reaction
to
G
##RA
##NI
##X
is
bone
pain
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
T
##E
##VA
at
1
-
86
##6
-
83
##2
-
85
##37
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
(
5
.
1
)
*
Inter
##rup
##t
Fe
##rri
##p
##ro
##x
if
infection
develops
and
monitor
the
AN
##C
more
frequently
.
[SEP]
[CLS]
(
5
.
1
)
*
Pat
##ients
who
fail
to
show
substantial
clinical
benefit
after
adequate
t
##it
##ration
should
be
discontinued
from
P
##OT
##IG
##A
.
[SEP]
[CLS]
5
.
13
Drug
Inter
##actions
Women
who
take
medications
that
are
strong
c
##yt
##och
##rome
P
##45
##0
3
##A
##4
(
C
##YP
##3
##A
##4
)
induce
##rs
(
for
example
,
car
##ba
##ma
##ze
##pine
,
p
##hen
##yt
##oi
##n
,
r
##if
##amp
##ici
##n
,
and
St
.
John
'
s
w
##ort
)
should
not
choose
Nat
##azi
##a
as
their
oral
con
##tra
##ceptive
while
using
these
induce
##rs
and
for
at
least
28
days
after
disco
##ntin
##uation
of
these
induce
##rs
due
to
the
possibility
of
decreased
con
##tra
##ceptive
efficacy
.
[SEP]
[CLS]
Approximately
one
third
of
the
patients
who
had
eye
examinations
performed
after
approximately
4
years
of
treatment
were
found
to
have
re
##tina
##l
pig
##mentary
abnormal
##ities
.
[SEP]
[CLS]
For
the
100
mg
dose
of
PR
##IS
##TI
##Q
the
disco
##ntin
##uation
rate
due
to
an
adverse
reaction
was
8
.
7
%
.
[SEP]
[CLS]
*
A
24
-
week
open
-
label
trial
(
Trial
6
)
in
34
patients
2
to
less
than
6
years
of
age
.
[SEP]
[CLS]
May
worse
##n
,
especially
in
patients
with
re
##nal
imp
##air
##ment
.
[SEP]
[CLS]
However
,
across
clinical
trials
no
re
##nal
a
##bs
##cess
##es
were
confirmed
by
micro
##biology
tests
.
[SEP]
[CLS]
B
##OS
##U
##L
##IF
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
A
##cute
symptoms
should
be
treated
with
an
inhaled
short
-
acting
beta
##2
-
ago
##nist
.
[SEP]
[CLS]
Visual
Changes
AP
##TI
##OM
causes
dose
-
dependent
increases
in
events
related
to
visual
changes
including
dip
##lop
##ia
,
blurred
vision
,
and
impaired
vision
.
[SEP]
[CLS]
Other
adverse
reactions
occurred
at
a
rate
of
1
%
or
less
and
the
reported
events
consisted
of
headache
,
nausea
,
ve
##rt
##igo
,
dry
mouth
or
di
##zzi
##ness
.
[SEP]
[CLS]
You
and
your
healthcare
provider
should
talk
regularly
about
whether
you
still
need
treatment
with
D
##U
##AV
##EE
.
[SEP]
[CLS]
Please
see
www
.
pro
##lia
##safe
##ty
.
com
or
call
1
-
800
-
77
##2
-
64
##36
for
more
information
about
this
program
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
includes
the
following
events
:
so
##m
##no
##len
##ce
and
se
##dation
.
[SEP]
[CLS]
(
5
.
7
)
*
H
##yper
##cor
##tic
##ism
and
ad
##rena
##l
suppression
may
occur
with
very
high
dos
##ages
or
at
the
regular
dos
##age
in
susceptible
individuals
.
[SEP]
[CLS]
In
the
clinical
trials
of
ST
##RI
##BI
##LD
over
144
weeks
,
13
(
1
.
9
%
)
subjects
in
the
ST
##RI
##BI
##LD
group
(
N
=
70
##1
)
,
8
(
2
.
3
%
)
subjects
in
the
AT
##V
+
R
##TV
+
T
##R
##U
##VA
##DA
group
(
N
=
35
##5
)
and
no
subjects
in
the
AT
##RI
##PL
##A
group
(
N
=
35
##2
)
discontinued
study
drug
due
to
a
re
##nal
adverse
reaction
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
observed
with
M
##U
##LT
##A
##Q
400
mg
twice
daily
in
the
5
studies
were
di
##ar
##r
##hea
,
nausea
,
abdominal
pain
,
vomit
##ing
,
and
as
##the
##nia
.
[SEP]
[CLS]
Therefore
,
when
treating
patients
with
as
##th
##ma
,
physicians
should
only
pre
##s
##cribe
BR
##E
##O
E
##LL
##IP
##TA
for
patients
not
adequately
controlled
on
a
long
-
term
as
##th
##ma
control
medication
,
such
as
an
inhaled
co
##rt
##ico
##ster
##oid
,
or
whose
disease
severity
clearly
warrant
##s
initiation
of
treatment
with
both
an
inhaled
co
##rt
##ico
##ster
##oid
and
a
LA
##BA
.
[SEP]
[CLS]
Re
##mo
##ve
1
tablet
at
a
time
from
the
b
##list
##er
package
.
[SEP]
[CLS]
6
.
1
Clinical
Studies
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Ad
##mini
##ster
topic
##al
or
systemic
co
##rt
##ico
##ster
##oids
if
there
is
no
improvement
of
symptoms
within
1
week
.
[SEP]
[CLS]
*
N
##eu
##tro
##pen
##ic
deaths
have
been
reported
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
G
##RA
##NI
##X
in
patients
with
serious
all
##ergic
reactions
.
[SEP]
[CLS]
Basel
##ine
estimated
re
##nal
function
was
normal
or
mildly
impaired
(
e
##G
##F
##R
>
60
m
##L
/
min
/
1
.
73
m
2
)
in
91
%
of
the
study
population
and
moderately
impaired
(
e
##G
##F
##R
30
to
60
m
##L
/
min
/
1
.
73
m
2
)
in
9
%
.
[SEP]
[CLS]
With
##hold
tram
##eti
##ni
##b
for
any
fever
higher
than
104
##o
##F
.
[SEP]
[CLS]
*
Ang
##le
C
##losure
G
##lau
##com
##a
:
Ang
##le
closure
g
##lau
##com
##a
has
occurred
in
patients
with
un
##tre
##ated
an
##ato
##mic
##ally
narrow
angles
treated
with
anti
##de
##press
##ants
.
[SEP]
[CLS]
Sub
##jects
treated
with
a
##pi
##xa
##ban
with
diabetes
b
##led
more
(
3
.
0
%
per
year
)
than
did
subjects
without
diabetes
(
1
.
9
%
per
year
)
.
[SEP]
[CLS]
In
Trial
1
,
5
of
12
patients
with
a
history
of
diabetes
required
more
intensive
h
##y
##po
##gly
##ce
##mic
therapy
while
taking
T
##AF
##IN
##LA
##R
.
[SEP]
[CLS]
The
pool
##ed
analyses
of
place
##bo
-
controlled
studies
in
adults
with
MD
##D
or
other
psychiatric
disorders
included
a
total
of
295
short
-
term
studies
(
median
duration
of
2
months
)
of
11
anti
##de
##press
##ant
drugs
in
over
77
,
000
patients
.
[SEP]
[CLS]
Disco
##ntin
##ue
and
do
not
restart
AM
##P
##Y
##RA
if
this
occurs
(
5
.
4
)
5
.
1
Se
##iz
##ures
AM
##P
##Y
##RA
can
cause
seizure
##s
.
[SEP]
[CLS]
Pro
##phy
##lax
##is
of
Deep
V
##ein
T
##hr
##omb
##osis
Following
Hip
or
K
##nee
Rep
##lace
##ment
Surgery
The
safety
of
E
##L
##I
##Q
##UI
##S
has
been
evaluated
in
1
Phase
II
and
3
Phase
III
studies
including
59
##24
patients
exposed
to
E
##L
##I
##Q
##UI
##S
2
.
5
mg
twice
daily
undergoing
major
or
##th
##oped
##ic
surgery
of
the
lower
limbs
(
elect
##ive
hip
replacement
or
elect
##ive
knee
replacement
)
treated
for
up
to
38
days
.
[SEP]
[CLS]
Overall
,
20
.
2
%
of
patients
se
##ro
##con
##verted
to
anti
-
e
##cal
##lant
##ide
antibodies
.
[SEP]
[CLS]
Do
not
exceed
the
recommended
dose
;
the
risk
of
acute
kidney
injury
may
increase
with
higher
than
recommended
doses
.
[SEP]
[CLS]
Table
4
:
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
in
>
=
2
%
of
Pat
##ients
Re
##ceiving
Te
##f
##lar
##o
in
the
Poole
##d
Phase
3
Clinical
Trials
a
Co
##mp
##ara
##tors
included
van
##com
##y
##cin
1
gram
IV
every
12
##h
plus
a
##z
##tre
##ona
##m
1
gram
IV
every
12
##h
in
the
Phase
3
ABS
##SS
##I
trials
,
and
c
##ef
##tri
##ax
##one
1
gram
IV
every
24
##h
in
the
Phase
3
CA
##B
##P
trials
.
[SEP]
[CLS]
5
.
2
Use
of
Q
##T
Pro
##long
##ing
Drugs
and
Other
Anti
##mal
##aria
##ls
Hal
##of
##ant
##rine
and
Co
##arte
##m
Table
##ts
should
not
be
administered
within
1
month
of
each
other
due
to
the
long
elimination
half
-
life
of
l
##ume
##fant
##rine
(
3
to
6
days
)
and
potential
add
##itive
effects
on
the
Q
##T
interval
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
I
##mm
##une
System
Di
##sor
##ders
:
an
##aph
##yla
##xi
##s
,
an
##aph
##yla
##ctic
reaction
.
[SEP]
[CLS]
The
majority
of
reported
T
##NF
block
##er
cases
occurred
in
adolescent
and
young
adult
males
with
C
##ro
##hn
'
s
disease
or
ul
##cer
##ative
co
##lit
##is
.
[SEP]
[CLS]
In
short
-
term
,
fixed
-
dose
,
place
##bo
-
controlled
s
##chi
##zophrenia
adult
trials
,
so
##m
##no
##len
##ce
was
reported
in
15
%
(
41
/
27
##4
)
of
patients
on
SA
##P
##H
##RI
##S
5
mg
twice
daily
and
in
13
%
(
26
/
208
)
of
patients
on
SA
##P
##H
##RI
##S
10
mg
twice
daily
compared
to
7
%
(
26
/
37
##8
)
of
place
##bo
patients
.
[SEP]
[CLS]
at
1
-
800
-
32
##3
-
000
##0
,
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Ph
##os
##ph
##odies
##tera
##se
type
5
inhibitor
##s
,
including
ST
##EN
##DR
##A
,
and
alpha
-
ad
##rene
##rg
##ic
blocking
agents
are
both
v
##as
##od
##ila
##tors
with
blood
pressure
-
lowering
effects
.
[SEP]
[CLS]
Record
the
specific
GB
##CA
and
the
dose
ad
##mini
##stra
##ted
to
a
patient
.
[SEP]
[CLS]
(
5
.
1
,
5
.
2
,
7
.
7
,
12
.
3
)
*
Sub
##stra
##tes
,
inhibitor
##s
,
or
induce
##rs
of
C
##YP
##3
##A
##4
,
including
anti
##ret
##rov
##ira
##l
medications
,
should
be
used
cautiously
with
Co
##arte
##m
Table
##ts
,
due
to
a
potential
loss
of
efficacy
of
the
con
##com
##ita
##nt
drug
or
add
##itive
Q
##T
pro
##long
##ation
.
[SEP]
[CLS]
5
.
3
Risk
of
A
##cute
Card
##ior
##es
##pi
##rator
##y
F
##ail
##ure
Pat
##ients
with
acute
underlying
respiratory
illness
or
compromised
cardiac
and
/
or
respiratory
function
may
be
at
risk
of
serious
ex
##ace
##rb
##ation
of
their
cardiac
or
respiratory
compromise
during
in
##fusion
##s
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
AM
##P
##Y
##RA
can
cause
seizure
##s
;
the
risk
of
seizure
##s
increases
with
increasing
AM
##P
##Y
##RA
doses
;
disco
##ntin
##ue
AM
##P
##Y
##RA
and
do
not
restart
if
a
seizure
occurs
(
5
.
1
)
*
AM
##P
##Y
##RA
should
not
be
taken
with
other
forms
of
4
-
amino
##py
##rid
##ine
(
4
-
AP
,
f
##amp
##rid
##ine
)
,
since
the
active
ingredient
is
the
same
(
5
.
3
)
*
AM
##P
##Y
##RA
can
cause
an
##aph
##yla
##xi
##s
.
[SEP]
[CLS]
These
patients
may
also
develop
marked
elevations
of
serum
para
##thy
##roid
hormone
(
PT
##H
)
.
[SEP]
[CLS]
In
these
patients
,
extensive
dental
surgery
to
treat
ON
##J
may
ex
##ace
##rb
##ate
the
condition
.
[SEP]
[CLS]
Inc
##reased
thy
##roid
-
binding
g
##lo
##bul
##in
)
leading
to
increased
circulating
total
thy
##roid
hormone
by
radio
##im
##mu
##no
##ass
##ay
.
[SEP]
[CLS]
Table
1
shows
common
adverse
reactions
excluding
h
##y
##po
##gly
##ce
##mia
associated
with
the
use
of
T
##AN
##Z
##E
##UM
in
the
pool
of
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
There
was
no
adverse
reaction
that
was
more
than
2
%
more
common
on
C
##lev
##ip
##re
##x
than
on
the
average
of
all
com
##par
##ators
.
[SEP]
[CLS]
In
##tra
##c
##rani
##al
bleed
includes
sub
##ara
##ch
##no
##id
bleeding
.
[SEP]
[CLS]
Some
drugs
that
are
inhibitor
##s
of
C
##YP
##2
##D
##6
and
C
##YP
##3
##A
are
con
##tra
##ind
##ica
##ted
with
CE
##RD
##EL
##GA
depending
on
the
patient
'
s
C
##YP
##2
##D
##6
meta
##bol
##izer
status
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
Pat
##ients
with
a
history
of
chronic
or
re
##current
u
##rina
##ry
tract
infections
were
more
likely
to
experience
a
u
##rina
##ry
tract
infection
.
[SEP]
[CLS]
IL
##AR
##IS
should
not
be
administered
to
patients
during
an
active
infection
requiring
medical
intervention
.
[SEP]
[CLS]
The
same
dose
of
H
##OR
##I
##Z
##AN
##T
results
in
different
plasma
concentrations
of
g
##aba
##pent
##in
relative
to
other
g
##aba
##pent
##in
products
.
[SEP]
[CLS]
(
5
.
1
)
*
ST
##RI
##BI
##LD
is
not
approved
for
the
treatment
of
chronic
he
##pa
##titis
B
virus
(
H
##B
##V
)
infection
.
[SEP]
[CLS]
*
Use
in
Pat
##ients
with
He
##pa
##tic
I
##mp
##air
##ment
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
.
[SEP]
[CLS]
(
5
.
5
)
*
Dec
##rease
##s
in
bone
mineral
density
)
:
Consider
monitoring
B
##MD
in
patients
with
a
history
of
path
##olo
##gic
fracture
or
other
risk
factors
of
o
##ste
##op
##oro
##sis
or
bone
loss
.
[SEP]
[CLS]
Among
the
32
patients
with
e
##val
##ua
##ble
p
##har
##ma
##co
##kin
##etic
(
P
##K
)
samples
,
5
patients
tested
positive
for
up
##take
in
##hibition
.
[SEP]
[CLS]
In
S
##ING
##LE
,
83
##3
subjects
were
random
##ized
and
received
at
least
1
dose
of
either
T
##I
##VI
##CA
##Y
50
mg
with
fixed
-
dose
a
##ba
##ca
##vir
su
##lf
##ate
and
la
##mi
##vu
##dine
(
EP
##Z
##IC
##OM
)
once
daily
or
fixed
-
dose
e
##fa
##vir
##en
##z
/
em
##tric
##ita
##bine
/
ten
##of
##ov
##ir
(
AT
##RI
##PL
##A
(
r
)
)
once
daily
.
[SEP]
[CLS]
5
.
11
El
##eva
##tion
of
Live
##r
En
##zy
##mes
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
AL
##T
)
elevations
of
all
grades
occurred
in
22
%
of
patients
on
both
arms
,
with
Grade
3
/
4
events
in
<
1
%
of
patients
on
the
IN
##L
##Y
##TA
arm
and
2
%
of
patients
on
the
so
##ra
##fen
##ib
arm
.
[SEP]
[CLS]
Grade
3
/
4
cardiac
failure
was
observed
in
2
/
35
##9
patients
(
1
%
)
receiving
IN
##L
##Y
##TA
and
1
/
35
##5
patients
(
<
1
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
Re
##sul
##ting
o
##li
##go
##hy
##dra
##m
##nio
##s
can
be
associated
with
f
##etal
lung
h
##y
##pop
##lasia
.
[SEP]
[CLS]
Ser
##ious
psychiatric
events
were
reported
in
0
.
8
%
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
(
0
.
6
%
and
1
.
2
%
with
1
and
10
mg
/
kg
,
respectively
)
and
0
.
4
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
If
such
changes
occur
,
disco
##ntin
##ue
BR
##E
##O
E
##LL
##IP
##TA
slowly
.
[SEP]
[CLS]
(
5
.
1
)
*
Do
not
initiate
in
acute
##ly
de
##ter
##ior
##ating
CO
##PD
or
as
##th
##ma
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
incidence
>
=
7
%
and
higher
than
place
##bo
)
:
upper
respiratory
tract
infection
,
r
##ash
,
and
u
##rina
##ry
tract
infection
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
UC
##B
,
Inc
.
at
1
-
86
##6
-
82
##2
-
00
##6
##8
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
6
.
1
Clinical
Trial
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Monitor
with
electro
##card
##io
##gram
##s
and
electro
##ly
##tes
in
patients
who
have
a
history
of
or
pre
##dis
##position
for
Q
##T
##c
pro
##long
##ation
,
or
who
are
taking
medications
that
pro
##long
Q
##T
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
and
fatigue
were
also
observed
in
mon
##otherapy
trials
.
[SEP]
[CLS]
Disco
##ntin
##ue
X
##AL
##KO
##RI
in
patients
with
severe
visual
loss
.
[SEP]
[CLS]
These
data
reflect
exposure
of
1976
patients
to
J
##AR
##DI
##AN
##CE
with
a
mean
exposure
duration
of
approximately
23
weeks
.
[SEP]
[CLS]
Bo
##su
##tin
##ib
caused
em
##b
##ryo
##fe
##tal
toxic
##ities
in
rabbits
at
maternal
exposure
##s
that
were
greater
than
the
clinical
exposure
at
the
recommended
b
##os
##uti
##ni
##b
dose
of
500
mg
/
day
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
He
##pa
##to
##to
##xi
##city
:
Fat
##al
he
##pa
##to
##to
##xi
##city
occurred
in
0
.
1
%
of
patients
.
[SEP]
[CLS]
Treatment
to
Inc
##rease
Bone
Mass
in
Men
with
O
##ste
##op
##oro
##sis
The
safety
of
Pro
##lia
in
the
treatment
of
men
with
o
##ste
##op
##oro
##sis
was
assessed
in
a
1
-
year
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
study
.
[SEP]
[CLS]
The
mean
age
of
the
population
was
60
years
and
5
%
were
older
than
75
years
of
age
.
[SEP]
[CLS]
Pat
##ients
with
MP
##S
IV
##A
should
be
monitored
for
signs
and
symptoms
of
SC
##C
(
including
back
pain
,
para
##lysis
of
limbs
below
the
level
of
compression
,
u
##rina
##ry
and
f
##eca
##l
in
##con
##tine
##nce
)
and
given
appropriate
clinical
care
.
[SEP]
[CLS]
Consider
interrupt
##ion
of
T
##EC
##FI
##DE
##RA
in
patients
with
l
##ymph
##oc
##yte
counts
<
0
.
5
x
10
9
/
L
per
##sist
##ing
for
more
than
six
months
.
[SEP]
[CLS]
Ser
##ious
and
sometimes
fatal
der
##mat
##olo
##gic
reactions
,
including
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
(
T
##EN
)
and
S
##J
##S
,
have
been
reported
in
patients
using
o
##x
##car
##ba
##ze
##pine
or
car
##ba
##ma
##ze
##pine
which
are
chemical
##ly
related
to
AP
##TI
##OM
.
[SEP]
[CLS]
Pat
##ients
treated
with
T
##RE
##AN
##DA
may
also
have
changes
in
their
c
##rea
##tin
##ine
levels
.
[SEP]
[CLS]
Ana
##phy
##lax
##is
and
H
##yper
##sen
##si
##ti
##vity
Re
##actions
:
Life
-
threatening
an
##aph
##yla
##xi
##s
and
h
##yper
##sen
##si
##ti
##vity
reactions
have
been
observed
in
some
patients
during
treatment
with
V
##im
##iz
##im
.
[SEP]
[CLS]
A
##pp
##rise
women
of
reproductive
potential
of
the
potential
hazard
to
a
f
##etus
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
The
incidence
of
new
cases
of
infections
in
controlled
clinical
studies
in
r
##he
##uma
##to
##id
art
##hr
##itis
was
0
.
91
per
patient
-
year
for
all
C
##IM
##Z
##IA
-
treated
patients
and
0
.
72
per
patient
-
year
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
(
5
.
9
)
*
Em
##b
##ryo
##fe
##tal
toxicity
:
Can
cause
f
##etal
harm
.
[SEP]
[CLS]
Some
studies
suggest
that
CO
##Cs
are
associated
with
an
increase
in
the
risk
of
c
##er
##vic
##al
cancer
.
[SEP]
[CLS]
Monitor
liver
function
tests
and
o
##mit
or
modify
dos
##age
for
he
##pa
##tic
toxic
##ities
.
[SEP]
[CLS]
(
5
.
3
)
*
Ser
##ious
Der
##mat
##ological
Re
##actions
(
including
Stevens
-
Johnson
syndrome
and
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
)
:
Disco
##ntin
##ue
ON
##FI
at
first
sign
of
r
##ash
unless
the
r
##ash
is
clearly
not
drug
-
related
.
[SEP]
[CLS]
There
have
been
rare
reports
of
deaths
,
primarily
in
pre
##ter
##m
infants
,
associated
with
exposure
to
excessive
amounts
of
ben
##zy
##l
alcohol
[
see
Des
##cription
(
11
)
]
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
Se
##vere
,
potentially
life
threatening
and
fatal
skin
reactions
have
been
reported
.
[SEP]
[CLS]
(
5
.
3
)
*
Fat
##al
and
serious
in
##test
##inal
per
##fo
##ration
can
occur
in
Z
##yd
##eli
##g
-
treated
patients
across
clinical
trials
.
[SEP]
[CLS]
Control
h
##yper
##tens
##ion
and
correct
h
##y
##po
##kal
##emia
before
treatment
.
[SEP]
[CLS]
Prior
to
administration
,
question
the
patient
for
a
history
of
prior
reactions
to
i
##od
##ine
,
an
i
##od
##ine
-
containing
contrast
agent
or
other
products
containing
i
##od
##ine
.
[SEP]
[CLS]
If
path
##ology
and
pregnancy
are
excluded
,
bleeding
irregular
##ities
may
resolve
over
time
or
with
a
change
to
a
different
CO
##C
.
[SEP]
[CLS]
C
##ab
##oz
##anti
##ni
##b
was
em
##b
##ryo
##let
##hal
in
rats
at
exposure
##s
below
the
recommended
human
dose
,
with
increased
incidence
##s
of
skeletal
variations
in
rats
and
v
##is
##cer
##al
variations
in
rabbits
.
[SEP]
[CLS]
Laboratory
A
##b
##nor
##mal
##ities
in
Treatment
-
Experience
##d
Pat
##ients
Selected
Grade
2
to
Grade
4
laboratory
abnormal
##ities
that
represent
a
worse
##ning
from
base
##line
observed
in
adult
subjects
treated
with
IN
##TE
##LE
##NC
##E
(
r
)
are
presented
in
Table
2
.
[SEP]
[CLS]
Un
##con
##tro
##lled
h
##yper
##am
##mon
##emia
can
rapidly
result
in
brain
injury
/
damage
or
death
,
and
pro
##mpt
use
of
all
the
##rap
##ies
necessary
to
reduce
plasma
am
##monia
levels
is
essential
.
[SEP]
[CLS]
BR
##E
##O
E
##LL
##IP
##TA
has
not
been
studied
in
subjects
with
acute
##ly
de
##ter
##ior
##ating
CO
##PD
or
as
##th
##ma
.
[SEP]
[CLS]
In
patients
with
base
##line
moderate
he
##pa
##tic
imp
##air
##ment
receiving
a
reduced
Z
##Y
##TI
##GA
dose
of
250
mg
,
measure
AL
##T
,
AS
##T
,
and
bi
##li
##ru
##bin
prior
to
the
start
of
treatment
,
every
week
for
the
first
month
,
every
two
weeks
for
the
following
two
months
of
treatment
and
monthly
thereafter
.
[SEP]
[CLS]
If
p
##ne
##um
##oni
##tis
is
suspected
,
interrupt
Z
##yd
##eli
##g
until
the
et
##iology
of
the
pulmonary
symptoms
has
been
determined
.
[SEP]
[CLS]
In
general
,
so
##m
##no
##len
##ce
and
se
##dation
begin
within
the
first
month
of
treatment
and
may
dim
##ini
##sh
with
continued
treatment
.
[SEP]
[CLS]
5
.
5
Se
##vere
Cut
##aneous
Re
##actions
One
case
of
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
(
T
##EN
)
occurred
in
a
study
of
Z
##yd
##eli
##g
in
combination
with
r
##it
##ux
##ima
##b
and
bend
##am
##ust
##ine
.
[SEP]
[CLS]
Pat
##ients
with
a
pre
-
existing
low
W
##BC
or
a
history
of
drug
induced
le
##uk
##ope
##nia
/
ne
##ut
##rop
##enia
should
have
their
complete
blood
count
(
CBC
)
monitored
frequently
during
the
first
few
months
of
therapy
and
should
disco
##ntin
##ue
FA
##NA
##P
##T
at
the
first
sign
of
a
decline
in
W
##BC
in
the
absence
of
other
ca
##usa
##tive
factors
.
[SEP]
[CLS]
The
population
in
these
studies
was
69
%
White
,
7
%
Black
or
African
American
,
13
%
Asian
;
30
%
were
of
Hispanic
or
Latino
ethnicity
.
[SEP]
[CLS]
In
pool
##ed
analysis
from
clinical
studies
including
longer
term
trials
,
in
321
##0
adults
treated
with
il
##oper
##ido
##ne
,
g
##yne
##com
##ast
##ia
was
reported
in
2
male
subjects
(
0
.
1
%
)
compared
to
0
%
in
place
##bo
-
treated
patients
,
and
gal
##actor
##r
##hea
was
reported
in
8
female
subjects
(
0
.
2
%
)
compared
to
3
female
subjects
(
0
.
5
%
)
in
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Ad
##verse
drug
reactions
for
S
##IR
##TU
##RO
were
identified
from
the
pool
##ed
safety
data
from
335
S
##IR
##TU
##RO
-
exposed
patients
who
received
8
weeks
(
Study
2
)
and
24
weeks
(
Studies
1
and
3
)
at
the
proposed
dose
.
[SEP]
[CLS]
Of
the
34
patients
with
Grade
3
-
5
enter
##oc
##oli
##tis
,
74
%
experienced
complete
resolution
,
3
%
experienced
improvement
to
Grade
2
severity
,
and
24
%
did
not
improve
.
[SEP]
[CLS]
In
the
double
-
blind
,
place
##bo
-
controlled
portions
of
the
clinical
trials
in
P
##ey
##ron
##ie
'
s
disease
(
Studies
1
and
2
)
,
a
greater
proportion
of
XI
##AF
##LE
##X
-
treated
patients
(
4
%
)
compared
to
place
##bo
-
treated
patients
(
1
%
)
had
localized
p
##ru
##rit
##us
after
up
to
4
treatment
cycles
(
involving
up
to
8
XI
##AF
##LE
##X
injection
procedures
)
.
[SEP]
[CLS]
Per
##form
an
oral
examination
prior
to
initiation
of
CO
##ME
##TR
##I
##Q
and
periodically
during
CO
##ME
##TR
##I
##Q
therapy
.
[SEP]
[CLS]
Risk
factors
for
bleeding
include
the
con
##com
##ita
##nt
use
of
other
drugs
that
increase
the
risk
of
bleeding
(
e
.
g
.
,
anti
-
plate
##let
agents
,
he
##par
##in
,
fi
##bri
##no
##ly
##tic
therapy
,
and
chronic
use
of
NSA
##ID
##s
)
.
[SEP]
[CLS]
However
,
if
severe
h
##yper
##sen
##si
##ti
##vity
reactions
occur
,
immediately
stop
the
in
##fusion
of
V
##im
##iz
##im
and
initiate
appropriate
treatment
.
[SEP]
[CLS]
A
##vo
##id
using
X
##AL
##KO
##RI
in
combination
with
other
agents
known
to
cause
bra
##dy
##card
##ia
(
e
.
g
.
,
beta
-
block
##ers
,
non
-
di
##hy
##dr
##opy
##rid
##ine
calcium
channel
block
##ers
,
c
##lon
##id
##ine
and
dig
##ox
##in
)
to
the
extent
possible
.
[SEP]
[CLS]
In
controlled
and
un
##con
##tro
##lled
clinical
trials
,
2
%
of
patients
experienced
l
##ymph
##oc
##yte
counts
<
0
.
5
x
10
9
/
L
for
at
least
six
months
.
[SEP]
[CLS]
Consider
the
benefit
-
risk
of
with
##holding
I
##MB
##R
##U
##VI
##CA
for
at
least
3
to
7
days
pre
and
post
-
surgery
depending
upon
the
type
of
surgery
and
the
risk
of
bleeding
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
5
.
3
He
##pa
##tic
To
##xi
##city
One
case
consistent
with
drug
induced
liver
injury
(
defined
as
concurrent
elevations
in
AL
##T
greater
than
or
equal
to
3
*
U
##L
##N
with
total
bi
##li
##ru
##bin
greater
than
2
*
U
##L
##N
and
al
##kal
##ine
p
##hos
##pha
##tase
less
than
2
*
U
##L
##N
)
occurred
in
a
trial
of
B
##OS
##U
##L
##IF
in
combination
with
let
##ro
##zo
##le
.
[SEP]
[CLS]
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
has
not
been
investigated
in
patients
whose
diabetes
me
##lli
##tus
is
not
well
controlled
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
(
r
)
(
as
##ena
##pine
)
is
not
approved
for
the
treatment
of
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
,
5
.
2
)
]
.
[SEP]
[CLS]
Use
IN
##L
##Y
##TA
with
caution
in
patients
who
are
at
risk
for
,
or
who
have
a
history
of
,
these
events
.
[SEP]
[CLS]
In
patients
receiving
anti
-
T
##NF
therapy
,
limited
data
are
available
on
the
response
to
live
v
##ac
##cin
##ation
,
or
on
the
secondary
transmission
of
infection
by
live
vaccine
##s
.
[SEP]
[CLS]
have
occurred
following
administration
of
D
##Y
##SP
##OR
##T
(
r
)
.
[SEP]
[CLS]
Some
patients
required
hospital
##ization
and
re
##nal
replacement
therapy
.
[SEP]
[CLS]
These
may
include
as
##the
##nia
,
generalized
muscle
weakness
,
dip
##lop
##ia
,
blurred
vision
,
p
##tosis
,
d
##ys
##pha
##gia
,
d
##ys
##phon
##ia
,
d
##ys
##art
##hr
##ia
,
u
##rina
##ry
in
##con
##tine
##nce
and
breathing
difficulties
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
have
been
associated
with
T
##RE
##AN
##DA
in
clinical
trials
and
are
discussed
in
greater
detail
in
other
sections
of
the
label
.
[SEP]
[CLS]
The
study
population
characteristics
were
:
median
age
53
years
,
age
less
than
65
(
84
%
)
,
female
(
53
%
)
,
Caucasian
(
63
%
)
,
Asian
(
34
%
)
,
N
##SC
##LC
ad
##eno
##car
##cin
##oma
his
##tology
(
90
%
)
,
never
or
former
smoke
##r
(
97
%
)
,
EC
##O
##G
PS
0
or
1
(
89
%
)
,
brain
meta
##sta
##sis
(
49
%
)
,
and
number
of
prior
the
##rap
##ies
2
or
more
(
67
%
)
.
[SEP]
[CLS]
Two
patients
treated
with
K
##AL
##Y
##DE
##CO
were
reported
to
have
serious
adverse
reactions
of
elevated
liver
trans
##ami
##nas
##es
compared
to
none
on
place
##bo
.
[SEP]
[CLS]
All
reported
reactions
are
included
except
those
already
listed
in
Table
7
,
or
other
parts
of
the
Ad
##verse
Re
##actions
(
6
)
section
,
those
considered
in
the
Warning
##s
and
Pre
##ca
##ution
##s
(
5
)
,
those
reaction
terms
which
were
so
general
as
to
be
un
##in
##form
##ative
,
reactions
reported
in
fewer
than
3
patients
and
which
were
neither
serious
nor
life
-
threatening
,
reactions
that
are
otherwise
common
as
background
reactions
,
and
reactions
considered
unlikely
to
be
drug
related
.
[SEP]
[CLS]
During
the
controlled
trials
in
patients
with
R
##LS
,
so
##m
##no
##len
##ce
/
se
##dation
was
reported
in
20
%
of
patients
treated
with
600
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
compared
with
6
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
Do
##se
adjustments
(
interrupt
##ions
or
reduction
##s
)
were
more
frequent
among
patients
in
the
A
##FI
##NI
##TO
##R
plus
ex
##em
##esta
##ne
arm
than
in
the
place
##bo
plus
ex
##em
##esta
##ne
arm
(
63
%
versus
14
%
)
.
[SEP]
[CLS]
If
appropriate
,
initiation
of
anti
-
he
##pa
##titis
B
therapy
may
be
warrant
##ed
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Therefore
,
co
-
administration
is
not
recommended
.
[SEP]
[CLS]
During
the
controlled
period
of
the
trials
in
ps
##oria
##sis
,
weight
decrease
between
5
%
-
10
%
of
body
weight
occurred
in
12
%
(
96
/
78
##4
)
of
subjects
treated
with
O
##TE
##Z
##LA
compared
to
5
%
(
19
/
38
##2
)
treated
with
place
##bo
.
[SEP]
[CLS]
L
##ymph
##oc
##yte
counts
generally
return
to
the
normal
range
within
1
-
2
months
of
stopping
therapy
[
see
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
Ad
##vise
patients
to
seek
pro
##mpt
medical
attention
if
they
develop
signs
or
symptoms
of
severe
infection
,
including
cell
##uli
##tis
.
[SEP]
[CLS]
*
Se
##iz
##ure
:
Can
occur
.
[SEP]
[CLS]
In
##jection
site
reactions
.
[SEP]
[CLS]
Pat
##ients
were
allowed
,
but
not
required
,
to
take
g
##lu
##co
##cor
##tic
##oids
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
The
data
described
below
reflect
exposure
to
B
##EN
##L
##Y
##ST
##A
plus
standard
of
care
compared
with
place
##bo
plus
standard
of
care
in
2
,
133
patients
in
3
controlled
trials
.
[SEP]
[CLS]
The
majority
of
elevations
occurred
within
6
to
9
months
.
[SEP]
[CLS]
(
5
.
2
)
*
Di
##hy
##dr
##opy
##rid
##ine
calcium
channel
block
##ers
can
produce
negative
in
##ot
##ropic
effects
and
ex
##ace
##rb
##ate
heart
failure
.
[SEP]
[CLS]
Number
(
%
)
of
Pat
##ients
Place
##bo
##N
=
99
##5
J
##AR
##DI
##AN
##CE
10
mg
##N
=
99
##9
J
##AR
##DI
##AN
##CE
25
mg
##N
=
97
##7
U
##rina
##ry
tract
infection
a
7
.
6
%
9
.
3
%
7
.
6
%
Female
g
##eni
##tal
my
##cot
##ic
infections
b
1
.
5
%
5
.
4
%
6
.
4
%
Upper
respiratory
tract
infection
3
.
8
%
3
.
1
%
4
.
0
%
Inc
##reased
u
##rina
##tion
c
1
.
0
%
3
.
4
%
3
.
2
%
D
##ys
##lip
##ide
##mia
3
.
4
%
3
.
9
%
2
.
9
%
Art
##hra
##l
##gia
2
.
2
%
2
.
4
%
2
.
3
%
Male
g
##eni
##tal
my
##cot
##ic
infections
d
0
.
4
%
3
.
1
%
1
.
6
%
Na
##use
##a
1
.
4
%
2
.
3
%
1
.
1
%
T
##hir
##st
(
including
p
##oly
##di
##ps
##ia
)
was
reported
in
0
%
,
1
.
7
%
,
and
1
.
5
%
for
place
##bo
,
J
##AR
##DI
##AN
##CE
10
mg
,
and
J
##AR
##DI
##AN
##CE
25
mg
,
respectively
.
[SEP]
[CLS]
The
most
common
fatal
adverse
reactions
in
J
##E
##V
##TA
##NA
-
treated
patients
were
infections
(
n
=
5
)
and
re
##nal
failure
(
n
=
4
)
.
[SEP]
[CLS]
There
were
differences
in
absolute
risk
of
su
##icidal
##ity
across
the
different
indication
##s
,
with
the
highest
incidence
in
MD
##D
.
[SEP]
[CLS]
The
duration
of
E
##L
##I
##Q
##UI
##S
exposure
was
>
=
12
months
for
93
##75
patients
and
>
=
24
months
for
33
##6
##9
patients
in
the
two
studies
.
[SEP]
[CLS]
Through
Week
24
,
the
incidence
of
serious
infections
per
100
patient
-
years
of
follow
-
up
was
2
.
2
(
95
%
C
##I
0
.
61
,
5
.
71
)
for
the
S
##IM
##PO
##NI
ARIA
group
,
and
0
(
0
.
00
,
3
.
79
)
for
the
place
##bo
group
.
[SEP]
[CLS]
Pat
##ients
must
have
a
negative
pregnancy
test
prior
to
therapy
;
use
two
or
more
forms
of
con
##tra
##ception
,
and
have
monthly
pregnancy
tests
.
[SEP]
[CLS]
In
limited
comparative
studies
,
the
adverse
reaction
profile
of
Co
##arte
##m
Table
##ts
appeared
similar
to
that
of
another
anti
##mal
##aria
##l
regime
##n
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
measures
such
as
fluid
and
electro
##ly
##te
management
,
protein
supplement
##ation
,
anti
##ba
##cter
##ial
treatment
of
C
.
di
##ff
##ici
##le
,
and
surgical
evaluation
should
be
instituted
as
clinical
##ly
indicated
.
[SEP]
[CLS]
V
##omi
##ting
was
the
primary
adverse
reaction
leading
to
disco
##ntin
##uation
of
dos
##ing
;
this
occurred
at
an
incidence
of
0
.
5
%
in
both
the
fi
##da
##x
##omi
##cin
and
van
##com
##y
##cin
patients
in
Phase
3
studies
.
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
of
bleeding
.
[SEP]
[CLS]
The
risk
differences
(
drug
vs
.
place
##bo
)
,
however
,
were
relatively
stable
within
age
s
##trata
and
across
indication
##s
.
[SEP]
[CLS]
E
##stro
##gens
may
be
poorly
meta
##bol
##ized
in
women
with
impaired
liver
function
.
[SEP]
[CLS]
Pro
##phy
##lax
##is
with
anti
##py
##ret
##ics
may
be
required
when
re
##suming
T
##AF
##IN
##LA
##R
or
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Table
1
:
B
##lee
##ding
Events
in
Pat
##ients
with
Non
##val
##vu
##lar
At
##rial
Fi
##bri
##lla
##tion
in
AR
##IS
##TO
##TL
##E
*
E
##L
##I
##Q
##UI
##SN
=
90
##8
##8
##n
(
per
100
p
##t
-
year
)
War
##fari
##n
##N
=
90
##5
##2
##n
(
per
100
p
##t
-
year
)
Ha
##zard
Rat
##io
(
95
%
C
##I
)
P
-
value
*
B
##lee
##ding
events
within
each
sub
##cate
##gor
##y
were
counted
once
per
subject
,
but
subjects
may
have
contributed
events
to
multiple
end
##points
.
[SEP]
[CLS]
Monitor
for
symptoms
of
motor
or
sensory
ne
##uro
##pathy
such
as
un
##ila
##teral
or
bilateral
weakness
,
sensory
alterations
,
or
par
##est
##hesia
.
[SEP]
[CLS]
He
##pa
##tic
function
should
be
monitored
closely
with
both
clinical
and
laboratory
follow
-
up
for
at
least
several
months
in
patients
who
are
coin
##fected
with
HIV
-
1
and
H
##B
##V
and
disco
##ntin
##ue
ST
##RI
##BI
##LD
.
[SEP]
[CLS]
Weight
decrease
of
>
=
10
%
of
body
weight
occurred
in
2
%
(
16
/
78
##4
)
of
subjects
treated
with
O
##TE
##Z
##LA
30
mg
twice
daily
compared
to
1
%
(
3
/
38
##2
)
subjects
treated
with
place
##bo
.
[SEP]
[CLS]
K
##AL
##Y
##DE
##CO
was
permanently
discontinued
in
one
patient
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
The
clearance
values
for
4
of
these
5
patients
were
approximately
1
.
2
-
to
1
.
8
-
fold
greater
in
the
presence
of
inhibitor
##y
antibodies
(
Week
52
)
as
compared
to
in
the
absence
of
inhibitor
##y
antibodies
(
Week
0
)
[
see
##C
##lini
##cal
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
Once
as
##th
##ma
control
is
achieved
and
maintained
,
assess
the
patient
at
regular
intervals
and
step
down
therapy
(
e
.
g
.
,
disco
##ntin
##ue
BR
##E
##O
E
##LL
##IP
##TA
)
if
possible
without
loss
of
as
##th
##ma
control
and
maintain
the
patient
on
a
long
-
term
as
##th
##ma
control
medication
,
such
as
an
inhaled
co
##rt
##ico
##ster
##oid
.
[SEP]
[CLS]
The
most
common
in
##fusion
reactions
(
>
=
3
%
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
)
were
headache
,
nausea
,
and
skin
reactions
.
[SEP]
[CLS]
Dry
mouth
led
to
disco
##ntin
##uation
in
0
.
4
%
,
0
.
4
%
,
and
0
.
8
%
of
patients
receiving
place
##bo
,
To
##via
##z
4
mg
,
and
To
##via
##z
8
mg
,
respectively
.
[SEP]
[CLS]
H
##yper
##thy
##roid
##ism
was
reported
in
4
/
35
##9
patients
(
1
%
)
receiving
IN
##L
##Y
##TA
and
4
/
35
##5
patients
(
1
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
Who
should
not
take
D
##U
##AV
##EE
?
[SEP]
[CLS]
N
##SF
may
result
in
fatal
or
de
##bil
##itating
fi
##bro
##sis
affecting
the
skin
,
muscle
and
internal
organs
.
[SEP]
[CLS]
It
is
unknown
if
treatment
with
B
##EN
##L
##Y
##ST
##A
is
associated
with
increased
risk
for
these
events
.
[SEP]
[CLS]
(
5
.
1
)
*
Drugs
that
act
directly
on
the
re
##nin
-
an
##gio
##tens
##in
system
can
cause
death
to
the
developing
f
##etus
.
[SEP]
[CLS]
Six
X
##E
##OM
##IN
treated
subjects
experienced
six
serious
adverse
events
.
[SEP]
[CLS]
Some
medicines
may
affect
how
D
##U
##AV
##EE
works
.
[SEP]
[CLS]
Some
of
these
events
have
been
fatal
or
life
-
threatening
.
[SEP]
[CLS]
(
5
.
13
,
8
.
1
)
5
.
1
H
##yper
##tens
##ion
and
H
##yper
##tensive
Crisis
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
h
##yper
##tens
##ion
was
reported
in
145
/
35
##9
patients
(
40
%
)
receiving
IN
##L
##Y
##TA
and
103
/
35
##5
patients
(
29
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
medical
support
and
monitoring
measures
should
be
available
during
in
##fusion
(
5
.
3
)
.
[SEP]
[CLS]
The
percentage
of
patients
who
withdrew
from
the
study
due
to
adverse
events
was
6
.
1
%
and
7
.
0
%
for
the
place
##bo
and
Pro
##lia
groups
,
respectively
.
[SEP]
[CLS]
S
##IR
##TU
##RO
has
not
been
studied
in
patients
with
vent
##ric
##ular
a
##rr
##hy
##th
##mia
##s
or
recent
my
##oc
##ard
##ial
in
##far
##ction
.
[SEP]
[CLS]
Using
an
electro
##che
##mi
##lum
##ines
##cent
br
##id
##ging
im
##mu
##no
##ass
##ay
,
less
than
1
%
(
55
out
of
81
##13
)
of
patients
treated
with
Pro
##lia
for
up
to
5
years
tested
positive
for
binding
antibodies
(
including
pre
-
existing
,
trans
##ient
,
and
developing
antibodies
)
.
[SEP]
[CLS]
Prior
to
ne
##ura
##xial
intervention
the
physician
should
consider
the
potential
benefit
versus
the
risk
in
anti
##coa
##gu
##lated
patients
or
in
patients
to
be
anti
##coa
##gu
##lated
for
th
##rom
##bo
##p
##rop
##hyl
##ax
##is
.
[SEP]
[CLS]
Limited
information
is
presented
on
the
110
mg
dos
##ing
arm
because
this
dose
is
not
approved
.
[SEP]
[CLS]
5
.
5
Ren
##al
To
##xi
##city
An
on
-
treatment
decline
in
estimated
g
##lo
##mer
##ular
fi
##ltration
rate
(
e
##G
##F
##R
)
has
occurred
in
patients
treated
with
B
##OS
##U
##L
##IF
.
[SEP]
[CLS]
Pat
##ient
exposure
PR
##IS
##TI
##Q
was
evaluated
for
safety
in
8
,
39
##4
patients
diagnosed
with
major
de
##pressive
disorder
who
participated
in
multiple
-
dose
pre
-
marketing
studies
,
representing
2
,
78
##4
patient
-
years
of
exposure
.
[SEP]
[CLS]
After
initiation
of
NE
##SI
##NA
,
patients
should
be
observed
carefully
for
signs
and
symptoms
of
pan
##cre
##ati
##tis
.
[SEP]
[CLS]
Re
##quire
##d
components
of
the
XI
##AF
##LE
##X
R
##EM
##S
Program
include
the
following
:
*
Pre
##s
##cribe
##rs
must
be
certified
with
the
program
by
en
##roll
##ing
and
completing
training
in
the
administration
of
XI
##AF
##LE
##X
treatment
for
P
##ey
##ron
##ie
'
s
disease
.
[SEP]
[CLS]
Approximately
one
third
(
3
%
,
39
of
1
,
50
##9
)
of
these
patients
had
antibodies
with
neutral
##izing
activity
in
v
##it
##ro
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
discussed
in
greater
detail
in
other
sections
of
the
label
:
*
H
##yper
##sen
##si
##ti
##vity
reactions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
Pan
##cre
##ati
##tis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
G
##lu
##cos
##e
into
##ler
##ance
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
T
##hr
##omb
##osis
and
hem
##or
##r
##hage
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
The
most
common
adverse
reactions
(
incidence
1
%
or
greater
)
with
ER
##WI
##NA
##Z
##E
treatment
are
systemic
h
##yper
##sen
##si
##ti
##vity
,
h
##yper
##gly
##ce
##mia
,
trans
##ami
##nas
##es
abnormal
,
fever
,
pan
##cre
##ati
##tis
,
local
reactions
,
vomit
##ing
,
nausea
,
th
##rom
##bos
##is
,
h
##yper
##bil
##ir
##ubi
##ne
##mia
,
abdominal
pain
,
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
When
pre
##s
##cribing
BR
##E
##O
E
##LL
##IP
##TA
,
the
healthcare
provider
should
also
pre
##s
##cribe
an
inhaled
,
short
-
acting
beta
##2
-
ago
##nist
and
ins
##truct
the
patient
on
how
it
should
be
used
.
[SEP]
[CLS]
Other
severe
or
life
-
threatening
(
Grade
>
=
3
)
cut
##aneous
reactions
,
including
der
##mat
##itis
ex
##folia
##tive
,
r
##ash
,
r
##ash
er
##yt
##hem
##ato
##us
,
r
##ash
generalized
,
r
##ash
mac
##ular
,
r
##ash
mac
##ulo
-
p
##ap
##ular
,
r
##ash
p
##ap
##ular
,
r
##ash
p
##ru
##ritic
,
ex
##folia
##tive
r
##ash
,
and
skin
disorder
,
have
been
reported
in
Z
##yd
##eli
##g
-
treated
patients
.
[SEP]
[CLS]
The
safety
of
Z
##Y
##TI
##GA
re
-
treatment
of
patients
who
develop
AS
##T
or
AL
##T
greater
than
or
equal
to
20
*
U
##L
##N
and
/
or
bi
##li
##ru
##bin
greater
than
or
equal
to
10
*
U
##L
##N
is
unknown
.
[SEP]
[CLS]
For
a
##gra
##nu
##loc
##yt
##osis
(
AN
##C
<
0
.
5
x
10
9
/
L
)
:
Consider
hospital
##ization
and
other
management
as
clinical
##ly
appropriate
.
[SEP]
[CLS]
Image
interpretation
should
be
performed
independently
of
the
patient
'
s
clinical
information
.
[SEP]
[CLS]
In
the
place
##bo
-
controlled
study
,
a
similar
rate
of
non
-
fatal
and
fatal
clinical
my
##oc
##ard
##ial
in
##far
##ction
was
reported
in
patients
who
received
PR
##AD
##A
##X
##A
[
1
(
0
.
32
per
100
patient
-
years
)
]
and
in
those
who
received
place
##bo
[
1
(
0
.
34
per
100
patient
-
years
)
]
.
[SEP]
[CLS]
5
.
6
Brady
##card
##ia
Brady
##card
##ia
can
occur
in
patients
receiving
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
The
observed
incidence
of
anti
##body
(
including
neutral
##izing
anti
##body
)
p
##os
##iti
##vity
in
an
ass
##ay
is
highly
dependent
on
several
factors
,
including
ass
##ay
sensitivity
and
specific
##ity
,
ass
##ay
methodology
,
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
The
more
severe
withdrawal
symptoms
have
usually
been
limited
to
patients
who
received
excessive
doses
over
an
extended
period
of
time
,
followed
by
an
abrupt
disco
##ntin
##uation
.
[SEP]
[CLS]
The
initiation
of
BR
##E
##O
E
##LL
##IP
##TA
in
this
setting
is
not
appropriate
.
[SEP]
[CLS]
5
.
5
Physical
and
Psychological
De
##pen
##dence
Pat
##ients
with
a
history
of
substance
abuse
should
be
under
careful
surveillance
when
receiving
ON
##FI
or
other
ps
##ych
##ot
##ropic
agents
because
of
the
pre
##dis
##position
of
such
patients
to
habit
##uation
and
dependence
[
see
Drug
Abu
##se
and
De
##pen
##dence
(
9
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
25
%
)
reported
in
patients
receiving
H
##AL
##AV
##EN
were
ne
##ut
##rop
##enia
,
an
##emia
,
as
##the
##nia
/
fatigue
,
al
##ope
##cia
,
peripheral
ne
##uro
##pathy
,
nausea
,
and
con
##st
##ip
##ation
.
[SEP]
[CLS]
Per
##ip
##her
##al
ne
##uro
##pathy
was
the
most
common
toxicity
leading
to
disco
##ntin
##uation
of
H
##AL
##AV
##EN
(
5
%
of
patients
;
24
/
50
##3
)
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Z
##Y
##KA
##DI
##A
in
patients
who
develop
Q
##T
##c
interval
pro
##long
##ation
in
combination
with
Tor
##sad
##e
de
point
##es
or
p
##oly
##morphic
vent
##ric
##ular
ta
##chy
##card
##ia
or
signs
/
symptoms
of
serious
a
##rr
##hy
##th
##mia
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
The
mean
age
at
study
entry
was
38
years
(
range
18
to
83
years
)
,
64
%
were
female
,
and
95
%
were
white
.
[SEP]
[CLS]
In
the
controlled
r
##he
##uma
##to
##id
art
##hr
##itis
studies
,
there
were
more
new
cases
of
serious
infection
adverse
reactions
in
the
C
##IM
##Z
##IA
treatment
groups
,
compared
to
the
place
##bo
groups
(
0
.
06
per
patient
-
year
for
all
C
##IM
##Z
##IA
doses
vs
.
0
.
02
per
patient
-
year
for
place
##bo
)
.
[SEP]
[CLS]
In
Studies
1
and
2
the
N
##U
##L
##O
##J
##IX
regime
##n
is
identical
to
the
recommended
regime
##n
,
but
is
slightly
different
in
Study
3
.
[SEP]
[CLS]
With
##hold
CO
##ME
##TR
##I
##Q
in
patients
with
de
##his
##cence
or
wound
healing
complications
requiring
medical
intervention
.
[SEP]
[CLS]
The
total
number
of
N
##U
##L
##O
##J
##IX
patients
from
these
three
studies
(
94
##9
)
was
compared
to
the
pool
##ed
c
##y
##c
##los
##por
##ine
control
groups
from
all
three
studies
(
47
##6
patients
)
.
[SEP]
[CLS]
In
short
-
term
,
place
##bo
-
controlled
trials
,
so
##m
##no
##len
##ce
(
including
se
##dation
)
was
reported
in
11
.
9
%
(
104
/
87
##4
)
of
adult
patients
treated
with
FA
##NA
##P
##T
at
doses
of
10
mg
/
day
or
greater
versus
5
.
3
%
(
31
/
58
##7
)
treated
with
place
##bo
.
[SEP]
[CLS]
The
following
adverse
events
were
reported
in
C
##ro
##hn
'
s
disease
patients
who
were
anti
##body
-
positive
(
N
=
100
)
at
an
incidence
at
least
3
%
higher
compared
to
anti
##body
-
negative
patients
(
N
=
1
,
242
)
:
abdominal
pain
,
art
##hra
##l
##gia
,
ed
##ema
peripheral
,
er
##yt
##hem
##a
nod
##os
##um
,
injection
site
er
##yt
##hem
##a
,
injection
site
pain
,
pain
in
ex
##tre
##mity
,
and
upper
respiratory
tract
infection
.
[SEP]
[CLS]
ON
##J
can
manifest
as
jaw
pain
,
o
##ste
##omy
##eli
##tis
,
o
##ste
##itis
,
bone
erosion
,
period
##ont
##al
infection
,
tooth
##ache
,
g
##ing
##ival
ul
##cer
##ation
,
persistent
jaw
pain
or
slow
healing
of
the
mouth
or
jaw
after
dental
surgery
.
[SEP]
[CLS]
Non
-
hem
##ato
##log
##ic
adverse
reactions
(
any
grade
)
in
the
T
##RE
##AN
##DA
group
that
occurred
with
a
frequency
greater
than
15
%
were
p
##yre
##xia
(
24
%
)
,
nausea
(
20
%
)
,
and
vomit
##ing
(
16
%
)
.
[SEP]
[CLS]
Monitor
with
liver
function
tests
including
AL
##T
and
total
bi
##li
##ru
##bin
every
2
weeks
during
the
first
2
months
of
treatment
,
then
once
a
month
and
as
clinical
##ly
indicated
,
with
more
frequent
repeat
testing
for
increased
liver
trans
##ami
##nas
##es
,
al
##kal
##ine
p
##hos
##pha
##tase
,
or
total
bi
##li
##ru
##bin
in
patients
who
develop
trans
##ami
##nas
##e
elevations
.
[SEP]
[CLS]
Monitor
and
manage
patients
using
standards
of
care
.
[SEP]
[CLS]
If
para
##dox
##ical
br
##on
##cho
##sp
##as
##m
occurs
,
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
should
be
discontinued
immediately
and
alternative
therapy
instituted
.
[SEP]
[CLS]
5
.
7
Su
##icidal
Be
##ha
##vior
and
I
##dea
##tion
Anti
##ep
##ile
##ptic
drugs
(
A
##ED
##s
)
,
including
P
##OT
##IG
##A
,
increase
the
risk
of
su
##icidal
thoughts
in
patients
taking
these
drugs
for
any
indication
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
the
patient
becomes
pregnant
while
taking
this
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
the
f
##etus
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
(
5
.
1
)
The
##rap
##eu
##tic
Monitor
##ing
:
P
##las
##ma
am
##monia
levels
should
be
maintained
within
normal
range
for
age
via
individual
dose
adjustment
.
[SEP]
[CLS]
6
.
3
I
##mm
##uno
##genic
##ity
Den
##os
##uma
##b
is
a
human
mon
##oc
##lon
##al
anti
##body
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
in
Pat
##ients
with
Per
##ip
##her
##al
T
-
Cell
L
##ymph
##oma
The
safety
of
Bel
##eo
##da
##q
was
evaluated
in
129
patients
with
re
##lap
##sed
or
re
##fra
##ctor
##y
PT
##CL
in
the
single
arm
clinical
trial
in
which
patients
were
administered
Bel
##eo
##da
##q
at
a
dos
##age
of
1
,
000
mg
/
m
##2
administered
over
30
minutes
by
IV
in
##fusion
once
daily
on
Days
1
-
5
of
a
21
-
day
cycle
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Because
most
trials
included
in
the
analysis
did
not
extend
beyond
24
weeks
,
the
risk
of
su
##icidal
thoughts
or
behavior
beyond
24
weeks
could
not
be
assessed
.
[SEP]
[CLS]
5
.
4
T
##hr
##omb
##osis
and
He
##mor
##r
##hage
Ser
##ious
th
##rom
##bot
##ic
events
,
including
sa
##git
##tal
sin
##us
th
##rom
##bos
##is
and
pulmonary
em
##bol
##ism
have
been
reported
with
both
E
.
co
##li
and
Erwin
##ia
-
derived
L
-
as
##par
##agi
##nas
##e
therapy
.
[SEP]
[CLS]
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
Grade
3
/
4
art
##erial
th
##rom
##boe
##mbo
##lic
events
were
reported
in
4
/
35
##9
patients
(
1
%
)
receiving
IN
##L
##Y
##TA
and
4
/
35
##5
patients
(
1
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
Study
2
:
Ch
##em
##otherapy
-
naive
Met
##ast
##atic
Cast
##ration
-
Re
##sist
##ant
Pro
##state
Cancer
Study
2
enrolled
171
##7
patients
with
meta
##static
CR
##PC
who
had
not
received
prior
c
##yt
##oto
##xi
##c
ch
##em
##otherapy
,
of
whom
1715
received
at
least
one
dose
of
study
drug
.
[SEP]
[CLS]
Keep
a
list
of
your
medicines
and
show
it
to
your
healthcare
provider
and
p
##har
##ma
##cist
when
you
get
a
new
medicine
.
[SEP]
[CLS]
*
Risk
of
A
##cute
Card
##ior
##es
##pi
##rator
##y
F
##ail
##ure
:
Pat
##ients
with
compromised
cardiac
or
respiratory
function
may
be
at
risk
of
acute
card
##ior
##es
##pi
##rator
##y
failure
.
[SEP]
[CLS]
It
is
important
to
note
that
early
manifest
##ations
of
h
##yper
##sen
##si
##ti
##vity
,
such
as
fever
or
l
##ymph
##ade
##no
##pathy
,
may
be
present
even
though
r
##ash
is
not
evident
.
[SEP]
[CLS]
Fat
##al
hem
##or
##r
##hage
was
reported
in
1
/
35
##9
patients
(
<
1
%
)
receiving
IN
##L
##Y
##TA
(
gas
##tric
hem
##or
##r
##hage
)
and
3
/
35
##5
patients
(
1
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
R
##out
##ine
monitoring
of
estimated
c
##rea
##tin
##ine
clearance
,
urine
glucose
,
and
urine
protein
should
be
performed
during
ST
##RI
##BI
##LD
therapy
in
all
patients
.
[SEP]
[CLS]
(
5
.
2
)
*
Monitor
for
worse
##ning
re
##nal
function
in
patients
with
re
##nal
imp
##air
##ment
.
[SEP]
[CLS]
Monitor
##ing
for
protein
##uria
before
initiation
of
,
and
periodically
throughout
,
treatment
with
IN
##L
##Y
##TA
is
recommended
.
[SEP]
[CLS]
Di
##zzi
##ness
was
reported
in
13
%
of
patients
receiving
600
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
compared
with
4
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
AS
##TH
##MA
-
R
##EL
##AT
##ED
DE
##AT
##H
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
The
median
duration
of
exposure
to
Z
##Y
##KA
##DI
##A
was
6
months
.
[SEP]
[CLS]
Fat
##ig
##ue
/
as
##the
##nia
was
reported
in
6
%
of
patients
treated
with
1
,
200
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
compared
with
1
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
*
My
##elo
##su
##pp
##ression
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
In
##fect
##ions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
Ana
##phy
##lax
##is
and
In
##fusion
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
Tu
##mor
L
##ys
##is
S
##yn
##drome
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
Skin
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
*
Other
Mali
##gna
##ncies
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
*
Extra
##vas
##ation
injury
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
7
)
]
*
*
Most
common
non
-
hem
##ato
##log
##ic
adverse
reactions
for
C
##LL
(
frequency
>
=
15
%
)
are
p
##yre
##xia
,
nausea
,
and
vomit
##ing
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Most
common
all
grades
adverse
reactions
(
>
=
10
%
)
are
ne
##ut
##rop
##enia
,
an
##emia
,
le
##uk
##ope
##nia
,
th
##rom
##bo
##cy
##top
##enia
,
di
##ar
##r
##hea
,
fatigue
,
nausea
,
vomit
##ing
,
con
##st
##ip
##ation
,
as
##the
##nia
,
abdominal
pain
,
hem
##at
##uria
,
back
pain
,
an
##ore
##xia
,
peripheral
ne
##uro
##pathy
,
p
##yre
##xia
,
d
##ys
##p
##nea
,
d
##ys
##ge
##us
##ia
,
cough
,
art
##hra
##l
##gia
,
and
al
##ope
##cia
.
[SEP]
[CLS]
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
:
P
##ru
##rit
##us
.
[SEP]
[CLS]
(
5
.
2
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
worse
##ning
re
##nal
imp
##air
##ment
:
Can
include
acute
re
##nal
failure
and
Fan
##con
##i
syndrome
.
[SEP]
[CLS]
Table
2
compares
the
incidence
of
treatment
-
emerge
##nt
adverse
reactions
reported
with
an
incidence
of
>
=
10
%
for
patients
receiving
A
##FI
##NI
##TO
##R
10
mg
daily
versus
place
##bo
.
[SEP]
[CLS]
The
data
described
below
are
based
on
two
pool
##ed
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
trials
through
Day
90
in
patients
with
Du
##pu
##yt
##ren
'
s
contract
##ure
(
Studies
1
and
2
)
.
[SEP]
[CLS]
Because
there
was
no
apparent
dose
-
related
increase
in
the
majority
of
adverse
events
observed
with
B
##EN
##L
##Y
##ST
##A
,
the
safety
data
summarized
below
are
presented
for
the
3
doses
pool
##ed
,
unless
otherwise
indicated
;
the
adverse
reaction
table
displays
the
results
for
the
recommended
dose
of
10
mg
/
kg
compared
with
place
##bo
.
[SEP]
[CLS]
Ser
##ious
skin
infections
,
as
well
as
infections
of
the
abdomen
,
were
more
frequent
in
patients
treated
with
Pro
##lia
.
[SEP]
[CLS]
Two
random
##ized
clinical
trials
enrolled
patients
with
meta
##static
pro
##state
cancer
that
has
progressed
on
and
##rogen
de
##p
##ri
##vation
therapy
(
G
##n
##R
##H
therapy
or
bilateral
or
##chi
##ec
##tom
##y
)
,
a
disease
setting
that
is
also
defined
as
meta
##static
CR
##PC
.
[SEP]
[CLS]
Although
no
high
risk
group
has
been
identified
,
exercise
caution
in
patients
being
treated
with
C
##IM
##Z
##IA
who
have
ongoing
,
or
a
history
of
,
significant
hem
##ato
##log
##ic
abnormal
##ities
.
[SEP]
[CLS]
In
the
random
##ized
,
place
##bo
-
controlled
portion
of
S
##J
##IA
Study
2
decreased
white
blood
cell
counts
)
less
than
or
equal
to
0
.
8
times
lower
limit
of
normal
(
LL
##N
)
were
reported
in
5
patients
(
10
.
4
%
)
in
the
IL
##AR
##IS
group
compared
to
2
(
4
.
0
%
)
in
the
place
##bo
group
.
[SEP]
[CLS]
Per
##cent
##ages
calculated
with
the
number
of
female
subjects
in
each
group
as
den
##omi
##nat
##or
:
place
##bo
(
N
=
48
##1
)
,
J
##AR
##DI
##AN
##CE
10
mg
(
N
=
44
##3
)
,
J
##AR
##DI
##AN
##CE
25
mg
(
N
=
420
)
.
[SEP]
[CLS]
(
5
.
1
,
2
.
3
)
*
Tu
##mor
Promotion
in
BR
##AF
Wild
-
Type
Mel
##ano
##ma
:
Inc
##reased
cell
proliferation
can
occur
with
BR
##AF
inhibitor
##s
.
[SEP]
[CLS]
Experience
in
Classical
Ho
##d
##g
##kin
L
##ymph
##oma
Su
##mma
##ry
of
Clinical
Trial
Experience
in
Re
##lap
##sed
Classical
H
##L
(
Study
1
)
AD
##CE
##TR
##IS
was
studied
in
102
patients
with
classical
H
##L
in
a
single
arm
clinical
trial
in
which
the
recommended
starting
dose
and
schedule
was
1
.
8
mg
/
kg
in
##tra
##ven
##ously
every
3
weeks
.
[SEP]
[CLS]
If
a
h
##yper
##sen
##si
##ti
##vity
reaction
occurs
,
disco
##ntin
##ue
Te
##f
##lar
##o
.
[SEP]
[CLS]
Pat
##ients
who
have
serum
AL
##T
greater
than
three
times
the
reference
range
with
serum
total
bi
##li
##ru
##bin
greater
than
two
times
the
reference
range
without
alternative
et
##iol
##ogies
are
at
risk
for
severe
drug
-
induced
liver
injury
and
should
not
be
restart
##ed
on
U
##L
##OR
##IC
.
[SEP]
[CLS]
Since
no
data
are
available
on
either
the
efficacy
or
on
the
risks
of
secondary
transmission
of
infection
by
live
vaccine
##s
in
patients
receiving
IL
##AR
##IS
,
live
vaccine
##s
should
not
be
given
concurrently
with
IL
##AR
##IS
.
[SEP]
[CLS]
Ch
##ronic
He
##pa
##titis
C
-
associated
T
##hr
##omb
##oc
##yt
##ope
##nia
:
In
the
two
place
##bo
-
controlled
trials
,
95
##5
patients
with
chronic
he
##pa
##titis
C
-
associated
th
##rom
##bo
##cy
##top
##enia
received
PR
##OM
##AC
##TA
.
[SEP]
[CLS]
The
safety
of
J
##E
##V
##TA
##NA
in
combination
with
pre
##dn
##ison
##e
was
evaluated
in
37
##1
patients
with
hormone
-
re
##fra
##ctor
##y
meta
##static
pro
##state
cancer
treated
in
a
single
random
##ized
trial
,
compared
to
mit
##ox
##ant
##rone
plus
pre
##dn
##ison
##e
.
[SEP]
[CLS]
The
ca
##usal
relationship
of
these
events
to
C
##IM
##Z
##IA
remains
unclear
.
[SEP]
[CLS]
c
Pre
##de
##fine
##d
adverse
event
grouping
,
including
,
but
not
limited
to
,
p
##oly
##uria
,
poll
##aki
##uria
,
and
no
##ct
##uria
d
Male
g
##eni
##tal
my
##cot
##ic
infections
include
the
following
adverse
reactions
:
b
##alan
##op
##ost
##hit
##is
,
b
##alan
##itis
,
g
##eni
##tal
infections
fun
##gal
,
g
##eni
##tour
##ina
##ry
tract
infection
,
b
##alan
##itis
can
##di
##da
,
s
##c
##rot
##al
a
##bs
##cess
,
pen
##ile
infection
.
[SEP]
[CLS]
Use
of
D
##U
##AV
##EE
in
patients
with
he
##pa
##tic
imp
##air
##ment
is
con
##tra
##ind
##ica
##ted
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
5
.
17
Drug
-
Laboratory
Test
Inter
##actions
A
##cc
##ele
##rated
pro
##th
##rom
##bin
time
;
increased
plate
##let
count
;
increased
factors
II
;
decreased
levels
of
anti
##fa
##ctor
X
##a
,
decreased
anti
##th
##rom
##bin
III
activity
;
increased
levels
of
fi
##bri
##no
##gen
;
increased
p
##las
##min
##ogen
anti
##gen
.
[SEP]
[CLS]
B
##ili
##ru
##bin
As
##ym
##pt
##oma
##tic
and
mild
elevations
of
serum
bi
##li
##ru
##bin
have
been
observed
in
patients
treated
with
IL
##AR
##IS
without
con
##com
##ita
##nt
elevations
of
trans
##ami
##nas
##es
.
[SEP]
[CLS]
If
a
diagnosis
of
invasive
systemic
fun
##gal
infection
is
made
,
disco
##ntin
##ue
A
##FI
##NI
##TO
##R
and
treat
with
appropriate
anti
##fu
##nga
##l
therapy
.
[SEP]
[CLS]
Therefore
,
exercise
caution
when
considering
re
##sumption
of
C
##IM
##Z
##IA
therapy
in
this
situation
and
monitor
patients
closely
.
[SEP]
[CLS]
Across
clinical
trials
of
T
##AF
##IN
##LA
##R
administered
in
combination
with
tram
##eti
##ni
##b
(
N
=
202
)
,
the
incidence
of
p
##yre
##xia
was
57
%
(
116
/
202
)
.
[SEP]
[CLS]
AM
##P
##Y
##RA
is
con
##tra
##ind
##ica
##ted
in
patients
with
a
history
of
seizure
##s
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
The
adverse
events
observed
within
one
hour
of
the
end
of
the
in
##fusion
were
similar
in
patients
who
received
C
##lev
##ip
##re
##x
and
in
those
who
received
com
##par
##ator
agents
.
[SEP]
[CLS]
During
Pro
##lia
treatment
,
patients
should
be
advised
to
report
new
or
unusual
thigh
,
hip
,
or
groin
pain
.
[SEP]
[CLS]
In
the
clinical
trials
,
one
subject
treated
with
O
##TE
##Z
##LA
attempted
suicide
while
one
who
received
place
##bo
committed
suicide
.
[SEP]
[CLS]
Do
##se
-
Re
##lated
Ad
##verse
Re
##actions
in
Clinical
Trials
Based
on
the
pool
##ed
data
from
4
place
##bo
-
controlled
,
4
-
or
6
-
week
,
fixed
-
or
flexible
-
dose
studies
,
adverse
reactions
that
occurred
with
a
greater
than
2
%
incidence
in
the
patients
treated
with
FA
##NA
##P
##T
,
and
for
which
the
incidence
in
patients
treated
with
FA
##NA
##P
##T
20
to
24
mg
/
day
were
twice
than
the
incidence
in
patients
treated
with
FA
##NA
##P
##T
10
to
16
mg
/
day
were
:
abdominal
discomfort
,
di
##zzi
##ness
,
h
##y
##pot
##ens
##ion
,
m
##us
##cu
##los
##kel
##etal
stiff
##ness
,
ta
##chy
##card
##ia
,
and
weight
increased
.
[SEP]
[CLS]
In
this
study
,
the
majority
of
my
##oc
##ard
##ial
in
##far
##ctions
occurred
between
1
and
4
months
after
initiation
of
treatment
.
[SEP]
[CLS]
The
safety
evaluation
of
Z
##Y
##KA
##DI
##A
is
based
on
255
AL
##K
-
positive
patients
in
Study
1
(
246
patients
with
N
##SC
##LC
and
9
patients
with
other
cancer
##s
who
received
Z
##Y
##KA
##DI
##A
at
a
dose
of
750
mg
daily
)
.
[SEP]
[CLS]
In
patients
who
had
thy
##roid
s
##ti
##mulating
hormone
(
T
##S
##H
)
<
5
m
##u
##U
/
m
##L
before
treatment
,
elevations
of
T
##S
##H
to
>
=
10
m
##u
##U
/
m
##L
occurred
in
79
/
245
patients
(
32
%
)
receiving
IN
##L
##Y
##TA
and
25
/
232
patients
(
11
%
)
receiving
so
##ra
##fen
##ib
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Some
patients
in
the
clinical
studies
or
in
the
post
##market
##ing
setting
have
undergone
testing
for
al
##g
##lu
##cos
##idas
##e
al
##fa
-
specific
I
##g
##E
antibodies
.
[SEP]
[CLS]
If
h
##y
##pot
##ens
##ion
does
occur
,
the
patient
should
be
placed
in
the
su
##pine
position
and
,
if
necessary
,
given
an
in
##tra
##ven
##ous
in
##fusion
of
normal
sa
##line
.
[SEP]
[CLS]
10
22
P
##sy
##chia
##tric
disorders
In
##so
##m
##nia
8
10
V
##as
##cular
disorders
H
##yper
##tens
##ion
<
1
3
D
##ys
##ton
##ia
:
S
##ym
##pt
##oms
of
d
##ys
##ton
##ia
,
prolonged
abnormal
contraction
##s
of
muscle
groups
,
may
occur
in
susceptible
individuals
during
the
first
few
days
of
treatment
.
[SEP]
[CLS]
In
most
cases
,
initial
symptoms
occurred
within
minutes
of
D
##OT
##AR
##EM
administration
and
resolved
with
pro
##mpt
emergency
treatment
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
5
.
10
H
##yper
##sen
##si
##ti
##vity
Re
##actions
In
post
-
marketing
experience
,
serious
systemic
h
##yper
##sen
##si
##ti
##vity
reactions
(
including
an
##aph
##yla
##ctic
reaction
)
have
been
reported
following
administration
of
the
sub
##cut
##aneous
formulation
of
go
##lim
##uma
##b
.
[SEP]
[CLS]
(
e
.
g
.
,
high
-
dose
or
multiple
non
-
s
##tero
##idal
anti
-
inflammatory
drugs
(
NSA
##ID
##s
)
)
[
see
Drug
Inter
##actions
(
7
.
4
)
]
.
[SEP]
[CLS]
How
should
I
take
D
##U
##AV
##EE
?
[SEP]
[CLS]
The
median
number
of
cycles
initiated
was
4
(
range
1
-
35
)
.
[SEP]
[CLS]
The
following
adverse
reactions
have
been
identified
during
post
approval
use
of
Pro
##lia
:
*
Drug
-
related
h
##yper
##sen
##si
##ti
##vity
reactions
:
an
##aph
##yla
##xi
##s
,
r
##ash
,
u
##rt
##ica
##ria
,
facial
swelling
,
and
er
##yt
##hem
##a
*
H
##y
##po
##cal
##ce
##mia
:
severe
h
##y
##po
##cal
##ce
##mia
*
Mu
##s
##cu
##los
##kel
##etal
pain
,
including
severe
cases
*
Para
##thy
##roid
Ho
##rmon
##e
(
PT
##H
)
:
Mark
##ed
elevation
in
serum
PT
##H
in
patients
with
severe
re
##nal
imp
##air
##ment
(
c
##rea
##tin
##ine
clearance
<
30
m
##L
/
min
)
or
receiving
dial
##ys
##is
.
[SEP]
[CLS]
Females
of
reproductive
potential
should
be
advised
to
avoid
pregnancy
while
being
treated
with
B
##OS
##U
##L
##IF
.
[SEP]
[CLS]
Pro
##mpt
use
of
all
the
##rap
##ies
necessary
to
reduce
plasma
am
##monia
levels
is
essential
.
[SEP]
[CLS]
*
Cho
##king
has
been
reported
by
patients
,
some
of
whom
may
have
also
experienced
or
##op
##har
##yn
##ge
##al
muscular
d
##ys
##function
or
h
##y
##po
##est
##hesia
.
[SEP]
[CLS]
A
total
of
120
men
were
exposed
to
place
##bo
and
120
men
were
exposed
to
Pro
##lia
administered
sub
##cut
##aneous
##ly
once
every
6
months
as
a
single
60
mg
dose
.
[SEP]
[CLS]
Per
##form
complete
blood
counts
weekly
for
the
first
month
of
therapy
and
then
monthly
thereafter
,
or
as
clinical
##ly
indicated
.
[SEP]
[CLS]
The
numbers
of
patients
and
their
exposure
##s
are
described
in
Table
1
.
[SEP]
[CLS]
Ad
##verse
reactions
were
reported
according
to
NC
##I
CT
##C
v
.
2
.
0
.
[SEP]
[CLS]
*
Healthcare
sites
must
be
certified
with
the
program
and
ensure
that
XI
##AF
##LE
##X
is
only
di
##spense
##d
for
use
by
certified
pre
##s
##cribe
##rs
.
[SEP]
[CLS]
Table
4
.
[SEP]
[CLS]
The
median
time
to
onset
was
7
.
4
weeks
(
range
:
1
.
6
-
13
.
4
)
and
6
.
3
weeks
(
range
:
0
.
3
-
18
.
9
)
after
the
initiation
of
Y
##ER
##VO
##Y
for
patients
with
Grade
3
-
5
enter
##oc
##oli
##tis
and
with
Grade
2
enter
##oc
##oli
##tis
,
respectively
.
[SEP]
[CLS]
One
of
the
47
##6
patients
treated
with
c
##y
##c
##los
##por
##ine
developed
PT
##LD
,
without
C
##NS
involvement
.
[SEP]
[CLS]
In
this
trial
,
elevated
plasma
pro
##la
##ct
##in
levels
were
observed
in
26
%
of
adults
treated
with
FA
##NA
##P
##T
compared
to
12
%
in
the
place
##bo
-
group
.
[SEP]
[CLS]
With
##hold
Z
##Y
##KA
##DI
##A
in
patients
who
develop
a
Q
##T
##c
interval
greater
than
500
m
##se
##c
on
at
least
2
separate
EC
##G
##s
until
the
Q
##T
##c
interval
is
less
than
48
##1
m
##se
##c
or
recovery
to
base
##line
if
the
Q
##T
##c
interval
is
greater
than
or
equal
to
48
##1
m
##se
##c
,
then
resume
Z
##Y
##KA
##DI
##A
at
a
reduced
dose
as
described
in
Table
1
.
[SEP]
[CLS]
However
,
the
incidence
of
p
##ru
##rit
##us
increased
with
more
injection
##s
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
EC
##G
analysis
did
not
identify
Q
##T
##c
pro
##long
##ation
.
[SEP]
[CLS]
O
##bs
##erve
infants
for
signs
or
symptoms
of
ben
##zy
##l
alcohol
toxicity
following
Ad
##re
##V
##ie
##w
administration
.
[SEP]
[CLS]
Monitor
serum
AL
##T
values
monthly
during
therapy
with
Fe
##rri
##p
##ro
##x
,
and
consider
interrupt
##ion
of
therapy
if
there
is
a
persistent
increase
in
the
serum
trans
##ami
##nas
##e
levels
.
[SEP]
[CLS]
CO
##PD
may
de
##ter
##ior
##ate
acute
##ly
over
a
period
of
hours
or
chronic
##ally
over
several
days
or
longer
.
[SEP]
[CLS]
On
##going
monitoring
of
plasma
am
##monia
levels
,
ne
##uro
##logical
status
,
laboratory
tests
and
clinical
responses
in
patients
receiving
Car
##bag
##lu
is
crucial
to
assess
patient
response
to
treatment
.
[SEP]
[CLS]
Across
the
clinical
development
program
for
Y
##ER
##VO
##Y
,
my
##co
##phe
##no
##late
treatment
has
been
administered
in
patients
who
have
persistent
severe
he
##pa
##titis
despite
high
-
dose
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
Monitor
patients
for
the
development
of
severe
cut
##aneous
reactions
and
disco
##ntin
##ue
Z
##yd
##eli
##g
.
[SEP]
[CLS]
Co
##rre
##ct
h
##y
##po
##kal
##emia
or
h
##y
##po
##ma
##gne
##se
##mia
prior
to
in
##iti
##ating
H
##AL
##AV
##EN
and
monitor
these
electro
##ly
##tes
periodically
during
therapy
.
[SEP]
[CLS]
Di
##ar
##r
##hea
can
occur
at
any
time
.
[SEP]
[CLS]
In
each
cycle
,
two
injection
##s
of
XI
##AF
##LE
##X
or
two
injection
##s
of
place
##bo
were
administered
1
to
3
days
apart
.
[SEP]
[CLS]
Testing
should
include
visual
a
##cu
##ity
and
di
##lated
fund
##us
photography
.
[SEP]
[CLS]
In
the
studies
with
C
##IM
##Z
##IA
in
RA
,
there
were
36
cases
of
T
##B
among
2
,
36
##7
exposed
patients
,
including
some
fatal
cases
.
[SEP]
[CLS]
The
long
-
term
clinical
effects
of
the
increase
in
H
##R
have
not
been
established
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
7
)
]
.
[SEP]
[CLS]
In
clinical
trials
,
rapid
co
##rt
##ico
##ster
##oid
tape
##ring
resulted
in
re
##cu
##rrence
or
worse
##ning
symptoms
of
enter
##oc
##oli
##tis
in
some
patients
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
C
##Y
##TO
##K
##IN
##E
R
##EL
##EA
##SE
S
##Y
##ND
##RO
##ME
and
NE
##UR
##OL
##O
##GI
##CA
##L
TO
##X
##IC
##IT
##IE
##S
WA
##R
##NI
##NG
:
C
##Y
##TO
##K
##IN
##E
R
##EL
##EA
##SE
S
##Y
##ND
##RO
##ME
and
NE
##UR
##OL
##O
##GI
##CA
##L
TO
##X
##IC
##IT
##IE
##S
*
Cy
##tok
##ine
Release
S
##yn
##drome
(
CR
##S
)
,
which
may
be
life
-
threatening
or
fatal
,
occurred
in
patients
receiving
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
The
pre
##ser
##vat
##ive
in
D
##UR
##E
##Z
##OL
may
be
absorbed
by
soft
contact
lenses
.
[SEP]
[CLS]
Sleep
a
##p
##nea
is
common
in
MP
##S
IV
##A
patients
.
[SEP]
[CLS]
The
safety
of
Pro
##lia
in
the
treatment
of
bone
loss
in
women
with
non
##met
##ast
##atic
breast
cancer
receiving
a
##roma
##tase
inhibitor
(
AI
)
therapy
was
assessed
in
a
2
-
year
,
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
,
multinational
study
of
252
post
##men
##op
##aus
##al
women
aged
35
to
84
years
.
[SEP]
[CLS]
Pain
in
ex
##tre
##mity
(
7
.
7
%
place
##bo
vs
.
9
.
9
%
Pro
##lia
)
and
m
##us
##cu
##los
##kel
##etal
pain
(
3
.
8
%
place
##bo
vs
.
6
.
0
%
Pro
##lia
)
have
also
been
reported
in
clinical
trials
.
[SEP]
[CLS]
The
laboratory
findings
in
these
4
subjects
improved
but
did
not
completely
resolve
in
all
subjects
upon
disco
##ntin
##uation
of
ST
##RI
##BI
##LD
.
[SEP]
[CLS]
H
##yper
##tens
##ion
In
the
two
random
##ized
trials
,
h
##yper
##tens
##ion
was
reported
in
11
%
of
patients
receiving
X
##TA
##ND
##I
and
4
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
Therefore
,
the
combination
of
an
##aki
##n
##ra
with
T
##NF
-
block
##ers
,
including
S
##IM
##PO
##NI
ARIA
,
is
not
recommended
[
see
Drug
Inter
##actions
(
7
.
2
)
]
.
[SEP]
[CLS]
Ask
your
healthcare
provider
if
you
do
not
know
if
you
take
any
of
these
medicines
.
[SEP]
[CLS]
*
have
any
other
medical
conditions
.
[SEP]
[CLS]
Treatment
-
experienced
,
In
##te
##gra
##se
Strand
Transfer
In
##hibit
##or
-
experienced
Sub
##jects
:
In
a
multi
##cent
##er
,
open
-
label
,
single
-
arm
trial
(
IN
##G
##11
##25
##7
##4
,
VI
##K
##ING
-
3
)
,
183
HIV
-
1
-
infected
,
anti
##ret
##rov
##ira
##l
treatment
-
experienced
adults
with
v
##iro
##logical
failure
and
current
or
historical
evidence
of
r
##al
##te
##gra
##vir
and
/
or
el
##vi
##te
##gra
##vir
resistance
received
T
##I
##VI
##CA
##Y
50
mg
twice
daily
with
the
current
failing
background
regime
##n
for
7
days
and
with
op
##ti
##mized
background
therapy
from
Day
8
.
[SEP]
[CLS]
Trans
##ami
##nas
##e
elevations
were
more
common
in
patients
who
had
abnormal
trans
##ami
##nas
##es
at
base
##line
.
[SEP]
[CLS]
(
5
.
3
)
*
A
##vo
##id
co
##ad
##mini
##stra
##tion
with
other
anti
-
re
##tro
##vir
##al
products
:
Do
not
use
with
products
containing
any
of
the
components
of
ST
##RI
##BI
##LD
(
co
##bic
##ista
##t
,
el
##vi
##te
##gra
##vir
,
em
##tric
##ita
##bine
,
and
ten
##of
##ov
##ir
di
##so
##p
##ro
##xi
##l
f
##uma
##rate
)
,
including
AT
##RI
##PL
##A
,
CO
##MP
##LE
##RA
,
E
##MT
##RI
##VA
,
T
##R
##U
##VA
##DA
,
T
##Y
##BO
##ST
,
VI
##RE
##AD
,
or
VI
##TE
##K
##TA
;
with
drugs
containing
la
##mi
##vu
##dine
;
or
with
drugs
or
regime
##ns
containing
r
##ito
##na
##vir
.
[SEP]
[CLS]
Fat
##al
adverse
reactions
in
G
##IL
##OT
##RI
##F
-
treated
patients
in
Study
1
included
pulmonary
toxicity
/
IL
##D
-
like
adverse
reactions
(
1
.
3
%
)
,
se
##psis
(
0
.
43
%
)
,
and
pneumonia
(
0
.
43
%
)
.
[SEP]
[CLS]
Di
##zzi
##ness
was
reported
in
17
%
of
patients
receiving
1
,
200
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
compared
with
15
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
Some
patients
(
13
%
)
received
pre
##med
##ica
##tion
,
which
may
have
mit
##igate
##d
or
masked
a
h
##yper
##sen
##si
##ti
##vity
response
;
however
,
there
is
insufficient
evidence
to
determine
whether
pre
##med
##ica
##tion
dim
##ini
##shes
the
frequency
or
severity
of
h
##yper
##sen
##si
##ti
##vity
reactions
.
[SEP]
[CLS]
5
.
3
Ang
##io
##ede
##ma
with
Con
##com
##ita
##nt
Use
of
Ang
##iot
##ens
##in
-
Con
##vert
##ing
En
##zy
##me
(
AC
##E
)
In
##hibit
##ors
Pat
##ients
taking
con
##com
##ita
##nt
AC
##E
inhibitor
therapy
may
be
at
increased
risk
for
an
##gio
##ede
##ma
(
e
.
g
.
,
swelling
of
the
air
##ways
,
with
or
without
respiratory
imp
##air
##ment
)
.
[SEP]
[CLS]
Physicians
should
exercise
caution
when
administer
##ing
IL
##AR
##IS
to
patients
with
infections
,
a
history
of
recurring
infections
or
underlying
conditions
which
may
pre
##dis
##pose
them
to
infections
.
[SEP]
[CLS]
Basel
##ine
re
##nal
function
was
normal
or
mildly
impaired
in
91
%
of
patients
and
moderately
impaired
in
9
%
of
patients
(
mean
e
##G
##F
##R
86
.
8
m
##L
/
min
/
1
.
73
m
2
)
.
[SEP]
[CLS]
B
##lee
##ding
in
Pat
##ients
with
Non
##val
##vu
##lar
At
##rial
Fi
##bri
##lla
##tion
in
AR
##IS
##TO
##TL
##E
and
A
##VE
##R
##RO
##ES
Table
##s
1
and
2
show
the
number
of
patients
experiencing
major
bleeding
during
the
treatment
period
and
the
bleeding
rate
(
percentage
of
subjects
with
at
least
one
bleeding
event
per
100
patient
-
years
)
in
AR
##IS
##TO
##TL
##E
and
A
##VE
##R
##RO
##ES
.
[SEP]
[CLS]
Across
clinical
trials
of
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
(
N
=
202
)
,
severe
skin
toxicity
and
secondary
infections
of
the
skin
requiring
hospital
##ization
occurred
in
2
.
5
%
(
5
/
202
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
An
increased
incidence
of
serious
infections
has
been
associated
with
administration
of
another
IL
-
1
block
##er
in
combination
with
T
##NF
inhibitor
##s
.
[SEP]
[CLS]
Blood
pressure
should
be
monitored
during
treatment
with
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
5
.
3
Con
##current
Treatment
with
Other
Form
##s
of
4
-
Am
##ino
##py
##rid
##ine
AM
##P
##Y
##RA
should
not
be
taken
with
other
forms
of
4
-
amino
##py
##rid
##ine
(
4
-
AP
,
f
##amp
##rid
##ine
)
since
the
active
ingredient
is
the
same
.
[SEP]
[CLS]
K
##AL
##IB
##IT
##OR
##N
=
100
Place
##bo
##N
=
81
Ad
##verse
Re
##actions
n
(
%
)
a
n
(
%
)
a
Head
##ache
8
(
8
%
)
6
(
7
%
)
Na
##use
##a
5
(
5
%
)
1
(
1
%
)
Di
##ar
##r
##hea
4
(
4
%
)
3
(
4
%
)
P
##yre
##xia
4
(
4
%
)
0
In
##jection
site
reactions
3
(
3
%
)
1
(
1
%
)
Na
##so
##pha
##ryn
##git
##is
3
(
3
%
)
0
Some
patients
in
E
##DE
##MA
##3
and
E
##DE
##MA
##4
received
a
second
,
open
-
label
30
mg
sub
##cut
##aneous
dose
of
K
##AL
##BI
##TO
##R
within
24
hours
following
the
initial
dose
.
[SEP]
[CLS]
During
controlled
and
open
-
labeled
portions
of
C
##IM
##Z
##IA
studies
of
C
##ro
##hn
'
s
disease
and
other
diseases
,
ma
##li
##gna
##ncies
(
excluding
non
-
me
##lan
##oma
skin
cancer
)
were
observed
at
a
rate
(
95
%
confidence
interval
)
of
0
.
5
(
0
.
4
,
0
.
7
)
per
100
patient
-
years
among
4
,
650
C
##IM
##Z
##IA
-
treated
patients
versus
a
rate
of
0
.
6
(
0
.
1
,
1
.
7
)
per
100
patient
-
years
among
1
,
31
##9
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Card
##io
##vert
patients
who
are
in
at
##rial
fi
##bri
##lla
##tion
(
if
clinical
##ly
indicated
)
or
disco
##ntin
##ue
M
##U
##LT
##A
##Q
.
[SEP]
[CLS]
For
patients
taking
con
##com
##ita
##nt
strong
C
##YP
##3
##A
##4
inhibitor
##s
(
including
k
##eto
##cona
##zo
##le
,
r
##ito
##na
##vir
,
at
##az
##ana
##vir
,
c
##lar
##ith
##rom
##y
##cin
,
in
##dina
##vir
,
it
##rac
##ona
##zo
##le
,
ne
##fa
##zo
##don
##e
,
ne
##lf
##ina
##vir
,
sa
##quin
##avi
##r
,
and
te
##lit
##hr
##omy
##cin
)
,
do
not
use
ST
##EN
##DR
##A
[
see
##D
##rug
Inter
##actions
(
7
.
2
)
]
.
[SEP]
[CLS]
Pat
##ients
who
experience
an
##aph
##yla
##ctic
or
h
##yper
##sen
##si
##ti
##vity
reactions
may
also
be
tested
for
I
##g
##E
antibodies
to
al
##g
##lu
##cos
##idas
##e
al
##fa
and
other
media
##tors
of
an
##aph
##yla
##xi
##s
[
see
##A
##d
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
The
data
described
below
reflect
exposure
of
PR
##OM
##AC
##TA
to
44
##6
patients
with
chronic
IT
##P
aged
18
to
85
years
,
of
whom
65
%
were
female
,
across
the
IT
##P
clinical
development
program
including
three
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
(
5
.
10
)
*
Em
##b
##ryo
##fe
##tal
To
##xi
##city
:
Can
cause
f
##etal
harm
.
[SEP]
[CLS]
Consider
disco
##ntin
##uation
of
D
##U
##AV
##EE
if
pan
##cre
##ati
##tis
occurs
.
[SEP]
[CLS]
If
a
go
##ut
flare
occurs
during
treatment
,
U
##L
##OR
##IC
need
not
be
discontinued
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Go
##ut
F
##lar
##e
:
An
increase
in
go
##ut
flare
##s
is
frequently
observed
during
initiation
of
anti
-
h
##yper
##uri
##ce
##mic
agents
,
including
U
##L
##OR
##IC
.
[SEP]
[CLS]
6
.
1
Ad
##verse
Re
##actions
from
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
However
,
prior
to
in
##iti
##ating
treatment
with
an
anti
##de
##press
##ant
,
patients
with
de
##pressive
symptoms
should
be
adequately
screened
to
determine
if
they
are
at
risk
for
bi
##pol
##ar
disorder
;
such
screening
should
include
a
detailed
psychiatric
history
,
including
a
family
history
of
suicide
,
bi
##pol
##ar
disorder
,
and
depression
.
[SEP]
[CLS]
Motion
artifacts
may
di
##sto
##rt
the
image
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
5
.
5
Risk
of
Anti
##body
Development
As
with
all
therapeutic
proteins
,
there
is
potential
for
im
##mu
##no
##genic
##ity
.
[SEP]
[CLS]
In
the
controlled
phase
of
Trial
1
through
Week
24
,
infections
were
observed
in
27
%
of
S
##IM
##PO
##NI
ARIA
-
treated
patients
compared
with
24
%
of
control
-
treated
patients
,
and
serious
infections
were
observed
in
0
.
9
%
of
S
##IM
##PO
##NI
ARIA
-
treated
patients
and
0
.
0
%
of
control
-
treated
patients
.
[SEP]
[CLS]
Ad
##verse
events
such
as
dry
mouth
,
nausea
,
vomit
##ing
and
di
##ar
##r
##hea
were
also
reported
at
an
increased
frequency
in
subjects
receiving
VI
##CT
##RE
##L
##IS
in
combination
with
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
.
[SEP]
[CLS]
Pat
##ients
treated
with
drone
##dar
##one
should
undergo
monitoring
of
cardiac
rhythm
no
less
often
than
every
3
months
.
[SEP]
[CLS]
5
.
2
Mali
##gna
##ncies
In
the
controlled
portions
of
clinical
studies
of
some
T
##NF
block
##ers
,
more
cases
of
ma
##li
##gna
##ncies
have
been
observed
among
patients
receiving
T
##NF
block
##ers
compared
to
control
patients
.
[SEP]
[CLS]
Do
not
administer
le
##uc
##ovo
##rin
within
2
hours
before
or
after
a
dose
of
V
##OR
##A
##X
##A
##Z
##E
because
le
##uc
##ovo
##rin
is
a
substrate
for
V
##OR
##A
##X
##A
##Z
##E
[
see
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
H
##yper
##tens
##ion
was
reported
as
an
adverse
reaction
in
8
%
of
patients
on
G
##IL
##EN
##Y
##A
0
.
5
mg
and
in
4
%
of
patients
on
place
##bo
.
[SEP]
[CLS]
The
incidence
of
grade
>
=
2
hem
##at
##uria
was
6
%
in
J
##E
##V
##TA
##NA
-
treated
patients
and
2
%
in
mit
##ox
##ant
##rone
-
treated
patients
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
G
##lax
##o
##S
##mith
##K
##line
at
1
-
87
##7
-
42
##3
-
65
##9
##7
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
The
most
common
reason
for
treatment
disco
##ntin
##uation
in
both
studies
was
for
bleeding
-
related
adverse
reactions
;
in
AR
##IS
##TO
##TL
##E
this
occurred
in
1
.
7
%
and
2
.
5
%
of
patients
treated
with
E
##L
##I
##Q
##UI
##S
and
war
##fari
##n
,
respectively
,
and
in
A
##VE
##R
##RO
##ES
,
in
1
.
5
%
and
1
.
3
%
on
E
##L
##I
##Q
##UI
##S
and
as
##pi
##rin
,
respectively
.
[SEP]
[CLS]
P
##ey
##ron
##ie
'
s
Disease
(
6
.
2
)
The
most
frequently
reported
adverse
drug
reactions
reported
with
>
=
25
%
of
patients
treated
with
XI
##AF
##LE
##X
and
at
an
incidence
greater
than
place
##bo
were
pen
##ile
hem
##ato
##ma
,
pen
##ile
swelling
and
pen
##ile
pain
.
[SEP]
[CLS]
L
##D
##L
-
C
increased
by
2
.
3
%
,
4
.
6
%
,
and
6
.
5
%
in
patients
treated
with
place
##bo
,
J
##AR
##DI
##AN
##CE
10
mg
,
and
J
##AR
##DI
##AN
##CE
25
mg
,
respectively
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
.
[SEP]
[CLS]
These
trials
evaluated
the
use
of
T
##AN
##Z
##E
##UM
as
mon
##otherapy
,
and
as
add
-
on
therapy
to
oral
anti
##dia
##bet
##ic
agents
,
and
as
add
-
on
therapy
to
basal
insulin
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Women
dependent
on
thy
##roid
hormone
replacement
therapy
who
are
also
receiving
est
##rogen
##s
may
require
increased
doses
of
their
thy
##roid
replacement
therapy
.
[SEP]
[CLS]
The
majority
(
4
of
5
patients
)
of
fatal
infection
-
related
adverse
reactions
occurred
after
a
single
dose
of
J
##E
##V
##TA
##NA
.
[SEP]
[CLS]
Pat
##ients
who
are
carriers
of
H
##B
##V
and
require
treatment
with
C
##IM
##Z
##IA
should
be
closely
monitored
for
clinical
and
laboratory
signs
of
active
H
##B
##V
infection
throughout
therapy
and
for
several
months
following
termination
of
therapy
.
[SEP]
[CLS]
All
patients
being
treated
with
anti
##de
##press
##ants
for
any
indication
should
be
monitored
appropriately
and
observed
closely
for
clinical
worse
##ning
,
su
##icidal
##ity
,
and
unusual
changes
in
behavior
,
especially
during
the
initial
few
months
of
a
course
of
drug
therapy
,
or
at
times
of
dose
changes
,
either
increases
or
decreases
.
[SEP]
[CLS]
5
.
13
Here
##dit
##ary
Ang
##io
##ede
##ma
Ex
##ogen
##ous
est
##rogen
##s
may
ex
##ace
##rb
##ate
symptoms
of
an
##gio
##ede
##ma
in
women
with
hereditary
an
##gio
##ede
##ma
.
[SEP]
[CLS]
Basel
##ine
estimated
re
##nal
function
was
normal
or
mildly
impaired
(
e
##G
##F
##R
>
60
m
##L
/
min
/
1
.
73
m
2
)
in
92
%
of
the
population
and
moderately
impaired
(
e
##G
##F
##R
30
to
60
m
##L
/
min
/
1
.
73
m
2
)
in
8
%
of
the
population
.
[SEP]
[CLS]
IL
##AR
##IS
has
been
associated
with
an
increased
incidence
of
serious
infections
.
[SEP]
[CLS]
In
those
patients
treated
with
1
,
200
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
who
reported
di
##zzi
##ness
,
symptoms
persisted
during
treatment
in
about
6
%
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
disco
##ntin
##uation
for
patients
taking
O
##TE
##Z
##LA
were
nausea
(
1
.
8
%
)
,
di
##ar
##r
##hea
(
1
.
8
%
)
,
and
headache
(
1
.
2
%
)
.
[SEP]
[CLS]
The
decision
to
resume
IN
##L
##Y
##TA
therapy
after
surgery
should
be
based
on
clinical
judgment
of
adequate
wound
healing
.
[SEP]
[CLS]
Ad
##mini
##ster
systemic
co
##rt
##ico
##ster
##oids
at
a
dose
of
1
to
2
mg
/
kg
/
day
of
pre
##dn
##ison
##e
or
equivalent
.
[SEP]
[CLS]
Death
##s
during
double
-
blind
treatment
where
an
adverse
event
was
the
primary
cause
occurred
in
seven
patients
on
A
##FI
##NI
##TO
##R
and
one
patient
on
place
##bo
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
GE
Healthcare
at
1
-
800
-
65
##4
-
01
##18
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Long
-
term
cumulative
radiation
exposure
is
associated
with
an
increased
risk
of
cancer
.
[SEP]
[CLS]
c
D
##ys
##p
##nea
includes
the
preferred
terms
of
d
##ys
##p
##nea
,
d
##ys
##p
##nea
ex
##ert
##ional
.
[SEP]
[CLS]
Especially
tell
your
healthcare
provider
if
you
take
other
ho
##rmon
##al
medicines
,
including
pro
##ges
##tin
##s
or
other
medicines
like
D
##U
##AV
##EE
.
[SEP]
[CLS]
Fall
-
related
injuries
were
more
severe
in
patients
treated
with
X
##TA
##ND
##I
and
included
non
-
path
##olo
##gic
fracture
##s
,
joint
injuries
,
and
hem
##ato
##mas
.
[SEP]
[CLS]
WA
##R
##NI
##NG
:
IN
##CR
##EA
##SE
##D
M
##OR
##TA
##L
##IT
##Y
IN
E
##LD
##ER
##L
##Y
PA
##TI
##EN
##TS
W
##IT
##H
DE
##ME
##NT
##IA
-
R
##EL
##AT
##ED
PS
##Y
##CH
##OS
##IS
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
There
were
13
(
0
.
8
%
)
patients
with
Grade
3
and
4
(
0
.
2
%
)
patients
with
Grade
4
visual
imp
##air
##ment
.
[SEP]
[CLS]
Therefore
,
use
of
E
##L
##I
##Q
##UI
##S
is
not
recommended
in
these
patients
.
[SEP]
[CLS]
These
adverse
reactions
were
not
present
at
base
##line
,
occurred
more
commonly
on
IN
##VO
##KA
##NA
than
on
place
##bo
,
and
occurred
in
at
least
2
%
of
patients
treated
with
either
IN
##VO
##KA
##NA
100
mg
or
IN
##VO
##KA
##NA
300
mg
.
Table
1
:
Ad
##verse
Re
##actions
From
Pool
of
Four
26
-
Week
Place
##bo
-
Control
##led
Studies
Report
##ed
in
>
=
2
%
of
IN
##VO
##KA
##NA
-
T
##reate
##d
Pat
##ients
##T
##he
four
place
##bo
-
controlled
trials
included
one
mon
##otherapy
trial
and
three
add
-
on
combination
trials
with
met
##form
##in
,
met
##form
##in
and
su
##lf
##ony
##lu
##rea
,
or
met
##form
##in
and
p
##io
##gli
##ta
##zone
.
[SEP]
[CLS]
Therefore
,
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
,
like
other
s
##ym
##path
##omi
##met
##ic
am
##ines
,
should
be
used
with
caution
in
patients
with
card
##iovascular
disorders
,
especially
co
##rona
##ry
ins
##uff
##iciency
,
cardiac
a
##rr
##hy
##th
##mia
##s
,
and
h
##yper
##tens
##ion
.
[SEP]
[CLS]
Test
for
viral
he
##pa
##titis
and
disco
##ntin
##ue
other
he
##pa
##to
##to
##xi
##c
medications
if
evidence
of
new
or
worse
##ning
liver
d
##ys
##function
occurs
.
[SEP]
[CLS]
The
management
of
N
##MS
should
include
:
1
)
immediate
disco
##ntin
##uation
of
anti
##psy
##cho
##tic
drugs
and
other
drugs
not
essential
to
concurrent
therapy
;
2
)
intensive
s
##ym
##pt
##oma
##tic
treatment
and
medical
monitoring
;
and
3
)
treatment
of
any
con
##com
##ita
##nt
serious
medical
problems
for
which
specific
treatments
are
available
.
[SEP]
[CLS]
Consider
periodic
monitoring
with
electro
##card
##io
##gram
##s
(
EC
##G
##s
)
and
electro
##ly
##tes
in
patients
with
con
##ges
##tive
heart
failure
,
bra
##dy
##ar
##r
##hy
##th
##mia
##s
,
electro
##ly
##te
abnormal
##ities
,
or
who
are
taking
medications
that
are
known
to
pro
##long
the
Q
##T
interval
.
[SEP]
[CLS]
These
cases
generally
occurred
within
3
months
after
the
initiation
of
X
##AL
##KO
##RI
.
[SEP]
[CLS]
Care
##ful
consideration
should
be
given
to
the
patient
'
s
clinical
status
prior
to
administration
of
V
##im
##iz
##im
and
consider
delay
##ing
the
V
##im
##iz
##im
in
##fusion
.
[SEP]
[CLS]
AP
##TI
##OM
should
be
discontinued
and
not
be
resumed
if
an
alternative
et
##iology
for
the
signs
or
symptoms
can
not
be
established
.
[SEP]
[CLS]
Monitor
patients
for
symptoms
of
per
##fo
##rations
and
fist
##ula
##s
.
[SEP]
[CLS]
In
the
XI
##AF
##LE
##X
controlled
trials
in
P
##ey
##ron
##ie
'
s
disease
(
Studies
1
and
2
)
,
65
.
5
%
of
XI
##AF
##LE
##X
-
treated
patients
developed
pen
##ile
hem
##ato
##ma
,
and
14
.
5
%
developed
pen
##ile
e
##cc
##hy
##mos
##is
(
see
Table
4
)
.
[SEP]
[CLS]
In
Study
1
,
CT
##CA
##E
Grade
3
-
4
h
##yper
##gly
##ce
##mia
,
based
on
laboratory
values
,
occurred
in
13
%
of
255
patients
.
[SEP]
[CLS]
5
.
6
Ana
##phy
##lax
##is
Ser
##ious
all
##ergic
reactions
,
including
an
##aph
##yla
##xi
##s
,
have
been
reported
in
patients
on
Z
##yd
##eli
##g
.
[SEP]
[CLS]
One
percent
(
1
%
)
of
patients
discontinued
Z
##Y
##KA
##DI
##A
in
Study
1
due
to
IL
##D
/
p
##ne
##um
##oni
##tis
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
incidence
>
=
25
%
)
were
ne
##ut
##rop
##enia
,
an
##emia
,
as
##the
##nia
/
fatigue
,
al
##ope
##cia
,
peripheral
ne
##uro
##pathy
,
nausea
,
and
con
##st
##ip
##ation
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
E
##isa
##i
Inc
.
at
(
1
-
87
##7
-
87
##3
-
47
##24
)
or
contact
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
the
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
other
clinical
trials
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Me
##as
##ure
the
absolute
ne
##ut
##rop
##hil
count
(
AN
##C
)
before
starting
Fe
##rri
##p
##ro
##x
therapy
and
monitor
the
AN
##C
weekly
on
therapy
.
[SEP]
[CLS]
5
.
4
High
Blood
Press
##ure
For
women
with
well
-
controlled
h
##yper
##tens
##ion
,
monitor
blood
pressure
and
stop
Nat
##azi
##a
if
blood
pressure
rises
significantly
.
[SEP]
[CLS]
5
.
10
Drug
Inter
##actions
A
##vo
##id
administration
of
CO
##ME
##TR
##I
##Q
with
agents
that
are
strong
C
##YP
##3
##A
##4
induce
##rs
or
inhibitor
##s
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
and
Drug
Inter
##actions
(
7
.
1
,
7
.
2
)
]
.
[SEP]
[CLS]
I
##mm
##une
-
mediated
he
##pa
##titis
:
Eva
##lu
##ate
liver
function
tests
before
each
dose
of
Y
##ER
##VO
##Y
.
[SEP]
[CLS]
Pat
##ients
received
6
doses
of
ER
##WI
##NA
##Z
##E
25
,
000
International
Units
/
m
2
in
##tra
##mus
##cular
##ly
on
a
Monday
,
Wednesday
,
and
Friday
schedule
as
a
replacement
for
each
scheduled
dose
of
p
##eg
##as
##par
##gas
##e
remaining
on
their
original
treatment
protocol
.
[SEP]
[CLS]
Di
##zzi
##ness
36
##20
##14
31
<
1
P
##sy
##chia
##tric
disorders
In
##so
##m
##nia
15
0
Re
##sp
##ira
##tory
,
th
##ora
##ci
##c
,
and
media
##st
##inal
disorders
Co
##ugh
D
##ys
##p
##nea
##D
##ys
##p
##nea
includes
the
following
terms
:
acute
respiratory
failure
,
br
##on
##chia
##l
h
##yper
##act
##ivity
,
br
##on
##cho
##sp
##as
##m
,
d
##ys
##p
##nea
,
d
##ys
##p
##nea
ex
##ert
##ional
,
respiratory
distress
,
respiratory
failure
,
and
w
##hee
##zing
.
[SEP]
[CLS]
If
h
##yper
##sen
##si
##ti
##vity
reactions
occur
,
disco
##ntin
##ue
use
of
FA
##R
##X
##IG
##A
;
treat
per
standard
of
care
and
monitor
until
signs
and
symptoms
resolve
.
[SEP]
[CLS]
*
At
##rial
Fi
##bri
##lla
##tion
:
Monitor
patients
for
at
##rial
fi
##bri
##lla
##tion
(
5
.
4
)
.
[SEP]
[CLS]
With
##hold
X
##AL
##KO
##RI
in
patients
who
develop
Q
##T
##c
greater
than
500
m
##s
on
at
least
2
separate
EC
##G
##s
until
recovery
to
a
Q
##T
##c
less
than
or
equal
to
480
m
##s
,
then
resume
X
##AL
##KO
##RI
at
a
reduced
dose
as
described
in
Table
2
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
and
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
H
##y
##po
##nat
##rem
##ia
was
also
observed
in
mon
##otherapy
trials
.
[SEP]
[CLS]
Basel
##ine
evaluation
##s
of
liver
laboratory
tests
are
recommended
.
[SEP]
[CLS]
N
##eur
##op
##athy
N
##eur
##op
##athy
in
nature
,
occurred
in
41
##9
(
25
%
)
of
166
##9
patients
.
[SEP]
[CLS]
(
5
.
5
)
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
:
H
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
and
an
##gio
##ede
##ma
,
have
been
observed
.
[SEP]
[CLS]
Ser
##um
c
##rea
##tin
##ine
levels
and
estimated
G
##F
##R
may
not
re
##lia
##bly
assess
re
##nal
function
in
the
setting
of
acute
kidney
injury
.
[SEP]
[CLS]
No
patients
experienced
h
##yper
##tensive
crisis
.
[SEP]
[CLS]
The
most
common
adverse
reaction
leading
to
treatment
disco
##ntin
##uation
was
fatigue
/
as
##the
##nia
,
which
occurred
in
1
%
of
patients
on
each
treatment
arm
.
[SEP]
[CLS]
In
addition
,
the
observed
incidence
of
anti
##body
p
##os
##iti
##vity
in
an
ass
##ay
may
be
influenced
by
several
factors
including
ass
##ay
methodology
,
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
A
trans
##ient
h
##y
##pot
##ens
##ive
response
is
not
a
con
##tra
##ind
##ica
##tion
to
further
treatment
,
which
usually
can
be
continued
without
difficulty
once
the
blood
pressure
has
stab
##ilized
.
[SEP]
[CLS]
You
should
not
do
both
.
[SEP]
[CLS]
H
##yper
##tens
##ion
was
managed
with
standard
anti
##hy
##pert
##ens
##ive
therapy
.
[SEP]
[CLS]
Table
3
compares
the
incidence
of
the
most
frequent
adverse
reactions
from
a
single
treatment
cycle
of
500
Units
of
D
##Y
##SP
##OR
##T
(
r
)
compared
to
place
##bo
[
see
##C
##lini
##cal
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
(
5
.
5
)
*
Not
recommended
in
patients
with
complete
gas
##tro
##int
##est
##inal
o
##bs
##truction
or
in
patients
who
have
surgery
for
correction
of
complete
bow
##el
o
##bs
##truction
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
R
##IS
##K
OF
AN
##AP
##H
##Y
##LA
##X
##IS
,
H
##YP
##ER
##SE
##NS
##IT
##I
##VI
##TY
AND
I
##MM
##UN
##E
-
ME
##DI
##AT
##ED
R
##EA
##CT
##ION
##S
,
AND
R
##IS
##K
OF
CA
##RD
##IO
##RE
##SP
##IR
##AT
##OR
##Y
FA
##IL
##UR
##E
WA
##R
##NI
##NG
:
R
##IS
##K
OF
AN
##AP
##H
##Y
##LA
##X
##IS
,
H
##YP
##ER
##SE
##NS
##IT
##I
##VI
##TY
AND
I
##MM
##UN
##E
-
ME
##DI
##AT
##ED
R
##EA
##CT
##ION
##S
,
AND
R
##IS
##K
OF
CA
##RD
##IO
##RE
##SP
##IR
##AT
##OR
##Y
FA
##IL
##UR
##E
Life
-
threatening
an
##aph
##yla
##ctic
reactions
and
severe
h
##yper
##sen
##si
##ti
##vity
reactions
,
presenting
as
respiratory
distress
,
h
##y
##pox
##ia
,
a
##p
##nea
,
d
##ys
##p
##nea
,
bra
##dy
##card
##ia
,
ta
##chy
##card
##ia
,
br
##on
##cho
##sp
##as
##m
,
throat
tight
##ness
,
h
##y
##pot
##ens
##ion
,
an
##gio
##ede
##ma
(
including
lip
swelling
,
per
##ior
##bit
##al
ed
##ema
,
and
face
ed
##ema
)
,
and
u
##rt
##ica
##ria
,
have
occurred
in
some
patients
during
and
after
al
##g
##lu
##cos
##idas
##e
al
##fa
in
##fusion
##s
.
[SEP]
[CLS]
(
6
.
1
)
*
Most
common
hem
##ato
##log
##ic
abnormal
##ities
for
both
indication
##s
(
frequency
>
=
15
%
)
are
l
##ymph
##ope
##nia
,
an
##emia
,
le
##uk
##ope
##nia
,
th
##rom
##bo
##cy
##top
##enia
,
and
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
A
place
##bo
-
controlled
trial
with
another
LA
##BA
(
sa
##lm
##eter
##ol
)
showed
an
increase
in
as
##th
##ma
-
related
deaths
.
[SEP]
[CLS]
The
major
hem
##or
##r
##ha
##gic
events
of
gas
##tric
hem
##or
##r
##hage
occurred
in
5
%
(
3
/
55
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
compared
with
none
of
the
53
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
Table
1
shows
common
adverse
reactions
(
excluding
h
##y
##po
##gly
##ce
##mia
)
associated
with
the
use
of
J
##AR
##DI
##AN
##CE
.
[SEP]
[CLS]
At
base
##line
,
the
population
had
diabetes
for
an
average
of
8
years
and
had
a
mean
H
##b
##A
##1
##c
of
8
.
2
%
.
[SEP]
[CLS]
Ser
##ious
f
##eb
##ril
##e
reactions
and
fever
of
any
severity
complicated
by
h
##y
##pot
##ens
##ion
,
rig
##ors
or
chill
##s
occurred
in
3
.
7
%
(
7
/
187
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
and
in
none
of
the
59
patients
treated
with
da
##car
##ba
##zine
.
[SEP]
[CLS]
No
patient
required
dose
reduction
or
permanent
disco
##ntin
##uation
of
T
##AF
##IN
##LA
##R
or
tram
##eti
##ni
##b
for
skin
toxicity
.
[SEP]
[CLS]
Table
##s
1
and
2
show
the
most
frequently
reported
adverse
reactions
(
>
=
3
%
)
in
adults
and
children
respectively
who
received
the
6
-
dose
regime
##n
of
Co
##arte
##m
Table
##ts
.
[SEP]
[CLS]
Most
h
##yper
##sen
##si
##ti
##vity
reactions
to
E
##O
##VI
##ST
have
occurred
within
half
an
hour
after
administration
.
[SEP]
[CLS]
C
##IM
##Z
##IA
has
not
been
formally
studied
in
patients
with
CH
##F
;
however
,
in
clinical
studies
in
patients
with
CH
##F
with
another
T
##NF
block
##er
,
worse
##ning
con
##ges
##tive
heart
failure
)
and
increased
mortality
due
to
CH
##F
were
observed
.
[SEP]
[CLS]
D
##ys
##pha
##gia
was
reported
in
0
.
2
%
and
0
%
(
1
/
57
##2
,
0
/
37
##9
)
of
patients
treated
with
therapeutic
doses
(
5
-
10
mg
twice
daily
)
of
SA
##P
##H
##RI
##S
as
compared
to
0
%
(
0
/
37
##8
,
0
/
203
)
of
patients
treated
with
place
##bo
in
short
-
term
s
##chi
##zophrenia
and
bi
##pol
##ar
man
##ia
adult
trials
,
respectively
.
[SEP]
[CLS]
Overall
,
312
patients
(
95
%
)
received
H
##SV
and
V
##Z
##V
prop
##hyl
##ax
##is
with
a
median
duration
of
11
.
1
months
(
range
,
0
-
20
)
and
31
##9
patients
(
98
%
)
received
PC
##P
prop
##hyl
##ax
##is
with
a
median
duration
of
6
.
5
months
(
range
,
0
-
20
)
.
[SEP]
[CLS]
In
patients
with
abnormal
##ly
high
(
>
3
mg
/
d
##L
)
serum
bi
##li
##ru
##bin
,
reduced
he
##pa
##tic
contrast
was
observed
.
[SEP]
[CLS]
This
is
approximately
2
-
fold
higher
than
expected
in
the
general
population
.
[SEP]
[CLS]
In
addition
,
women
taking
D
##U
##AV
##EE
should
be
advised
to
move
about
periodically
during
travel
involving
prolonged
im
##mo
##bil
##ization
.
[SEP]
[CLS]
CD
##AD
must
be
considered
in
all
patients
who
present
with
di
##ar
##r
##hea
following
anti
##biotic
use
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
go
##lim
##uma
##b
exposure
.
[SEP]
[CLS]
In
A
##VE
##R
##RO
##ES
,
the
mean
duration
of
exposure
was
approximately
59
weeks
(
>
3000
patient
-
years
)
.
[SEP]
[CLS]
5
.
9
Blood
Press
##ure
Effects
In
MS
controlled
clinical
trials
,
patients
treated
with
G
##IL
##EN
##Y
##A
0
.
5
mg
had
an
average
increase
over
place
##bo
of
approximately
3
mm
##H
##g
in
s
##ys
##to
##lic
pressure
,
first
detected
after
approximately
1
month
of
treatment
initiation
,
and
per
##sist
##ing
with
continued
treatment
.
[SEP]
[CLS]
There
were
suicide
##s
in
the
adult
studies
,
but
the
number
was
not
sufficient
to
reach
any
conclusion
about
drug
effect
on
suicide
.
[SEP]
[CLS]
No
complications
at
##tri
##but
##able
to
le
##uk
##oc
##yt
##osis
were
reported
in
clinical
studies
.
[SEP]
[CLS]
S
In
##tra
##c
##rani
##al
,
in
##tras
##pina
##l
,
in
##tra
##oc
##ular
,
per
##ica
##rdi
##al
,
an
operated
joint
requiring
re
-
operation
or
intervention
,
in
##tra
##mus
##cular
with
compartment
syndrome
,
or
re
##tro
##per
##ito
##nea
##l
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
that
led
to
dose
reduction
in
the
patients
treated
with
G
##IL
##OT
##RI
##F
were
di
##ar
##r
##hea
(
20
%
)
,
r
##ash
/
a
##c
##ne
(
19
%
)
,
par
##ony
##chia
(
14
%
)
,
and
s
##tom
##ati
##tis
(
10
%
)
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Nova
##rt
##is
Ph
##arma
##ce
##utical
##s
Corporation
at
1
-
88
##8
-
66
##9
-
66
##8
##2
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
T
##rea
##t
h
##y
##pot
##hy
##roid
##ism
and
h
##yper
##thy
##roid
##ism
according
to
standard
medical
practice
to
maintain
e
##uth
##yr
##oid
state
.
[SEP]
[CLS]
P
##OT
##IG
##A
was
administered
as
ad
##junct
##ive
therapy
to
1
,
365
patients
with
e
##pile
##psy
in
all
controlled
and
un
##con
##tro
##lled
clinical
studies
during
the
pre
##market
##ing
development
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reactions
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
5
.
4
F
##lu
##id
Re
##ten
##tion
F
##lu
##id
retention
occurs
with
B
##OS
##U
##L
##IF
and
may
manifest
as
per
##ica
##rdi
##al
e
##ff
##usion
,
p
##le
##ural
e
##ff
##usion
,
pulmonary
ed
##ema
,
and
/
or
peripheral
ed
##ema
.
[SEP]
[CLS]
Table
6
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
Inc
##reased
Mortal
##ity
An
increased
risk
of
death
was
seen
in
the
S
##IR
##TU
##RO
treatment
group
(
9
/
79
,
11
.
4
%
)
compared
to
the
place
##bo
treatment
group
(
2
/
81
,
2
.
5
%
)
in
one
place
##bo
-
controlled
trial
(
based
on
the
120
-
week
visit
window
)
.
[SEP]
[CLS]
*
He
##mat
##olo
##gic
To
##xi
##city
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
In
##fect
##ion
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
He
##pa
##to
##to
##xi
##city
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
Tu
##mor
L
##ys
##is
S
##yn
##drome
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
Gas
##tro
##int
##est
##inal
To
##xi
##city
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
The
most
common
adverse
reactions
observed
in
the
trial
of
patients
with
re
##lap
##sed
or
re
##fra
##ctor
##y
PT
##CL
treated
with
Bel
##eo
##da
##q
were
nausea
,
fatigue
,
p
##yre
##xia
,
an
##emia
,
and
vomit
##ing
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
H
##y
##po
##cal
##ce
##mia
(
serum
calcium
<
8
.
4
mg
/
d
##L
)
was
reported
only
in
Pro
##lia
-
treated
patients
(
2
.
4
%
vs
.
0
%
)
at
the
month
1
visit
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
are
discussed
in
greater
detail
in
other
sections
of
the
label
.
[SEP]
[CLS]
5
.
2
H
##yper
##sen
##si
##ti
##vity
Re
##actions
There
have
been
post
##market
##ing
reports
of
serious
h
##yper
##sen
##si
##ti
##vity
reactions
in
patients
treated
with
NE
##SI
##NA
.
[SEP]
[CLS]
I
##b
##ru
##tin
##ib
caused
ma
##lf
##orm
##ations
in
rats
at
exposure
##s
14
times
those
reported
in
patients
with
MC
##L
and
20
times
those
reported
in
patients
with
C
##LL
or
W
##M
,
receiving
the
i
##b
##ru
##tin
##ib
dose
of
560
mg
per
day
and
420
mg
per
day
,
respectively
.
[SEP]
[CLS]
These
effects
were
dose
-
related
and
generally
appeared
within
the
first
8
weeks
of
treatment
(
as
early
as
after
3
days
)
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Bay
##er
Health
##C
##are
Ph
##arma
##ce
##utical
##s
Inc
.
at
1
-
88
##8
-
84
##2
-
29
##37
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Abd
##omi
##nal
pain
V
##omi
##ting
252
##0
##20
##15
##13
0
<
112
##0
General
disorders
and
administration
site
conditions
P
##yre
##xia
Per
##ip
##her
##al
ed
##ema
Fat
##ig
##ue
Chi
##lls
Ch
##est
pain
62
##25
##17
##15
##11
7
<
110
##1
I
##mm
##une
system
disorders
Cy
##tok
##ine
release
syndrome
11
1
In
##fect
##ions
and
in
##fest
##ations
Other
path
##ogen
infections
Ba
##cter
##ial
infections
Fun
##gal
infections
V
##ira
##l
infections
P
##ne
##um
##onia
Sep
##sis
44
##19
##15
##13
##9
##7
251
##27
##48
##6
Investigation
##s
Inc
##reased
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
Inc
##reased
as
##par
##tate
amino
##tra
##ns
##fer
##ase
Inc
##reased
weight
121
##11
##1
640
Met
##ab
##olis
##m
and
nutrition
disorders
H
##y
##po
##kal
##emia
H
##y
##po
##ma
##gne
##se
##mia
H
##yper
##gly
##ce
##mia
Dec
##reased
appetite
H
##y
##pop
##hos
##phate
##mia
231
##21
##11
##0
##6
60
##7
##35
Mu
##s
##cu
##los
##kel
##etal
and
connect
##ive
tissue
disorders
Back
pain
Pain
in
ex
##tre
##mity
Bone
pain
Art
##hra
##l
##gia
141
##21
##11
##0
213
##2
N
##er
##vous
system
disorders
Head
##ache
T
##rem
##or
##T
##rem
##or
includes
the
following
terms
:
resting
t
##rem
##or
and
t
##rem
##or
.
[SEP]
[CLS]
5
.
2
Growth
of
Re
##sist
##ant
Organ
##isms
with
Pro
##long
##ed
Use
As
with
other
anti
-
in
##fect
##ives
,
prolonged
use
of
Be
##si
##vance
(
be
##si
##f
##lo
##xa
##cin
op
##ht
##hal
##mic
suspension
)
0
.
6
%
may
result
in
over
##gro
##wth
of
non
-
susceptible
organisms
.
[SEP]
[CLS]
The
overall
percentage
of
anti
##body
positive
patients
was
8
%
in
patients
continuously
exposed
to
C
##IM
##Z
##IA
,
approximately
6
%
were
neutral
##izing
in
v
##it
##ro
.
[SEP]
[CLS]
Table
1
:
Ad
##verse
Re
##actions
in
Place
##bo
-
Control
##led
Trials
Report
##ed
in
>
=
5
%
of
T
##R
##U
##L
##IC
##IT
##Y
-
T
##reate
##d
Pat
##ients
a
Includes
di
##ar
##r
##hea
,
f
##eca
##l
volume
increased
,
frequent
bow
##el
movements
.
[SEP]
[CLS]
Monitor
lip
##ase
and
am
##yla
##se
prior
to
the
start
of
Z
##Y
##KA
##DI
##A
treatment
and
periodically
thereafter
as
clinical
##ly
indicated
.
[SEP]
[CLS]
Mac
##ular
Ed
##ema
Following
Re
##tina
##l
V
##ein
O
##cc
##lusion
(
R
##VO
)
The
data
described
below
reflect
6
months
exposure
to
E
##Y
##LE
##A
with
a
monthly
2
mg
dose
in
218
patients
following
CR
##VO
in
2
clinical
studies
(
CO
##P
##ER
##NI
##CU
##S
and
GA
##L
##IL
##E
##O
)
and
91
patients
following
BR
##VO
in
one
clinical
study
(
VI
##BR
##AN
##T
)
[
see
##C
##lini
##cal
Studies
(
14
.
2
)
,
(
14
.
3
)
]
.
[SEP]
[CLS]
In
general
,
adverse
events
reported
by
IN
##TE
##LE
##NC
##E
(
r
)
-
treated
subjects
with
he
##pa
##titis
B
and
/
or
he
##pa
##titis
C
virus
co
-
infection
were
similar
to
IN
##TE
##LE
##NC
##E
(
r
)
-
treated
subjects
without
he
##pa
##titis
B
and
/
or
he
##pa
##titis
C
virus
co
-
infection
.
[SEP]
[CLS]
There
was
a
6
-
fold
increase
in
the
risk
of
CT
##CA
##E
Grade
3
-
4
h
##yper
##gly
##ce
##mia
in
patients
with
diabetes
or
glucose
into
##ler
##ance
and
a
2
-
fold
increase
in
patients
taking
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
Di
##ar
##r
##hea
due
to
Z
##yd
##eli
##g
responds
poorly
to
anti
##mot
##ility
agents
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
*
The
most
common
adverse
reactions
are
(
incidence
>
=
5
%
)
ch
##roma
##tur
##ia
,
nausea
,
vomit
##ing
and
abdominal
pain
,
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
increased
,
art
##hra
##l
##gia
and
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
Co
##mp
##aris
##ons
between
place
##bo
and
S
##IM
##PO
##NI
ARIA
were
based
on
the
first
24
weeks
of
exposure
.
[SEP]
[CLS]
P
##OT
##IG
##A
was
discontinued
in
3
of
the
5
patients
who
required
cat
##he
##ter
##ization
,
and
all
were
able
to
void
spontaneous
##ly
;
however
,
1
of
the
3
patients
continued
intermittent
self
-
cat
##he
##ter
##ization
.
[SEP]
[CLS]
St
##ero
##ids
should
be
used
with
caution
in
the
presence
of
g
##lau
##com
##a
.
[SEP]
[CLS]
S
A
medical
##ly
important
event
that
may
be
life
-
threatening
or
result
in
death
or
hospital
##ization
or
pro
##long
##ation
of
existing
hospital
##ization
.
[SEP]
[CLS]
Tu
##ber
##cu
##los
##is
and
her
##pes
infections
were
reported
more
frequently
in
patients
receiving
N
##U
##L
##O
##J
##IX
than
c
##y
##c
##los
##por
##ine
.
[SEP]
[CLS]
Or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
was
reported
in
5
%
of
patients
given
20
to
24
mg
/
day
,
3
%
of
patients
given
10
to
16
mg
/
day
,
and
1
%
of
patients
given
place
##bo
.
[SEP]
[CLS]
In
this
study
13
patients
experienced
bone
fracture
##s
for
treatment
duration
##s
up
to
104
weeks
.
[SEP]
[CLS]
The
rate
of
withdrawal
##s
due
to
adverse
events
in
place
##bo
-
controlled
mon
##otherapy
and
combination
therapy
trials
was
2
.
4
%
(
19
/
80
##1
)
for
place
##bo
,
2
.
2
%
(
24
/
107
##2
)
for
Ed
##ar
##bi
40
mg
,
and
2
.
7
%
(
29
/
107
##4
)
for
Ed
##ar
##bi
80
mg
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Pharmacy
##c
##lic
##s
at
1
-
87
##7
-
87
##7
-
35
##36
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
The
role
of
l
##ymph
##ope
##nia
in
this
case
is
unknown
.
[SEP]
[CLS]
In
the
clinical
study
of
78
##0
##8
post
##men
##op
##aus
##al
women
with
o
##ste
##op
##oro
##sis
,
the
incidence
of
infections
resulting
in
death
was
0
.
2
%
in
both
place
##bo
and
Pro
##lia
treatment
groups
.
[SEP]
[CLS]
Inc
##rease
##s
in
Ser
##um
Ma
##gnesium
Do
##se
-
related
increases
in
serum
ma
##gnesium
were
observed
early
after
initiation
of
IN
##VO
##KA
##NA
(
within
6
weeks
)
and
remained
elevated
throughout
treatment
.
[SEP]
[CLS]
Do
##se
reduction
##s
due
to
adverse
reactions
were
required
in
16
%
of
X
##AL
##KO
##RI
-
treated
patients
.
[SEP]
[CLS]
After
the
Clean
##sing
G
##el
has
been
wiped
off
,
wash
the
area
with
soap
and
water
.
[SEP]
[CLS]
Monitor
and
manage
patients
using
standards
of
care
,
including
anti
##dia
##rr
##hea
##ls
,
anti
##em
##etics
,
and
fluid
replacement
.
[SEP]
[CLS]
Table
##s
3
and
4
sum
##mar
##ize
common
adverse
reactions
and
laboratory
abnormal
##ities
in
X
##AL
##KO
##RI
-
treated
patients
.
[SEP]
[CLS]
At
the
end
of
treatment
,
0
.
8
%
,
4
.
0
%
,
and
2
.
7
%
of
patients
treated
with
place
##bo
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
,
had
hem
##og
##lo
##bin
above
the
upper
limit
of
normal
.
[SEP]
[CLS]
Other
adverse
reactions
reported
in
patients
receiving
Be
##si
##vance
occurring
in
approximately
1
-
2
%
of
patients
included
:
blurred
vision
,
eye
pain
,
eye
irritation
,
eye
p
##ru
##rit
##us
and
headache
.
[SEP]
[CLS]
Monitor
L
##D
##L
-
C
and
treat
if
appropriate
after
in
##iti
##ating
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
The
pot
##ency
Units
of
D
##Y
##SP
##OR
##T
(
r
)
are
not
interchange
##able
with
other
preparations
of
b
##ot
##ulin
##um
to
##xin
products
and
,
therefore
,
units
of
biological
activity
of
D
##Y
##SP
##OR
##T
(
r
)
can
not
be
compared
to
or
converted
into
units
of
any
other
b
##ot
##ulin
##um
to
##xin
products
(
5
.
1
)
*
Re
##com
##men
##ded
dose
and
frequency
of
administration
should
not
be
exceeded
(
5
.
4
)
*
I
##mme
##dia
##te
medical
attention
may
be
required
in
cases
of
swallowing
difficulties
(
5
.
3
)
*
Con
##com
##ita
##nt
ne
##uro
##mus
##cular
disorder
may
ex
##ace
##rb
##ate
clinical
effects
of
treatment
(
5
.
5
)
*
D
##Y
##SP
##OR
##T
(
r
)
contains
human
album
##in
.
[SEP]
[CLS]
N
##MS
is
an
uncommon
but
life
-
threatening
syndrome
characterized
by
fever
or
h
##yper
##ther
##mia
,
muscle
rigid
##ity
,
in
##vo
##lu
##ntary
movements
,
altered
consciousness
,
and
mental
status
changes
.
[SEP]
[CLS]
6
.
3
Post
##market
##ing
Experience
Similar
adverse
reactions
have
been
observed
in
post
##market
##ing
use
as
compared
to
the
clinical
trials
.
[SEP]
[CLS]
5
.
7
Risk
of
Ser
##ious
Ad
##verse
Re
##actions
in
Pan
##cre
##atic
and
Gas
##tric
Ana
##sto
##mos
##es
E
##NT
##ER
##EG
has
not
been
studied
in
patients
having
pan
##cre
##atic
or
gas
##tric
an
##ast
##omo
##sis
.
[SEP]
[CLS]
Table
4
displays
the
mean
changes
in
serum
c
##rea
##tin
##ine
and
e
##G
##F
##R
levels
at
Week
144
and
the
percentage
of
subjects
with
elevations
in
serum
c
##rea
##tin
##ine
(
All
Grades
)
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
>
1
%
and
more
common
than
with
place
##bo
)
:
o
##cular
irritation
,
application
site
irritation
,
and
application
site
an
##est
##hesia
.
[SEP]
[CLS]
The
proportion
of
subjects
with
ps
##oria
##sis
who
discontinued
treatment
due
to
any
adverse
reaction
was
6
.
1
%
for
subjects
treated
with
O
##TE
##Z
##LA
30
mg
twice
daily
and
4
.
1
%
for
place
##bo
-
treated
subjects
.
[SEP]
[CLS]
It
is
recommended
that
patients
being
considered
for
FA
##NA
##P
##T
treatment
who
are
at
risk
for
significant
electro
##ly
##te
disturbance
##s
have
base
##line
serum
potassium
and
ma
##gnesium
measurements
with
periodic
monitoring
.
[SEP]
[CLS]
5
.
4
Risk
of
Ser
##ious
Ad
##verse
Re
##actions
in
Pat
##ients
with
Se
##vere
He
##pa
##tic
I
##mp
##air
##ment
Pat
##ients
with
severe
he
##pa
##tic
imp
##air
##ment
may
be
at
higher
risk
of
serious
adverse
reactions
(
including
dose
-
related
serious
adverse
reactions
)
because
up
to
10
-
fold
higher
plasma
levels
of
drug
have
been
observed
in
such
patients
compared
with
patients
with
normal
he
##pa
##tic
function
.
[SEP]
[CLS]
Therefore
,
the
use
of
PR
##AD
##A
##X
##A
is
con
##tra
##ind
##ica
##ted
in
patients
with
mechanical
pro
##st
##hetic
valves
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
Have
an
##aph
##yla
##ctic
and
h
##yper
##sen
##si
##ti
##vity
treatment
measures
available
prior
to
Da
##T
##sca
##n
administration
and
,
following
administration
,
observe
patients
for
symptoms
or
signs
of
a
h
##yper
##sen
##si
##ti
##vity
reaction
.
[SEP]
[CLS]
In
the
random
##ized
trial
,
five
patients
(
1
.
3
%
)
experienced
fatal
infectious
adverse
events
(
se
##psis
or
se
##ptic
shock
)
.
[SEP]
[CLS]
Live
##r
En
##zy
##me
A
##b
##nor
##mal
##ities
In
the
pool
of
place
##bo
-
and
active
-
controlled
trials
,
a
similar
proportion
of
patients
experienced
at
least
one
event
of
AL
##T
)
increase
of
3
-
fold
or
greater
above
the
upper
limit
of
normal
(
0
.
9
%
and
0
.
9
%
for
all
com
##par
##ators
versus
T
##AN
##Z
##E
##UM
)
.
[SEP]
[CLS]
6
.
1
.
1
Safety
Experience
with
K
##y
##p
##rol
##is
in
Co
##mb
##ination
with
Lena
##lid
##omi
##de
and
Dex
##ame
##tha
##son
##e
in
Pat
##ients
with
Multiple
My
##elo
##ma
The
safety
of
K
##y
##p
##rol
##is
in
combination
with
le
##nal
##ido
##mi
##de
and
de
##xa
##met
##has
##one
(
K
##R
##d
)
was
evaluated
in
an
open
-
label
random
##ized
study
in
patients
with
re
##lap
##sed
multiple
my
##elo
##ma
.
[SEP]
[CLS]
*
He
##pa
##titis
B
react
##ivation
-
Monitor
H
##B
##V
carriers
during
and
several
months
after
therapy
.
[SEP]
[CLS]
The
most
commonly
occurring
adverse
reactions
(
>
=
20
%
)
in
patients
treated
with
T
##AF
##IN
##LA
##R
were
,
in
order
of
decreasing
frequency
:
h
##yper
##ker
##ato
##sis
,
headache
,
p
##yre
##xia
,
art
##hra
##l
##gia
,
p
##ap
##illo
##ma
,
al
##ope
##cia
,
and
palm
##ar
-
plant
##ar
er
##yt
##hr
##ody
##ses
##the
##sia
syndrome
(
PP
##ES
)
.
[SEP]
[CLS]
How
do
I
store
D
##U
##AV
##EE
?
[SEP]
[CLS]
The
addition
of
VI
##CT
##RE
##L
##IS
to
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
is
associated
with
an
additional
decrease
in
hem
##og
##lo
##bin
concentrations
.
[SEP]
[CLS]
5
.
4
Cat
##ara
##cts
In
the
three
controlled
clinical
trials
in
adults
with
chronic
IT
##P
,
cat
##ara
##cts
developed
or
worse
##ned
in
15
(
7
%
)
patients
who
received
50
mg
of
PR
##OM
##AC
##TA
daily
and
8
(
7
%
)
place
##bo
-
group
patients
.
[SEP]
[CLS]
In
a
trial
of
T
##AN
##Z
##E
##UM
in
patients
with
re
##nal
imp
##air
##ment
[
see
Clinical
Studies
(
14
.
3
)
]
,
the
frequency
of
such
gas
##tro
##int
##est
##inal
reactions
increased
as
re
##nal
function
declined
[
see
Use
in
S
##pecific
Population
##s
(
8
.
6
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reactions
requiring
intervention
in
clinical
trials
were
h
##yper
##sen
##si
##ti
##vity
reactions
,
occurring
in
20
of
39
(
51
%
)
patients
treated
with
al
##g
##lu
##cos
##idas
##e
al
##fa
,
and
included
r
##ash
,
p
##yre
##xia
,
u
##rt
##ica
##ria
,
flush
##ing
,
decreased
oxygen
sat
##uration
,
cough
,
ta
##chy
##p
##nea
,
ta
##chy
##card
##ia
,
h
##yper
##tens
##ion
/
increased
blood
pressure
,
p
##allo
##r
,
rig
##ors
,
vomit
##ing
,
c
##yan
##osis
,
agitation
,
and
t
##rem
##or
.
[SEP]
[CLS]
A
specific
anti
##dote
for
E
##L
##I
##Q
##UI
##S
is
not
available
.
[SEP]
[CLS]
(
5
.
3
)
*
C
##los
##tri
##dium
di
##ff
##ici
##le
-
associated
di
##ar
##r
##hea
(
CD
##AD
)
has
been
reported
with
nearly
all
systemic
anti
##ba
##cter
##ial
agents
,
including
D
##AL
##VA
##NC
##E
.
[SEP]
[CLS]
ST
##EN
##DR
##A
should
be
used
with
caution
,
and
only
when
the
anticipated
benefits
out
##wei
##gh
the
risks
,
in
patients
with
a
history
of
N
##A
##ION
.
[SEP]
[CLS]
Pat
##ients
greater
than
65
years
of
age
,
patients
with
co
-
m
##or
##bid
conditions
and
/
or
patients
taking
con
##com
##ita
##nt
im
##mu
##nos
##up
##press
##ants
such
as
co
##rt
##ico
##ster
##oids
or
met
##hot
##re
##xa
##te
may
be
at
greater
risk
of
infection
.
[SEP]
[CLS]
*
Card
##iac
arrest
*
N
##ep
##hr
##ogenic
System
##ic
Fi
##bro
##sis
(
N
##SF
)
*
H
##yper
##sen
##si
##ti
##vity
reactions
(
an
##aph
##yla
##ctic
shock
,
c
##ir
##cula
##tory
collapse
,
respiratory
arrest
,
pulmonary
ed
##ema
,
br
##on
##cho
##sp
##as
##m
,
c
##yan
##osis
,
or
##op
##har
##yn
##ge
##al
swelling
,
la
##ryn
##ge
##al
ed
##ema
,
blood
pressure
increased
,
chest
pain
,
an
##gio
##ede
##ma
,
con
##junct
##iv
##itis
,
h
##yper
##hi
##dr
##osis
,
cough
,
s
##nee
##zing
,
burning
sensation
,
and
p
##allo
##r
)
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
NE
##P
##H
##RO
##GE
##NI
##C
S
##Y
##ST
##EM
##IC
F
##IB
##RO
##SI
##S
WA
##R
##NI
##NG
:
NE
##P
##H
##RO
##GE
##NI
##C
S
##Y
##ST
##EM
##IC
F
##IB
##RO
##SI
##S
G
##ado
##lini
##um
-
based
contrast
agents
(
GB
##CA
##s
)
increase
the
risk
for
N
##SF
among
patients
with
impaired
elimination
of
the
drugs
.
[SEP]
[CLS]
If
such
an
acute
reaction
occurs
,
combination
therapy
should
be
discontinued
and
appropriate
medical
therapy
immediately
instituted
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
Monitor
plate
##let
counts
regularly
.
[SEP]
[CLS]
Monitor
closely
.
[SEP]
[CLS]
(
5
.
2
)
*
?
[SEP]
[CLS]
U
##ve
##itis
(
including
i
##rit
##is
)
occurred
in
1
%
(
6
/
58
##6
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
and
u
##ve
##itis
occurred
in
1
%
(
2
/
202
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
The
long
-
term
consequences
of
the
degree
of
suppression
of
bone
re
##mo
##del
##ing
observed
with
Pro
##lia
may
contribute
to
adverse
outcomes
such
as
o
##ste
##one
##c
##rosis
of
the
jaw
,
at
##y
##pical
fracture
##s
,
and
delayed
fracture
healing
.
[SEP]
[CLS]
(
5
.
8
)
5
.
1
Post
-
Trans
##p
##lant
L
##ymph
##op
##rol
##ifer
##ative
Di
##sor
##der
N
##U
##L
##O
##J
##IX
-
treated
patients
have
an
increased
risk
for
developing
post
-
transplant
l
##ymph
##op
##rol
##ifer
##ative
disorder
(
PT
##LD
)
,
predominantly
involving
the
C
##NS
,
compared
to
patients
on
a
c
##y
##c
##los
##por
##ine
-
based
regime
##n
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
and
Table
2
]
.
[SEP]
[CLS]
*
Ren
##al
failure
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
A
dose
-
dependent
increase
in
the
risk
of
mac
##ular
ed
##ema
occurred
in
the
G
##IL
##EN
##Y
##A
clinical
development
program
.
[SEP]
[CLS]
Therefore
,
E
##NT
##ER
##EG
is
not
recommended
for
use
in
these
patients
.
[SEP]
[CLS]
5
.
5
Pre
-
existing
N
##eur
##om
##us
##cular
Di
##sor
##ders
and
other
Special
Population
##s
Individuals
with
peripheral
motor
ne
##uro
##pathic
diseases
,
am
##yo
##tro
##phic
lateral
s
##cle
##rosis
,
or
ne
##uro
##mus
##cular
junction
##al
disorders
(
e
.
g
.
,
my
##ast
##hen
##ia
g
##ra
##vis
or
Lambert
-
Eaton
syndrome
)
should
be
monitored
particularly
closely
when
given
b
##ot
##ulin
##um
to
##xin
.
[SEP]
[CLS]
5
(
ta
##rt
##raz
##ine
)
which
may
cause
all
##ergic
-
type
reactions
(
including
br
##on
##chia
##l
as
##th
##ma
)
in
certain
susceptible
persons
.
[SEP]
[CLS]
Table
1
lists
adverse
reactions
,
regardless
of
ca
##usal
##ity
,
occurring
in
at
least
3
%
of
patients
with
SL
##E
who
received
B
##EN
##L
##Y
##ST
##A
10
mg
/
kg
and
at
an
incidence
at
least
1
%
greater
than
that
observed
with
place
##bo
in
the
3
controlled
studies
.
[SEP]
[CLS]
Monitor
for
evidence
of
T
##LS
during
treatment
and
manage
promptly
including
interrupt
##ion
of
K
##y
##p
##rol
##is
until
T
##LS
is
resolved
[
see
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
In
several
ex
##p
##lora
##tory
trials
of
other
T
##NF
-
block
##ers
in
the
treatment
of
CH
##F
,
there
were
greater
proportions
of
T
##NF
-
block
##er
treated
patients
who
had
CH
##F
ex
##ace
##rb
##ations
requiring
hospital
##ization
or
increased
mortality
.
[SEP]
[CLS]
breathing
difficulties
can
be
life
threatening
and
there
have
been
reports
of
death
.
[SEP]
[CLS]
(
5
.
1
)
*
ve
##nous
th
##rom
##bot
##ic
events
have
been
observed
and
can
be
fatal
.
[SEP]
[CLS]
Use
with
drugs
that
pro
##long
the
Q
##T
interval
may
cause
add
##itive
Q
##T
pro
##long
##ation
.
[SEP]
[CLS]
Approximately
80
%
of
these
patients
had
>
10
weeks
exposure
to
To
##via
##z
in
these
trials
.
[SEP]
[CLS]
5
.
4
Application
Associated
Pain
Even
following
use
of
a
local
an
##est
##hetic
prior
to
administration
of
Q
##ute
##nza
,
patients
may
experience
substantial
pro
##cedural
pain
.
[SEP]
[CLS]
Dec
##rease
##s
in
Bone
Mine
##ral
Den
##sity
Bone
mineral
density
(
B
##MD
)
was
measured
by
dual
-
energy
X
-
ray
a
##bs
##or
##pt
##io
##metry
in
a
clinical
trial
of
71
##4
older
adults
(
mean
age
64
years
)
[
see
Clinical
Studies
(
14
.
3
)
]
.
[SEP]
[CLS]
In
the
pool
of
four
place
##bo
-
controlled
trials
,
the
mean
percent
change
in
serum
ma
##gnesium
levels
was
8
.
1
%
and
9
.
3
%
with
IN
##VO
##KA
##NA
100
mg
and
IN
##VO
##KA
##NA
300
mg
,
respectively
,
compared
to
-
0
.
6
%
with
place
##bo
.
[SEP]
[CLS]
The
most
commonly
occurring
adverse
reactions
in
the
W
##M
trial
(
>
=
20
%
)
were
ne
##ut
##rop
##enia
,
th
##rom
##bo
##cy
##top
##enia
,
di
##ar
##r
##hea
,
r
##ash
,
nausea
,
muscle
spa
##sm
##s
,
and
fatigue
.
[SEP]
[CLS]
The
use
of
NE
##SI
##NA
as
add
-
on
therapy
to
g
##ly
##bur
##ide
or
insulin
did
not
increase
the
incidence
of
h
##y
##po
##gly
##ce
##mia
compared
to
place
##bo
.
[SEP]
[CLS]
Of
the
patients
treated
with
the
N
##U
##L
##O
##J
##IX
recommended
regime
##n
,
5
%
(
14
/
304
)
developed
NO
##DA
##T
by
the
end
of
one
year
compared
to
10
%
(
27
/
280
)
of
patients
on
the
c
##y
##c
##los
##por
##ine
control
regime
##n
.
[SEP]
[CLS]
The
most
common
laboratory
abnormal
##ities
(
>
25
%
)
were
increased
AS
##T
,
increased
AL
##T
,
l
##ymph
##ope
##nia
,
increased
AL
##P
,
h
##y
##po
##cal
##ce
##mia
,
ne
##ut
##rop
##enia
,
th
##rom
##bo
##cy
##top
##enia
,
h
##y
##pop
##hos
##phate
##mia
,
and
h
##yper
##bil
##ir
##ubi
##ne
##mia
.
[SEP]
[CLS]
In
all
controlled
and
un
##con
##tro
##lled
trials
across
various
patient
populations
,
more
than
2
,
300
patients
have
received
H
##OR
##I
##Z
##AN
##T
oral
##ly
in
daily
doses
ranging
from
600
to
3
,
600
mg
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
occurring
in
>
=
5
%
of
C
##IM
##Z
##IA
-
treated
patients
,
and
with
a
higher
incidence
compared
to
place
##bo
)
in
controlled
clinical
studies
with
C
##IM
##Z
##IA
were
upper
respiratory
infections
(
e
.
g
.
[SEP]
[CLS]
The
op
##ht
##hal
##mo
##log
##ic
monitoring
program
should
include
visual
a
##cu
##ity
testing
and
di
##lated
fund
##us
photography
.
[SEP]
[CLS]
Treatment
with
Ed
##ar
##bi
was
well
-
tolerate
##d
with
an
overall
incidence
of
adverse
reactions
similar
to
place
##bo
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
CO
##RP
##OR
##AL
R
##UP
##TU
##RE
(
P
##EN
##IL
##E
F
##RA
##CT
##UR
##E
)
OR
O
##TH
##ER
SE
##RI
##O
##US
P
##EN
##IL
##E
IN
##J
##UR
##Y
IN
THE
T
##RE
##AT
##ME
##NT
OF
P
##E
##Y
##RO
##NI
##E
'
S
D
##IS
##EA
##SE
WA
##R
##NI
##NG
:
CO
##RP
##OR
##AL
R
##UP
##TU
##RE
(
P
##EN
##IL
##E
F
##RA
##CT
##UR
##E
)
OR
O
##TH
##ER
SE
##RI
##O
##US
P
##EN
##IL
##E
IN
##J
##UR
##Y
IN
THE
T
##RE
##AT
##ME
##NT
OF
P
##E
##Y
##RO
##NI
##E
'
S
D
##IS
##EA
##SE
Corporal
r
##up
##ture
(
pen
##ile
fracture
)
was
reported
as
an
adverse
reaction
in
5
of
104
##4
(
0
.
5
%
)
XI
##AF
##LE
##X
-
treated
patients
in
clinical
studies
.
[SEP]
[CLS]
Grade
3
or
greater
th
##rom
##bo
##cy
##top
##enia
occurred
in
1
%
(
7
/
50
##3
)
of
patients
.
[SEP]
[CLS]
Figure
1
Gas
##tro
##int
##est
##inal
Ad
##verse
Re
##actions
Pat
##ients
on
PR
##AD
##A
##X
##A
150
mg
had
an
increased
incidence
of
gas
##tro
##int
##est
##inal
adverse
reactions
(
35
%
vs
.
24
%
on
war
##fari
##n
)
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Forest
Laboratories
,
LLC
,
at
1
-
800
-
67
##8
-
160
##5
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Risk
by
In
##dication
for
Anti
##ep
##ile
##ptic
Drugs
in
the
Poole
##d
Analysis
In
##dication
Place
##bo
Pat
##ients
with
Events
per
1000
Pat
##ients
Drug
Pat
##ients
with
Events
per
1000
Pat
##ients
Re
##lative
Risk
:
Inc
##iden
##ce
of
Drug
Events
in
Drug
Pat
##ients
/
Inc
##iden
##ce
##in
Place
##bo
Pat
##ients
Risk
Di
##fference
:
Additional
Drug
Pat
##ients
with
Events
per
1000
Pat
##ients
E
##pile
##psy
1
.
0
3
.
4
3
.
5
2
.
4
P
##sy
##chia
##tric
5
.
7
8
.
5
1
.
5
2
.
9
Other
1
.
0
1
.
8
1
.
9
0
.
9
Total
2
.
4
4
.
3
1
.
8
1
.
9
The
relative
risk
for
su
##icidal
thoughts
was
higher
in
clinical
trials
for
e
##pile
##psy
than
in
clinical
trials
for
psychiatric
or
other
conditions
,
but
the
absolute
risk
differences
were
similar
for
the
e
##pile
##psy
and
psychiatric
indication
##s
.
[SEP]
[CLS]
Studies
1
and
2
were
not
designed
to
support
comparative
claims
for
N
##U
##L
##O
##J
##IX
for
the
adverse
reactions
reported
in
this
table
.
[SEP]
[CLS]
Auto
##im
##mu
##ne
disorders
(
such
as
Graves
'
disease
,
p
##oly
##my
##os
##itis
,
and
G
##uil
##lain
-
Barr
##e
syndrome
)
have
also
been
reported
to
occur
in
the
setting
of
immune
re
##con
##st
##itution
;
however
,
the
time
to
onset
is
more
variable
,
and
can
occur
many
months
after
initiation
of
treatment
.
[SEP]
[CLS]
[
See
Con
##tra
##ind
##ica
##tions
(
4
)
.
]
[SEP]
[CLS]
Other
Ad
##verse
Re
##actions
Ad
##verse
reactions
that
occurred
at
a
frequency
of
>
=
10
%
in
patients
treated
with
the
N
##U
##L
##O
##J
##IX
recommended
regime
##n
or
c
##y
##c
##los
##por
##ine
control
regime
##n
in
Studies
1
and
2
through
three
years
are
summarized
by
preferred
term
in
decreasing
order
of
frequency
within
Table
4
.
[SEP]
[CLS]
Ad
##verse
reactions
were
predominantly
of
mild
to
moderate
severity
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
was
reported
in
22
%
of
patients
treated
with
P
##OT
##IG
##A
and
12
%
of
patients
treated
with
place
##bo
.
[SEP]
[CLS]
(
See
the
respective
package
insert
##s
for
complete
V
##Z
##IG
and
I
##G
pre
##s
##cribing
information
.
)
[SEP]
[CLS]
The
conditions
and
duration
of
treatment
with
FA
##NA
##P
##T
varied
greatly
and
included
(
in
overlapping
categories
)
,
open
-
label
and
double
-
blind
phases
of
studies
,
in
##patient
##s
and
out
##patient
##s
,
fixed
-
dose
and
flexible
-
dose
studies
,
and
short
-
term
and
longer
-
term
exposure
.
[SEP]
[CLS]
(
5
.
5
)
5
.
1
Ten
##don
R
##up
##ture
or
Other
Ser
##ious
In
##ju
##ry
to
the
In
##jected
Fin
##ger
/
Hand
in
the
Treatment
of
Du
##pu
##yt
##ren
'
s
Con
##tract
##ure
In
the
controlled
and
un
##con
##tro
##lled
portions
of
clinical
trials
in
Du
##pu
##yt
##ren
'
s
contract
##ure
,
fl
##ex
##or
tend
##on
r
##up
##tures
occurred
after
XI
##AF
##LE
##X
injection
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
PR
##IS
##TI
##Q
should
be
prescribed
with
caution
in
patients
with
a
seizure
disorder
.
[SEP]
[CLS]
(
5
.
6
)
*
Pre
##par
##ation
and
Administration
E
##rro
##rs
:
St
##ric
##tly
follow
instructions
for
preparation
(
including
ad
##mi
##xing
)
and
administration
.
[SEP]
[CLS]
Fat
##al
adverse
reactions
occurred
in
6
%
of
patients
receiving
CO
##ME
##TR
##I
##Q
and
resulted
from
hem
##or
##r
##hage
,
pneumonia
,
se
##ptic
##emia
,
fist
##ula
##s
,
cardiac
arrest
,
respiratory
failure
,
and
un
##sp
##ec
##ified
death
.
[SEP]
[CLS]
Act
##ivation
of
man
##ia
has
also
been
reported
in
a
small
proportion
of
patients
with
major
affect
##ive
disorder
who
were
treated
with
other
marketed
anti
##de
##press
##ants
.
[SEP]
[CLS]
bladder
infection
,
b
##act
##eri
##uria
,
c
##ys
##titis
)
in
7
%
of
C
##IM
##Z
##IA
-
treated
patients
and
in
6
%
of
place
##bo
-
treated
patients
,
and
art
##hra
##l
##gia
(
6
%
C
##IM
##Z
##IA
,
4
%
place
##bo
)
.
[SEP]
[CLS]
If
liver
injury
is
detected
,
promptly
interrupt
NE
##SI
##NA
and
assess
patient
for
probable
cause
,
then
treat
cause
if
possible
,
to
resolution
or
stab
##ilization
.
[SEP]
[CLS]
In
these
two
studies
combined
,
55
##4
patients
received
To
##via
##z
4
mg
/
day
and
56
##6
patients
received
To
##via
##z
8
mg
/
day
.
[SEP]
[CLS]
These
adverse
reactions
are
:
h
##yper
##sen
##si
##ti
##vity
reactions
,
para
##dox
##ical
br
##on
##cho
##sp
##as
##m
,
ta
##chy
##card
##ia
/
heart
rate
increase
/
p
##al
##pit
##ations
,
p
##ru
##rit
##us
/
r
##ash
and
di
##zzi
##ness
.
[SEP]
[CLS]
Male
patients
who
developed
g
##eni
##tal
my
##cot
##ic
infections
on
IN
##VO
##KA
##NA
were
more
likely
to
experience
re
##current
infections
(
22
%
on
IN
##VO
##KA
##NA
versus
none
on
place
##bo
)
,
and
require
treatment
with
oral
or
topic
##al
anti
##fu
##nga
##l
agents
and
anti
-
micro
##bial
agents
than
patients
on
com
##par
##ators
.
[SEP]
[CLS]
Ex
##cess
##ive
use
or
use
in
conjunction
with
other
medications
containing
LA
##BA
can
result
in
clinical
##ly
significant
card
##iovascular
effects
and
may
be
fatal
(
5
.
3
)
*
I
##mme
##dia
##te
h
##yper
##sen
##si
##ti
##vity
reactions
may
occur
.
[SEP]
[CLS]
The
incidence
of
non
##fa
##tal
serious
adverse
events
was
24
.
2
%
in
the
place
##bo
group
and
25
.
0
%
in
the
Pro
##lia
group
.
[SEP]
[CLS]
D
##U
##AV
##EE
has
been
shown
to
reduce
the
risk
of
end
##ome
##tri
##al
h
##yper
##p
##lasia
,
which
may
be
a
precursor
to
end
##ome
##tri
##al
cancer
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
disco
##ntin
##uation
were
hot
flush
,
abdominal
pain
upper
,
and
nausea
.
[SEP]
[CLS]
If
a
decision
is
made
to
administer
S
##IM
##PO
##NI
ARIA
to
RA
patients
with
CH
##F
,
these
patients
should
be
closely
monitored
during
therapy
,
and
S
##IM
##PO
##NI
ARIA
should
be
discontinued
if
new
or
worse
##ning
symptoms
of
CH
##F
appear
.
[SEP]
[CLS]
In
the
E
##MT
##P
trial
,
the
planned
number
of
doses
of
ER
##WI
##NA
##Z
##E
ranged
from
3
to
48
doses
.
[SEP]
[CLS]
Limited
safety
data
are
available
in
patients
with
pre
##dis
##po
##sing
factors
for
seizure
because
these
patients
were
generally
excluded
from
the
trials
.
[SEP]
[CLS]
The
effects
of
X
##E
##OM
##IN
and
all
b
##ot
##ulin
##um
to
##xin
products
may
spread
from
the
area
of
injection
to
produce
symptoms
consistent
with
b
##ot
##ulin
##um
to
##xin
effects
.
[SEP]
[CLS]
(
1
,
5
.
2
,
7
.
1
,
7
.
3
,
12
.
3
)
*
N
##eur
##ole
##ptic
Mali
##gnant
S
##yn
##drome
:
Man
##age
with
immediate
disco
##ntin
##uation
of
drug
and
close
monitoring
.
[SEP]
[CLS]
The
safety
of
re
##ini
##tia
##ting
K
##y
##p
##rol
##is
therapy
in
patients
previously
experiencing
T
##TP
/
H
##US
is
not
known
.
[SEP]
[CLS]
Monitor
C
##r
##C
##l
at
least
daily
in
patients
with
changing
re
##nal
function
and
adjust
the
dos
##age
of
Z
##ER
##BA
##X
##A
accordingly
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
No
new
safety
findings
were
observed
following
the
switch
to
4000
L
scale
of
al
##g
##lu
##cos
##idas
##e
al
##fa
.
[SEP]
[CLS]
Pat
##ients
with
a
pre
-
existing
low
white
blood
cell
count
(
W
##BC
)
or
a
history
of
le
##uk
##ope
##nia
/
ne
##ut
##rop
##enia
should
have
their
complete
blood
count
(
CBC
)
monitored
frequently
during
the
first
few
months
of
therapy
and
should
disco
##ntin
##ue
FA
##NA
##P
##T
at
the
first
sign
of
a
decline
in
W
##BC
in
the
absence
of
other
ca
##usa
##tive
factors
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
were
reported
in
65
%
of
patients
.
[SEP]
[CLS]
R
##P
##ED
occurred
in
2
%
(
1
/
55
)
of
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
5
.
[SEP]
[CLS]
S
##J
##IA
Study
2
was
a
two
-
part
study
with
an
open
-
label
,
single
-
arm
active
treatment
period
(
Part
I
)
followed
by
a
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
,
event
-
driven
withdrawal
design
(
Part
II
)
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ser
##ious
infections
-
Do
not
start
S
##IM
##PO
##NI
ARIA
during
an
active
infection
.
[SEP]
[CLS]
5
.
2
Para
##dox
##ical
B
##ron
##cho
##sp
##as
##m
In
##hale
##d
medicines
,
including
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
,
may
cause
para
##dox
##ical
br
##on
##cho
##sp
##as
##m
.
[SEP]
[CLS]
30
.
6
%
had
diabetes
me
##lli
##tus
.
[SEP]
[CLS]
Con
##ges
##tive
Heart
F
##ail
##ure
No
serious
adverse
reactions
to
Ad
##re
##V
##ie
##w
were
observed
in
clinical
studies
.
[SEP]
[CLS]
Det
##ails
of
the
study
treatment
are
described
in
Section
14
.
1
.
[SEP]
[CLS]
Mine
##ral
##ization
De
##fect
##s
:
Case
##s
of
o
##ste
##oma
##la
##cia
associated
with
pro
##ximal
re
##nal
tub
##ulo
##pathy
,
manifest
##ed
as
bone
pain
or
pain
in
ex
##tre
##mit
##ies
and
which
may
contribute
to
fracture
##s
,
have
been
reported
in
association
with
the
use
of
ten
##of
##ov
##ir
D
##F
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
A
majority
of
reported
events
occurred
in
patients
who
had
experienced
nausea
,
vomit
##ing
,
di
##ar
##r
##hea
,
or
de
##hy
##dra
##tion
.
[SEP]
[CLS]
R
##out
##ine
monitoring
of
serum
ca
##l
##ci
##ton
##in
or
using
thy
##roid
ultra
##sound
is
of
uncertain
value
for
early
detection
of
M
##TC
in
patients
treated
with
T
##AN
##Z
##E
##UM
.
[SEP]
[CLS]
The
adverse
events
reported
in
the
long
term
safety
trials
were
similar
to
those
occurring
in
the
place
##bo
-
controlled
trials
of
3
to
6
months
.
[SEP]
[CLS]
Pat
##ients
with
thy
##roid
nod
##ules
noted
on
physical
examination
or
neck
imaging
should
also
be
further
evaluated
.
[SEP]
[CLS]
In
##du
##ration
of
5
mm
or
greater
with
tube
##rc
##ulin
skin
testing
should
be
considered
a
positive
test
result
when
assessing
if
treatment
for
late
##nt
tuberculosis
is
needed
prior
to
in
##iti
##ating
C
##IM
##Z
##IA
,
even
for
patients
previously
v
##ac
##cin
##ated
with
Ba
##ci
##lle
Cal
##mett
##e
-
G
##uer
##in
(
BC
##G
)
.
[SEP]
[CLS]
El
##eva
##tion
of
serum
iron
laboratory
values
were
reported
in
less
than
1
%
of
patients
after
administration
of
E
##O
##VI
##ST
.
[SEP]
[CLS]
If
an
infection
develops
,
monitor
carefully
,
and
stop
S
##IM
##PO
##NI
ARIA
if
infection
becomes
serious
(
5
.
1
)
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
measures
should
be
taken
to
identify
causes
of
re
##nal
failure
and
treat
aggressively
.
[SEP]
[CLS]
For
s
##ym
##pt
##oma
##tic
card
##io
##my
##op
##athy
or
persistent
,
as
##ym
##pt
##oma
##tic
L
##V
d
##ys
##function
that
does
not
resolve
within
4
weeks
,
permanently
disco
##ntin
##ue
tram
##eti
##ni
##b
and
with
##hold
T
##AF
##IN
##LA
##R
.
[SEP]
[CLS]
Ad
##verse
reactions
related
to
bleeding
occurred
in
41
##7
(
15
.
6
%
)
E
##L
##I
##Q
##UI
##S
-
treated
patients
compared
to
66
##1
(
24
.
6
%
)
en
##ox
##apa
##rin
/
war
##fari
##n
-
treated
patients
.
[SEP]
[CLS]
*
I
##mp
##aire
##d
wound
healing
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
.
[SEP]
[CLS]
As
the
total
burden
of
im
##mu
##nos
##up
##press
##ion
is
a
risk
factor
for
PT
##LD
,
higher
than
the
recommended
doses
or
more
frequent
dos
##ing
of
N
##U
##L
##O
##J
##IX
and
higher
than
recommended
doses
of
con
##com
##ita
##nt
im
##mu
##nos
##up
##pressive
agents
are
not
recommended
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
.
[SEP]
[CLS]
U
##ve
##itis
and
I
##rit
##is
:
U
##ve
##itis
and
i
##rit
##is
can
occur
when
T
##AF
##IN
##LA
##R
is
administered
as
a
single
agent
or
when
used
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
5
.
3
Other
Mali
##gna
##ncies
Pat
##ients
receiving
im
##mu
##nos
##up
##press
##ants
,
including
N
##U
##L
##O
##J
##IX
,
are
at
increased
risk
of
developing
PT
##LD
[
see
Box
##ed
Warning
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
A
total
of
69
##6
HIV
-
positive
patients
in
three
place
##bo
-
controlled
trials
received
F
##U
##L
##Y
##Z
##A
##Q
for
a
mean
duration
of
78
days
.
[SEP]
[CLS]
*
T
##AN
##Z
##E
##UM
is
con
##tra
##ind
##ica
##ted
in
patients
with
a
personal
or
family
history
of
M
##TC
or
in
patients
with
Multiple
End
##oc
##rine
Neo
##p
##lasia
syndrome
type
2
(
ME
##N
2
)
.
[SEP]
[CLS]
Prior
to
administration
,
question
the
patient
for
a
history
of
prior
reactions
to
Da
##T
##sca
##n
.
[SEP]
[CLS]
(
5
.
2
)
*
C
##los
##tri
##dium
di
##ff
##ici
##le
-
associated
di
##ar
##r
##hea
(
CD
##AD
)
has
been
reported
with
nearly
all
systemic
anti
##ba
##cter
##ial
agents
,
including
Z
##ER
##BA
##X
##A
.
[SEP]
[CLS]
Table
4
compares
the
incidence
of
treatment
-
emerge
##nt
adverse
reactions
reported
with
an
incidence
of
>
=
10
%
for
patients
receiving
A
##FI
##NI
##TO
##R
10
mg
daily
versus
place
##bo
.
[SEP]
[CLS]
(
5
.
8
)
*
Suicide
:
Close
supervision
of
high
risk
patients
.
[SEP]
[CLS]
The
rates
of
treatment
-
emerge
##nt
adverse
events
(
i
##rre
##spective
of
ca
##usal
##ity
)
resulting
in
permanent
disco
##ntin
##uation
were
14
%
and
3
%
for
the
A
##FI
##NI
##TO
##R
and
place
##bo
treatment
groups
,
respectively
.
[SEP]
[CLS]
Table
4
:
Clinical
Cure
Rate
##s
in
a
Phase
3
Trial
of
c
##IA
##I
by
Basel
##ine
Ren
##al
Fun
##ction
(
MIT
##T
Population
)
Basel
##ine
Ren
##al
Fun
##ction
Z
##ER
##BA
##X
##A
plus
metro
##ni
##da
##zo
##len
/
N
(
%
)
Me
##rop
##ene
##m
##n
/
N
(
%
)
Normal
/
mild
imp
##air
##ment
(
C
##r
##C
##l
>
=
50
m
##L
/
min
)
312
/
36
##6
(
85
.
2
)
35
##5
/
404
(
87
.
9
)
Mode
##rate
imp
##air
##ment
(
C
##r
##C
##l
30
to
<
=
50
m
##L
/
min
)
11
/
23
(
47
.
8
)
9
/
13
(
69
.
2
)
5
.
2
H
##yper
##sen
##si
##ti
##vity
Re
##actions
Ser
##ious
and
occasionally
fatal
an
##aph
##yla
##ctic
)
reactions
have
been
reported
in
patients
receiving
beta
-
la
##ct
##am
anti
##ba
##cter
##ial
drugs
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
the
patient
becomes
pregnant
while
taking
this
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
the
f
##etus
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
Some
of
these
events
have
been
fatal
.
[SEP]
[CLS]
There
is
no
clinical
trial
experience
re
-
administer
##ing
X
##TA
##ND
##I
to
patients
who
experienced
seizure
.
[SEP]
[CLS]
The
conduct
##ion
abnormal
##ities
were
usually
trans
##ient
and
as
##ym
##pt
##oma
##tic
,
and
resolved
within
the
first
24
hours
on
treatment
,
but
they
occasionally
required
treatment
with
at
##rop
##ine
or
is
##op
##rote
##ren
##ol
.
[SEP]
[CLS]
G
##la
##bella
##r
Lines
(
5
.
7
)
:
*
Risk
of
p
##tosis
(
5
.
7
)
.
[SEP]
[CLS]
Use
with
caution
in
patients
who
are
at
increased
risk
for
these
events
.
[SEP]
[CLS]
(
5
.
11
)
*
T
##hr
##omb
##otic
th
##rom
##bo
##cy
##top
##eni
##c
pu
##rp
##ura
/
hem
##oly
##tic
u
##rem
##ic
syndrome
(
T
##TP
/
H
##US
)
.
[SEP]
[CLS]
However
,
e
##pid
##em
##iol
##ogical
studies
suggest
an
increased
risk
of
treatment
-
emerge
##nt
h
##yper
##gly
##ce
##mia
-
related
adverse
events
in
patients
treated
with
the
at
##y
##pical
anti
##psy
##cho
##tics
included
in
these
studies
.
[SEP]
[CLS]
The
im
##bal
##ance
in
deaths
is
une
##x
##plain
##ed
;
no
disc
##ern
##ible
pattern
between
death
and
s
##put
##um
conversion
,
re
##lap
##se
,
sensitivity
to
other
drugs
used
to
treat
tuberculosis
,
HIV
status
,
and
severity
of
disease
was
observed
.
[SEP]
[CLS]
Of
the
176
patients
,
65
%
were
White
,
23
%
Asian
,
3
%
Black
,
and
10
%
Other
race
.
[SEP]
[CLS]
E
##os
##ino
##phi
##lia
A
trans
##ient
increase
in
mean
e
##os
##ino
##phi
##l
counts
was
seen
during
the
first
2
months
of
therapy
.
[SEP]
[CLS]
Disco
##ntin
##ue
T
##RE
##AN
##DA
for
patients
with
Grade
4
in
##fusion
reactions
.
[SEP]
[CLS]
Fifty
-
eight
percent
(
58
%
)
of
the
population
were
male
;
84
%
were
White
,
9
%
were
Asian
,
and
3
%
were
Black
or
African
American
.
[SEP]
[CLS]
In
the
P
##ey
##ron
##ie
'
s
disease
clinical
studies
,
at
6
weeks
after
the
first
treatment
cycle
of
XI
##AF
##LE
##X
0
.
58
mg
,
approximately
75
%
of
patients
had
antibodies
against
AU
##X
-
I
and
approximately
55
%
of
patients
had
antibodies
against
AU
##X
-
II
.
[SEP]
[CLS]
El
##eva
##ted
AL
##T
(
5
.
3
)
,
Dec
##reased
plasma
zinc
concentrations
(
5
.
3
)
.
[SEP]
[CLS]
All
of
these
patients
who
received
FA
##NA
##P
##T
were
participating
in
multiple
-
dose
clinical
trials
.
[SEP]
[CLS]
Place
##bo
plus
pre
##dn
##ison
##e
5
mg
twice
daily
was
given
to
control
patients
.
[SEP]
[CLS]
Sign
##s
or
symptoms
that
may
reflect
serious
pen
##ile
injury
should
be
promptly
evaluated
to
assess
for
co
##rp
##oral
r
##up
##ture
or
severe
pen
##ile
hem
##ato
##ma
which
may
require
surgical
intervention
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Mine
##ral
##oc
##ort
##ico
##id
excess
:
Use
Z
##Y
##TI
##GA
with
caution
in
patients
with
a
history
of
card
##iovascular
disease
.
[SEP]
[CLS]
Pat
##ients
were
not
eligible
if
AS
##T
and
/
or
AL
##T
>
=
2
.
5
*
U
##L
##N
in
the
absence
of
liver
meta
##sta
##ses
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Nova
##rt
##is
Ph
##arma
##ce
##utical
##s
Corporation
at
1
-
88
##8
-
66
##9
-
66
##8
##2
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
C
##lev
##ip
##re
##x
clinical
development
included
19
studies
,
with
99
healthy
subjects
and
130
##7
h
##yper
##tensive
patients
who
received
at
least
one
dose
of
c
##lev
##id
##ip
##ine
(
140
##6
total
exposure
##s
)
.
[SEP]
[CLS]
5
.
4
N
##eur
##ops
##ych
##ia
##tric
S
##ym
##pt
##oms
Con
##fusion
##al
state
,
ps
##ych
##otic
symptoms
,
and
hall
##uc
##ination
##s
were
reported
more
frequently
as
adverse
reactions
in
patients
treated
with
P
##OT
##IG
##A
than
in
those
treated
with
place
##bo
in
place
##bo
-
controlled
e
##pile
##psy
trials
(
see
Table
2
)
.
[SEP]
[CLS]
Re
##sp
##ira
##tory
,
th
##ora
##ci
##c
and
media
##st
##inal
disorders
:
acute
respiratory
distress
syndrome
,
e
##pis
##ta
##xi
##s
,
hem
##op
##ty
##sis
,
pulmonary
em
##bol
##ism
.
[SEP]
[CLS]
Do
not
use
N
##U
##L
##O
##J
##IX
in
transplant
recipients
who
are
E
##B
##V
se
##rone
##gat
##ive
or
with
unknown
E
##B
##V
se
##ros
##tat
##us
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Su
##sta
##ined
blood
pressure
increases
could
have
adverse
consequences
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
leading
to
permanent
disco
##ntin
##uation
in
patients
treated
with
CO
##ME
##TR
##I
##Q
were
:
h
##y
##po
##cal
##ce
##mia
,
increased
lip
##ase
,
PP
##ES
,
di
##ar
##r
##hea
,
fatigue
,
h
##yper
##tens
##ion
,
nausea
,
pan
##cre
##ati
##tis
,
t
##rac
##hea
##l
fist
##ula
formation
and
vomit
##ing
.
[SEP]
[CLS]
Su
##sta
##ined
decreases
in
e
##G
##F
##R
were
seen
in
patients
with
moderate
re
##nal
imp
##air
##ment
(
e
##G
##F
##R
30
to
less
than
60
m
##L
/
min
/
1
.
73
m
2
)
.
[SEP]
[CLS]
Across
all
short
-
and
long
-
term
studies
,
the
overall
mean
change
from
base
##line
at
end
##point
was
2
.
1
kg
.
[SEP]
[CLS]
(
5
.
6
)
}
}
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Al
##con
Laboratories
,
Inc
.
at
1
-
800
-
75
##7
-
91
##9
##5
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Table
1
sum
##mar
##izes
the
most
common
adverse
reactions
that
occurred
in
the
place
##bo
-
controlled
trial
with
an
incidence
of
>
=
10
%
in
patients
treated
with
V
##im
##iz
##im
2
mg
/
kg
once
per
week
and
with
a
higher
incidence
than
in
the
place
##bo
-
treated
patients
.
[SEP]
[CLS]
The
following
risks
,
including
appropriate
action
to
be
taken
,
are
discussed
in
greater
detail
in
other
sections
of
the
label
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
-
5
.
13
)
]
:
h
##yper
##tens
##ion
,
art
##erial
th
##rom
##boe
##mbo
##lic
events
,
ve
##nous
th
##rom
##boe
##mbo
##lic
events
,
hem
##or
##r
##hage
,
cardiac
failure
,
gas
##tro
##int
##est
##inal
per
##fo
##ration
and
fist
##ula
formation
,
thy
##roid
d
##ys
##function
,
wound
healing
complications
,
R
##PL
##S
,
protein
##uria
,
elevation
of
liver
enzymes
,
he
##pa
##tic
imp
##air
##ment
and
f
##etal
development
.
[SEP]
[CLS]
Approximately
116
##2
patients
have
received
more
than
2
years
of
treatment
with
T
##EC
##FI
##DE
##RA
.
[SEP]
[CLS]
Laboratory
and
I
##maging
Tests
Inc
##rease
##s
in
Ser
##um
Po
##tas
##sium
In
a
pool
##ed
population
of
patients
(
N
=
72
##3
)
with
moderate
re
##nal
imp
##air
##ment
(
e
##G
##F
##R
45
to
less
than
60
m
##L
/
min
/
1
.
73
m
2
)
,
increases
in
serum
potassium
to
greater
than
5
.
4
m
##E
##q
/
L
and
15
%
above
base
##line
occurred
in
5
.
3
%
,
5
.
0
%
,
and
8
.
8
%
of
patients
treated
with
place
##bo
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
A
total
of
38
##7
##6
women
were
exposed
to
place
##bo
and
38
##86
women
were
exposed
to
Pro
##lia
administered
sub
##cut
##aneous
##ly
once
every
6
months
as
a
single
60
mg
dose
.
[SEP]
[CLS]
S
Includes
patients
treated
with
flexible
dose
of
SA
##P
##H
##RI
##S
5
or
10
mg
twice
daily
(
N
=
90
)
.
[SEP]
[CLS]
In
a
trial
of
patients
with
moderate
re
##nal
imp
##air
##ment
[
see
Clinical
Studies
(
14
.
3
)
]
,
serum
ma
##gnesium
levels
increased
by
0
.
2
%
,
9
.
2
%
,
and
14
.
8
%
with
place
##bo
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
No
deaths
,
in
##tub
##ations
,
or
serious
adverse
reactions
related
to
as
##th
##ma
ex
##ace
##rb
##ation
were
reported
in
this
trial
.
[SEP]
[CLS]
(
5
.
1
)
5
.
1
Se
##iz
##ure
In
Study
1
,
which
enrolled
patients
who
previously
received
do
##ce
##ta
##xe
##l
,
7
of
800
(
0
.
9
%
)
patients
treated
with
X
##TA
##ND
##I
experienced
a
seizure
and
no
patients
treated
with
place
##bo
experienced
a
seizure
.
[SEP]
[CLS]
Pre
##s
##cribe
##rs
should
exercise
caution
in
considering
the
use
of
T
##NF
-
block
##ers
,
including
S
##IM
##PO
##NI
ARIA
,
in
patients
with
central
or
peripheral
nervous
system
dem
##ye
##lina
##ting
disorders
.
[SEP]
[CLS]
Three
additional
subjects
tested
positive
for
binding
antibodies
after
receiving
D
##Y
##SP
##OR
##T
(
r
)
treatment
.
[SEP]
[CLS]
*
Screen
patients
for
acute
kidney
injury
and
other
conditions
that
may
reduce
re
##nal
function
.
[SEP]
[CLS]
The
risk
of
symptoms
is
probably
greatest
in
children
treated
for
spa
##stic
##ity
but
symptoms
can
also
occur
in
adults
,
particularly
in
those
patients
who
have
underlying
conditions
that
would
pre
##dis
##pose
them
to
these
symptoms
.
[SEP]
[CLS]
The
most
common
key
laboratory
abnormal
##ities
(
incidence
>
=
50
%
)
were
h
##yper
##cho
##les
##tero
##lem
##ia
and
elevated
partial
th
##rom
##bo
##p
##last
##in
time
.
[SEP]
[CLS]
In
Study
1
,
all
Grades
of
adverse
events
were
reported
for
the
following
adverse
events
of
special
interest
:
all
##er
##gy
,
pan
##cre
##ati
##tis
,
co
##agu
##lop
##athy
(
hem
##or
##r
##hage
,
th
##rom
##bos
##is
or
in
##far
##ct
)
,
h
##yper
##bil
##ir
##ubi
##ne
##mia
,
h
##yper
##gly
##ce
##mia
,
h
##yper
##lip
##ide
##mia
,
k
##eto
##ac
##ido
##sis
,
and
C
##NS
events
,
and
cerebral
ve
##nous
th
##rom
##bos
##is
)
and
only
Grade
3
and
4
events
were
reported
for
other
adverse
events
.
[SEP]
[CLS]
The
most
commonly
observed
adverse
reactions
(
incidence
>
=
5
%
)
more
frequently
reported
in
women
treated
with
D
##U
##AV
##EE
than
place
##bo
are
presented
in
Table
1
.
[SEP]
[CLS]
Pat
##ients
treated
with
b
##ot
##ulin
##um
to
##xin
may
require
immediate
medical
attention
should
they
develop
problems
with
swallowing
,
speech
or
respiratory
disorders
.
[SEP]
[CLS]
5
.
2
Con
##com
##ita
##nt
Use
with
C
##YP
##3
##A
In
##du
##cer
##s
Use
of
K
##AL
##Y
##DE
##CO
with
strong
C
##YP
##3
##A
induce
##rs
,
such
as
r
##if
##amp
##in
,
substantially
decreases
the
exposure
of
i
##va
##ca
##ft
##or
,
which
may
reduce
the
therapeutic
effectiveness
of
K
##AL
##Y
##DE
##CO
.
[SEP]
[CLS]
All
subjects
were
que
##ried
about
the
presence
of
skin
and
scalp
symptoms
;
the
results
are
presented
in
Table
2
.
[SEP]
[CLS]
6
-
Month
Trials
The
incidence
of
adverse
reactions
associated
with
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
in
Table
1
is
based
on
2
place
##bo
-
controlled
,
6
-
month
clinical
trials
(
Trials
1
and
2
;
n
=
1
,
224
and
n
=
1
,
03
##0
,
respectively
)
.
[SEP]
[CLS]
6
.
3
I
##mm
##uno
##genic
##ity
A
bio
##sen
##sor
binding
ass
##ay
or
a
br
##id
##ging
im
##mu
##no
##ass
##ay
was
used
to
detect
antibodies
directed
against
can
##aki
##num
##ab
in
patients
who
received
IL
##AR
##IS
.
[SEP]
[CLS]
Pre
##sen
##ce
of
anti
##body
did
not
co
##rrel
##ate
with
reduced
efficacy
as
measured
by
H
##b
##A
##1
##c
and
fast
##ing
plasma
glucose
or
specific
adverse
reactions
.
[SEP]
[CLS]
With
##hold
tram
##eti
##ni
##b
and
continue
T
##AF
##IN
##LA
##R
at
the
same
dose
for
un
##com
##plicate
##d
D
##V
##T
or
P
##E
;
if
improved
within
3
weeks
,
tram
##eti
##ni
##b
may
be
resumed
at
a
lower
dose
level
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
(
5
.
3
)
*
Ren
##al
failure
,
including
cases
with
fatal
outcomes
,
has
been
reported
.
[SEP]
[CLS]
(
5
.
2
)
*
Development
of
drug
-
resistant
bacteria
:
Only
use
D
##IF
##IC
##ID
for
infection
proven
or
strongly
suspected
to
be
caused
by
C
.
di
##ff
##ici
##le
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Ad
##vise
pregnant
women
of
the
potential
hazard
to
the
f
##etus
(
5
.
12
)
.
[SEP]
[CLS]
Consider
disco
##ntin
##uing
use
if
severe
symptoms
develop
[
see
Pat
##ient
Counsel
##ing
Information
(
17
.
8
)
]
.
[SEP]
[CLS]
This
protein
##uria
was
not
associated
with
increases
in
B
##UN
and
was
generally
trans
##ient
.
[SEP]
[CLS]
Consider
these
risks
when
scheduling
patients
for
spinal
procedures
.
[SEP]
[CLS]
Table
3
presents
the
adverse
reactions
reported
in
this
study
.
[SEP]
[CLS]
E
##ar
and
Lab
##yrinth
Di
##sor
##ders
:
deaf
##ness
,
tin
##ni
##tus
,
ve
##rt
##igo
.
[SEP]
[CLS]
Anti
##em
##etic
prop
##hyl
##ax
##is
is
recommended
.
[SEP]
[CLS]
The
population
exposed
to
T
##AF
##IN
##LA
##R
was
60
%
male
,
99
%
white
,
and
had
a
median
age
of
53
years
.
[SEP]
[CLS]
Tests
for
late
##nt
tuberculosis
infection
may
also
be
falsely
negative
while
on
therapy
with
C
##IM
##Z
##IA
.
[SEP]
[CLS]
Monitor
patients
closely
for
the
development
of
signs
and
symptoms
of
infection
during
and
after
treatment
with
S
##IM
##PO
##NI
ARIA
,
including
the
possible
development
of
tuberculosis
in
patients
who
tested
negative
for
late
##nt
tuberculosis
infection
prior
to
in
##iti
##ating
therapy
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Per
##ip
##her
##al
ne
##uro
##pathy
:
Monitor
patients
for
ne
##uro
##pathy
and
institute
dose
modifications
accordingly
(
5
.
1
)
.
[SEP]
[CLS]
5
.
3
He
##pa
##tic
Effects
In
Phase
2
and
3
clinical
trials
,
more
D
##AL
##VA
##NC
##E
-
than
com
##par
##ator
-
treated
subjects
with
normal
base
##line
trans
##ami
##nas
##e
levels
had
post
-
base
##line
AL
##T
)
elevation
greater
than
3
times
the
upper
limit
of
normal
(
U
##L
##N
)
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
T
##hy
##roid
C
-
cell
Tu
##mor
##s
:
See
Box
##ed
Warning
.
[SEP]
[CLS]
This
is
supplemented
with
information
on
adverse
drug
reactions
in
132
##6
patients
with
AL
##K
-
positive
meta
##static
N
##SC
##LC
who
received
X
##AL
##KO
##RI
250
mg
twice
daily
across
clinical
trials
,
for
a
total
of
166
##9
patients
across
all
clinical
studies
.
[SEP]
[CLS]
5
.
9
Su
##pp
##ression
of
Bone
Turn
##over
In
clinical
trials
in
women
with
post
##men
##op
##aus
##al
o
##ste
##op
##oro
##sis
,
treatment
with
Pro
##lia
resulted
in
significant
suppression
of
bone
re
##mo
##del
##ing
as
evidenced
by
markers
of
bone
turnover
and
bone
his
##tom
##or
##ph
##ome
##try
[
see
Clinical
Ph
##arma
##cology
(
12
.
2
)
and
Clinical
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
5
.
7
Laboratory
Tests
HC
##V
-
RNA
levels
should
be
monitored
at
Treatment
Weeks
4
,
8
,
12
,
and
24
,
at
the
end
of
treatment
,
during
treatment
follow
-
up
,
and
for
other
time
points
as
clinical
##ly
indicated
.
[SEP]
[CLS]
I
##dent
##ify
cause
and
manage
aggressively
.
[SEP]
[CLS]
(
5
.
6
)
*
Or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
:
Di
##zzi
##ness
,
ta
##chy
##card
##ia
,
and
s
##ync
##ope
can
occur
with
standing
.
[SEP]
[CLS]
(
5
.
3
)
*
Su
##icidal
thoughts
:
H
##OR
##I
##Z
##AN
##T
is
a
pro
##dr
##ug
of
g
##aba
##pent
##in
,
an
anti
##ep
##ile
##ptic
drug
(
A
##ED
)
.
[SEP]
[CLS]
Table
2
:
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
in
>
=
5
%
of
G
##D
##1
Pat
##ients
S
##witch
##ing
from
En
##zy
##me
Rep
##lace
##ment
Therapy
to
CE
##RD
##EL
##GA
and
More
Fr
##e
##quent
##ly
than
I
##mi
##g
##lu
##cer
##ase
(
Trial
2
)
Trial
2
was
not
designed
to
support
comparative
claims
for
CE
##RD
##EL
##GA
for
the
adverse
reactions
reported
in
this
table
.
[SEP]
[CLS]
If
k
##era
##titis
is
diagnosed
,
the
benefits
and
risks
of
continuing
treatment
should
be
carefully
considered
.
[SEP]
[CLS]
5
(
ta
##rt
##raz
##ine
)
sensitivity
in
the
general
population
is
low
,
it
is
frequently
seen
in
patients
who
also
have
as
##pi
##rin
h
##yper
##sen
##si
##ti
##vity
.
[SEP]
[CLS]
5
.
12
T
##hr
##omb
##otic
T
##hr
##omb
##oc
##yt
##ope
##nic
P
##ur
##pura
/
He
##mo
##ly
##tic
U
##rem
##ic
S
##yn
##drome
Case
##s
of
th
##rom
##bot
##ic
th
##rom
##bo
##cy
##top
##eni
##c
pu
##rp
##ura
/
hem
##oly
##tic
u
##rem
##ic
syndrome
(
T
##TP
/
H
##US
)
including
fatal
outcome
have
been
reported
in
patients
who
received
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
During
the
clinical
trials
,
0
.
3
%
(
4
/
144
##1
)
of
subjects
treated
with
O
##TE
##Z
##LA
discontinued
treatment
due
to
depression
or
depressed
mood
compared
with
none
in
place
##bo
treated
subjects
(
0
/
49
##5
)
.
[SEP]
[CLS]
Key
observed
laboratory
abnormal
##ities
are
presented
in
Table
5
.
[SEP]
[CLS]
E
##NT
##ER
##EG
is
con
##tra
##ind
##ica
##ted
in
patients
who
have
taken
therapeutic
doses
of
op
##io
##ids
for
more
than
7
consecutive
days
immediately
prior
to
taking
E
##NT
##ER
##EG
.
[SEP]
[CLS]
(
5
.
12
)
*
Post
##eri
##or
re
##versible
en
##ce
##pha
##lop
##athy
syndrome
(
PR
##ES
)
:
Consider
ne
##uro
-
radio
##logical
imaging
(
MR
##I
)
for
onset
of
visual
or
ne
##uro
##logical
symptoms
;
disco
##ntin
##ue
K
##y
##p
##rol
##is
if
suspected
.
[SEP]
[CLS]
5
.
7
Bone
Fr
##act
##ure
An
increased
risk
of
bone
fracture
,
occurring
as
early
as
12
weeks
after
treatment
initiation
,
was
observed
in
patients
using
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
Per
##form
appropriate
monitoring
and
treat
h
##yper
##gly
##ce
##mia
with
insulin
,
as
necessary
(
5
.
3
)
*
T
##hr
##omb
##osis
,
hem
##or
##r
##hage
:
disco
##ntin
##ue
ER
##WI
##NA
##Z
##E
until
resolved
(
5
.
4
)
5
.
1
H
##yper
##sen
##si
##ti
##vity
Re
##actions
Grade
3
and
4
h
##yper
##sen
##si
##ti
##vity
reactions
after
the
use
of
ER
##WI
##NA
##Z
##E
have
occurred
in
5
%
of
patients
in
clinical
trials
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
The
risk
of
the
symptoms
is
probably
greatest
in
children
treated
for
spa
##stic
##ity
but
symptoms
can
also
occur
in
adults
treated
for
spa
##stic
##ity
and
other
conditions
,
and
particularly
in
those
patients
who
have
underlying
conditions
that
would
pre
##dis
##pose
them
to
these
symptoms
.
[SEP]
[CLS]
Se
##iz
##ure
occurred
from
31
to
60
##3
days
after
initiation
of
X
##TA
##ND
##I
.
[SEP]
[CLS]
Table
10
compares
the
incidence
of
adverse
reactions
reported
with
an
incidence
of
>
=
10
%
for
patients
receiving
A
##FI
##NI
##TO
##R
and
occurring
more
frequently
with
A
##FI
##NI
##TO
##R
than
with
place
##bo
.
[SEP]
[CLS]
Disco
##ntin
##uation
of
S
##IM
##PO
##NI
ARIA
should
be
considered
if
these
disorders
develop
.
[SEP]
[CLS]
The
adult
information
below
is
derived
from
a
clinical
trial
database
for
SA
##P
##H
##RI
##S
consisting
of
over
45
##65
patients
and
/
or
healthy
subjects
exposed
to
one
or
more
sub
##ling
##ual
doses
of
SA
##P
##H
##RI
##S
.
[SEP]
[CLS]
Ser
##ious
Ad
##verse
Re
##actions
and
Ad
##verse
Re
##actions
Leading
to
Disco
##ntin
##uation
Ser
##ious
adverse
reactions
occurred
in
109
/
1778
(
6
.
1
%
)
of
patients
treated
with
D
##AL
##VA
##NC
##E
and
in
80
/
122
##4
(
6
.
5
%
)
of
patients
treated
with
com
##par
##ator
.
[SEP]
[CLS]
Of
these
,
two
studies
were
random
##ized
,
double
-
blind
,
single
treatment
,
place
##bo
controlled
studies
with
subsequent
optional
open
label
treatment
in
which
dose
optimization
(
250
to
1000
Units
per
treatment
)
over
the
course
of
5
treatment
cycles
was
allowed
.
[SEP]
[CLS]
Ana
##phy
##lax
##is
,
presenting
as
cough
,
er
##yt
##hem
##a
,
throat
tight
##ness
,
u
##rt
##ica
##ria
,
flush
##ing
,
c
##yan
##osis
,
h
##y
##pot
##ens
##ion
,
r
##ash
,
d
##ys
##p
##nea
,
chest
discomfort
,
and
gas
##tro
##int
##est
##inal
symptoms
(
e
.
g
.
,
nausea
,
abdominal
pain
,
re
##tch
##ing
,
and
vomit
##ing
)
in
conjunction
with
u
##rt
##ica
##ria
,
have
been
reported
to
occur
during
V
##im
##iz
##im
in
##fusion
##s
,
regardless
of
duration
of
the
course
of
treatment
.
[SEP]
[CLS]
After
adjusting
for
age
and
sex
,
the
mean
change
from
base
##line
to
end
##point
in
weight
z
-
score
for
SA
##P
##H
##RS
2
.
5
mg
,
5
mg
,
and
10
mg
twice
daily
,
was
0
.
11
,
0
.
08
and
0
.
09
SD
versus
0
.
02
SD
for
place
##bo
,
respectively
.
[SEP]
[CLS]
Volume
De
##ple
##tion
FA
##R
##X
##IG
##A
causes
an
o
##smo
##tic
di
##ures
##is
,
which
may
lead
to
reduction
##s
in
in
##tra
##vas
##cular
volume
.
[SEP]
[CLS]
5
.
7
Or
##th
##ost
##atic
H
##y
##pot
##ens
##ion
and
S
##ync
##ope
FA
##NA
##P
##T
can
induce
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
associated
with
di
##zzi
##ness
,
ta
##chy
##card
##ia
,
and
s
##ync
##ope
.
[SEP]
[CLS]
*
Ren
##al
I
##mp
##air
##ment
:
Monitor
re
##nal
function
in
patients
with
re
##nal
imp
##air
##ment
reporting
severe
adverse
gas
##tro
##int
##est
##inal
reactions
(
5
.
5
)
.
[SEP]
[CLS]
B
##lee
##ding
events
related
to
SSR
##I
##s
and
S
##NR
##I
##s
have
ranged
from
e
##cc
##hy
##mos
##is
,
hem
##ato
##ma
,
e
##pis
##ta
##xi
##s
,
and
pet
##ech
##iae
to
life
-
threatening
hem
##or
##r
##hage
##s
.
[SEP]
[CLS]
Re
##ci
##pie
##nts
without
immunity
to
E
##ps
##tein
-
Barr
virus
(
E
##B
##V
)
are
at
a
particularly
increased
risk
;
therefore
,
use
in
E
##B
##V
se
##rop
##os
##itive
patients
only
.
[SEP]
[CLS]
5
.
9
Pre
##par
##ation
and
Administration
E
##rro
##rs
Pre
##par
##ation
and
administration
errors
have
occurred
with
B
##L
##IN
##C
##Y
##TO
treatment
.
[SEP]
[CLS]
Cy
##top
##enia
##s
:
Grade
3
ne
##ut
##rop
##enia
occurred
in
28
%
(
143
/
50
##3
)
of
patients
who
received
H
##AL
##AV
##EN
in
Study
1
,
and
29
%
(
144
/
50
##3
)
of
patients
experienced
Grade
4
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
Because
most
trials
included
in
the
analysis
did
not
extend
beyond
24
weeks
,
the
risk
of
su
##icidal
thoughts
beyond
24
weeks
could
not
be
assessed
.
[SEP]
[CLS]
Skin
,
sub
##cut
##aneous
tissue
disorders
:
h
##yper
##hi
##dr
##osis
,
per
##ior
##bit
##al
ed
##ema
,
photos
##ens
##iti
##vity
reaction
,
p
##ru
##rit
##is
,
u
##rt
##ica
##ria
,
r
##ash
,
He
##no
##ch
-
Sc
##hon
##lein
pu
##rp
##ura
.
[SEP]
[CLS]
Safe
handling
should
be
ensured
to
minimize
radiation
exposure
to
the
patient
and
health
care
workers
[
see
Do
##sa
##ge
and
Administration
(
2
.
[SEP]
[CLS]
The
most
serious
adverse
reaction
reported
in
clinical
trials
with
Fe
##rri
##p
##ro
##x
was
a
##gra
##nu
##loc
##yt
##osis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
were
reported
in
73
(
50
%
)
subjects
.
[SEP]
[CLS]
Six
weeks
after
the
eighth
injection
(
fourth
treatment
cycle
)
of
XI
##AF
##LE
##X
,
>
99
%
of
XI
##AF
##LE
##X
-
treated
patients
developed
high
t
##iter
##s
of
antibodies
to
both
AU
##X
-
I
and
AU
##X
-
II
.
[SEP]
[CLS]
Pat
##ients
received
5
-
10
days
of
an
approved
parent
##eral
anti
##coa
##gu
##lant
therapy
followed
by
6
months
,
with
mean
exposure
of
164
days
,
of
oral
only
treatment
;
war
##fari
##n
was
overlap
##ped
with
parent
##eral
therapy
.
[SEP]
[CLS]
Four
percent
(
20
/
50
##3
)
of
patients
experienced
peripheral
motor
ne
##uro
##pathy
of
any
grade
and
2
%
(
8
/
50
##3
)
of
patients
developed
Grade
3
peripheral
motor
ne
##uro
##pathy
.
[SEP]
[CLS]
Only
physicians
experienced
in
im
##mu
##nos
##up
##pressive
therapy
and
management
of
kidney
transplant
patients
should
pre
##s
##cribe
N
##U
##L
##O
##J
##IX
.
[SEP]
[CLS]
Other
serious
adverse
reactions
included
th
##rom
##boe
##mbo
##lic
complications
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
The
incidence
of
r
##ash
was
higher
in
females
[
see
Ad
##verse
Re
##actions
(
6
)
]
Disco
##ntin
##ue
IN
##TE
##LE
##NC
##E
(
r
)
immediately
if
signs
or
symptoms
of
severe
skin
reactions
or
h
##yper
##sen
##si
##ti
##vity
reactions
develop
(
including
,
but
not
limited
to
,
severe
r
##ash
or
r
##ash
accompanied
by
fever
,
general
ma
##lai
##se
,
fatigue
,
muscle
or
joint
ache
##s
,
b
##list
##ers
,
oral
lesions
,
con
##junct
##iv
##itis
,
facial
ed
##ema
,
he
##pa
##titis
,
e
##os
##ino
##phi
##lia
,
an
##gio
##ede
##ma
)
.
[SEP]
[CLS]
Major
bleeding
is
defined
as
bleeding
accompanied
by
one
or
more
of
the
following
:
a
decrease
in
hem
##og
##lo
##bin
of
>
=
2
g
/
d
##L
,
a
trans
##fusion
of
>
=
2
units
of
packed
red
blood
cells
,
bleeding
at
a
critical
site
or
with
a
fatal
outcome
.
[SEP]
[CLS]
(
6
.
1
)
E
##X
##CE
##RP
##T
:
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
As
##tra
##Z
##ene
##ca
at
1
-
800
-
236
-
99
##33
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Ad
##re
##V
##ie
##w
may
increase
release
of
nor
##ep
##ine
##ph
##rine
from
ch
##roma
##ffin
g
##ran
##ules
and
produce
a
trans
##ient
episode
of
h
##yper
##tens
##ion
,
although
this
was
not
observed
in
the
clinical
studies
.
[SEP]
[CLS]
*
Fat
##al
and
serious
p
##ne
##um
##oni
##tis
can
occur
in
Z
##yd
##eli
##g
-
treated
patients
.
[SEP]
[CLS]
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
:
Disco
##ntin
##ue
T
##R
##U
##L
##IC
##IT
##Y
if
suspected
.
[SEP]
[CLS]
(
N
for
males
:
Place
##bo
=
71
##6
,
FA
##R
##X
##IG
##A
5
mg
=
56
##4
,
FA
##R
##X
##IG
##A
10
mg
=
59
##5
)
.
[SEP]
[CLS]
Pat
##ients
who
develop
symptoms
of
h
##yper
##gly
##ce
##mia
during
treatment
with
at
##y
##pical
anti
##psy
##cho
##tics
should
undergo
fast
##ing
blood
glucose
testing
.
[SEP]
[CLS]
The
abnormal
##ities
seen
in
patients
treated
with
P
##OT
##IG
##A
have
fund
##us
##copic
features
similar
to
those
seen
in
re
##tina
##l
pig
##ment
d
##ys
##tro
##phi
##es
that
are
known
to
result
in
damage
to
photo
##re
##ceptor
##s
and
vision
loss
.
[SEP]
[CLS]
*
He
##pa
##to
##to
##xi
##city
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
Se
##vere
Di
##ar
##r
##hea
or
Col
##itis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
P
##ne
##um
##oni
##tis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
In
##test
##inal
Per
##fo
##ration
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
Se
##vere
Cut
##aneous
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
*
Ana
##phy
##lax
##is
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
*
N
##eu
##tro
##pen
##ia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
7
)
]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
incidence
>
=
20
%
)
are
di
##ar
##r
##hea
,
p
##yre
##xia
,
fatigue
,
nausea
,
cough
,
pneumonia
,
abdominal
pain
,
chill
##s
,
and
r
##ash
(
6
.
1
)
.
[SEP]
[CLS]
Six
patients
out
of
the
40
##3
who
were
treated
with
the
N
##U
##L
##O
##J
##IX
regime
##n
of
higher
cumulative
dose
and
more
frequent
dos
##ing
than
recommended
in
Studies
1
and
2
(
1
.
5
%
)
were
reported
to
have
developed
C
##NS
infections
,
including
2
cases
of
cry
##pt
##oc
##oc
##cal
men
##ing
##itis
,
one
case
of
Cha
##gas
en
##ce
##pha
##lit
##is
with
cry
##pt
##oc
##oc
##cal
men
##ing
##itis
,
one
case
of
cerebral
as
##per
##gill
##osis
,
one
case
of
West
Nile
en
##ce
##pha
##lit
##is
,
and
one
case
of
PM
##L
(
discussed
above
)
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Arbor
Ph
##arma
##ce
##utical
##s
,
LLC
at
1
-
86
##6
-
51
##6
-
49
##50
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Other
Ad
##verse
Re
##actions
Other
in
##f
##re
##quent
adverse
reactions
(
occurring
in
less
than
3
%
of
RA
patients
)
were
similar
to
those
seen
in
C
##ro
##hn
'
s
disease
patients
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
C
##Y
##TO
##K
##IN
##E
R
##EL
##EA
##SE
S
##Y
##ND
##RO
##ME
and
NE
##UR
##OL
##O
##GI
##CA
##L
TO
##X
##IC
##IT
##IE
##S
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
The
clinical
development
program
excluded
patients
with
active
auto
##im
##mu
##ne
disease
or
those
receiving
systemic
im
##mu
##nos
##up
##press
##ion
for
organ
transplant
##ation
.
[SEP]
[CLS]
R
##out
##ine
monitoring
of
serum
ca
##l
##ci
##ton
##in
or
using
thy
##roid
ultra
##sound
is
of
uncertain
value
for
early
detection
of
M
##TC
in
patients
treated
with
T
##R
##U
##L
##IC
##IT
##Y
[
see
Con
##tra
##ind
##ica
##tions
(
4
.
1
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Table
2
:
Risk
of
Su
##icidal
Thought
##s
by
In
##dication
for
Anti
##ep
##ile
##ptic
Drugs
in
the
Poole
##d
Analysis
In
##dication
Place
##bo
Pat
##ients
with
Events
Per
1000
Pat
##ients
Drug
Pat
##ients
with
Events
Per
1000
Pat
##ients
Re
##lative
Risk
:
Inc
##iden
##ce
of
Events
in
Drug
Pat
##ients
/
Inc
##iden
##ce
in
Place
##bo
Pat
##ients
Risk
Di
##fference
##s
:
Additional
Drug
Pat
##ients
with
Events
Per
1000
Pat
##ients
E
##pile
##psy
1
.
0
3
.
4
3
.
5
2
.
4
P
##sy
##chia
##tric
5
.
7
8
.
5
1
.
5
2
.
9
Other
1
.
0
1
.
8
1
.
9
0
.
9
Total
2
.
4
4
.
3
1
.
8
1
.
9
The
relative
risk
for
su
##icidal
thoughts
was
higher
in
clinical
trials
in
patients
with
e
##pile
##psy
than
in
clinical
trials
in
patients
with
psychiatric
or
other
conditions
,
but
the
absolute
risk
differences
were
similar
for
e
##pile
##psy
and
psychiatric
indication
##s
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
The
median
duration
of
treatment
was
6
.
4
months
(
range
0
.
03
to
22
.
0
)
for
patients
who
received
IN
##L
##Y
##TA
and
5
.
0
months
(
range
0
.
03
to
20
.
1
)
for
patients
who
received
so
##ra
##fen
##ib
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
A
##cute
pan
##cre
##ati
##tis
:
There
have
been
post
##market
##ing
reports
of
acute
pan
##cre
##ati
##tis
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
I
##pse
##n
B
##io
##pha
##rma
##ce
##utical
##s
,
Inc
.
at
87
##7
-
39
##7
-
76
##7
##1
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
T
##AF
##IN
##LA
##R
was
studied
in
open
-
label
,
single
-
arm
trials
and
in
an
open
-
label
,
random
##ized
,
active
-
controlled
trial
.
[SEP]
[CLS]
In
non
-
clinical
studies
in
rats
and
rabbits
,
cab
##azi
##ta
##xe
##l
was
em
##b
##ryo
##to
##xi
##c
,
f
##eto
##to
##xi
##c
,
and
a
##bor
##ti
##fa
##cie
##nt
at
exposure
##s
significantly
lower
than
those
expected
at
the
recommended
human
dose
level
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
one
clinical
trial
of
a
drug
can
not
be
directly
compared
with
the
rates
in
the
clinical
trials
of
the
same
or
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
A
##cor
##da
The
##rap
##eu
##tics
at
1
-
87
##7
-
900
-
64
##7
##9
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
##S
:
IN
##CR
##EA
##SE
##D
M
##OR
##TA
##L
##IT
##Y
;
Q
##T
PR
##OL
##ON
##GA
##TI
##ON
WA
##R
##NI
##NG
##S
:
IN
##CR
##EA
##SE
##D
M
##OR
##TA
##L
##IT
##Y
;
Q
##T
PR
##OL
##ON
##GA
##TI
##ON
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
##S
:
IN
##CR
##EA
##SE
##D
M
##OR
##TA
##L
##IT
##Y
;
Q
##T
PR
##OL
##ON
##GA
##TI
##ON
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
In
a
3
-
week
mon
##otherapy
trial
,
the
most
common
adverse
reactions
(
>
=
5
%
and
at
least
twice
the
rate
of
place
##bo
)
reported
in
p
##ediatric
patients
with
bi
##pol
##ar
I
disorder
treated
with
SA
##P
##H
##RI
##S
were
so
##m
##no
##len
##ce
,
di
##zzi
##ness
,
d
##ys
##ge
##us
##ia
,
oral
par
##est
##hesia
,
nausea
,
increased
appetite
,
fatigue
,
and
increased
weight
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
frequently
reported
adverse
events
(
>
=
4
%
)
for
To
##via
##z
were
:
dry
mouth
(
place
##bo
,
7
%
;
To
##via
##z
4
mg
,
19
%
;
To
##via
##z
8
mg
,
35
%
)
and
con
##st
##ip
##ation
(
place
##bo
,
2
%
;
To
##via
##z
4
mg
,
4
%
;
To
##via
##z
8
mg
,
6
%
)
.
[SEP]
[CLS]
*
The
risk
for
N
##SF
appears
highest
among
patients
with
:
Ch
##ronic
,
severe
kidney
disease
(
G
##F
##R
<
30
m
##L
/
min
/
1
.
73
m
##2
)
,
or
##A
##cute
kidney
injury
.
[SEP]
[CLS]
Because
the
elimination
of
fin
##gol
##imo
##d
after
disco
##ntin
##uation
may
take
up
to
2
months
,
continue
monitoring
for
infections
throughout
this
period
.
[SEP]
[CLS]
The
median
duration
of
blinded
study
treatment
was
52
weeks
(
range
24
to
89
weeks
)
for
patients
receiving
A
##FI
##NI
##TO
##R
and
47
weeks
(
range
14
to
88
weeks
)
for
those
receiving
place
##bo
.
[SEP]
[CLS]
Monitor
for
h
##yper
##tens
##ion
and
treat
as
needed
.
[SEP]
[CLS]
Case
##s
of
central
dem
##ye
##lina
##tion
,
MS
,
op
##tic
ne
##uri
##tis
,
and
peripheral
dem
##ye
##lina
##ting
p
##oly
##ne
##uro
##pathy
have
rarely
been
reported
in
patients
treated
with
the
sub
##cut
##aneous
formulation
of
go
##lim
##uma
##b
.
[SEP]
[CLS]
If
a
serious
h
##yper
##sen
##si
##ti
##vity
reaction
occurs
,
disco
##ntin
##ue
ER
##WI
##NA
##Z
##E
and
initiate
appropriate
therapy
.
[SEP]
[CLS]
In
un
##ap
##p
##roved
uses
,
including
spa
##stic
##ity
in
children
,
and
in
approved
indication
##s
,
cases
of
spread
of
effect
have
been
reported
at
doses
comparable
to
or
lower
than
the
maximum
recommended
total
dose
.
[SEP]
[CLS]
Due
to
the
low
rate
of
events
in
both
groups
,
it
is
not
possible
to
conclude
that
the
risk
of
ve
##nous
th
##rom
##boe
##mbo
##lis
##m
with
D
##U
##AV
##EE
is
different
from
that
seen
with
other
est
##rogen
the
##rap
##ies
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Although
other
risk
factors
were
present
in
some
cases
(
such
as
co
##rt
##ico
##ster
##oid
use
and
/
or
exposure
to
radiation
)
,
a
possible
risk
at
##tri
##but
##able
to
K
##AL
##Y
##DE
##CO
can
not
be
excluded
.
[SEP]
[CLS]
Disco
##ntin
##ue
G
##IL
##OT
##RI
##F
in
patients
who
develop
life
-
threatening
bull
##ous
,
b
##list
##ering
,
or
ex
##folia
##ting
lesions
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
In
one
trial
IN
##VO
##KA
##NA
was
used
as
mon
##otherapy
and
in
three
trials
IN
##VO
##KA
##NA
was
used
as
add
-
on
therapy
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
*
F
##lus
##hing
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
The
ass
##ay
should
have
a
lower
limit
of
HC
##V
-
RNA
q
##uant
##ification
of
equal
to
or
less
than
25
I
##U
per
m
##L
,
and
a
limit
of
HC
##V
-
RNA
detection
of
approximately
10
to
15
I
##U
per
m
##L
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
Not
for
System
##ic
In
##fect
##ions
Since
there
is
minimal
systemic
absorption
of
fi
##da
##x
##omi
##cin
,
D
##IF
##IC
##ID
is
not
effective
for
treatment
of
systemic
infections
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
disorders
:
Pan
##cre
##ati
##tis
(
including
fatal
outcomes
)
.
[SEP]
[CLS]
Before
using
D
##AL
##VA
##NC
##E
,
in
##quire
carefully
about
previous
h
##yper
##sen
##si
##ti
##vity
reactions
to
g
##ly
##cope
##pt
##ides
,
and
due
to
the
possibility
of
cross
-
sensitivity
,
exercise
caution
in
patients
with
a
history
of
g
##ly
##cope
##pt
##ide
all
##er
##gy
[
see
Pat
##ient
Counsel
##ing
Information
(
17
)
]
.
[SEP]
[CLS]
In
clinical
trials
with
VI
##CT
##RE
##L
##IS
,
dose
modifications
(
generally
of
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
)
due
to
an
##emia
occurred
twice
as
often
in
subjects
treated
with
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
(
26
%
)
compared
to
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
(
13
%
)
.
[SEP]
[CLS]
If
the
Q
##T
##c
Ba
##ze
##tt
interval
is
>
=
500
m
##s
,
disco
##ntin
##ue
M
##U
##LT
##A
##Q
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
It
may
harm
them
.
[SEP]
[CLS]
5
.
3
N
##eu
##tro
##pen
##ia
(
Use
with
R
##iba
##vir
##in
and
P
##eg
##int
##er
##fer
##on
Alfa
)
In
Phase
2
and
3
clinical
trials
,
seven
percent
of
subjects
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
had
ne
##ut
##rop
##hil
counts
of
less
than
0
.
5
*
10
9
per
L
compared
to
4
%
of
subjects
receiving
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
(
see
Table
4
)
.
[SEP]
[CLS]
Op
##port
##uni
##stic
infections
organisms
including
as
##per
##gill
##osis
,
blast
##omy
##cos
##is
,
can
##di
##dia
##sis
,
co
##cci
##dio
##ido
##my
##cos
##is
,
his
##top
##las
##mos
##is
,
leg
##ione
##llo
##sis
,
list
##eri
##osis
,
p
##ne
##um
##oc
##ys
##tosis
,
and
tuberculosis
have
been
reported
with
T
##NF
-
block
##ers
.
[SEP]
[CLS]
Disco
##ntin
##ue
PR
##OM
##AC
##TA
if
AL
##T
levels
increase
to
greater
than
or
equal
to
3
x
U
##L
##N
in
patients
with
normal
liver
function
or
greater
than
or
equal
to
3
x
base
##line
in
patients
with
pre
-
treatment
elevations
in
trans
##ami
##nas
##es
and
are
:
*
progressively
increasing
,
or
*
persistent
for
greater
than
or
equal
to
4
weeks
,
or
*
accompanied
by
increased
direct
bi
##li
##ru
##bin
,
or
*
accompanied
by
clinical
symptoms
of
liver
injury
or
evidence
for
he
##pa
##tic
de
##com
##pen
##sation
.
[SEP]
[CLS]
This
Pat
##ient
Information
sum
##mar
##izes
the
most
important
information
about
D
##U
##AV
##EE
.
[SEP]
[CLS]
Overall
,
abnormal
##ities
in
liver
tests
(
AL
##T
)
were
reported
with
similar
frequency
in
the
D
##AL
##VA
##NC
##E
and
com
##par
##ator
arms
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
The
proportion
of
subjects
who
discontinued
study
drug
due
to
an
##emia
was
1
%
in
subjects
treated
with
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
and
1
%
in
subjects
who
received
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
.
[SEP]
[CLS]
Ad
##vise
pregnant
women
of
the
potential
risk
to
a
f
##etus
.
[SEP]
[CLS]
5
.
4
Development
of
Drug
-
Re
##sist
##ant
Ba
##cter
##ia
Pre
##s
##cribing
Te
##f
##lar
##o
in
the
absence
of
a
proven
or
strongly
suspected
bacterial
infection
is
unlikely
to
provide
benefit
to
the
patient
and
increases
the
risk
of
the
development
of
drug
-
resistant
bacteria
.
[SEP]
[CLS]
If
pan
##cre
##ati
##tis
is
confirmed
,
T
##AN
##Z
##E
##UM
should
not
be
restart
##ed
.
[SEP]
[CLS]
N
##SF
may
result
in
fatal
or
de
##bil
##itating
fi
##bro
##sis
affecting
the
skin
,
muscle
and
internal
organs
.
[SEP]
[CLS]
If
an
all
##ergic
reaction
occurs
,
treatment
with
D
##AL
##VA
##NC
##E
should
be
discontinued
.
[SEP]
[CLS]
F
##ail
##ure
to
block
thy
##roid
up
##take
of
i
##od
##ine
123
may
result
in
an
increased
long
term
risk
for
thy
##roid
neo
##p
##lasia
.
[SEP]
[CLS]
Twenty
-
five
of
these
121
patients
(
21
%
)
had
detect
##able
anti
-
g
##lu
##car
##pid
##ase
antibodies
following
V
##OR
##A
##X
##A
##Z
##E
administration
,
of
which
19
received
a
single
dose
of
V
##OR
##A
##X
##A
##Z
##E
and
6
received
two
doses
of
V
##OR
##A
##X
##A
##Z
##E
.
[SEP]
[CLS]
Table
1
sum
##mar
##izes
adverse
reactions
reported
at
a
rate
of
at
least
1
%
in
U
##L
##OR
##IC
treatment
groups
and
at
least
0
.
5
%
greater
than
place
##bo
.
[SEP]
[CLS]
E
##B
##V
Ser
##ost
##atus
The
risk
of
PT
##LD
was
higher
in
E
##B
##V
se
##rone
##gat
##ive
patients
compared
to
E
##B
##V
se
##rop
##os
##itive
patients
.
[SEP]
[CLS]
The
principal
efficacy
study
evaluating
the
efficacy
and
safety
of
H
##OR
##I
##Z
##AN
##T
in
the
management
of
P
##H
##N
was
a
12
-
week
,
double
-
blind
,
multi
##cent
##er
study
comparing
1
,
200
mg
/
day
,
2
,
400
mg
/
day
and
3
,
600
mg
/
day
to
place
##bo
.
[SEP]
[CLS]
Red
##uce
or
disco
##ntin
##ue
NO
##RT
##H
##ER
##A
if
su
##pine
h
##yper
##tens
##ion
per
##sist
##s
.
[SEP]
[CLS]
The
study
population
included
34
males
and
26
females
(
n
=
60
)
in
the
al
##g
##lu
##cos
##idas
##e
al
##fa
group
and
11
males
and
19
females
(
n
=
30
)
in
the
place
##bo
group
.
[SEP]
[CLS]
*
Co
##rr
##uga
##tor
injection
##s
should
be
placed
at
least
1
cm
above
the
bony
su
##pra
##or
##bit
##al
ridge
.
[SEP]
[CLS]
Care
##fully
weigh
risks
and
benefits
of
treatment
with
O
##TE
##Z
##LA
in
patients
with
a
history
of
depression
and
/
or
su
##icidal
thoughts
or
behavior
.
[SEP]
[CLS]
(
5
.
7
)
5
.
1
Mortal
##ity
There
were
more
deaths
reported
with
B
##EN
##L
##Y
##ST
##A
than
with
place
##bo
during
the
controlled
period
of
the
clinical
trials
.
[SEP]
[CLS]
Typical
symptoms
associated
with
PM
##L
are
diverse
,
progress
over
days
to
weeks
,
and
include
progressive
weakness
on
one
side
of
the
body
or
c
##lums
##iness
of
limbs
,
disturbance
of
vision
,
and
changes
in
thinking
leading
to
confusion
and
personality
changes
.
[SEP]
[CLS]
The
rates
of
adverse
reactions
below
were
derived
from
two
random
##ized
,
multi
-
center
,
vehicle
-
controlled
clinical
trials
and
one
open
-
label
study
in
subjects
with
head
l
##ice
in
##fest
##ation
.
[SEP]
[CLS]
Because
of
its
anti
##cho
##liner
##gic
effects
,
X
##E
##OM
##IN
should
be
used
with
caution
in
patients
at
risk
of
developing
narrow
angle
g
##lau
##com
##a
.
[SEP]
[CLS]
There
is
no
known
treatment
for
established
cases
of
ta
##rdi
##ve
d
##ys
##kin
##esi
##a
,
although
the
syndrome
may
re
##mit
,
partially
or
completely
,
if
anti
##psy
##cho
##tic
treatment
is
withdrawn
.
[SEP]
[CLS]
The
most
frequently
reported
AD
##R
at
least
Grade
2
in
severity
was
r
##ash
(
10
.
0
%
)
.
[SEP]
[CLS]
The
duration
of
Pro
##lia
exposure
to
time
of
at
##y
##pical
f
##em
##oral
fracture
diagnosis
was
as
early
as
21
/
2
years
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
The
causes
of
death
in
the
remaining
subjects
varied
.
[SEP]
[CLS]
5
.
4
Tu
##mor
L
##ys
##is
S
##yn
##drome
Tu
##mor
l
##ys
##is
syndrome
associated
with
T
##RE
##AN
##DA
treatment
has
occurred
in
patients
in
clinical
trials
and
in
post
##market
##ing
reports
.
[SEP]
[CLS]
If
pan
##cre
##ati
##tis
is
suspected
,
promptly
disco
##ntin
##ue
NE
##SI
##NA
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
reactions
including
an
##aph
##yla
##ctic
shock
(
fatal
)
,
u
##rt
##ica
##ria
,
and
an
##gio
##ede
##ma
have
been
reported
.
[SEP]
[CLS]
Typical
symptoms
associated
with
PM
##L
are
diverse
,
progress
over
days
to
weeks
,
and
include
progressive
weakness
on
one
side
of
the
body
or
c
##lums
##iness
of
limbs
,
disturbance
of
vision
,
and
changes
in
thinking
,
memory
,
and
orientation
leading
to
confusion
and
personality
changes
.
[SEP]
[CLS]
Local
skin
reactions
typically
occurred
within
1
day
of
treatment
initiation
,
peaked
in
intensity
up
to
1
week
following
completion
of
treatment
,
and
resolved
within
2
weeks
for
areas
treated
on
the
face
and
scalp
,
and
within
4
weeks
for
areas
treated
on
the
trunk
and
ex
##tre
##mit
##ies
.
[SEP]
[CLS]
P
##sor
##ia
##tic
Art
##hr
##itis
Clinical
Study
C
##IM
##Z
##IA
has
been
studied
in
40
##9
patients
with
ps
##oria
##tic
art
##hr
##itis
(
P
##s
##A
)
in
a
place
##bo
-
controlled
trial
.
[SEP]
[CLS]
*
Cy
##tok
##ine
Release
S
##yn
##drome
(
CR
##S
)
,
which
may
be
life
-
threatening
or
fatal
,
occurred
in
patients
receiving
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
All
infections
#
27
(
7
)
26
(
6
)
55
(
14
)
46
(
11
)
Tu
##ber
##cu
##los
##is
2
(
1
)
1
(
<
1
)
6
(
2
)
1
(
<
1
)
In
##fect
##ions
Report
##ed
in
the
C
##NS
Following
three
years
of
treatment
in
Studies
1
and
2
,
cry
##pt
##oc
##oc
##cal
men
##ing
##itis
was
reported
in
one
patient
out
of
401
patients
treated
with
the
N
##U
##L
##O
##J
##IX
recommended
regime
##n
(
0
.
2
%
)
and
one
patient
out
of
the
405
treated
with
the
c
##y
##c
##los
##por
##ine
control
(
0
.
2
%
)
.
[SEP]
[CLS]
(
5
.
5
)
item
{
Fun
##gal
infections
-
Fun
##gal
infections
of
the
corn
##ea
are
particularly
prone
to
develop
coincide
##ntal
##ly
with
long
-
term
local
s
##tero
##id
application
.
[SEP]
[CLS]
The
median
number
of
dos
##ing
delays
was
one
in
patients
receiving
CO
##ME
##TR
##I
##Q
compared
to
none
in
patients
receiving
place
##bo
.
[SEP]
[CLS]
5
.
4
A
##b
##nor
##mal
B
##lee
##ding
SSR
##I
##s
and
S
##NR
##I
##s
,
including
PR
##IS
##TI
##Q
,
may
increase
the
risk
of
bleeding
events
.
[SEP]
[CLS]
In
the
patients
who
developed
antibodies
during
treatment
,
the
median
t
##iter
(
by
di
##lution
method
)
was
8
,
with
a
range
of
5
to
80
.
[SEP]
[CLS]
Prior
to
Ad
##re
##V
##ie
##w
administration
,
ensure
emergency
cardiac
and
anti
-
h
##yper
##tensive
treatments
are
readily
available
.
[SEP]
[CLS]
Effects
of
flu
##tica
##son
##e
fur
##oat
##e
on
the
HP
##A
axis
are
not
observed
with
the
therapeutic
doses
of
BR
##E
##O
E
##LL
##IP
##TA
.
[SEP]
[CLS]
In
addition
,
no
clinical
safety
concerns
related
to
the
in
##hibition
of
end
##ogen
##ous
M
##MP
##s
have
been
observed
.
[SEP]
[CLS]
5
.
10
P
##ul
##mona
##ry
To
##xi
##city
Events
of
non
##in
##fect
##ious
pulmonary
toxicity
including
p
##ne
##um
##oni
##tis
,
inter
##st
##iti
##al
lung
disease
,
and
acute
respiratory
distress
syndrome
(
AR
##DS
)
,
some
with
fatal
outcomes
,
have
been
reported
.
[SEP]
[CLS]
Table
1
shows
adverse
reactions
on
the
Z
##Y
##TI
##GA
arm
in
Study
1
that
occurred
with
a
>
=
2
%
absolute
increase
in
frequency
compared
to
place
##bo
or
were
events
of
special
interest
.
[SEP]
